{"PMC7191637": [["INTRODUCTIONChronic respiratory diseases are a prominent cause of morbidity and mortality worldwide (5), with chronic obstructive pulmonary disease (COPD) being the third leading cause of death in the United States.", [["respiratory", "ANATOMY", 20, 31], ["pulmonary", "ANATOMY", 130, 139], ["respiratory diseases", "DISEASE", 20, 40], ["chronic obstructive pulmonary disease", "DISEASE", 110, 147], ["COPD", "DISEASE", 149, 153], ["death", "DISEASE", 188, 193], ["pulmonary", "ORGAN", 130, 139], ["INTRODUCTIONChronic respiratory diseases", "PROBLEM", 0, 40], ["morbidity", "PROBLEM", 66, 75], ["chronic obstructive pulmonary disease", "PROBLEM", 110, 147], ["COPD)", "PROBLEM", 149, 154], ["respiratory diseases", "OBSERVATION", 20, 40], ["prominent", "OBSERVATION_MODIFIER", 47, 56], ["morbidity", "OBSERVATION", 66, 75], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["obstructive", "OBSERVATION_MODIFIER", 118, 129], ["pulmonary", "ANATOMY", 130, 139], ["disease", "OBSERVATION", 140, 147], ["COPD", "OBSERVATION", 149, 153]]], ["Chronic lung diseases, such as COPD and idiopathic pulmonary fibrosis (IPF), are characterized by extensive changes in the extracellular matrix (ECM), the three-dimensional (3D) scaffold that provides mechanical and biochemical support/signals to cells.", [["lung", "ANATOMY", 8, 12], ["pulmonary", "ANATOMY", 51, 60], ["extracellular matrix", "ANATOMY", 123, 143], ["ECM", "ANATOMY", 145, 148], ["cells", "ANATOMY", 247, 252], ["Chronic lung diseases", "DISEASE", 0, 21], ["COPD", "DISEASE", 31, 35], ["idiopathic pulmonary fibrosis", "DISEASE", 40, 69], ["IPF", "DISEASE", 71, 74], ["lung", "ORGAN", 8, 12], ["pulmonary", "ORGAN", 51, 60], ["extracellular matrix", "CELLULAR_COMPONENT", 123, 143], ["ECM", "CELLULAR_COMPONENT", 145, 148], ["cells", "CELL", 247, 252], ["Chronic lung diseases", "PROBLEM", 0, 21], ["COPD", "PROBLEM", 31, 35], ["idiopathic pulmonary fibrosis", "PROBLEM", 40, 69], ["extensive changes in the extracellular matrix (ECM)", "PROBLEM", 98, 149], ["the three-dimensional (3D) scaffold", "TREATMENT", 151, 186], ["mechanical and biochemical support", "TREATMENT", 201, 235], ["lung", "ANATOMY", 8, 12], ["diseases", "OBSERVATION", 13, 21], ["COPD", "OBSERVATION", 31, 35], ["idiopathic", "OBSERVATION_MODIFIER", 40, 50], ["pulmonary", "ANATOMY", 51, 60], ["fibrosis", "OBSERVATION", 61, 69], ["IPF", "OBSERVATION", 71, 74], ["extensive", "OBSERVATION_MODIFIER", 98, 107], ["extracellular", "ANATOMY_MODIFIER", 123, 136], ["matrix", "ANATOMY_MODIFIER", 137, 143]]], ["The ECM is often an underrecognized element in lung disease (4, 13, 29).", [["ECM", "ANATOMY", 4, 7], ["lung", "ANATOMY", 47, 51], ["lung disease", "DISEASE", 47, 59], ["ECM", "CELLULAR_COMPONENT", 4, 7], ["lung", "ORGAN", 47, 51], ["lung disease", "PROBLEM", 47, 59], ["underrecognized", "OBSERVATION_MODIFIER", 20, 35], ["element", "OBSERVATION_MODIFIER", 36, 43], ["lung", "ANATOMY", 47, 51], ["disease", "OBSERVATION", 52, 59]]], ["However, increasing evidence suggests that the ECM plays an active role in lung pathophysiology.INTRODUCTIONMechanical properties of the ECM dictate, in part, cellular responses to injury, with stiffness being explored most commonly (3, 14, 19).", [["ECM", "ANATOMY", 47, 50], ["lung", "ANATOMY", 75, 79], ["ECM", "ANATOMY", 137, 140], ["cellular", "ANATOMY", 159, 167], ["ECM", "CELLULAR_COMPONENT", 47, 50], ["lung", "ORGAN", 75, 79], ["ECM", "CELLULAR_COMPONENT", 137, 140], ["cellular", "CELL", 159, 167], ["ECM", "PROTEIN", 47, 50], ["ECM", "PROTEIN", 137, 140], ["injury", "PROBLEM", 181, 187], ["stiffness", "PROBLEM", 194, 203], ["active", "OBSERVATION_MODIFIER", 60, 66], ["lung", "ANATOMY", 75, 79], ["injury", "OBSERVATION", 181, 187]]], ["The lung ECM is a viscoelastic network of both elastic and nonelastic constructive fibrillar proteins embedded in a water-retaining gel of proteoglycans and glycosaminoglycans.", [["lung ECM", "ANATOMY", 4, 12], ["fibrillar", "ANATOMY", 83, 92], ["lung", "ORGAN", 4, 8], ["proteoglycans", "SIMPLE_CHEMICAL", 139, 152], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 157, 175], ["nonelastic constructive fibrillar proteins", "PROTEIN", 59, 101], ["both elastic and nonelastic constructive fibrillar proteins", "TREATMENT", 42, 101], ["a water-retaining gel of proteoglycans", "TREATMENT", 114, 152], ["glycosaminoglycans", "TREATMENT", 157, 175], ["lung", "ANATOMY", 4, 8], ["ECM", "OBSERVATION", 9, 12], ["viscoelastic network", "OBSERVATION", 18, 38], ["both", "OBSERVATION_MODIFIER", 42, 46], ["elastic", "OBSERVATION_MODIFIER", 47, 54], ["fibrillar proteins", "OBSERVATION", 83, 101]]], ["Viscoelastic materials exhibit time-dependent strain often measured as relaxation when undergoing deformation (6).", [["Viscoelastic materials", "PROBLEM", 0, 22], ["dependent strain", "PROBLEM", 36, 52], ["dependent strain", "OBSERVATION_MODIFIER", 36, 52]]], ["Viscoelasticity as a mechanical property influences cellular spreading, proliferation, and differentiation, together with or independently of stiffness (7, 8).", [["cellular", "ANATOMY", 52, 60], ["Viscoelasticity", "DISEASE", 0, 15], ["cellular", "CELL", 52, 60], ["Viscoelasticity", "PROBLEM", 0, 15], ["mechanical property", "OBSERVATION_MODIFIER", 21, 40], ["cellular", "OBSERVATION_MODIFIER", 52, 60], ["spreading", "OBSERVATION_MODIFIER", 61, 70], ["proliferation", "OBSERVATION_MODIFIER", 72, 85], ["differentiation", "OBSERVATION_MODIFIER", 91, 106], ["stiffness", "OBSERVATION_MODIFIER", 142, 151]]], ["For the lung, which undergoes repeated stretch and relaxation, usually greater than 14,000 times each day, replicating the mechanical properties of the ECM is essential to accurately model the cellular environment in vitro.INTRODUCTIONSynthetic hydrogels have found their way into tissue engineering as ECM mimics.", [["lung", "ANATOMY", 8, 12], ["ECM", "ANATOMY", 152, 155], ["cellular", "ANATOMY", 193, 201], ["tissue", "ANATOMY", 281, 287], ["ECM", "ANATOMY", 303, 306], ["lung", "ORGAN", 8, 12], ["ECM", "CELLULAR_COMPONENT", 152, 155], ["cellular", "CELL", 193, 201], ["tissue", "TISSUE", 281, 287], ["ECM", "CELLULAR_COMPONENT", 303, 306], ["repeated stretch and relaxation", "TREATMENT", 30, 61], ["INTRODUCTIONSynthetic hydrogels", "TREATMENT", 223, 254], ["lung", "ANATOMY", 8, 12], ["stretch", "OBSERVATION_MODIFIER", 39, 46], ["mechanical properties", "OBSERVATION_MODIFIER", 123, 144], ["cellular environment", "OBSERVATION", 193, 213]]], ["Natural hydrogels have been generated from, e.g. decellularized human adipose (20), heart (15), and liver (17) tissue and more (1, 9, 23, 25).", [["adipose", "ANATOMY", 70, 77], ["heart", "ANATOMY", 84, 89], ["liver (17) tissue", "ANATOMY", 100, 117], ["human", "ORGANISM", 64, 69], ["adipose", "TISSUE", 70, 77], ["heart", "ORGAN", 84, 89], ["liver", "ORGAN", 100, 105], ["tissue", "TISSUE", 111, 117], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["Natural hydrogels", "TREATMENT", 0, 17], ["heart", "ANATOMY", 84, 89], ["liver", "ANATOMY", 100, 105]]], ["As for the lung, hydrogels have been generated from porcine lung ECM (22).", [["lung", "ANATOMY", 11, 15], ["lung ECM", "ANATOMY", 60, 68], ["lung", "ORGAN", 11, 15], ["porcine", "ORGANISM", 52, 59], ["lung ECM", "MULTI-TISSUE_STRUCTURE", 60, 68], ["porcine", "SPECIES", 52, 59], ["hydrogels", "TREATMENT", 17, 26], ["porcine lung ECM", "TREATMENT", 52, 68], ["lung", "ANATOMY", 11, 15], ["hydrogels", "OBSERVATION", 17, 26], ["lung", "ANATOMY", 60, 64]]], ["ECM hydrogels are generated from intact tissue by detergent-based decellularization then gentle proteolytic solubilization (often with pepsin).", [["ECM", "ANATOMY", 0, 3], ["tissue", "ANATOMY", 40, 46], ["ECM", "CELLULAR_COMPONENT", 0, 3], ["tissue", "TISSUE", 40, 46], ["pepsin", "GENE_OR_GENE_PRODUCT", 135, 141], ["pepsin", "PROTEIN", 135, 141], ["ECM hydrogels", "TREATMENT", 0, 13], ["detergent-based decellularization", "TREATMENT", 50, 83], ["gentle proteolytic solubilization", "TREATMENT", 89, 122], ["hydrogels", "OBSERVATION", 4, 13], ["intact tissue", "OBSERVATION", 33, 46]]], ["Upon pH neutralization and bringing to physiological osmolarity, hydrogels form spontaneously at 37\u00b0C. As such, these hydrogels comprise the native ECM composition, albeit not the macroscopic (micrometer sized) architecture (10, 23).INTRODUCTIONIn this study we report for the first time the generation of ECM hydrogels from control and diseased [COPD Global Initiative for Chronic Obstructive Lung Disease (GOLD) IV and IPF] human lung tissues.", [["ECM", "ANATOMY", 148, 151], ["ECM", "ANATOMY", 306, 309], ["Lung", "ANATOMY", 394, 398], ["lung tissues", "ANATOMY", 432, 444], ["Chronic Obstructive Lung Disease", "DISEASE", 374, 406], ["IPF", "DISEASE", 421, 424], ["ECM", "CELLULAR_COMPONENT", 148, 151], ["human", "ORGANISM", 426, 431], ["lung tissues", "TISSUE", 432, 444], ["human", "SPECIES", 426, 431], ["human", "SPECIES", 426, 431], ["pH neutralization", "TEST", 5, 22], ["these hydrogels", "TREATMENT", 112, 127], ["this study", "TEST", 248, 258], ["ECM hydrogels", "TREATMENT", 306, 319], ["diseased [COPD", "PROBLEM", 337, 351], ["Chronic Obstructive Lung Disease", "PROBLEM", 374, 406], ["(GOLD) IV and IPF] human lung tissues", "TREATMENT", 407, 444], ["pH neutralization", "OBSERVATION", 5, 22], ["native", "OBSERVATION_MODIFIER", 141, 147], ["ECM", "OBSERVATION_MODIFIER", 148, 151], ["composition", "OBSERVATION_MODIFIER", 152, 163], ["Chronic", "OBSERVATION_MODIFIER", 374, 381], ["Obstructive", "OBSERVATION_MODIFIER", 382, 393], ["Lung", "ANATOMY", 394, 398], ["Disease", "OBSERVATION", 399, 406], ["IPF", "OBSERVATION", 421, 424], ["lung tissues", "ANATOMY", 432, 444]]], ["The mechanical features of these human lung ECM hydrogels as well as intact human lung stiffness and viscoelasticity were measured.", [["lung ECM", "ANATOMY", 39, 47], ["lung", "ANATOMY", 82, 86], ["human", "ORGANISM", 33, 38], ["lung ECM", "MULTI-TISSUE_STRUCTURE", 39, 47], ["human", "ORGANISM", 76, 81], ["lung", "ORGAN", 82, 86], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 76, 81], ["these human lung ECM hydrogels", "TREATMENT", 27, 57], ["mechanical", "OBSERVATION_MODIFIER", 4, 14], ["human", "ANATOMY_MODIFIER", 33, 38], ["lung", "ANATOMY", 39, 43], ["ECM hydrogels", "OBSERVATION", 44, 57], ["lung", "ANATOMY", 82, 86], ["stiffness", "OBSERVATION", 87, 96], ["viscoelasticity", "OBSERVATION_MODIFIER", 101, 116]]], ["Our data indicate that the ECM hydrogels partially replicate the mechanical properties of human lung tissue.Processing of human lung tissue. ::: ::: MATERIALS AND METHODSTissue from human explanted lungs was obtained through the Department of Pathology, remaining after diagnostic procedures from control (nonusable donor lungs and tumor resection material; n = 13) and COPD GOLD IV (n = 15) or IPF (n = 12) patients undergoing lung transplantation or lung resection in the University Medical Center Groningen.", [["ECM", "ANATOMY", 27, 30], ["lung tissue", "ANATOMY", 96, 107], ["lung tissue", "ANATOMY", 128, 139], ["lungs", "ANATOMY", 198, 203], ["lungs", "ANATOMY", 322, 327], ["tumor", "ANATOMY", 332, 337], ["lung", "ANATOMY", 428, 432], ["lung", "ANATOMY", 452, 456], ["tumor", "DISEASE", 332, 337], ["COPD", "DISEASE", 370, 374], ["IPF", "DISEASE", 395, 398], ["ECM", "CELLULAR_COMPONENT", 27, 30], ["human", "ORGANISM", 90, 95], ["lung tissue", "TISSUE", 96, 107], ["human", "ORGANISM", 122, 127], ["lung tissue", "TISSUE", 128, 139], ["human", "ORGANISM", 182, 187], ["lungs", "ORGAN", 198, 203], ["lungs", "ORGAN", 322, 327], ["tumor", "CANCER", 332, 337], ["patients", "ORGANISM", 408, 416], ["lung", "ORGAN", 428, 432], ["lung", "ORGAN", 452, 456], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 182, 187], ["patients", "SPECIES", 408, 416], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 182, 187], ["Our data", "TEST", 0, 8], ["the ECM hydrogels", "TREATMENT", 23, 40], ["diagnostic procedures", "TEST", 270, 291], ["control (nonusable donor lungs", "TREATMENT", 297, 327], ["tumor resection material", "TREATMENT", 332, 356], ["COPD GOLD IV (n", "TREATMENT", 370, 385], ["IPF", "PROBLEM", 395, 398], ["lung transplantation", "TREATMENT", 428, 448], ["lung resection", "TREATMENT", 452, 466], ["ECM hydrogels", "OBSERVATION", 27, 40], ["mechanical properties", "OBSERVATION", 65, 86], ["human lung tissue", "OBSERVATION", 90, 107], ["human", "ANATOMY_MODIFIER", 122, 127], ["lung", "ANATOMY", 128, 132], ["tissue", "OBSERVATION", 133, 139], ["lungs", "ANATOMY", 198, 203], ["lungs", "ANATOMY", 322, 327], ["tumor resection", "OBSERVATION", 332, 347], ["IPF", "OBSERVATION", 395, 398], ["lung", "ANATOMY", 428, 432], ["transplantation", "OBSERVATION", 433, 448], ["lung", "ANATOMY", 452, 456], ["resection", "OBSERVATION", 457, 466]]], ["Deidentified control and IPF human lung tissue were provided by the University of Michigan; as the tissues were deidentified and coming from deceased donors, the University of Michigan Institutional Review Board deemed this work exempt from oversight.Decellularization of human lung tissue. ::: ::: MATERIALS AND METHODSLung tissues (control n = 3, COPD GOLD IV n = 10, or IPF n = 3) were minced with a blender, washed with demineralized H2O (dH2O), treated with trypsin (0.05% final concentration; Thermo Fisher Scientific, Waltham, MA), and incubated (37\u00b0C, 3 h) (Fig. 1A).", [["lung tissue", "ANATOMY", 35, 46], ["tissues", "ANATOMY", 99, 106], ["lung tissue", "ANATOMY", 278, 289], ["METHODSLung tissues", "ANATOMY", 313, 332], ["IPF", "DISEASE", 25, 28], ["COPD", "DISEASE", 349, 353], ["IPF", "DISEASE", 373, 376], ["H2O", "CHEMICAL", 438, 441], ["H2O", "CHEMICAL", 438, 441], ["human", "ORGANISM", 29, 34], ["lung tissue", "TISSUE", 35, 46], ["tissues", "TISSUE", 99, 106], ["donors", "ORGANISM", 150, 156], ["human", "ORGANISM", 272, 277], ["lung tissue", "TISSUE", 278, 289], ["METHODSLung tissues", "TISSUE", 313, 332], ["dH2O", "SIMPLE_CHEMICAL", 443, 447], ["trypsin", "SIMPLE_CHEMICAL", 463, 470], ["trypsin", "PROTEIN", 463, 470], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 272, 277], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 272, 277], ["IPF human lung tissue", "PROBLEM", 25, 46], ["Decellularization of human lung tissue", "PROBLEM", 251, 289], ["METHODSLung tissues (control n", "TREATMENT", 313, 343], ["COPD GOLD IV n", "TREATMENT", 349, 363], ["IPF n", "TREATMENT", 373, 378], ["a blender", "TREATMENT", 401, 410], ["demineralized H2O (dH2O)", "TREATMENT", 424, 448], ["trypsin", "TREATMENT", 463, 470], ["IPF", "OBSERVATION", 25, 28], ["lung", "ANATOMY", 35, 39], ["tissue", "OBSERVATION", 40, 46], ["human", "ANATOMY_MODIFIER", 272, 277], ["lung", "ANATOMY", 278, 282], ["tissue", "OBSERVATION", 283, 289]]], ["The homogenate was repeatedly washed with dH2O until the supernatant remained clear before being sequentially treated with saturated NaCl (6 M) solution, 70% ethanol, 1% SDS solution, 1% Triton X-100, 1% sodium deoxycholate, and 30 \u00b5g/mL DNase (in 1.3 mM MgSO4 and 2 mM CaCl2) solution, with three washes with dH2O between treatments, each for 24 h at room temperature (RT) with constant shaking, except for the enzymatic treatments, which were at 37\u00b0C with shaking.", [["homogenate", "ANATOMY", 4, 14], ["supernatant", "ANATOMY", 57, 68], ["NaCl", "CHEMICAL", 133, 137], ["ethanol", "CHEMICAL", 158, 165], ["Triton X-100", "CHEMICAL", 187, 199], ["sodium deoxycholate", "CHEMICAL", 204, 223], ["MgSO4", "CHEMICAL", 255, 260], ["CaCl2", "CHEMICAL", 270, 275], ["dH2O", "CHEMICAL", 42, 46], ["NaCl", "CHEMICAL", 133, 137], ["ethanol", "CHEMICAL", 158, 165], ["SDS", "CHEMICAL", 170, 173], ["sodium deoxycholate", "CHEMICAL", 204, 223], ["MgSO4", "CHEMICAL", 255, 260], ["CaCl2", "CHEMICAL", 270, 275], ["dH2O", "SIMPLE_CHEMICAL", 42, 46], ["ethanol", "SIMPLE_CHEMICAL", 158, 165], ["Triton X-100", "SIMPLE_CHEMICAL", 187, 199], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 204, 223], ["DNase", "SIMPLE_CHEMICAL", 238, 243], ["MgSO4", "SIMPLE_CHEMICAL", 255, 260], ["dH2O", "SIMPLE_CHEMICAL", 310, 314], ["DNase", "PROTEIN", 238, 243], ["dH2O", "TREATMENT", 42, 46], ["saturated NaCl", "TREATMENT", 123, 137], ["1% sodium deoxycholate", "TREATMENT", 201, 223], ["1.3 mM MgSO4", "TREATMENT", 248, 260], ["2 mM CaCl2) solution", "TREATMENT", 265, 285], ["dH2O between treatments", "TREATMENT", 310, 333], ["constant shaking", "PROBLEM", 379, 395], ["the enzymatic treatments", "TREATMENT", 408, 432], ["shaking", "PROBLEM", 458, 465], ["clear", "OBSERVATION", 78, 83]]], ["The resultant decellularized ECM (dECM) was stored in sterile PBS containing 1% penicillin-streptomycin at 4\u00b0C. Decellularized tissues (3) were provided by the University of Michigan (control n = 6, IPF n = 6).Generating lung dECM hydrogels. ::: ::: MATERIALS AND METHODSThe dECM samples were snap frozen in liquid nitrogen and lyophilized with a FreeZone Plus lyophilizer (Labconco, Kansas City, MO) and then ground to a powder with an ULTRA-TURRAX (IKA, Staufen, Germany). dECM samples from different donors from the same disease group (control n = 9, COPD GOLD IV n = 10, or IPF n = 9) were pooled.", [["ECM", "ANATOMY", 29, 32], ["dECM", "ANATOMY", 34, 38], ["tissues", "ANATOMY", 127, 134], ["lung", "ANATOMY", 221, 225], ["dECM samples", "ANATOMY", 275, 287], ["dECM samples", "ANATOMY", 475, 487], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 91, 103], ["IPF", "DISEASE", 199, 202], ["COPD", "DISEASE", 554, 558], ["IPF", "DISEASE", 578, 581], ["penicillin", "CHEMICAL", 80, 90], ["streptomycin", "CHEMICAL", 91, 103], ["nitrogen", "CHEMICAL", 315, 323], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 80, 103], ["tissues", "TISSUE", 127, 134], ["lung", "ORGAN", 221, 225], ["dECM samples", "CANCER", 275, 287], ["dECM samples", "CANCER", 475, 487], ["donors", "ORGANISM", 503, 509], ["The resultant decellularized ECM", "TREATMENT", 0, 32], ["sterile PBS", "TREATMENT", 54, 65], ["1% penicillin", "TREATMENT", 77, 90], ["streptomycin", "TREATMENT", 91, 103], ["IPF n", "TEST", 199, 204], ["METHODSThe dECM samples", "TEST", 264, 287], ["liquid nitrogen", "TREATMENT", 308, 323], ["a FreeZone Plus lyophilizer", "TREATMENT", 345, 372], ["dECM samples", "TEST", 475, 487], ["different donors", "PROBLEM", 493, 509], ["COPD GOLD IV n", "TREATMENT", 554, 568], ["IPF n", "TEST", 578, 583], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["decellularized", "OBSERVATION_MODIFIER", 14, 28], ["ECM", "OBSERVATION_MODIFIER", 29, 32], ["lung", "ANATOMY", 221, 225], ["dECM hydrogels", "OBSERVATION", 226, 240], ["different donors", "OBSERVATION", 493, 509]]], ["The lung dECM powder (20 mg/mL) was digested with 2 mg/mL porcine pepsin (Sigma-Aldrich, St. Louis, MO; Fig. 1B) in 0.01 M HCl with constant agitation at RT for 72 h.", [["lung", "ANATOMY", 4, 8], ["HCl", "CHEMICAL", 123, 126], ["agitation", "DISEASE", 141, 150], ["HCl", "CHEMICAL", 123, 126], ["lung", "ORGAN", 4, 8], ["porcine", "ORGANISM", 58, 65], ["pepsin", "GENE_OR_GENE_PRODUCT", 66, 72], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 74, 87], ["St. Louis", "ORGANISM", 89, 98], ["The lung dECM powder", "TREATMENT", 0, 20], ["constant agitation", "PROBLEM", 132, 150], ["lung", "ANATOMY", 4, 8]]], ["The digest was centrifuged at 500 g for 3 min to remove any remaining undigested insoluble aggregates.", [["any remaining undigested insoluble aggregates", "PROBLEM", 56, 101], ["insoluble aggregates", "OBSERVATION", 81, 101]]], ["The pH was neutralized with 0.1 M NaOH and brought to 1\u00d7 PBS with one-tenth volume 10\u00d7 PBS: this generated the pre-gel.", [["NaOH", "CHEMICAL", 34, 38], ["NaOH", "CHEMICAL", 34, 38], ["The pH", "TEST", 0, 6], ["PBS", "TEST", 57, 60]]], ["Human lung ECM hydrogels were prepared in 48-well plates with 300 \u00b5L of pre-gel per well at 37\u00b0C for 1 h.", [["lung ECM", "ANATOMY", 6, 14], ["Human", "ORGANISM", 0, 5], ["lung ECM", "CELL", 6, 14], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human lung ECM hydrogels", "TREATMENT", 0, 24], ["pre-gel", "TREATMENT", 72, 79], ["lung", "ANATOMY", 6, 10]]], ["Lung ECM gels were covered with 500 \u00b5L of Hanks\u2019 balanced salt solution (Lonza, Verviers, Belgium) to prevent desiccation before mechanical testing.", [["Lung ECM", "ANATOMY", 0, 8], ["Hanks\u2019 balanced salt solution", "TREATMENT", 42, 71], ["Verviers", "TREATMENT", 80, 88], ["desiccation", "PROBLEM", 110, 121], ["mechanical testing", "TEST", 129, 147]]], ["Sections of lung ECM hydrogels were stained with hematoxylin and eosin (H&E) (12); images were captured with a slide scanner (Nanozoomer 2.0 HT; Hamamatsu Photonics).Protein distribution of whole, decellularized, and pepsin-digested lung tissue. ::: ::: MATERIALS AND METHODSThe protein content of native lung tissue, dECM powder, and pepsin-digested dECM (pre-gel) was examined.", [["lung ECM", "ANATOMY", 12, 20], ["lung tissue", "ANATOMY", 233, 244], ["lung tissue", "ANATOMY", 305, 316], ["HT", "DISEASE", 141, 143], ["hematoxylin", "CHEMICAL", 49, 60], ["eosin", "CHEMICAL", 65, 70], ["lung ECM", "MULTI-TISSUE_STRUCTURE", 12, 20], ["hematoxylin", "SIMPLE_CHEMICAL", 49, 60], ["decellularized", "TISSUE", 197, 211], ["pepsin", "GENE_OR_GENE_PRODUCT", 217, 223], ["lung tissue", "TISSUE", 233, 244], ["lung tissue", "TISSUE", 305, 316], ["dECM", "SIMPLE_CHEMICAL", 318, 322], ["pepsin", "GENE_OR_GENE_PRODUCT", 335, 341], ["dECM", "GENE_OR_GENE_PRODUCT", 351, 355], ["pre-gel", "SIMPLE_CHEMICAL", 357, 364], ["pepsin", "PROTEIN", 335, 341], ["dECM", "PROTEIN", 351, 355], ["lung ECM hydrogels", "TREATMENT", 12, 30], ["hematoxylin", "TREATMENT", 49, 60], ["eosin", "TREATMENT", 65, 70], ["images", "TEST", 83, 89], ["a slide scanner (Nanozoomer", "TREATMENT", 109, 136], ["Hamamatsu Photonics", "TREATMENT", 145, 164], ["Protein distribution", "TEST", 166, 186], ["METHODSThe protein content", "TEST", 268, 294], ["native lung tissue", "TREATMENT", 298, 316], ["dECM powder", "TREATMENT", 318, 329], ["pepsin", "TEST", 335, 341], ["lung", "ANATOMY", 12, 16], ["ECM", "ANATOMY_MODIFIER", 17, 20], ["lung", "ANATOMY", 233, 237], ["tissue", "OBSERVATION", 238, 244], ["native", "ANATOMY_MODIFIER", 298, 304], ["lung", "ANATOMY", 305, 309], ["tissue", "ANATOMY_MODIFIER", 310, 316]]], ["Twenty milligrams of whole tissue and dECM powder was solubilized in 1 mL of RIPA buffer (Thermo Fisher Scientific, Waltham, MA) containing 4 \u00b5L of proteinase inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) and 10 \u00b5L of phosphatase inhibitor cocktail (Thermo Fisher Scientific, Waltham, MA), and 20 mg of pre-gel was prepared.", [["whole tissue", "ANATOMY", 21, 33], ["tissue", "TISSUE", 27, 33], ["dECM powder", "ORGANISM_SUBSTANCE", 38, 49], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 179, 192], ["St. Louis", "ORGANISM", 194, 203], ["MO", "ORGANISM", 205, 207], ["pre-gel", "SIMPLE_CHEMICAL", 307, 314], ["whole tissue and dECM powder", "TREATMENT", 21, 49], ["RIPA buffer", "TREATMENT", 77, 88], ["Waltham, MA)", "TREATMENT", 116, 128], ["proteinase inhibitor cocktail", "TREATMENT", 148, 177], ["phosphatase inhibitor cocktail", "TREATMENT", 222, 252], ["whole tissue", "OBSERVATION_MODIFIER", 21, 33]]], ["The solubilized tissue, dECM powder, and pepsin-digested ECM solution were mixed 1:1 with 2\u00d7 sample buffer and separated on 5% and 10% SDS-PAGE gels.", [["tissue", "ANATOMY", 16, 22], ["ECM", "ANATOMY", 57, 60], ["tissue", "TISSUE", 16, 22], ["dECM", "SIMPLE_CHEMICAL", 24, 28], ["pepsin", "GENE_OR_GENE_PRODUCT", 41, 47], ["pepsin", "PROTEIN", 41, 47], ["The solubilized tissue, dECM powder", "TREATMENT", 0, 35], ["pepsin-digested ECM solution", "TREATMENT", 41, 69], ["2\u00d7 sample buffer", "TREATMENT", 90, 106]]], ["The gels were stained with Coomassie brilliant blue for 1 h and destained with 50% methanol, 10% acetic acid.", [["Coomassie brilliant blue", "CHEMICAL", 27, 51], ["methanol", "CHEMICAL", 83, 91], ["acetic acid", "CHEMICAL", 97, 108], ["Coomassie brilliant blue", "CHEMICAL", 27, 51], ["methanol", "CHEMICAL", 83, 91], ["acetic acid", "CHEMICAL", 97, 108], ["Coomassie", "SIMPLE_CHEMICAL", 27, 36], ["methanol", "SIMPLE_CHEMICAL", 83, 91], ["acetic acid", "SIMPLE_CHEMICAL", 97, 108], ["Coomassie brilliant blue", "SPECIES", 27, 51], ["Coomassie brilliant blue", "TREATMENT", 27, 51], ["50% methanol", "TREATMENT", 79, 91], ["10% acetic acid", "TREATMENT", 93, 108]]], ["Images of the stained gels were subsequently digitized.Mechanical properties. ::: ::: MATERIALS AND METHODSFresh tissue (control n = 4, COPD GOLD IV n = 5, or IPF n = 3) and lung dECM hydrogels from control, COPD GOLD IV, and IPF were subjected to stress relaxation testing with a low-load compression tester (LLCT) at RT (Fig. 1C), as described previously (24).", [["METHODSFresh tissue", "ANATOMY", 100, 119], ["lung", "ANATOMY", 174, 178], ["COPD", "DISEASE", 136, 140], ["IPF", "DISEASE", 159, 162], ["COPD", "DISEASE", 208, 212], ["IPF", "DISEASE", 226, 229], ["METHODSFresh tissue", "TISSUE", 100, 119], ["lung", "ORGAN", 174, 178], ["the stained gels", "TEST", 10, 26], ["METHODSFresh tissue (control n", "TREATMENT", 100, 130], ["COPD GOLD IV n", "TREATMENT", 136, 150], ["IPF n", "TREATMENT", 159, 164], ["lung dECM hydrogels", "TREATMENT", 174, 193], ["COPD GOLD IV", "PROBLEM", 208, 220], ["IPF", "PROBLEM", 226, 229], ["stress relaxation testing", "TEST", 248, 273], ["a low-load compression tester", "TREATMENT", 279, 308], ["lung", "ANATOMY", 174, 178], ["COPD", "OBSERVATION", 208, 212], ["IPF", "OBSERVATION", 226, 229]]], ["The LabVIEW 7.1 program was used for the LLCT load cell and linear positioning for control and data acquisition.", [["cell", "ANATOMY", 51, 55], ["cell", "CELL", 51, 55], ["The LabVIEW", "TEST", 0, 11], ["the LLCT load cell", "TREATMENT", 37, 55], ["data acquisition", "TEST", 95, 111]]], ["The resolution in position, load, and time determination was 0.1 mm, 2 mg, and 25 ms, respectively, and the velocity of motion was controlled in feedback mode.", [["resolution", "OBSERVATION_MODIFIER", 4, 14], ["position", "OBSERVATION_MODIFIER", 18, 26]]], ["The top plate moved downward (5 \u00b5m/s) until it experienced a counterforce of 10\u22124 N. Samples were deformed by 20% of their original thickness (strain \u03b5 = 0.2) at a deformation speed of 20%/s (strain rate \u03b5\u0307 = 0.2 s\u22121).", [["The top plate", "TEST", 0, 13], ["a deformation speed", "TEST", 162, 181], ["strain rate", "TEST", 192, 203], ["top", "OBSERVATION_MODIFIER", 4, 7], ["plate", "OBSERVATION_MODIFIER", 8, 13]]], ["The diameter of the indentation probe was 2.5 mm.", [["diameter", "OBSERVATION_MODIFIER", 4, 12], ["indentation", "OBSERVATION_MODIFIER", 20, 31], ["2.5 mm", "OBSERVATION_MODIFIER", 42, 48]]], ["The deformation was held constant for 200 s and the required stress monitored.", [["The deformation", "PROBLEM", 0, 15], ["deformation", "OBSERVATION", 4, 15]]], ["During compression, the required stress was plotted against the strain.", [["compression", "TREATMENT", 7, 18], ["the strain", "PROBLEM", 60, 70], ["compression", "OBSERVATION", 7, 18]]], ["In this plot, a linear increase in stress as a function of strain was observed between a strain of 0.04 and 0.1; the slope of the line fit to this region was taken as stiffness (Young\u2019s modulus).", [["a linear increase in stress", "PROBLEM", 14, 41], ["strain", "PROBLEM", 59, 65], ["the line fit", "TREATMENT", 126, 138], ["stiffness", "PROBLEM", 167, 176], ["linear", "OBSERVATION_MODIFIER", 16, 22], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["stress", "OBSERVATION", 35, 41], ["line fit", "OBSERVATION", 130, 138]]], ["Since the stiffness of the viscoelastic gel depends on the strain rate, values reported here are valid only at a strain rate of 0.2 s\u22121.Mechanical properties. ::: ::: MATERIALS AND METHODSStress relaxation, the required stress to maintain a constant strain of 0.2, continuously decreases with time, which is a clear indication of the viscoelastic nature of materials.", [["the viscoelastic gel", "TREATMENT", 23, 43], ["the strain rate", "TEST", 55, 70], ["a strain rate", "TEST", 111, 124], ["METHODSStress relaxation", "TREATMENT", 181, 205], ["a constant strain", "PROBLEM", 239, 256], ["stiffness", "OBSERVATION_MODIFIER", 10, 19]]], ["The shape of the stress relaxation curve was mathematically modeled with a generalized Maxwell model (2) (Fig. 1C).", [["the stress relaxation curve", "TEST", 13, 40], ["a generalized Maxwell model", "TEST", 73, 100], ["shape", "OBSERVATION_MODIFIER", 4, 9], ["stress relaxation", "OBSERVATION", 17, 34]]], ["The continuously changing stress [\u03c3(t)] was converted into continuously changing stiffness [E(t)] by dividing with the constant strain of 0.2.", [["the constant strain", "TEST", 115, 134]]], ["E(t) was fitted to Eq.", [["E(t)", "DNA", 0, 4]]], ["2 provided relative importance (Ri) for each Maxwell element.(1)E(t)=E1et\u03c41+E2et\u03c42+E3et\u03c43+E4et\u03c44(2)Ri=EiE1+E2+E3+E4where i varies from 1 to 4 or from 1 to 3 when necessary.", [["E2", "CHEMICAL", 107, 109], ["Maxwell element", "DNA", 45, 60], ["EiE1", "PROTEIN", 102, 106], ["E2", "PROTEIN", 107, 109], ["E3", "PROTEIN", 110, 112], ["E4", "PROTEIN", 113, 115], ["E1et", "TEST", 69, 73], ["\u03c4", "TEST", 73, 74], ["E2et", "TEST", 76, 80], ["\u03c4", "TEST", 80, 81], ["E3et", "TEST", 83, 87], ["\u03c4", "TEST", 87, 88], ["E4et", "TEST", 90, 94], ["\u03c4", "TEST", 94, 95], ["Ri", "TEST", 99, 101], ["EiE1", "TEST", 102, 106], ["E2", "TEST", 107, 109], ["E3", "TEST", 110, 112], ["E4", "TEST", 113, 115], ["varies", "TEST", 123, 129], ["E2", "ANATOMY_MODIFIER", 107, 109], ["E3", "ANATOMY_MODIFIER", 110, 112], ["+E4", "ANATOMY_MODIFIER", 112, 115]]], ["The optimal number of Maxwell elements was determined with the chi-square function expressed by Eq.", [["Maxwell elements", "DNA", 22, 38], ["Maxwell elements", "OBSERVATION", 22, 38]]], ["3 (typically 3 or 4) and visually matching the modeled stress relaxation curve to the measured curve (Fig. 1C).(3)\u03c72=\u2211j=0200Ej\u2212Etj\u03c3jwhere j varies from 0 to 200 s, Ej is the experimentally measured value at time j, E(tj) is the fit values at time j calculated with Eq.", [["the modeled stress relaxation curve", "PROBLEM", 43, 78], ["Ej", "ANATOMY", 124, 126], ["Ej", "ANATOMY", 164, 166]]], ["1, and \u03c3j is the standard error that the LLCT makes because of inherent errors in position, time, and load measurements.Statistical analyses. ::: ::: MATERIALS AND METHODSMechanical characterization measurements were obtained from three locations per tissue piece, and for each hydrogel four replicate gels were made and measured on three separate occasions.", [["tissue", "ANATOMY", 251, 257], ["tissue", "TISSUE", 251, 257], ["inherent errors in position", "PROBLEM", 63, 90], ["load measurements", "TEST", 102, 119], ["METHODSMechanical characterization measurements", "TEST", 164, 211], ["each hydrogel four replicate gels", "TREATMENT", 273, 306], ["position", "OBSERVATION_MODIFIER", 82, 90]]], ["Statistical analyzes were performed with Prism 7 software (GraphPad, San Diego, CA).", [["Statistical analyzes", "TEST", 0, 20], ["Prism", "TEST", 41, 46]]], ["Differences between tissue and corresponding ECM hydrogels were tested by Mann\u2013Whitney U test and considered significant when P < 0.05.Protein distribution of whole, decellularized, and pepsin-digested lung tissue. ::: ::: RESULTSThe banding pattern did not differ between control, COPD GOLD IV, and IPF whole tissue (Fig. 2A).", [["tissue", "ANATOMY", 20, 26], ["ECM", "ANATOMY", 45, 48], ["lung tissue", "ANATOMY", 202, 213], ["IPF whole tissue", "ANATOMY", 300, 316], ["COPD", "DISEASE", 282, 286], ["IPF", "DISEASE", 300, 303], ["tissue", "TISSUE", 20, 26], ["ECM", "CELLULAR_COMPONENT", 45, 48], ["decellularized", "TISSUE", 166, 180], ["pepsin", "GENE_OR_GENE_PRODUCT", 186, 192], ["lung tissue", "TISSUE", 202, 213], ["tissue", "TISSUE", 310, 316], ["Differences between tissue and corresponding ECM hydrogels", "PROBLEM", 0, 58], ["Mann\u2013Whitney U test", "TEST", 74, 93], ["Protein distribution", "TEST", 135, 155], ["COPD GOLD IV", "TREATMENT", 282, 294], ["IPF whole tissue", "PROBLEM", 300, 316], ["lung", "ANATOMY", 202, 206], ["tissue", "OBSERVATION", 207, 213], ["COPD", "OBSERVATION", 282, 286], ["IPF", "OBSERVATION", 300, 303]]], ["Decellularized IPF powder had the highest protein content, whereas decellularized control and COPD GOLD IV protein contents were hardly detectable by Coomassie staining.", [["Coomassie", "CHEMICAL", 150, 159], ["Coomassie", "SIMPLE_CHEMICAL", 150, 159], ["Decellularized IPF powder", "TREATMENT", 0, 25], ["the highest protein content", "PROBLEM", 30, 57], ["decellularized control", "TREATMENT", 67, 89], ["COPD GOLD IV protein contents", "PROBLEM", 94, 123], ["IPF", "OBSERVATION", 15, 18]]], ["The banding pattern for pepsin-digested dECM was similar for all tissue types.Generation of human lung ECM hydrogels. ::: ::: RESULTSPepsin digestion times were varied from 8 to 72 h (data not shown), and after 72 h of digestion, with the addition of NaOH and 10\u00d7 PBS, a stable hydrogel was generated from control, COPD GOLD IV, and IPF pepsin-digested dECM.Human lung ECM hydrogel fiber organization. ::: ::: RESULTSH&E staining showed a difference in fiber organization between the ECM hydrogels (Fig. 2B).", [["tissue", "ANATOMY", 65, 71], ["lung ECM", "ANATOMY", 98, 106], ["lung ECM", "ANATOMY", 364, 372], ["fiber", "ANATOMY", 453, 458], ["ECM", "ANATOMY", 484, 487], ["NaOH", "CHEMICAL", 251, 255], ["NaOH", "CHEMICAL", 251, 255], ["pepsin", "GENE_OR_GENE_PRODUCT", 24, 30], ["dECM", "GENE_OR_GENE_PRODUCT", 40, 44], ["tissue", "TISSUE", 65, 71], ["human", "ORGANISM", 92, 97], ["lung ECM", "MULTI-TISSUE_STRUCTURE", 98, 106], ["NaOH", "SIMPLE_CHEMICAL", 251, 255], ["pepsin", "GENE_OR_GENE_PRODUCT", 337, 343], ["Human", "ORGANISM", 358, 363], ["lung ECM", "TISSUE", 364, 372], ["fiber", "TISSUE", 453, 458], ["ECM", "CELLULAR_COMPONENT", 484, 487], ["pepsin", "PROTEIN", 24, 30], ["digested dECM", "PROTEIN", 31, 44], ["human", "SPECIES", 92, 97], ["Human", "SPECIES", 358, 363], ["human", "SPECIES", 92, 97], ["Human", "SPECIES", 358, 363], ["pepsin-digested dECM", "PROBLEM", 24, 44], ["RESULTSPepsin digestion", "TEST", 126, 149], ["NaOH", "TREATMENT", 251, 255], ["PBS", "TREATMENT", 264, 267], ["a stable hydrogel", "TREATMENT", 269, 286], ["COPD GOLD IV", "TREATMENT", 315, 327], ["IPF pepsin", "TREATMENT", 333, 343], ["Human lung ECM hydrogel fiber organization", "TREATMENT", 358, 400], ["RESULTSH&E staining", "TEST", 410, 429], ["a difference in fiber organization", "PROBLEM", 437, 471], ["the ECM hydrogels", "TREATMENT", 480, 497], ["banding", "OBSERVATION", 4, 11], ["all tissue", "OBSERVATION_MODIFIER", 61, 71], ["human", "ANATOMY_MODIFIER", 92, 97], ["lung", "ANATOMY", 98, 102], ["ECM hydrogels", "OBSERVATION", 103, 116], ["stable", "OBSERVATION_MODIFIER", 271, 277], ["lung", "ANATOMY", 364, 368], ["ECM hydrogel", "OBSERVATION", 369, 381], ["fiber organization", "OBSERVATION", 382, 400], ["fiber organization", "OBSERVATION", 453, 471], ["ECM hydrogels", "OBSERVATION", 484, 497]]], ["The IPF ECM hydrogel fibers appeared to form a dense network structure, whereas control and COPD GOLD IV ECM hydrogels formed more open, loose structures.Stiffness of ECM hydrogels resembles native tissue. ::: ::: RESULTSThe stiffness of lung tissue displayed a degree of heterogeneity (Fig. 3A), which was most apparent in IPF tissue, ranging from 9 kPa to 38.5 kPa.", [["IPF ECM hydrogel fibers", "ANATOMY", 4, 27], ["ECM", "ANATOMY", 167, 170], ["tissue", "ANATOMY", 198, 204], ["lung tissue", "ANATOMY", 238, 249], ["IPF tissue", "ANATOMY", 324, 334], ["IPF", "DISEASE", 324, 327], ["ECM", "CELLULAR_COMPONENT", 167, 170], ["tissue", "TISSUE", 198, 204], ["lung tissue", "TISSUE", 238, 249], ["IPF tissue", "TISSUE", 324, 334], ["The IPF ECM hydrogel fibers", "TREATMENT", 0, 27], ["a dense network structure", "PROBLEM", 45, 70], ["COPD GOLD IV ECM hydrogels", "TREATMENT", 92, 118], ["Stiffness of ECM hydrogels", "PROBLEM", 154, 180], ["lung tissue", "PROBLEM", 238, 249], ["heterogeneity (Fig. 3A", "PROBLEM", 272, 294], ["IPF tissue", "PROBLEM", 324, 334], ["IPF", "OBSERVATION", 4, 7], ["hydrogel fibers", "OBSERVATION", 12, 27], ["dense", "OBSERVATION_MODIFIER", 47, 52], ["network structure", "OBSERVATION", 53, 70], ["COPD", "ANATOMY", 92, 96], ["IV ECM", "OBSERVATION_MODIFIER", 102, 108], ["hydrogels formed", "OBSERVATION", 109, 125], ["loose structures", "OBSERVATION", 137, 153], ["ECM hydrogels", "OBSERVATION", 167, 180], ["native tissue", "OBSERVATION", 191, 204], ["lung", "ANATOMY", 238, 242], ["tissue", "OBSERVATION", 243, 249], ["degree", "OBSERVATION_MODIFIER", 262, 268], ["heterogeneity", "OBSERVATION", 272, 285], ["most apparent", "UNCERTAINTY", 307, 320], ["IPF tissue", "OBSERVATION", 324, 334]]], ["Average IPF tissue stiffness (18.9 \u00b1 11.1 kPa) was higher than both control (3.7 \u00b1 1.3 kPa) (P < 0.05) and COPD GOLD IV (2.9 \u00b1 0.8 kPa) (P < 0.05) lung tissue. dECM hydrogel stiffness followed a similar pattern, with average IPF dECM hydrogel stiffness (6.8 \u00b1 2.8 kPa) also being greater than control (1.1 \u00b1 0.2 kPa) (P < 0.05) and COPD GOLD IV (1.5 \u00b1 0.4 kPa) (P < 0.05).", [["IPF tissue", "ANATOMY", 8, 18], ["lung tissue", "ANATOMY", 147, 158], ["IPF", "DISEASE", 8, 11], ["IPF", "DISEASE", 225, 228], ["COPD", "DISEASE", 332, 336], ["IPF tissue", "TISSUE", 8, 18], ["lung tissue", "TISSUE", 147, 158], ["Average IPF tissue stiffness", "TEST", 0, 28], ["kPa", "TEST", 42, 45], ["kPa", "TEST", 87, 90], ["P", "TEST", 93, 94], ["COPD GOLD IV", "TREATMENT", 107, 119], ["lung tissue", "PROBLEM", 147, 158], ["dECM hydrogel stiffness", "PROBLEM", 160, 183], ["average IPF dECM hydrogel stiffness", "PROBLEM", 217, 252], ["COPD GOLD IV", "TREATMENT", 332, 344], ["IPF tissue", "OBSERVATION_MODIFIER", 8, 18], ["stiffness", "OBSERVATION_MODIFIER", 19, 28], ["COPD", "OBSERVATION", 107, 111], ["lung", "ANATOMY", 147, 151], ["tissue", "OBSERVATION", 152, 158], ["hydrogel stiffness", "OBSERVATION", 165, 183]]], ["Each dECM hydrogel had a reduced stiffness compared with its intact tissue counterpart (P < 0.05).Total relaxation of ECM hydrogels does not mimic native tissue. ::: ::: RESULTSAfter initial compression of 20%, the dissipation of the force was monitored over 200 s (Fig. 3B).", [["tissue", "ANATOMY", 68, 74], ["ECM", "ANATOMY", 118, 121], ["tissue", "ANATOMY", 154, 160], ["tissue", "TISSUE", 68, 74], ["ECM", "CELLULAR_COMPONENT", 118, 121], ["tissue", "TISSUE", 154, 160], ["Each dECM hydrogel", "PROBLEM", 0, 18], ["a reduced stiffness", "PROBLEM", 23, 42], ["Total relaxation of ECM hydrogels", "TREATMENT", 98, 131], ["initial compression", "TEST", 183, 202], ["reduced", "OBSERVATION_MODIFIER", 25, 32], ["stiffness", "OBSERVATION", 33, 42], ["intact tissue", "OBSERVATION_MODIFIER", 61, 74], ["ECM hydrogels", "OBSERVATION", 118, 131], ["native tissue", "OBSERVATION", 147, 160], ["compression", "OBSERVATION", 191, 202]]], ["The total stress relaxation of IPF lung tissue was lower (72.1 \u00b1 13.1 kPa) than control lung tissue (88.7 \u00b1 10.4 kPa) (P < 0.05), which was similar to relaxation of COPD GOLD IV (87.0 \u00b1 7.9 kPa).", [["IPF lung tissue", "ANATOMY", 31, 46], ["lung tissue", "ANATOMY", 88, 99], ["IPF", "DISEASE", 31, 34], ["COPD", "DISEASE", 165, 169], ["IPF lung tissue", "TISSUE", 31, 46], ["lung tissue", "TISSUE", 88, 99], ["The total stress relaxation", "TEST", 0, 27], ["IPF lung tissue", "TEST", 31, 46], ["kPa)", "TEST", 70, 74], ["control lung tissue", "TEST", 80, 99], ["kPa", "TEST", 113, 116], ["P", "TEST", 119, 120], ["COPD GOLD IV", "TREATMENT", 165, 177], ["total", "OBSERVATION_MODIFIER", 4, 9], ["stress relaxation", "OBSERVATION", 10, 27], ["IPF", "OBSERVATION", 31, 34], ["lung tissue", "ANATOMY", 35, 46], ["lung", "ANATOMY", 88, 92], ["COPD", "OBSERVATION", 165, 169]]], ["The total relaxation percentage was 100% for all hydrogels except for IPF lung dECM hydrogels (99.3 \u00b1 0.8%).", [["lung", "ANATOMY", 74, 78], ["IPF", "DISEASE", 70, 73], ["The total relaxation percentage", "TEST", 0, 31], ["all hydrogels", "TREATMENT", 45, 58], ["IPF lung dECM hydrogels", "PROBLEM", 70, 93], ["total", "OBSERVATION_MODIFIER", 4, 9], ["lung", "ANATOMY", 74, 78]]], ["The total relaxation for all dECM hydrogels was higher (P < 0.05) than that of all corresponding lung tissues.Maxwell element relaxation time constants similar between hydrogels and tissue. ::: ::: RESULTSThe relaxation time constants (\u03c4) of all elements for tissue were longer than those of dECM hydrogels (P < 0.05) (Fig. 3C).", [["lung tissues", "ANATOMY", 97, 109], ["tissue", "ANATOMY", 182, 188], ["tissue", "ANATOMY", 259, 265], ["lung tissues", "TISSUE", 97, 109], ["tissue", "TISSUE", 182, 188], ["tissue", "TISSUE", 259, 265], ["The total relaxation", "TREATMENT", 0, 20], ["all dECM hydrogels", "TREATMENT", 25, 43], ["Maxwell element relaxation time constants", "PROBLEM", 110, 151], ["RESULTSThe relaxation time constants", "TEST", 198, 234], ["dECM hydrogels", "TREATMENT", 292, 306], ["total", "OBSERVATION_MODIFIER", 4, 9], ["relaxation", "OBSERVATION_MODIFIER", 10, 20], ["higher", "OBSERVATION_MODIFIER", 48, 54], ["lung tissues", "ANATOMY", 97, 109], ["element relaxation", "OBSERVATION", 118, 136]]], ["All lung tissues and IPF dECM hydrogels required 4 Maxwell elements to describe the total relaxation seen in Fig. 3B, whereas control and COPD GOLD IV dECM hydrogels needed only 3 elements.", [["lung tissues", "ANATOMY", 4, 16], ["COPD", "DISEASE", 138, 142], ["lung tissues", "TISSUE", 4, 16], ["Maxwell elements", "DNA", 51, 67], ["IPF dECM hydrogels", "TREATMENT", 21, 39], ["the total relaxation", "TREATMENT", 80, 100], ["COPD GOLD IV dECM hydrogels", "TREATMENT", 138, 165], ["lung tissues", "ANATOMY", 4, 16], ["IPF", "OBSERVATION", 21, 24], ["COPD", "OBSERVATION", 138, 142]]], ["The \u03c4 of control tissue Maxwell lasted longer than control ECM gels (and required 1 additional element).", [["tissue", "ANATOMY", 17, 23], ["ECM", "ANATOMY", 59, 62], ["tissue", "TISSUE", 17, 23]]], ["COPD GOLD IV tissue also required 1 additional element, and each individual element lasted longer than the equivalent element in COPD GOLD IV dECM hydrogel.", [["tissue", "ANATOMY", 13, 19], ["COPD", "DISEASE", 0, 4], ["COPD", "DISEASE", 129, 133], ["tissue", "TISSUE", 13, 19], ["COPD GOLD IV tissue", "PROBLEM", 0, 19], ["1 additional element", "TREATMENT", 34, 54], ["COPD GOLD IV dECM hydrogel", "TREATMENT", 129, 155], ["IV tissue", "OBSERVATION_MODIFIER", 10, 19], ["1 additional element", "OBSERVATION_MODIFIER", 34, 54], ["COPD", "OBSERVATION", 129, 133]]], ["Finally, IPF tissue and IPF dECM hydrogel both were described by 4 elements, with the IPF tissue elements lasting longer.Maxwell elements\u2019 relative importance to relaxation of ECM hydrogels and tissue. ::: ::: RESULTSThe Ri of the 4th Maxwell element described the largest proportion of the relaxation in native lung tissues (control 28.7%, COPD GOLD IV 31.2%), but especially in IPF tissue (44.6%) (Fig. 3D).", [["IPF tissue", "ANATOMY", 9, 19], ["tissue", "ANATOMY", 90, 96], ["ECM", "ANATOMY", 176, 179], ["tissue", "ANATOMY", 194, 200], ["lung tissues", "ANATOMY", 312, 324], ["IPF tissue", "ANATOMY", 380, 390], ["IPF", "DISEASE", 9, 12], ["IPF", "DISEASE", 86, 89], ["IPF", "DISEASE", 380, 383], ["IPF tissue", "TISSUE", 9, 19], ["IPF tissue", "TISSUE", 86, 96], ["ECM hydrogels", "CELLULAR_COMPONENT", 176, 189], ["tissue", "TISSUE", 194, 200], ["lung tissues", "TISSUE", 312, 324], ["IPF tissue", "TISSUE", 380, 390], ["IPF tissue elements", "DNA", 86, 105], ["Maxwell elements", "DNA", 121, 137], ["Ri", "DNA", 221, 223], ["4th Maxwell element", "DNA", 231, 250], ["IPF tissue", "PROBLEM", 9, 19], ["IPF dECM hydrogel", "TREATMENT", 24, 41], ["the IPF tissue elements", "PROBLEM", 82, 105], ["relaxation of ECM hydrogels", "TREATMENT", 162, 189], ["COPD GOLD IV", "TEST", 341, 353], ["IPF tissue", "TEST", 380, 390], ["IPF tissue", "OBSERVATION", 9, 19], ["IPF", "OBSERVATION", 24, 27], ["IPF tissue", "OBSERVATION", 86, 96], ["ECM hydrogels", "OBSERVATION", 176, 189], ["largest", "OBSERVATION_MODIFIER", 265, 272], ["proportion", "OBSERVATION_MODIFIER", 273, 283], ["relaxation", "OBSERVATION", 291, 301], ["native", "ANATOMY_MODIFIER", 305, 311], ["lung tissues", "ANATOMY", 312, 324], ["IPF tissue", "ANATOMY", 380, 390]]], ["In contrast, the Ri of the 1st Maxwell element contributed the most to the relaxation in the dECM hydrogels from all groups (44.6% for control, 44.8% for COPD GOLD IV, and 49.7% for IPF).", [["COPD", "DISEASE", 154, 158], ["IPF", "DISEASE", 182, 185], ["Ri", "DNA", 17, 19], ["1st Maxwell element", "DNA", 27, 46], ["the dECM hydrogels", "TREATMENT", 89, 107], ["COPD GOLD IV", "TREATMENT", 154, 166], ["IPF", "PROBLEM", 182, 185], ["relaxation", "OBSERVATION", 75, 85]]], ["Within the IPF dECM hydrogels, a 4th element with a low Ri (10.5%) also contributed to the relaxation.", [["IPF", "DISEASE", 11, 14], ["a low Ri", "PROBLEM", 50, 58], ["IPF", "OBSERVATION", 11, 14], ["low Ri", "OBSERVATION_MODIFIER", 52, 58], ["relaxation", "OBSERVATION_MODIFIER", 91, 101]]], ["The 2nd and 3rd element contributions were higher in all hydrogels compared with tissue (P < 0.05), with the exception of the contribution of the 3rd element in IPF tissue and hydrogel, which did not differ.DISCUSSIONThis study shows, for the first time, that human lung tissue can be decellularized, reduced to a powder, and reconstituted as a hydrogel.", [["tissue", "ANATOMY", 81, 87], ["IPF tissue", "ANATOMY", 161, 171], ["lung tissue", "ANATOMY", 266, 277], ["IPF", "DISEASE", 161, 164], ["tissue", "TISSUE", 81, 87], ["IPF tissue", "TISSUE", 161, 171], ["human", "ORGANISM", 260, 265], ["lung tissue", "TISSUE", 266, 277], ["2nd and 3rd element", "DNA", 4, 23], ["3rd element", "DNA", 146, 157], ["human", "SPECIES", 260, 265], ["human", "SPECIES", 260, 265], ["The 2nd and 3rd element contributions", "PROBLEM", 0, 37], ["the 3rd element in IPF tissue", "PROBLEM", 142, 171], ["hydrogel", "TREATMENT", 176, 184], ["DISCUSSIONThis study", "TEST", 207, 227], ["human lung tissue", "PROBLEM", 260, 277], ["a powder", "TREATMENT", 312, 320], ["a hydrogel", "TREATMENT", 343, 353], ["higher", "OBSERVATION_MODIFIER", 43, 49], ["all hydrogels", "OBSERVATION_MODIFIER", 53, 66], ["3rd element", "OBSERVATION_MODIFIER", 146, 157], ["IPF tissue", "OBSERVATION", 161, 171], ["lung", "ANATOMY", 266, 270], ["tissue", "OBSERVATION", 271, 277]]], ["Furthermore, this can be accomplished with control, COPD GOLD IV, and IPF lung tissues, generating a 3D hydrogel that reflects the stiffness of native tissue.DISCUSSIONThe protein contents detected by SDS-PAGE in native lung tissue, decellularized lung, and pepsin-digested lung dECM were consistent, with the exception of the dECM IPF, which was greater.", [["IPF lung tissues", "ANATOMY", 70, 86], ["tissue", "ANATOMY", 151, 157], ["lung tissue", "ANATOMY", 220, 231], ["lung", "ANATOMY", 248, 252], ["lung", "ANATOMY", 274, 278], ["IPF", "DISEASE", 70, 73], ["IPF", "DISEASE", 332, 335], ["IPF lung tissues", "TISSUE", 70, 86], ["tissue", "TISSUE", 151, 157], ["lung tissue", "TISSUE", 220, 231], ["lung", "ORGAN", 248, 252], ["pepsin", "GENE_OR_GENE_PRODUCT", 258, 264], ["lung", "ORGAN", 274, 278], ["pepsin", "PROTEIN", 258, 264], ["COPD GOLD IV, and IPF lung tissues", "PROBLEM", 52, 86], ["a 3D hydrogel", "TREATMENT", 99, 112], ["the stiffness of native tissue", "PROBLEM", 127, 157], ["protein contents", "TEST", 172, 188], ["SDS", "TEST", 201, 204], ["pepsin", "TEST", 258, 264], ["digested lung dECM", "PROBLEM", 265, 283], ["the dECM IPF", "PROBLEM", 323, 335], ["IPF", "ANATOMY", 70, 73], ["lung tissues", "ANATOMY", 74, 86], ["stiffness", "OBSERVATION_MODIFIER", 131, 140], ["native tissue", "OBSERVATION", 144, 157], ["lung tissue", "ANATOMY", 220, 231], ["decellularized", "OBSERVATION", 233, 247], ["lung", "ANATOMY", 248, 252], ["lung", "ANATOMY", 274, 278], ["dECM", "OBSERVATION", 279, 283], ["dECM", "OBSERVATION_MODIFIER", 327, 331], ["IPF", "OBSERVATION", 332, 335], ["greater", "OBSERVATION_MODIFIER", 347, 354]]], ["The native tissues contained total cellular and extracellular components, and given the equal loading of protein, the expected similarity in protein banding patterns was observed between control, COPD GOLD IV, and IPF.", [["tissues", "ANATOMY", 11, 18], ["cellular", "ANATOMY", 35, 43], ["extracellular components", "ANATOMY", 48, 72], ["COPD", "DISEASE", 196, 200], ["IPF", "DISEASE", 214, 217], ["tissues", "TISSUE", 11, 18], ["cellular", "CELL", 35, 43], ["extracellular components", "CELLULAR_COMPONENT", 48, 72], ["total cellular and extracellular components", "PROBLEM", 29, 72], ["protein banding patterns", "TREATMENT", 141, 165], ["COPD GOLD IV", "PROBLEM", 196, 208], ["IPF", "PROBLEM", 214, 217], ["native tissues", "ANATOMY", 4, 18], ["total", "OBSERVATION_MODIFIER", 29, 34], ["cellular", "OBSERVATION_MODIFIER", 35, 43], ["extracellular", "OBSERVATION_MODIFIER", 48, 61], ["components", "OBSERVATION_MODIFIER", 62, 72], ["protein banding", "OBSERVATION", 141, 156], ["COPD", "OBSERVATION", 196, 200], ["IPF", "OBSERVATION", 214, 217]]], ["Of the different dECM powders IPF yielded the highest protein content; however, it was not clear if this reflected a difference in protein yield or differential solubilization with RIPA buffer that may have been favorable to the proteins abundant in IPF tissue.", [["IPF tissue", "ANATOMY", 250, 260], ["IPF", "DISEASE", 30, 33], ["IPF", "DISEASE", 250, 253], ["IPF tissue", "TISSUE", 250, 260], ["the different dECM powders IPF", "TREATMENT", 3, 33], ["the highest protein content", "PROBLEM", 42, 69], ["a difference in protein yield", "PROBLEM", 115, 144], ["differential solubilization", "TREATMENT", 148, 175], ["RIPA buffer", "TREATMENT", 181, 192], ["IPF tissue", "PROBLEM", 250, 260], ["powders", "OBSERVATION_MODIFIER", 22, 29], ["IPF", "OBSERVATION", 30, 33], ["highest protein content", "OBSERVATION", 46, 69], ["IPF tissue", "OBSERVATION", 250, 260]]], ["Favorably, the protein yield and banding distribution after pepsin digestion were similar between the different groups.DISCUSSIONThe 72 h pepsin digestion required for generating human lung dECM hydrogels was substantially longer than that described for decellularized tissue ECMs from other organs (10).", [["lung", "ANATOMY", 185, 189], ["tissue ECMs", "ANATOMY", 269, 280], ["organs", "ANATOMY", 292, 298], ["pepsin", "GENE_OR_GENE_PRODUCT", 60, 66], ["pepsin", "GENE_OR_GENE_PRODUCT", 138, 144], ["human", "ORGANISM", 179, 184], ["lung", "ORGAN", 185, 189], ["tissue ECMs", "TISSUE", 269, 280], ["organs", "ORGAN", 292, 298], ["pepsin", "PROTEIN", 60, 66], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["the protein yield", "PROBLEM", 11, 28], ["banding distribution", "PROBLEM", 33, 53], ["pepsin digestion", "TREATMENT", 60, 76], ["pepsin digestion", "TREATMENT", 138, 154], ["generating human lung dECM hydrogels", "TREATMENT", 168, 204], ["decellularized tissue ECMs", "PROBLEM", 254, 280], ["banding", "OBSERVATION_MODIFIER", 33, 40], ["distribution", "OBSERVATION_MODIFIER", 41, 53], ["lung", "ANATOMY", 185, 189]]], ["In concert with our findings, Pouliot and colleagues recently described decellularization and gelation of porcine lung using a pepsin digestion of 42 h (22).", [["lung", "ANATOMY", 114, 118], ["porcine", "ORGANISM", 106, 113], ["lung", "ORGAN", 114, 118], ["pepsin", "GENE_OR_GENE_PRODUCT", 127, 133], ["porcine", "SPECIES", 106, 113], ["porcine", "SPECIES", 106, 113], ["gelation of porcine lung", "TREATMENT", 94, 118], ["a pepsin digestion", "TREATMENT", 125, 143], ["lung", "ANATOMY", 114, 118]]], ["This difference in required digestion times may reflect the complexity of the lung matrix.DISCUSSIONThe measured stiffness of the control and IPF dECM hydrogels resembled the stiffness previously reported in the literature for whole and decellularized human lung samples in these categories (3).", [["lung matrix", "ANATOMY", 78, 89], ["lung samples", "ANATOMY", 258, 270], ["lung matrix", "MULTI-TISSUE_STRUCTURE", 78, 89], ["human", "ORGANISM", 252, 257], ["lung samples", "CANCER", 258, 270], ["human", "SPECIES", 252, 257], ["human", "SPECIES", 252, 257], ["the lung matrix", "PROBLEM", 74, 89], ["The measured stiffness of the control and IPF dECM hydrogels", "PROBLEM", 100, 160], ["the stiffness", "PROBLEM", 171, 184], ["lung", "ANATOMY", 78, 82], ["matrix", "ANATOMY_MODIFIER", 83, 89], ["stiffness", "OBSERVATION_MODIFIER", 113, 122], ["IPF", "ANATOMY", 142, 145], ["dECM hydrogels", "OBSERVATION", 146, 160], ["stiffness", "OBSERVATION_MODIFIER", 175, 184], ["lung", "ANATOMY", 258, 262]]], ["Prior rheological data available on the stiffness of COPD GOLD IV lungs in literature are limited (16, 27).", [["lungs", "ANATOMY", 66, 71], ["COPD", "DISEASE", 53, 57], ["lungs", "ORGAN", 66, 71], ["Prior rheological data", "TEST", 0, 22], ["COPD GOLD IV lungs in literature", "PROBLEM", 53, 85], ["COPD", "OBSERVATION", 53, 57], ["lungs", "ANATOMY", 66, 71]]], ["Here, the average global stiffness of COPD GOLD IV tissue was similar to that of control lung tissue.DISCUSSIONThe dECM hydrogels relaxed completely after compression, whereas tissues did not, irrespective of the underlying disease.", [["COPD GOLD IV tissue", "ANATOMY", 38, 57], ["lung tissue", "ANATOMY", 89, 100], ["tissues", "ANATOMY", 176, 183], ["COPD", "DISEASE", 38, 42], ["tissue", "TISSUE", 51, 57], ["lung tissue", "TISSUE", 89, 100], ["tissues", "TISSUE", 176, 183], ["the average global stiffness of COPD GOLD IV tissue", "PROBLEM", 6, 57], ["dECM hydrogels", "TREATMENT", 115, 129], ["compression", "TREATMENT", 155, 166], ["the underlying disease", "PROBLEM", 209, 231], ["average", "OBSERVATION_MODIFIER", 10, 17], ["global", "OBSERVATION_MODIFIER", 18, 24], ["stiffness", "OBSERVATION_MODIFIER", 25, 34], ["COPD", "OBSERVATION", 38, 42], ["IV tissue", "OBSERVATION_MODIFIER", 48, 57], ["lung", "ANATOMY", 89, 93], ["tissue", "OBSERVATION", 94, 100], ["compression", "OBSERVATION", 155, 166], ["disease", "OBSERVATION", 224, 231]]], ["The relaxation behavior of a sample is dictated, in part, by the topical arrangement of ECM in intact tissue or degree and type (e.g., ionic or covalent) of internal cross-linking in hydrogels (28, 30).", [["sample", "ANATOMY", 29, 35], ["ECM", "ANATOMY", 88, 91], ["tissue", "ANATOMY", 102, 108], ["ECM", "CELLULAR_COMPONENT", 88, 91], ["tissue", "TISSUE", 102, 108], ["ECM", "PROTEIN", 88, 91], ["a sample", "TEST", 27, 35], ["internal cross-linking in hydrogels", "TREATMENT", 157, 192], ["intact tissue", "OBSERVATION_MODIFIER", 95, 108], ["degree", "OBSERVATION_MODIFIER", 112, 118], ["internal", "ANATOMY_MODIFIER", 157, 165], ["cross-linking", "OBSERVATION", 166, 179]]], ["This may explain the higher degree of relaxation seen in the dECM hydrogels and the reduced degree of relaxation of IPF tissue compared with COPD GOLD IV and control tissue.", [["IPF tissue", "ANATOMY", 116, 126], ["tissue", "ANATOMY", 166, 172], ["IPF", "DISEASE", 116, 119], ["IPF tissue", "TISSUE", 116, 126], ["tissue", "TISSUE", 166, 172], ["the dECM hydrogels", "PROBLEM", 57, 75], ["IPF tissue", "PROBLEM", 116, 126], ["COPD GOLD IV", "TREATMENT", 141, 153], ["higher", "OBSERVATION_MODIFIER", 21, 27], ["degree", "OBSERVATION_MODIFIER", 28, 34], ["relaxation", "OBSERVATION", 38, 48], ["dECM hydrogels", "OBSERVATION", 61, 75], ["reduced", "OBSERVATION_MODIFIER", 84, 91], ["degree", "OBSERVATION_MODIFIER", 92, 98], ["relaxation", "OBSERVATION_MODIFIER", 102, 112], ["IPF tissue", "OBSERVATION", 116, 126]]], ["The absence of cells in the dECM hydrogels would mean there were no new covalent cross-links established within the hydrogels.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["cells in the dECM hydrogels", "PROBLEM", 15, 42], ["new covalent cross-links", "PROBLEM", 68, 92], ["no", "UNCERTAINTY", 65, 67], ["new", "OBSERVATION_MODIFIER", 68, 71], ["covalent", "OBSERVATION", 72, 80]]], ["The greater degree of matrix organization in the IPF tissue (26) and the stiffer fibroblasts within these tissues (14) would also contribute to the differences in stress relaxation.DISCUSSIONThe total relaxation time was longer for lung tissue than for dECM hydrogels, with each Maxwell element contributing to the increased relaxation time.", [["matrix", "ANATOMY", 22, 28], ["IPF tissue", "ANATOMY", 49, 59], ["fibroblasts", "ANATOMY", 81, 92], ["tissues", "ANATOMY", 106, 113], ["lung tissue", "ANATOMY", 232, 243], ["IPF", "DISEASE", 49, 52], ["matrix", "CELLULAR_COMPONENT", 22, 28], ["IPF tissue", "TISSUE", 49, 59], ["fibroblasts", "CELL", 81, 92], ["tissues", "TISSUE", 106, 113], ["lung tissue", "TISSUE", 232, 243], ["stiffer fibroblasts", "CELL_TYPE", 73, 92], ["Maxwell element", "DNA", 279, 294], ["matrix organization in the IPF tissue", "PROBLEM", 22, 59], ["stress relaxation", "PROBLEM", 163, 180], ["The total relaxation time", "TREATMENT", 191, 216], ["lung tissue", "PROBLEM", 232, 243], ["dECM hydrogels", "TREATMENT", 253, 267], ["the increased relaxation time", "PROBLEM", 311, 340], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["degree", "OBSERVATION_MODIFIER", 12, 18], ["matrix", "OBSERVATION_MODIFIER", 22, 28], ["organization", "OBSERVATION", 29, 41], ["IPF tissue", "ANATOMY", 49, 59], ["stiffer", "OBSERVATION_MODIFIER", 73, 80], ["fibroblasts", "OBSERVATION", 81, 92], ["tissues", "ANATOMY", 106, 113], ["stress relaxation", "OBSERVATION", 163, 180], ["lung", "ANATOMY", 232, 236], ["increased relaxation", "OBSERVATION", 315, 335]]], ["However, the patterns of relative contributions for all the elements were similar between tissue and ECM hydrogels, suggesting that the composition of the ECM in the hydrogels contributes to the relaxation capacity.", [["tissue", "ANATOMY", 90, 96], ["ECM", "ANATOMY", 101, 104], ["ECM", "ANATOMY", 155, 158], ["tissue", "TISSUE", 90, 96], ["ECM hydrogels", "CELLULAR_COMPONENT", 101, 114], ["ECM", "CELLULAR_COMPONENT", 155, 158], ["tissue and ECM hydrogels", "PROBLEM", 90, 114], ["the ECM in the hydrogels", "PROBLEM", 151, 175], ["the relaxation capacity", "PROBLEM", 191, 214], ["ECM hydrogels", "OBSERVATION", 101, 114], ["relaxation capacity", "OBSERVATION", 195, 214]]], ["Linking specific hydrogel components such as water, molecules, cells, or ECM to individual Maxwell elements remains difficult, such that currently these remain mathematical entities with no clear biological correlations as yet.", [["cells", "ANATOMY", 63, 68], ["ECM", "ANATOMY", 73, 76], ["water", "SIMPLE_CHEMICAL", 45, 50], ["cells", "CELL", 63, 68], ["ECM", "CELLULAR_COMPONENT", 73, 76], ["ECM", "PROTEIN", 73, 76], ["Maxwell elements", "DNA", 91, 107], ["specific hydrogel components", "TREATMENT", 8, 36], ["hydrogel components", "OBSERVATION", 17, 36]]], ["However, in bacterial biofilms the constituent components were attributed to Maxwell elements with regard to their contributions to viscoelastic relaxation (21).", [["biofilms", "ANATOMY", 22, 30], ["Maxwell elements", "DNA", 77, 93], ["viscoelastic relaxation", "TREATMENT", 132, 155], ["bacterial biofilms", "OBSERVATION", 12, 30], ["viscoelastic relaxation", "OBSERVATION", 132, 155]]], ["For dECM hydrogels, the first element made the greatest contribution to the relaxation sequence, possibly reflecting the major role played by the water content of dECM hydrogels and absence of cell-derived or other tissue-related cross-links.", [["cell", "ANATOMY", 193, 197], ["tissue", "ANATOMY", 215, 221], ["water", "SIMPLE_CHEMICAL", 146, 151], ["dECM", "SIMPLE_CHEMICAL", 163, 167], ["cell", "CELL", 193, 197], ["tissue", "TISSUE", 215, 221], ["dECM hydrogels", "TREATMENT", 4, 18], ["the relaxation sequence", "TEST", 72, 95], ["dECM hydrogels", "TREATMENT", 163, 177], ["possibly reflecting", "UNCERTAINTY", 97, 116]]], ["In tissue each element contributed more equally to the relaxation process, except in IPF tissue.", [["tissue", "ANATOMY", 3, 9], ["IPF tissue", "ANATOMY", 85, 95], ["IPF", "DISEASE", 85, 88], ["tissue", "TISSUE", 3, 9], ["IPF tissue", "TISSUE", 85, 95], ["IPF tissue", "PROBLEM", 85, 95], ["relaxation process", "OBSERVATION", 55, 73], ["IPF tissue", "OBSERVATION", 85, 95]]], ["The 4th, slowest, element made the largest contribution to the relaxation in IPF tissue.", [["IPF tissue", "ANATOMY", 77, 87], ["IPF", "DISEASE", 77, 80], ["IPF tissue", "TISSUE", 77, 87], ["4th, slowest, element", "DNA", 4, 25], ["the relaxation in IPF tissue", "PROBLEM", 59, 87], ["largest", "OBSERVATION_MODIFIER", 35, 42], ["relaxation", "OBSERVATION", 63, 73], ["IPF tissue", "OBSERVATION", 77, 87]]], ["Interestingly, all tissues and the IPF ECM hydrogel required 4 Maxwell element models to describe their relaxation, whereas control and COPD GOLD IV dECM hydrogels required 3, further suggesting that ECM composition also plays a role in viscoelasticity.DISCUSSIONSome limitations of our experimental approach must be recognized.", [["tissues", "ANATOMY", 19, 26], ["IPF ECM", "ANATOMY", 35, 42], ["ECM", "ANATOMY", 200, 203], ["COPD", "DISEASE", 136, 140], ["tissues", "TISSUE", 19, 26], ["ECM", "CELLULAR_COMPONENT", 200, 203], ["the IPF ECM hydrogel", "TREATMENT", 31, 51], ["COPD GOLD IV dECM hydrogels", "TREATMENT", 136, 163], ["our experimental approach", "TREATMENT", 283, 308], ["all tissues", "OBSERVATION_MODIFIER", 15, 26], ["IPF", "OBSERVATION", 35, 38]]], ["Proteoglycans and growth factors were lost or disrupted during the preparation procedure (11, 18), and the influence of these molecules on the rheological properties of the tissues/hydrogels is not known.", [["Proteoglycans", "ANATOMY", 0, 13], ["tissues", "ANATOMY", 173, 180], ["Proteoglycans", "CELL", 0, 13], ["tissues", "TISSUE", 173, 180], ["growth factors", "PROTEIN", 18, 32], ["Proteoglycans and growth factors", "PROBLEM", 0, 32], ["the preparation procedure", "TREATMENT", 63, 88], ["growth", "OBSERVATION_MODIFIER", 18, 24], ["tissues", "ANATOMY", 173, 180]]], ["The approach used here for measuring the rheology was at a macro (millimeter) scale.", [["a macro (millimeter) scale", "TREATMENT", 57, 83]]], ["How these measurements compare to the nano scale of atomic force microscopy has yet to be examined.", [["atomic force microscopy", "TEST", 52, 75]]], ["All the LLCT measurements were recorded at RT and thus may not fully reflect the biomechanical properties of the lung in vivo.DISCUSSIONIn conclusion, human lung dECM gels provide new opportunities for simulating the lung microenvironment, enabling the generation of novel models for mimicking native lung ECM in a research environment.", [["lung", "ANATOMY", 113, 117], ["lung", "ANATOMY", 157, 161], ["lung", "ANATOMY", 217, 221], ["lung ECM", "ANATOMY", 301, 309], ["lung", "ORGAN", 113, 117], ["human", "ORGANISM", 151, 156], ["lung", "ORGAN", 157, 161], ["lung", "ORGAN", 217, 221], ["lung ECM", "MULTI-TISSUE_STRUCTURE", 301, 309], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["All the LLCT measurements", "TEST", 0, 25], ["simulating the lung microenvironment", "TREATMENT", 202, 238], ["may not fully reflect", "UNCERTAINTY", 55, 76], ["biomechanical", "OBSERVATION", 81, 94], ["lung", "ANATOMY", 113, 117], ["lung", "ANATOMY", 157, 161], ["lung", "ANATOMY", 217, 221], ["lung", "ANATOMY", 301, 305], ["ECM", "OBSERVATION", 306, 309]]], ["Exciting opportunities now exist for exploring the response of human lung-derived cells in 3D environments through modulation of parameters including stiffness, dimensionality, protein content, and protein distribution for ECM from control, COPD GOLD IV, and IPF lungs.GRANTSThis work was supported by ZonMW Grant project number 114021507 (M. N. Hylkema), an unrestricted research grant from Astra Zeneca (M. N. Hylkema), and a Rosalind Franklin fellowship (J. K. Burgess) funded by the European Union and the University of Groningen.DISCLOSURESNo conflicts of interest, financial or otherwise, are declared by the authors.AUTHOR CONTRIBUTIONSR.H.J.d.H., M.C.H., M.N.H., and J.K.B. conceived and designed research; R.H.J.d.H., M.R.J., E.A.G., and M.R. performed experiments; R.H.J.d.H., P.K.S., W.T., M.C.H., M.N.H., and J.K.B. analyzed data; R.H.J.d.H., P.K.S., E.S.W., M.C.H., M.N.H., and J.K.B. interpreted results of experiments; R.H.J.d.H. prepared figures; R.H.J.d.H., P.K.S., E.S.W., E.A.G., M.R., W.T., M.C.H., M.N.H., and J.K.B. drafted manuscript; R.H.J.d.H., P.K.S., M.R.J., E.S.W., E.A.G., M.R., W.T., M.C.H., M.N.H., and J.K.B. edited and revised manuscript; R.H.J.d.H., P.K.S., M.R.J., E.S.W., E.A.G., M.R., W.T., M.C.H., M.N.H., and J.K.B. approved final version of manuscript.", [["lung-derived cells", "ANATOMY", 69, 87], ["ECM", "ANATOMY", 223, 226], ["IPF lungs", "ANATOMY", 259, 268], ["COPD", "DISEASE", 241, 245], ["IPF", "DISEASE", 259, 262], ["human", "ORGANISM", 63, 68], ["lung-derived cells", "CELL", 69, 87], ["ECM", "CELLULAR_COMPONENT", 223, 226], ["lungs", "ORGAN", 263, 268], ["human lung-derived cells", "CELL_TYPE", 63, 87], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["human lung-derived cells", "PROBLEM", 63, 87], ["stiffness, dimensionality", "PROBLEM", 150, 175], ["protein content", "TEST", 177, 192], ["ECM from control", "TREATMENT", 223, 239], ["COPD GOLD IV, and IPF lungs", "PROBLEM", 241, 268], ["lung", "ANATOMY", 69, 73], ["protein content", "OBSERVATION", 177, 192], ["protein distribution", "OBSERVATION", 198, 218], ["COPD", "OBSERVATION", 241, 245], ["IPF", "OBSERVATION", 259, 262], ["lungs", "ANATOMY", 263, 268]]]], "eb8663183db01eb3758e486cd52e84a1f3437ab9": [["IntroductionEMMPRIN is a cell-surface-glycosylated TM protein that belongs to the Ig superfamily.", [["cell", "ANATOMY", 25, 29], ["cell", "CELL", 25, 29], ["Ig", "GENE_OR_GENE_PRODUCT", 82, 84], ["cell-surface-glycosylated TM protein", "PROTEIN", 25, 61], ["Ig superfamily", "PROTEIN", 82, 96], ["IntroductionEMMPRIN", "TREATMENT", 0, 19], ["a cell-surface-glycosylated TM protein", "TREATMENT", 23, 61]]], ["It was first discovered in a lung cancer cell line, where it stimulated the production of collagenase (MMP-1) in adjacent fibroblastic cells [1] ; thus, it was first designated as a tumor cell-derived collagenase stimulatory factor [1, 2] .", [["lung cancer cell line", "ANATOMY", 29, 50], ["fibroblastic cells", "ANATOMY", 122, 140], ["tumor cell", "ANATOMY", 182, 192], ["lung cancer", "DISEASE", 29, 40], ["tumor", "DISEASE", 182, 187], ["lung cancer cell line", "CELL", 29, 50], ["collagenase", "GENE_OR_GENE_PRODUCT", 90, 101], ["MMP-1", "GENE_OR_GENE_PRODUCT", 103, 108], ["fibroblastic cells", "CELL", 122, 140], ["tumor cell", "CELL", 182, 192], ["collagenase", "GENE_OR_GENE_PRODUCT", 201, 212], ["lung cancer cell line", "CELL_LINE", 29, 50], ["collagenase", "PROTEIN", 90, 101], ["MMP-1", "PROTEIN", 103, 108], ["fibroblastic cells", "CELL_TYPE", 122, 140], ["collagenase stimulatory factor", "PROTEIN", 201, 231], ["a lung cancer cell line", "TREATMENT", 27, 50], ["collagenase (MMP", "TEST", 90, 106], ["adjacent fibroblastic cells", "PROBLEM", 113, 140], ["a tumor cell", "PROBLEM", 180, 192], ["lung", "ANATOMY", 29, 33], ["cancer", "OBSERVATION", 34, 40], ["cell line", "OBSERVATION", 41, 50], ["fibroblastic cells", "OBSERVATION", 122, 140]]], ["Other names now include CD147, basigin, and HAb18G.", [["CD147", "GENE_OR_GENE_PRODUCT", 24, 29], ["basigin", "GENE_OR_GENE_PRODUCT", 31, 38], ["HAb18G", "GENE_OR_GENE_PRODUCT", 44, 50], ["CD147", "PROTEIN", 24, 29], ["basigin", "PROTEIN", 31, 38], ["HAb18G", "PROTEIN", 44, 50]]], ["Although studied most extensively in tumor biology, the role of EMMPRIN in normal cell function and other disease states has been investigated.", [["tumor", "ANATOMY", 37, 42], ["cell", "ANATOMY", 82, 86], ["tumor", "DISEASE", 37, 42], ["tumor", "CANCER", 37, 42], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 64, 71], ["cell", "CELL", 82, 86], ["EMMPRIN", "PROTEIN", 64, 71], ["other disease states", "PROBLEM", 100, 120], ["tumor", "OBSERVATION", 37, 42], ["normal cell function", "OBSERVATION", 75, 95]]], ["EMMPRIN levels are up-regulated and/or involved in diseases, including lung-injury models, ischemic myocardial injury, atherosclerosis, cancer, SLE, GVHD, RA, MS, and pathogenic invasion, among other insults.", [["lung", "ANATOMY", 71, 75], ["myocardial", "ANATOMY", 100, 110], ["cancer", "ANATOMY", 136, 142], ["lung-injury", "DISEASE", 71, 82], ["ischemic myocardial injury", "DISEASE", 91, 117], ["atherosclerosis", "DISEASE", 119, 134], ["cancer", "DISEASE", 136, 142], ["SLE", "DISEASE", 144, 147], ["GVHD", "DISEASE", 149, 153], ["RA", "DISEASE", 155, 157], ["MS", "DISEASE", 159, 161], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["lung", "ORGAN", 71, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 100, 110], ["cancer", "CANCER", 136, 142], ["EMMPRIN", "PROTEIN", 0, 7], ["EMMPRIN levels", "TEST", 0, 14], ["diseases", "PROBLEM", 51, 59], ["lung-injury models", "PROBLEM", 71, 89], ["ischemic myocardial injury", "PROBLEM", 91, 117], ["atherosclerosis", "PROBLEM", 119, 134], ["cancer", "PROBLEM", 136, 142], ["SLE", "PROBLEM", 144, 147], ["GVHD", "PROBLEM", 149, 153], ["RA", "PROBLEM", 155, 157], ["MS", "PROBLEM", 159, 161], ["pathogenic invasion", "PROBLEM", 167, 186], ["lung", "ANATOMY", 71, 75], ["injury", "OBSERVATION", 76, 82], ["ischemic", "OBSERVATION_MODIFIER", 91, 99], ["myocardial", "ANATOMY", 100, 110], ["injury", "OBSERVATION", 111, 117], ["atherosclerosis", "OBSERVATION", 119, 134], ["cancer", "OBSERVATION", 136, 142], ["GVHD", "OBSERVATION", 149, 153], ["RA", "ANATOMY", 155, 157], ["pathogenic", "OBSERVATION_MODIFIER", 167, 177], ["invasion", "OBSERVATION", 178, 186]]], ["In this review, we introduce the biochemistry of EMMPRIN, evaluate its multiple functions in T cells, and discuss its roles in immunologic disorders.EMMPRIN STRUCTURE AND BINDING PARTNERSEMMPRIN is a 269 aa TM protein with a nonglycosylated molecular weight of ;27 kDa and a glycosylated molecular weight with an approximate range of 43-66 kDa [3] .", [["T cells", "ANATOMY", 93, 100], ["immunologic disorders", "DISEASE", 127, 148], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 49, 56], ["T cells", "CELL", 93, 100], ["EMMPRIN", "PROTEIN", 49, 56], ["T cells", "CELL_TYPE", 93, 100], ["EMMPRIN", "PROTEIN", 149, 156], ["269 aa TM protein", "PROTEIN", 200, 217], ["EMMPRIN", "TREATMENT", 49, 56], ["immunologic disorders", "PROBLEM", 127, 148], ["a nonglycosylated molecular weight", "TEST", 223, 257], ["a glycosylated molecular weight", "TEST", 273, 304]]], ["Glycosylation patterns may vary in different organs or cell types [3] [4] [5] and may be a reason for its multiple physiologic roles.", [["organs", "ANATOMY", 45, 51], ["cell", "ANATOMY", 55, 59], ["organs", "ORGAN", 45, 51], ["cell", "CELL", 55, 59], ["Glycosylation patterns", "PROBLEM", 0, 22], ["cell types", "TEST", 55, 65]]], ["The structure of EMMPRIN consists of a heavily glycosylated EC domain, a TM domain, and a short cytoplasmic tail (Fig. 1) .", [["EC", "ANATOMY", 60, 62], ["cytoplasmic tail", "ANATOMY", 96, 112], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 17, 24], ["EC", "CELL", 60, 62], ["cytoplasmic tail", "CELLULAR_COMPONENT", 96, 112], ["EMMPRIN", "PROTEIN", 17, 24], ["EC domain", "PROTEIN", 60, 69], ["TM domain", "PROTEIN", 73, 82], ["short cytoplasmic tail", "PROTEIN", 90, 112], ["a heavily glycosylated EC domain", "PROBLEM", 37, 69], ["a TM domain", "TEST", 71, 82], ["a short cytoplasmic tail (Fig", "PROBLEM", 88, 117], ["tail", "OBSERVATION_MODIFIER", 108, 112]]], ["There are 4 isoforms of EMMPRIN that differ only in its EC domain [6, 7] .", [["EC", "ANATOMY", 56, 58], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 24, 31], ["EC", "CELL", 56, 58], ["EMMPRIN", "PROTEIN", 24, 31], ["EC domain", "PROTEIN", 56, 65], ["EMMPRIN", "TREATMENT", 24, 31], ["4 isoforms", "OBSERVATION_MODIFIER", 10, 20]]], ["The EC domain of the most prominent isoform, basigin-2 and here forward called EMMPRIN, is comprised of 2 Ig-like loops (EC1 and EC2) held together by disulfide bonds (Fig. 1) .", [["EC", "ANATOMY", 4, 6], ["disulfide", "CHEMICAL", 151, 160], ["EC", "CELL", 4, 6], ["basigin-2", "GENE_OR_GENE_PRODUCT", 45, 54], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 79, 86], ["Ig", "GENE_OR_GENE_PRODUCT", 106, 108], ["EC domain", "PROTEIN", 4, 13], ["basigin-2", "PROTEIN", 45, 54], ["EMMPRIN", "PROTEIN", 79, 86], ["Ig", "PROTEIN", 106, 108], ["EC1", "PROTEIN", 121, 124], ["EC2", "PROTEIN", 129, 132], ["EC1", "TEST", 121, 124], ["EC2", "TEST", 129, 132], ["most prominent", "OBSERVATION_MODIFIER", 21, 35], ["loops", "ANATOMY_MODIFIER", 114, 119]]], ["Sequence analyses and the crystal structure of EMMPRIN demonstrated that the EC1, the more N-terminal portion, structurally resembles the b-strand pattern of the C region of Igs, particularly the C2-set fold, a subclass that has some structural features of the V region of Igs in addition to the C region.", [["N", "CHEMICAL", 91, 92], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 47, 54], ["EC1", "GENE_OR_GENE_PRODUCT", 77, 80], ["Igs", "GENE_OR_GENE_PRODUCT", 174, 177], ["Igs", "GENE_OR_GENE_PRODUCT", 273, 276], ["EMMPRIN", "PROTEIN", 47, 54], ["EC1", "PROTEIN", 77, 80], ["N-terminal portion", "PROTEIN", 91, 109], ["C region", "PROTEIN", 162, 170], ["Igs", "PROTEIN", 174, 177], ["C2", "PROTEIN", 196, 198], ["V region", "PROTEIN", 261, 269], ["Igs", "PROTEIN", 273, 276], ["C region", "PROTEIN", 296, 304], ["Sequence analyses", "TEST", 0, 17], ["the EC1", "TEST", 73, 80], ["the C region of Igs", "PROBLEM", 158, 177], ["the C region", "PROBLEM", 292, 304], ["terminal", "ANATOMY_MODIFIER", 93, 101], ["b-strand pattern", "OBSERVATION", 138, 154], ["Igs", "OBSERVATION", 174, 177], ["C2", "ANATOMY", 196, 198], ["set fold", "ANATOMY_MODIFIER", 199, 207], ["subclass", "OBSERVATION_MODIFIER", 211, 219], ["Igs", "OBSERVATION", 273, 276]]], ["EC2, the C-terminal loop, is slightly longer and showed strong homology to the V region of Igs, thus termed as a shortened V-set fold or an I-set [8, 9] .", [["C", "CHEMICAL", 9, 10], ["EC2", "GENE_OR_GENE_PRODUCT", 0, 3], ["Igs", "GENE_OR_GENE_PRODUCT", 91, 94], ["EC2", "PROTEIN", 0, 3], ["C-terminal loop", "PROTEIN", 9, 24], ["V region", "PROTEIN", 79, 87], ["Igs", "PROTEIN", 91, 94], ["EC2", "TEST", 0, 3], ["the C-terminal loop", "PROBLEM", 5, 24], ["a shortened V-set fold", "PROBLEM", 111, 133], ["terminal", "ANATOMY_MODIFIER", 11, 19], ["loop", "OBSERVATION", 20, 24], ["slightly", "OBSERVATION_MODIFIER", 29, 37], ["Igs", "OBSERVATION", 91, 94]]], ["EMMPRIN is unique among Igs, as its EC2 domain has a high degree of homology to the V region of Igs as well as the MHCII b chain that contains a C region.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["Igs", "GENE_OR_GENE_PRODUCT", 24, 27], ["Igs", "GENE_OR_GENE_PRODUCT", 96, 99], ["MHCII b chain", "GENE_OR_GENE_PRODUCT", 115, 128], ["EMMPRIN", "PROTEIN", 0, 7], ["Igs", "PROTEIN", 24, 27], ["EC2 domain", "PROTEIN", 36, 46], ["V region", "PROTEIN", 84, 92], ["Igs", "PROTEIN", 96, 99], ["MHCII b chain", "PROTEIN", 115, 128], ["C region", "PROTEIN", 145, 153], ["its EC2 domain", "TEST", 32, 46], ["a C region", "PROBLEM", 143, 153], ["high degree", "OBSERVATION_MODIFIER", 53, 64], ["Igs", "OBSERVATION", 96, 99], ["MHCII", "OBSERVATION", 115, 120]]], ["For this reason, it is suggested that the EMMPRIN Ig domain may be a primordial form of the Ig superfamily [9, 10] .", [["EMMPRIN Ig", "GENE_OR_GENE_PRODUCT", 42, 52], ["Ig", "GENE_OR_GENE_PRODUCT", 92, 94], ["EMMPRIN Ig domain", "PROTEIN", 42, 59], ["Ig superfamily", "PROTEIN", 92, 106], ["the EMMPRIN Ig domain", "TREATMENT", 38, 59]]], ["The C2-V/I arrangement of the EC portion of EMMPRIN is also distinctive among Igs, as most follow a V/I-C arrangement and undergo V-V or I-I dimerization [8] .", [["EC", "ANATOMY", 30, 32], ["EC", "CELL", 30, 32], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 44, 51], ["Igs", "GENE_OR_GENE_PRODUCT", 78, 81], ["V-V", "GENE_OR_GENE_PRODUCT", 130, 133], ["I-I", "GENE_OR_GENE_PRODUCT", 137, 140], ["C2", "PROTEIN", 4, 6], ["EC portion", "PROTEIN", 30, 40], ["EMMPRIN", "PROTEIN", 44, 51], ["Igs", "PROTEIN", 78, 81], ["C2", "ANATOMY", 4, 6]]], ["Instead, the EC domain of EMMPRIN appears to undergo C2-C2 or C2-V/I dimerization based on the crystal structure [8] .", [["EC", "ANATOMY", 13, 15], ["C2-C2", "CHEMICAL", 53, 58], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 26, 33], ["C2-C2", "GENE_OR_GENE_PRODUCT", 53, 58], ["EC domain", "PROTEIN", 13, 22], ["EMMPRIN", "PROTEIN", 26, 33], ["C2", "TEST", 53, 55], ["C2-V/I dimerization", "TREATMENT", 62, 81], ["C2", "ANATOMY", 56, 58], ["C2", "ANATOMY", 62, 64]]], ["As inferred, the Ig superfamily, which encompass the most diverse group of receptors known, contains domains that share evolutionary homology and are identified to be associated with functions, such as adhesion, migration, cell recognition, and T cell activation [11, 12] , which EMMPRIN clearly exemplifies (as mentioned below).", [["cell", "ANATOMY", 223, 227], ["T cell", "ANATOMY", 245, 251], ["Ig", "GENE_OR_GENE_PRODUCT", 17, 19], ["cell", "CELL", 223, 227], ["T cell", "CELL", 245, 251], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 280, 287], ["Ig superfamily", "PROTEIN", 17, 31], ["EMMPRIN", "PROTEIN", 280, 287], ["cell recognition", "TEST", 223, 239]]], ["The complexity of EMMPRIN, in terms of its various glycosylation patterns, and types of homo/heterophilic interactions between domains all contribute to its multifunctional nature.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["EMMPRIN", "PROTEIN", 18, 25], ["EMMPRIN", "TREATMENT", 18, 25], ["homo/heterophilic interactions between domains", "PROBLEM", 88, 134], ["complexity", "OBSERVATION_MODIFIER", 4, 14], ["heterophilic interactions", "OBSERVATION", 93, 118]]], ["A rare isoform also exists, expressed only in the retina, comprised of 3 Ig-like loops and named basigin-1 [13] .", [["retina", "ANATOMY", 50, 56], ["retina", "MULTI-TISSUE_STRUCTURE", 50, 56], ["Ig", "GENE_OR_GENE_PRODUCT", 73, 75], ["basigin-1", "GENE_OR_GENE_PRODUCT", 97, 106], ["Ig", "PROTEIN", 73, 75], ["basigin", "PROTEIN", 97, 104], ["rare", "OBSERVATION_MODIFIER", 2, 6], ["isoform", "OBSERVATION", 7, 14], ["retina", "ANATOMY", 50, 56], ["loops", "ANATOMY_MODIFIER", 81, 86]]], ["Other rare and less understood variants include basigin-3 and -4, both comprising only 1 Ig-like loop in which the EC domain of basigin-4 is slightly extended from that of basigin-3 [6] .", [["EC", "ANATOMY", 115, 117], ["basigin-3", "GENE_OR_GENE_PRODUCT", 48, 57], ["-4", "GENE_OR_GENE_PRODUCT", 62, 64], ["Ig", "GENE_OR_GENE_PRODUCT", 89, 91], ["EC", "CELL", 115, 117], ["basigin-4", "GENE_OR_GENE_PRODUCT", 128, 137], ["basigin-3", "GENE_OR_GENE_PRODUCT", 172, 181], ["basigin-3 and -4", "DNA", 48, 64], ["Ig", "PROTEIN", 89, 91], ["EC domain", "PROTEIN", 115, 124], ["basigin-4", "PROTEIN", 128, 137], ["basigin", "PROTEIN", 172, 179], ["basigin", "TEST", 48, 55]]], ["Interestingly, basigin-3 was found to act as an inhibitor of EMMPRIN (basigin-2) likely by hetero-oligomerization [7] .", [["basigin-3", "CHEMICAL", 15, 24], ["basigin-3", "CHEMICAL", 15, 24], ["basigin-3", "GENE_OR_GENE_PRODUCT", 15, 24], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 61, 68], ["basigin-2", "GENE_OR_GENE_PRODUCT", 70, 79], ["basigin-3", "PROTEIN", 15, 24], ["EMMPRIN", "PROTEIN", 61, 68], ["basigin-2", "PROTEIN", 70, 79], ["EMMPRIN (basigin", "TREATMENT", 61, 77]]], ["This was demonstrated in HCC cells, where in contrast to basigin-2, basigin-3 overexpression inhibited cellular proliferation, MMP induction, and invasion [7] .", [["HCC cells", "ANATOMY", 25, 34], ["cellular", "ANATOMY", 103, 111], ["HCC", "DISEASE", 25, 28], ["HCC cells", "CELL", 25, 34], ["basigin-2", "GENE_OR_GENE_PRODUCT", 57, 66], ["basigin-3", "GENE_OR_GENE_PRODUCT", 68, 77], ["cellular", "CELL", 103, 111], ["HCC cells", "CELL_TYPE", 25, 34], ["basigin", "PROTEIN", 57, 64], ["basigin-3", "PROTEIN", 68, 77], ["MMP", "PROTEIN", 127, 130], ["HCC cells", "PROBLEM", 25, 34], ["cellular proliferation", "PROBLEM", 103, 125], ["MMP induction", "TREATMENT", 127, 140], ["HCC cells", "OBSERVATION", 25, 34], ["cellular proliferation", "OBSERVATION", 103, 125]]], ["A highly conserved glutamic acid residue and leucine zipper are found in the TM domain and hypothesized to interact with a number of yet-unidentified proteins in the plasma membrane.", [["plasma membrane", "ANATOMY", 166, 181], ["glutamic acid", "CHEMICAL", 19, 32], ["leucine", "CHEMICAL", 45, 52], ["glutamic acid", "CHEMICAL", 19, 32], ["leucine", "CHEMICAL", 45, 52], ["glutamic acid", "AMINO_ACID", 19, 32], ["leucine", "AMINO_ACID", 45, 52], ["zipper", "AMINO_ACID", 53, 59], ["plasma membrane", "CELLULAR_COMPONENT", 166, 181], ["leucine zipper", "PROTEIN", 45, 59], ["TM domain", "PROTEIN", 77, 86], ["unidentified proteins", "PROTEIN", 137, 158], ["A highly conserved glutamic acid residue", "PROBLEM", 0, 40], ["leucine zipper", "TREATMENT", 45, 59], ["unidentified proteins in the plasma membrane", "PROBLEM", 137, 181], ["glutamic acid residue", "OBSERVATION", 19, 40], ["leucine zipper", "OBSERVATION", 45, 59], ["proteins", "OBSERVATION", 150, 158], ["plasma membrane", "ANATOMY", 166, 181]]], ["Although the cytoplasmic tail is short (only ;40 aa), this does not rule out the involvement of EMMPRIN in the initiation of various signaling pathways, even as a coreceptor.", [["cytoplasmic tail", "ANATOMY", 13, 29], ["cytoplasmic", "ORGANISM_SUBSTANCE", 13, 24], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 96, 103], ["cytoplasmic tail", "PROTEIN", 13, 29], ["EMMPRIN", "PROTEIN", 96, 103], ["coreceptor", "PROTEIN", 163, 173], ["EMMPRIN", "TREATMENT", 96, 103], ["cytoplasmic", "OBSERVATION_MODIFIER", 13, 24], ["tail", "OBSERVATION_MODIFIER", 25, 29], ["short", "OBSERVATION_MODIFIER", 33, 38]]], ["The TM and cytoplasmic domains are highly conserved among species [14] , thus emphasizing a critical, functional role in this region of EMMPRIN.", [["cytoplasmic", "ANATOMY", 11, 22], ["TM", "GENE_OR_GENE_PRODUCT", 4, 6], ["cytoplasmic", "ORGANISM_SUBSTANCE", 11, 22], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 136, 143], ["TM and cytoplasmic domains", "PROTEIN", 4, 30], ["EMMPRIN", "PROTEIN", 136, 143], ["The TM and cytoplasmic domains", "TEST", 0, 30]]], ["A 22 kDa soluble form of EMMPRIN can be shed from the cell surface by MMP-14, cleaving off the first Ig-like domain [15] .", [["cell surface", "ANATOMY", 54, 66], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 25, 32], ["cell surface", "CELLULAR_COMPONENT", 54, 66], ["MMP-14", "GENE_OR_GENE_PRODUCT", 70, 76], ["Ig", "GENE_OR_GENE_PRODUCT", 101, 103], ["22 kDa soluble form", "PROTEIN", 2, 21], ["EMMPRIN", "PROTEIN", 25, 32], ["MMP-14", "PROTEIN", 70, 76], ["Ig", "PROTEIN", 101, 103], ["A 22 kDa soluble form of EMMPRIN", "TREATMENT", 0, 32], ["MMP", "TEST", 70, 73], ["22 kDa", "OBSERVATION_MODIFIER", 2, 8]]], ["In addition, full-length EMMPRIN can be released by cells via microvesicle shedding, an efficient vehicle to elicit communication between cells [16, 17] .", [["cells", "ANATOMY", 52, 57], ["microvesicle", "ANATOMY", 62, 74], ["cells", "ANATOMY", 138, 143], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 25, 32], ["cells", "CELL", 52, 57], ["microvesicle", "GENE_OR_GENE_PRODUCT", 62, 74], ["cells", "CELL", 138, 143], ["EMMPRIN", "PROTEIN", 25, 32], ["full-length EMMPRIN", "TREATMENT", 13, 32]]], ["It is reasoned that the outward budding of EMMPRIN-containing microvesicles from the plasma membrane of tumor cells shortly after breaks apart, giving rise to membrane fragment-associated EMMPRIN in the EC space; it is this soluble form (not the microvesicle-associated form) that primarily induced MMP activities in stromal cells [16] .", [["microvesicles", "ANATOMY", 62, 75], ["plasma membrane", "ANATOMY", 85, 100], ["tumor cells", "ANATOMY", 104, 115], ["membrane fragment", "ANATOMY", 159, 176], ["EC space", "ANATOMY", 203, 211], ["microvesicle", "ANATOMY", 246, 258], ["stromal cells", "ANATOMY", 317, 330], ["tumor", "DISEASE", 104, 109], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 43, 50], ["microvesicles", "CELLULAR_COMPONENT", 62, 75], ["plasma membrane", "CELLULAR_COMPONENT", 85, 100], ["tumor cells", "CELL", 104, 115], ["membrane fragment", "CELLULAR_COMPONENT", 159, 176], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 188, 195], ["EC", "CELL", 203, 205], ["MMP", "GENE_OR_GENE_PRODUCT", 299, 302], ["stromal cells", "CELL", 317, 330], ["EMMPRIN", "PROTEIN", 43, 50], ["tumor cells", "CELL_TYPE", 104, 115], ["membrane fragment", "PROTEIN", 159, 176], ["EMMPRIN", "PROTEIN", 188, 195], ["microvesicle-associated form", "PROTEIN", 246, 274], ["MMP", "PROTEIN", 299, 302], ["stromal cells", "CELL_TYPE", 317, 330], ["EMMPRIN-containing microvesicles", "TREATMENT", 43, 75], ["tumor cells", "PROBLEM", 104, 115], ["membrane fragment", "PROBLEM", 159, 176], ["MMP activities in stromal cells", "PROBLEM", 299, 330], ["plasma membrane", "OBSERVATION_MODIFIER", 85, 100], ["tumor cells", "OBSERVATION", 104, 115], ["membrane fragment", "OBSERVATION", 159, 176], ["stromal cells", "OBSERVATION", 317, 330]]], ["Since then, studies have described the involvement of EMMPRIN-containing microvesicles in aspects, such as angiogenesis [18] and the migration and invasion of cancer cells [19, 20] .EMMPRIN STRUCTURE AND BINDING PARTNERSEach domain of EMMPRIN has been identified to interact with different proteins and correspond to particular functions, such that mAbs toward EMMPRIN may alter 1 function without affecting another.", [["microvesicles", "ANATOMY", 73, 86], ["cancer cells", "ANATOMY", 159, 171], ["cancer", "DISEASE", 159, 165], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 54, 61], ["microvesicles", "CELL", 73, 86], ["cancer cells", "CELL", 159, 171], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 235, 242], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 361, 368], ["EMMPRIN", "PROTEIN", 54, 61], ["cancer cells", "CELL_TYPE", 159, 171], ["EMMPRIN", "PROTEIN", 182, 189], ["BINDING PARTNERSEach domain", "PROTEIN", 204, 231], ["EMMPRIN", "PROTEIN", 235, 242], ["mAbs", "PROTEIN", 349, 353], ["EMMPRIN", "PROTEIN", 361, 368], ["studies", "TEST", 12, 19], ["EMMPRIN-containing microvesicles", "TREATMENT", 54, 86], ["angiogenesis", "PROBLEM", 107, 119], ["the migration", "TREATMENT", 129, 142], ["invasion of cancer cells", "PROBLEM", 147, 171], ["EMMPRIN", "TREATMENT", 235, 242], ["microvesicles", "OBSERVATION", 73, 86], ["migration", "OBSERVATION_MODIFIER", 133, 142], ["invasion", "OBSERVATION_MODIFIER", 147, 155], ["cancer cells", "OBSERVATION", 159, 171]]], ["Importantly, N-linked glycosylation of asparagine residues and homophilic interactions is significant for the function and protein interactions of EMMPRIN [3, 4, 8] ; this was demonstrated when purified, deglycosylated EMMPRIN failed to induce MMP-1 and MMP-2 activity in tumor cells [5] .", [["tumor cells", "ANATOMY", 272, 283], ["asparagine", "CHEMICAL", 39, 49], ["tumor", "DISEASE", 272, 277], ["N", "CHEMICAL", 13, 14], ["asparagine", "CHEMICAL", 39, 49], ["asparagine", "AMINO_ACID", 39, 49], ["EMMPRIN [3", "GENE_OR_GENE_PRODUCT", 147, 157], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 219, 226], ["MMP-1", "GENE_OR_GENE_PRODUCT", 244, 249], ["MMP-2", "GENE_OR_GENE_PRODUCT", 254, 259], ["tumor cells", "CELL", 272, 283], ["EMMPRIN", "PROTEIN", 147, 154], ["EMMPRIN", "PROTEIN", 219, 226], ["MMP", "PROTEIN", 244, 247], ["MMP", "PROTEIN", 254, 257], ["tumor cells", "CELL_TYPE", 272, 283], ["N-linked glycosylation of asparagine residues", "TREATMENT", 13, 58], ["homophilic interactions", "PROBLEM", 63, 86], ["EMMPRIN", "TEST", 147, 154], ["deglycosylated EMMPRIN", "TREATMENT", 204, 226], ["MMP", "TEST", 244, 247], ["MMP", "TEST", 254, 257], ["tumor cells", "PROBLEM", 272, 283], ["tumor cells", "OBSERVATION", 272, 283]]], ["The EC1 domain of EMMPRIN is important in MMP induction (MMP-1, -2, -3, and -9, as well as MT1-MMP and MT2-MMP), oligomerization, the binding of integrins, and likely CD98 (a single TM glycoprotein involved in adhesion and amino acid transport; Fig. 1 ) [14, 21] .", [["amino acid", "CHEMICAL", 223, 233], ["amino acid", "CHEMICAL", 223, 233], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["MMP", "GENE_OR_GENE_PRODUCT", 42, 45], ["MMP-1", "GENE_OR_GENE_PRODUCT", 57, 62], ["-2", "GENE_OR_GENE_PRODUCT", 64, 66], ["-3", "GENE_OR_GENE_PRODUCT", 68, 70], ["-9", "GENE_OR_GENE_PRODUCT", 76, 78], ["MT1-MMP", "GENE_OR_GENE_PRODUCT", 91, 98], ["MT2-MMP", "GENE_OR_GENE_PRODUCT", 103, 110], ["integrins", "GENE_OR_GENE_PRODUCT", 145, 154], ["CD98", "GENE_OR_GENE_PRODUCT", 167, 171], ["amino acid", "AMINO_ACID", 223, 233], ["EC1 domain", "PROTEIN", 4, 14], ["EMMPRIN", "PROTEIN", 18, 25], ["MMP", "PROTEIN", 42, 45], ["MMP", "PROTEIN", 57, 60], ["MT1", "PROTEIN", 91, 94], ["MMP", "PROTEIN", 95, 98], ["MT2", "PROTEIN", 103, 106], ["MMP", "PROTEIN", 107, 110], ["integrins", "PROTEIN", 145, 154], ["CD98", "PROTEIN", 167, 171], ["TM glycoprotein", "PROTEIN", 182, 197], ["MMP induction", "TEST", 42, 55], ["MMP", "TEST", 57, 60], ["MT1", "TEST", 91, 94], ["MMP", "TEST", 95, 98], ["oligomerization", "PROBLEM", 113, 128], ["a single TM glycoprotein", "TREATMENT", 173, 197], ["amino acid transport", "TREATMENT", 223, 243]]], ["The EC2 domain has been described to bind cyclophilins (important in chemotaxis and adhesion) [14] and caveolin-1 (a negative regulator that binds EMMPRIN at its low glycosylated form, preventing its glycosylation and clustering at the cell surface; Fig. 1 ) [4] .", [["cell surface", "ANATOMY", 236, 248], ["cyclophilins", "GENE_OR_GENE_PRODUCT", 42, 54], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 103, 113], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 147, 154], ["cell surface", "CELLULAR_COMPONENT", 236, 248], ["EC2 domain", "PROTEIN", 4, 14], ["cyclophilins", "PROTEIN", 42, 54], ["caveolin-1", "PROTEIN", 103, 113], ["negative regulator", "PROTEIN", 117, 135], ["EMMPRIN", "PROTEIN", 147, 154], ["low glycosylated form", "PROTEIN", 162, 183], ["chemotaxis and adhesion)", "TREATMENT", 69, 93], ["caveolin", "TREATMENT", 103, 111], ["EMMPRIN at its low glycosylated form", "TREATMENT", 147, 183], ["its glycosylation", "TREATMENT", 196, 213]]], ["The TM domain binds cyclophilin 60 (serving to chaperone EMMPRIN up to the cell surface) [22] and likely involves interactions with CD43 (an adhesion molecule) [23] , syndecan-1 (a HSPG involved in adhesion) [24] , and b1 integrins [14] (Fig. 1) .", [["cell surface", "ANATOMY", 75, 87], ["cyclophilin 60", "GENE_OR_GENE_PRODUCT", 20, 34], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 57, 64], ["cell surface", "CELLULAR_COMPONENT", 75, 87], ["CD43", "GENE_OR_GENE_PRODUCT", 132, 136], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 167, 177], ["HSPG", "GENE_OR_GENE_PRODUCT", 181, 185], ["b1 integrins", "GENE_OR_GENE_PRODUCT", 219, 231], ["TM domain", "PROTEIN", 4, 13], ["cyclophilin 60", "PROTEIN", 20, 34], ["EMMPRIN", "PROTEIN", 57, 64], ["CD43", "PROTEIN", 132, 136], ["adhesion molecule", "PROTEIN", 141, 158], ["syndecan-1", "PROTEIN", 167, 177], ["HSPG", "PROTEIN", 181, 185], ["b1 integrins", "PROTEIN", 219, 231], ["The TM domain binds cyclophilin", "TREATMENT", 0, 31], ["chaperone EMMPRIN", "TREATMENT", 47, 64], ["CD43 (an adhesion molecule", "TREATMENT", 132, 158], ["b1 integrins", "TREATMENT", 219, 231]]], ["Lastly, both the TM and the cytoplasmic domain of EMMPRIN interact with MCTs [25] , such as MCT1 or MCT4 (both widely expressed) or MCT3 (predominantly expressed in the retinal pigment epithelium).", [["cytoplasmic", "ANATOMY", 28, 39], ["retinal pigment epithelium", "ANATOMY", 169, 195], ["TM", "CELLULAR_COMPONENT", 17, 19], ["cytoplasmic", "ORGANISM_SUBSTANCE", 28, 39], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 50, 57], ["MCTs [25]", "GENE_OR_GENE_PRODUCT", 72, 81], ["MCT1", "GENE_OR_GENE_PRODUCT", 92, 96], ["MCT4", "GENE_OR_GENE_PRODUCT", 100, 104], ["MCT3", "GENE_OR_GENE_PRODUCT", 132, 136], ["retinal pigment epithelium", "TISSUE", 169, 195], ["TM", "PROTEIN", 17, 19], ["cytoplasmic domain", "PROTEIN", 28, 46], ["EMMPRIN", "PROTEIN", 50, 57], ["MCT1", "PROTEIN", 92, 96], ["MCT4", "PROTEIN", 100, 104], ["MCT3", "PROTEIN", 132, 136], ["retinal", "ANATOMY", 169, 176], ["pigment epithelium", "OBSERVATION", 177, 195]]], ["EMMPRIN shuttles MCTs to the plasma membrane, where it plays essential metabolic roles through the transport of monocarboxylates, such as pyruvate and lactate [2, 14] (Fig. 1) .", [["plasma membrane", "ANATOMY", 29, 44], ["pyruvate", "CHEMICAL", 138, 146], ["lactate", "CHEMICAL", 151, 158], ["monocarboxylates", "CHEMICAL", 112, 128], ["pyruvate", "CHEMICAL", 138, 146], ["lactate", "CHEMICAL", 151, 158], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["MCTs", "GENE_OR_GENE_PRODUCT", 17, 21], ["plasma membrane", "CELLULAR_COMPONENT", 29, 44], ["monocarboxylates", "SIMPLE_CHEMICAL", 112, 128], ["pyruvate", "SIMPLE_CHEMICAL", 138, 146], ["lactate", "SIMPLE_CHEMICAL", 151, 158], ["2, 14]", "SIMPLE_CHEMICAL", 160, 166], ["EMMPRIN", "PROTEIN", 0, 7], ["monocarboxylates", "TREATMENT", 112, 128], ["lactate", "TEST", 151, 158]]], ["Other EMMPRINinteracting proteins include glycoprotein VI (involved in platelet rolling) [26] , annexin II (implicated in cytoskeleton rearrangement) [27] , shrew1 (influencing cell invasiveness) [28] , and the g-secretase complex (implicated in Alzheimer's disease in the production of amyloid b peptides) [29] .EMMPRIN KNOCKOUT MICE AND EXPRESSIONTo understand EMMPRIN function, EMMPRIN knockout mice had been generated.", [["platelet", "ANATOMY", 71, 79], ["cytoskeleton", "ANATOMY", 122, 134], ["cell", "ANATOMY", 177, 181], ["Alzheimer's disease", "DISEASE", 246, 265], ["glycoprotein VI", "GENE_OR_GENE_PRODUCT", 42, 57], ["platelet rolling) [26]", "GENE_OR_GENE_PRODUCT", 71, 93], ["annexin II", "GENE_OR_GENE_PRODUCT", 96, 106], ["cytoskeleton", "CELLULAR_COMPONENT", 122, 134], ["shrew1", "GENE_OR_GENE_PRODUCT", 157, 163], ["cell", "CELL", 177, 181], ["g-secretase", "GENE_OR_GENE_PRODUCT", 211, 222], ["amyloid b peptides", "GENE_OR_GENE_PRODUCT", 287, 305], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 363, 370], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 381, 388], ["mice", "ORGANISM", 398, 402], ["EMMPRINinteracting proteins", "PROTEIN", 6, 33], ["glycoprotein VI", "PROTEIN", 42, 57], ["annexin II", "PROTEIN", 96, 106], ["shrew1", "PROTEIN", 157, 163], ["g-secretase complex", "PROTEIN", 211, 230], ["EMMPRIN", "PROTEIN", 313, 320], ["EMMPRIN", "PROTEIN", 363, 370], ["EMMPRIN", "PROTEIN", 381, 388], ["mice", "SPECIES", 398, 402], ["mice", "SPECIES", 398, 402], ["glycoprotein VI", "TREATMENT", 42, 57], ["platelet rolling)", "TREATMENT", 71, 88], ["cell invasiveness", "TEST", 177, 194], ["the g-secretase complex", "PROBLEM", 207, 230], ["Alzheimer's disease", "PROBLEM", 246, 265], ["amyloid b peptides", "TREATMENT", 287, 305], ["EMMPRIN function", "TEST", 363, 379], ["EMMPRIN knockout mice", "TREATMENT", 381, 402]]], ["Although no gross abnormalities were observed histologically, these mice exhibited neurologic deficits associated with decreased sensitivity to irritating odors [30] and Figure 1 .", [["neurologic", "ANATOMY", 83, 93], ["neurologic deficits", "DISEASE", 83, 102], ["mice", "ORGANISM", 68, 72], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["gross abnormalities", "PROBLEM", 12, 31], ["neurologic deficits", "PROBLEM", 83, 102], ["decreased sensitivity", "PROBLEM", 119, 140], ["irritating odors", "PROBLEM", 144, 160], ["no", "UNCERTAINTY", 9, 11], ["gross", "OBSERVATION_MODIFIER", 12, 17], ["abnormalities", "OBSERVATION", 18, 31]]], ["EMMPRIN structure.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["EMMPRIN", "PROTEIN", 0, 7]]], ["EMMPRIN is a single TM protein consisting of 3 N-linked glycosylated sites at asparagine residues (Asn) in the EC region, a TM containing a highly conserved glutamic acid residue (Glu), and a short cytoplasmic tail.", [["EC region", "ANATOMY", 111, 120], ["cytoplasmic tail", "ANATOMY", 198, 214], ["asparagine", "CHEMICAL", 78, 88], ["glutamic acid", "CHEMICAL", 157, 170], ["Glu", "CHEMICAL", 180, 183], ["N", "CHEMICAL", 47, 48], ["asparagine", "CHEMICAL", 78, 88], ["Asn", "CHEMICAL", 99, 102], ["glutamic acid", "CHEMICAL", 157, 170], ["Glu", "CHEMICAL", 180, 183], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["asparagine residues", "AMINO_ACID", 78, 97], ["Asn", "AMINO_ACID", 99, 102], ["EC region", "CELLULAR_COMPONENT", 111, 120], ["glutamic acid", "AMINO_ACID", 157, 170], ["Glu", "AMINO_ACID", 180, 183], ["cytoplasmic tail", "CELLULAR_COMPONENT", 198, 214], ["EMMPRIN", "PROTEIN", 0, 7], ["TM protein", "PROTEIN", 20, 30], ["N-linked glycosylated sites", "PROTEIN", 47, 74], ["EC region", "PROTEIN", 111, 120], ["TM", "PROTEIN", 124, 126], ["cytoplasmic tail", "PROTEIN", 198, 214], ["a single TM protein", "TEST", 11, 30], ["3 N-linked glycosylated sites", "TREATMENT", 45, 74], ["asparagine residues", "TREATMENT", 78, 97], ["a TM", "TEST", 122, 126], ["a highly conserved glutamic acid residue", "PROBLEM", 138, 178], ["a short cytoplasmic tail", "PROBLEM", 190, 214], ["EC", "ANATOMY", 111, 113], ["region", "ANATOMY_MODIFIER", 114, 120], ["glutamic acid residue", "OBSERVATION", 157, 178], ["tail", "OBSERVATION_MODIFIER", 210, 214]]], ["The EC region can be broken into 2 Ig-like loops (EC1 and EC2), held together by disulfide bonds.", [["EC region", "ANATOMY", 4, 13], ["disulfide", "CHEMICAL", 81, 90], ["EC", "CELL", 4, 6], ["Ig", "GENE_OR_GENE_PRODUCT", 35, 37], ["EC region", "DNA", 4, 13], ["Ig", "PROTEIN", 35, 37], ["EC1", "PROTEIN", 50, 53], ["EC2", "PROTEIN", 58, 61], ["loops", "ANATOMY_MODIFIER", 43, 48]]], ["Each domain of EMMPRIN interacts with different proteins, thus, having different functional capabilities.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 15, 22], ["EMMPRIN", "PROTEIN", 15, 22]]], ["C, C-terminal; N, N-terminal; S-S, disulfide bond. light as a result of blindness [31] [32] [33] , hypersensitivity to electric foot shock, as well as deficits in learning and memory [34] .", [["blindness", "DISEASE", 72, 81], ["hypersensitivity", "DISEASE", 99, 115], ["shock", "DISEASE", 133, 138], ["deficits in learning and memory", "DISEASE", 151, 182], ["C", "CHEMICAL", 0, 1], ["N", "CHEMICAL", 15, 16], ["S-S", "CHEMICAL", 30, 33], ["disulfide", "CHEMICAL", 35, 44], ["C", "SIMPLE_CHEMICAL", 0, 1], ["S-S", "SIMPLE_CHEMICAL", 30, 33], ["foot", "ORGANISM_SUBDIVISION", 128, 132], ["C-terminal; N, N-terminal; S-S", "PROTEIN", 3, 33], ["blindness", "PROBLEM", 72, 81], ["hypersensitivity", "PROBLEM", 99, 115], ["electric foot shock", "PROBLEM", 119, 138], ["deficits", "PROBLEM", 151, 159], ["foot", "ANATOMY", 128, 132], ["shock", "OBSERVATION", 133, 138]]], ["These abnormalities appeared to correlate with the subregions of the mouse brain shown to express EMMPRIN [35] .", [["brain", "ANATOMY", 75, 80], ["mouse", "ORGANISM", 69, 74], ["brain", "ORGAN", 75, 80], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 98, 105], ["EMMPRIN", "PROTEIN", 98, 105], ["mouse", "SPECIES", 69, 74], ["mouse", "SPECIES", 69, 74], ["These abnormalities", "PROBLEM", 0, 19], ["brain", "ANATOMY", 75, 80]]], ["No abnormalities were found at the BBB in the mutant mice, even though EMMPRIN is expressed on endothelial vessels in the CNS [30, 34] .", [["BBB", "ANATOMY", 35, 38], ["endothelial vessels", "ANATOMY", 95, 114], ["CNS", "ANATOMY", 122, 125], ["BBB", "MULTI-TISSUE_STRUCTURE", 35, 38], ["mice", "ORGANISM", 53, 57], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 71, 78], ["endothelial vessels", "MULTI-TISSUE_STRUCTURE", 95, 114], ["CNS", "ANATOMICAL_SYSTEM", 122, 125], ["EMMPRIN", "PROTEIN", 71, 78], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["abnormalities", "PROBLEM", 3, 16], ["abnormalities", "OBSERVATION", 3, 16], ["endothelial vessels", "ANATOMY", 95, 114], ["CNS", "ANATOMY", 122, 125]]], ["Furthermore, EMMPRIN appears to be involved in early embryogenesis and reproduction, as EMMPRIN knockout mice were rarely born, and those that did survive were small, weak, and sterile, in which half died within 1 month as a result of interstitial pneumonia [36] .EMMPRIN KNOCKOUT MICE AND EXPRESSIONEMMPRIN is expressed on a wide variety of cell types at varying levels, including hematopoietic, epithelial, endothelial, and tumor cells.", [["interstitial", "ANATOMY", 235, 247], ["cell", "ANATOMY", 342, 346], ["hematopoietic", "ANATOMY", 382, 395], ["epithelial", "ANATOMY", 397, 407], ["endothelial", "ANATOMY", 409, 420], ["tumor cells", "ANATOMY", 426, 437], ["interstitial pneumonia", "DISEASE", 235, 257], ["tumor", "DISEASE", 426, 431], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 13, 20], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 88, 95], ["mice", "ORGANISM", 105, 109], ["cell", "CELL", 342, 346], ["hematopoietic", "CELL", 382, 395], ["epithelial", "CELL", 397, 407], ["endothelial", "CELL", 409, 420], ["tumor cells", "CELL", 426, 437], ["EMMPRIN", "PROTEIN", 13, 20], ["EMMPRIN", "PROTEIN", 88, 95], ["EMMPRIN", "PROTEIN", 264, 271], ["hematopoietic, epithelial, endothelial, and tumor cells", "CELL_TYPE", 382, 437], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["early embryogenesis", "PROBLEM", 47, 66], ["interstitial pneumonia", "PROBLEM", 235, 257], ["hematopoietic, epithelial, endothelial, and tumor cells", "PROBLEM", 382, 437], ["appears to be", "UNCERTAINTY", 21, 34], ["small", "OBSERVATION_MODIFIER", 160, 165], ["interstitial", "ANATOMY_MODIFIER", 235, 247], ["pneumonia", "OBSERVATION", 248, 257], ["cell types", "OBSERVATION", 342, 352], ["hematopoietic", "ANATOMY", 382, 395], ["epithelial", "ANATOMY", 397, 407], ["endothelial", "ANATOMY", 409, 420], ["tumor cells", "OBSERVATION", 426, 437]]], ["Expression profiling of EMMPRIN at the transcript level showed that in humans, EMMPRIN is highly expressed in the heart and skeletal muscle compared with other tested organs, likely demonstrating its importance in metabolism [7] .", [["heart", "ANATOMY", 114, 119], ["skeletal muscle", "ANATOMY", 124, 139], ["organs", "ANATOMY", 167, 173], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 24, 31], ["humans", "ORGANISM", 71, 77], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 79, 86], ["heart", "ORGAN", 114, 119], ["skeletal muscle", "ORGAN", 124, 139], ["organs", "ORGAN", 167, 173], ["EMMPRIN", "PROTEIN", 24, 31], ["EMMPRIN", "PROTEIN", 79, 86], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["EMMPRIN at the transcript level", "TEST", 24, 55], ["heart", "ANATOMY", 114, 119], ["skeletal muscle", "ANATOMY", 124, 139]]], ["The kidney also has high expression levels, as does the testis correlating to its involvement in spermatogenesis [7] .", [["kidney", "ANATOMY", 4, 10], ["testis", "ANATOMY", 56, 62], ["kidney", "ORGAN", 4, 10], ["testis", "ORGAN", 56, 62], ["high expression levels", "PROBLEM", 20, 42], ["kidney", "ANATOMY", 4, 10], ["high expression", "OBSERVATION", 20, 35], ["levels", "OBSERVATION_MODIFIER", 36, 42], ["testis", "ANATOMY", 56, 62]]], ["Of the hematopoietic cells, EMMPRIN is expressed on all leukocytes (monocytes, granulocytes, and lymphocytes) [37] , erythrocytes [38] , and platelets [39] .", [["hematopoietic cells", "ANATOMY", 7, 26], ["leukocytes", "ANATOMY", 56, 66], ["monocytes", "ANATOMY", 68, 77], ["granulocytes", "ANATOMY", 79, 91], ["lymphocytes", "ANATOMY", 97, 108], ["erythrocytes", "ANATOMY", 117, 129], ["platelets", "ANATOMY", 141, 150], ["hematopoietic cells", "CELL", 7, 26], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 28, 35], ["leukocytes", "CELL", 56, 66], ["monocytes", "CELL", 68, 77], ["granulocytes", "CELL", 79, 91], ["lymphocytes", "CELL", 97, 108], ["erythrocytes", "CELL", 117, 129], ["platelets", "CELL", 141, 150], ["hematopoietic cells", "CELL_TYPE", 7, 26], ["EMMPRIN", "PROTEIN", 28, 35], ["leukocytes", "CELL_TYPE", 56, 66], ["monocytes", "CELL_TYPE", 68, 77], ["granulocytes", "CELL_TYPE", 79, 91], ["lymphocytes", "CELL_TYPE", 97, 108], ["erythrocytes", "CELL_TYPE", 117, 129], ["platelets", "CELL_TYPE", 141, 150], ["the hematopoietic cells", "PROBLEM", 3, 26], ["all leukocytes", "TEST", 52, 66], ["monocytes", "TEST", 68, 77], ["granulocytes", "TEST", 79, 91], ["lymphocytes", "TEST", 97, 108], ["erythrocytes", "TEST", 117, 129], ["platelets", "TEST", 141, 150], ["hematopoietic cells", "OBSERVATION", 7, 26], ["lymphocytes", "ANATOMY", 97, 108]]], ["EMMPRIN is up-regulated on activated T cells and also shown recently to serve as a marker for aT regs (CD25 + EMMPRIN + ) versus rT reg or naive T reg (CD25 + EMMPRIN 2 ) in the human system [40, 41] .", [["T cells", "ANATOMY", 37, 44], ["aT regs", "ANATOMY", 94, 101], ["rT reg", "ANATOMY", 129, 135], ["T reg", "ANATOMY", 145, 150], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cells", "CELL", 37, 44], ["aT regs", "GENE_OR_GENE_PRODUCT", 94, 101], ["CD25", "GENE_OR_GENE_PRODUCT", 103, 107], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 110, 117], ["T reg", "GENE_OR_GENE_PRODUCT", 145, 150], ["CD25 + EMMPRIN 2", "GENE_OR_GENE_PRODUCT", 152, 168], ["human", "ORGANISM", 178, 183], ["EMMPRIN", "PROTEIN", 0, 7], ["activated T cells", "CELL_TYPE", 27, 44], ["aT regs", "CELL_TYPE", 94, 101], ["CD25", "PROTEIN", 103, 107], ["EMMPRIN", "PROTEIN", 110, 117], ["rT reg", "CELL_TYPE", 129, 135], ["naive T reg", "CELL_TYPE", 139, 150], ["CD25", "PROTEIN", 152, 156], ["EMMPRIN 2", "PROTEIN", 159, 168], ["human", "SPECIES", 178, 183], ["human", "SPECIES", 178, 183], ["activated T cells", "TREATMENT", 27, 44], ["CD25", "TEST", 103, 107], ["EMMPRIN", "TEST", 110, 117], ["naive T reg (CD25 + EMMPRIN", "TREATMENT", 139, 166]]], ["Furthermore, the labeling with FoxP3, a well-known intracellular T reg marker, and EMMPRIN enables the identification of 3 distinct populations: 1) EMMPRIN low FoxP3 + cells representing rT regs ; 2) EMMPRIN medium FoxP3 + cells, representing T regs that can produce cytokines (reviewed in ref.", [["intracellular", "ANATOMY", 51, 64], ["FoxP3 + cells", "ANATOMY", 160, 173], ["rT regs", "ANATOMY", 187, 194], ["FoxP3 + cells", "ANATOMY", 215, 228], ["T regs", "ANATOMY", 243, 249], ["FoxP3", "GENE_OR_GENE_PRODUCT", 31, 36], ["intracellular T reg", "CELL", 51, 70], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 83, 90], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 148, 155], ["FoxP3", "GENE_OR_GENE_PRODUCT", 160, 165], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 200, 207], ["FoxP3", "GENE_OR_GENE_PRODUCT", 215, 220], ["T regs", "GENE_OR_GENE_PRODUCT", 243, 249], ["FoxP3", "PROTEIN", 31, 36], ["intracellular T reg marker", "PROTEIN", 51, 77], ["EMMPRIN", "PROTEIN", 83, 90], ["EMMPRIN", "PROTEIN", 148, 155], ["FoxP3", "PROTEIN", 160, 165], ["EMMPRIN", "PROTEIN", 200, 207], ["FoxP3", "PROTEIN", 215, 220], ["T regs", "CELL_TYPE", 243, 249], ["cytokines", "PROTEIN", 267, 276], ["EMMPRIN low FoxP3 + cells", "TREATMENT", 148, 173], ["EMMPRIN medium FoxP3 + cells", "TREATMENT", 200, 228], ["rT", "ANATOMY_MODIFIER", 187, 189], ["regs", "ANATOMY", 190, 194]]], ["[41] ), including IL-2, IFN-g, TNF-a, and IL-17; and 3) EMMPRIN high FoxP3 + cells, representing aT regs that do not secrete high levels of cytokines, demonstrate highly suppressive activity, and exhibit demethylation in the T reg -specific demethylated region of the FOXP3 gene, a region whose demethylation status correlates to stabilized FoxP3 expression and suppressive activity [40] .", [["FoxP3 + cells", "ANATOMY", 69, 82], ["aT regs", "ANATOMY", 97, 104], ["T reg", "ANATOMY", 225, 230], ["IL-2", "GENE_OR_GENE_PRODUCT", 18, 22], ["IFN-g", "GENE_OR_GENE_PRODUCT", 24, 29], ["TNF-a", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-17", "GENE_OR_GENE_PRODUCT", 42, 47], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 56, 63], ["FoxP3", "GENE_OR_GENE_PRODUCT", 69, 74], ["aT regs", "GENE_OR_GENE_PRODUCT", 97, 104], ["T reg", "CELL", 225, 230], ["FOXP3", "GENE_OR_GENE_PRODUCT", 268, 273], ["FoxP3", "GENE_OR_GENE_PRODUCT", 341, 346], ["IL", "PROTEIN", 18, 20], ["IFN", "PROTEIN", 24, 27], ["TNF", "PROTEIN", 31, 34], ["EMMPRIN", "PROTEIN", 56, 63], ["FoxP3", "PROTEIN", 69, 74], ["aT regs", "CELL_TYPE", 97, 104], ["cytokines", "PROTEIN", 140, 149], ["T reg", "CELL_TYPE", 225, 230], ["FOXP3 gene", "DNA", 268, 278], ["FoxP3", "PROTEIN", 341, 346], ["IL", "TEST", 18, 20], ["IFN", "TEST", 24, 27], ["TNF", "TEST", 31, 34], ["IL", "TEST", 42, 44], ["EMMPRIN high FoxP3 + cells", "PROBLEM", 56, 82], ["secrete high levels of cytokines", "PROBLEM", 117, 149], ["demethylation in the T reg", "PROBLEM", 204, 230], ["suppressive activity", "OBSERVATION", 170, 190], ["FOXP3", "ANATOMY", 268, 273]]], ["It is unknown if EMMPRIN plays a role in immune homeostasis, but it may serve as a useful marker for T reg subsets when evaluating disease progression.EMMPRIN FUNCTION IN T CELLSEMMPRIN, first characterized as an MMP inducer, is now known to have multiple other functions in different cell types, including T cells [42] .", [["T reg", "ANATOMY", 101, 106], ["cell", "ANATOMY", 285, 289], ["T cells", "ANATOMY", 307, 314], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 17, 24], ["T reg subsets", "CELL", 101, 114], ["MMP", "GENE_OR_GENE_PRODUCT", 213, 216], ["cell", "CELL", 285, 289], ["T cells", "CELL", 307, 314], ["EMMPRIN", "PROTEIN", 17, 24], ["T reg subsets", "CELL_TYPE", 101, 114], ["EMMPRIN", "PROTEIN", 151, 158], ["T CELLSEMMPRIN", "PROTEIN", 171, 185], ["MMP", "PROTEIN", 213, 216], ["T cells", "CELL_TYPE", 307, 314], ["T reg subsets", "TREATMENT", 101, 114], ["disease progression", "PROBLEM", 131, 150], ["an MMP inducer", "PROBLEM", 210, 224], ["different cell types", "OBSERVATION", 275, 295]]], ["Evidence supports a functional role for EMMPRIN at many different stages of T cell activity, such as T cell development, activation, proliferation, migration, adhesion, and invasion (Fig. 2) ; these are steps important in the pathogenesis of various diseases.", [["T cell", "ANATOMY", 76, 82], ["T cell", "ANATOMY", 101, 107], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 40, 47], ["T cell", "CELL", 76, 82], ["T cell", "CELL", 101, 107], ["EMMPRIN", "PROTEIN", 40, 47], ["EMMPRIN", "TREATMENT", 40, 47], ["T cell activity", "PROBLEM", 76, 91], ["T cell development", "PROBLEM", 101, 119], ["proliferation", "PROBLEM", 133, 146], ["migration", "PROBLEM", 148, 157], ["adhesion", "PROBLEM", 159, 167], ["invasion", "PROBLEM", 173, 181], ["various diseases", "PROBLEM", 242, 258], ["cell activity", "OBSERVATION", 78, 91], ["proliferation", "OBSERVATION_MODIFIER", 133, 146], ["migration", "OBSERVATION_MODIFIER", 148, 157], ["adhesion", "OBSERVATION_MODIFIER", 159, 167], ["invasion", "OBSERVATION_MODIFIER", 173, 181], ["various", "OBSERVATION_MODIFIER", 242, 249], ["diseases", "OBSERVATION", 250, 258]]], ["Interestingly, EMMPRIN exemplifies positive/ inducing actions and negative/regulatory actions in T cells.", [["T cells", "ANATOMY", 97, 104], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 15, 22], ["T cells", "CELL", 97, 104], ["EMMPRIN", "PROTEIN", 15, 22], ["T cells", "CELL_TYPE", 97, 104]]], ["Here, we review the details of what is known about the function of EMMPRIN in T cell biology.EMMPRIN in T cell developmentThe thymus is the primary site of T cell ontogeny, where T lymphocyte precursors develop to yield mature CD4 + or CD8 + T cells.", [["T cell", "ANATOMY", 78, 84], ["T cell", "ANATOMY", 104, 110], ["thymus", "ANATOMY", 126, 132], ["T cell", "ANATOMY", 156, 162], ["T lymphocyte precursors", "ANATOMY", 179, 202], ["CD4 +", "ANATOMY", 227, 232], ["CD8 + T cells", "ANATOMY", 236, 249], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 67, 74], ["T cell", "CELL", 78, 84], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 93, 100], ["T cell", "CELL", 104, 110], ["thymus", "ORGAN", 126, 132], ["T cell", "CELL", 156, 162], ["T lymphocyte", "CELL", 179, 191], ["CD4", "GENE_OR_GENE_PRODUCT", 227, 230], ["CD8", "GENE_OR_GENE_PRODUCT", 236, 239], ["EMMPRIN", "PROTEIN", 67, 74], ["EMMPRIN", "PROTEIN", 93, 100], ["T lymphocyte precursors", "CELL_TYPE", 179, 202], ["mature CD4 + or CD8 + T cells", "CELL_TYPE", 220, 249], ["EMMPRIN in T cell development", "TREATMENT", 93, 122], ["T cell ontogeny", "PROBLEM", 156, 171], ["T lymphocyte precursors", "TEST", 179, 202], ["CD8 + T cells", "PROBLEM", 236, 249], ["thymus", "ANATOMY", 126, 132], ["T cell ontogeny", "OBSERVATION", 156, 171]]], ["Upon entry into the thymus, the T cell precursors are classified as DN thymocytes, in which CD4 + and CD8 + surface markers are not expressed.", [["thymus", "ANATOMY", 20, 26], ["T cell precursors", "ANATOMY", 32, 49], ["DN thymocytes", "ANATOMY", 68, 81], ["CD4 +", "ANATOMY", 92, 97], ["CD8 + surface", "ANATOMY", 102, 115], ["thymus", "ORGAN", 20, 26], ["T cell", "CELL", 32, 38], ["DN thymocytes", "CELL", 68, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["T cell precursors", "CELL_TYPE", 32, 49], ["DN thymocytes", "CELL_TYPE", 68, 81], ["CD4", "PROTEIN", 92, 95], ["CD8", "PROTEIN", 102, 105], ["the T cell precursors", "TEST", 28, 49], ["DN thymocytes", "PROBLEM", 68, 81], ["CD4", "TEST", 92, 95], ["surface markers", "TEST", 108, 123], ["thymus", "ANATOMY", 20, 26], ["cell precursors", "OBSERVATION", 34, 49], ["thymocytes", "ANATOMY", 71, 81], ["surface markers", "OBSERVATION", 108, 123]]], ["The first stage of development can be separated into 4 DN phases, distinguished by CD25 and CD44 expression ( Fig. 2A) .", [["CD25", "GENE_OR_GENE_PRODUCT", 83, 87], ["CD44", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD25", "PROTEIN", 83, 87], ["CD44", "PROTEIN", 92, 96], ["CD25", "ANATOMY", 83, 87]]], ["Here, the TCR-b chain is tested for functionality, and a dramatic expansion of functional pre-TCRs ensues, marking the end of the DN phase.", [["TCR", "CHEMICAL", 10, 13], ["TCR-b chain", "GENE_OR_GENE_PRODUCT", 10, 21], ["pre-TCRs", "GENE_OR_GENE_PRODUCT", 90, 98], ["TCR", "PROTEIN", 10, 13], ["pre-TCRs", "PROTEIN", 90, 98], ["the TCR", "TEST", 6, 13], ["a dramatic expansion of functional pre-TCRs", "PROBLEM", 55, 98], ["dramatic", "OBSERVATION_MODIFIER", 57, 65], ["expansion", "OBSERVATION_MODIFIER", 66, 75]]], ["The second stage of T cell development includes the DP thymocytes, which are positive for CD4 and CD8 surface markers, have undergone gene rearrangements for the TCR-a chain and express complete TCR: CD3 complexes.", [["T cell", "ANATOMY", 20, 26], ["DP thymocytes", "ANATOMY", 52, 65], ["CD8 surface", "ANATOMY", 98, 109], ["T cell", "CELL", 20, 26], ["DP thymocytes", "CELL", 52, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 90, 93], ["CD8", "GENE_OR_GENE_PRODUCT", 98, 101], ["TCR", "GENE_OR_GENE_PRODUCT", 162, 165], ["TCR", "GENE_OR_GENE_PRODUCT", 195, 198], ["CD3", "GENE_OR_GENE_PRODUCT", 200, 203], ["DP thymocytes", "CELL_TYPE", 52, 65], ["CD4", "PROTEIN", 90, 93], ["CD8 surface markers", "PROTEIN", 98, 117], ["TCR", "PROTEIN", 162, 165], ["TCR: CD3 complexes", "PROTEIN", 195, 213], ["T cell development", "PROBLEM", 20, 38], ["the DP thymocytes", "TEST", 48, 65], ["CD4", "TEST", 90, 93], ["CD8 surface markers", "TEST", 98, 117], ["gene rearrangements", "TREATMENT", 134, 153], ["the TCR", "TEST", 158, 165], ["T cell development", "OBSERVATION", 20, 38], ["DP thymocytes", "ANATOMY", 52, 65], ["positive for", "UNCERTAINTY", 77, 89], ["CD3 complexes", "OBSERVATION", 200, 213]]], ["Selection processes then occur leading to the 3rd stage: positive selection of CD4 + or CD8 + T cells to yield SP thymocytes and negative selection, which causes the elimination of potential autoreactive T cells by apoptosis [43] (Fig. 2A) .EMMPRIN in T cell developmentEMMPRIN is highly expressed on the surface of all thymocytes ( Fig. 2A) and shown to influence their maturation [44, 45] .", [["CD4 +", "ANATOMY", 79, 84], ["CD8 + T cells", "ANATOMY", 88, 101], ["SP thymocytes", "ANATOMY", 111, 124], ["autoreactive T cells", "ANATOMY", 191, 211], ["T cell", "ANATOMY", 252, 258], ["surface", "ANATOMY", 305, 312], ["thymocytes", "ANATOMY", 320, 330], ["CD4", "GENE_OR_GENE_PRODUCT", 79, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["SP thymocytes", "CELL", 111, 124], ["autoreactive T cells", "CELL", 191, 211], ["T cell", "CELL", 252, 258], ["surface", "CELLULAR_COMPONENT", 305, 312], ["thymocytes", "CELL", 320, 330], ["Fig. 2A", "CELL", 333, 340], ["CD4", "PROTEIN", 79, 82], ["CD8 + T cells", "CELL_TYPE", 88, 101], ["SP thymocytes", "CELL_TYPE", 111, 124], ["autoreactive T cells", "CELL_TYPE", 191, 211], [".EMMPRIN", "PROTEIN", 240, 248], ["developmentEMMPRIN", "PROTEIN", 259, 277], ["thymocytes", "CELL_TYPE", 320, 330], ["CD4", "TEST", 79, 82], ["CD8", "PROBLEM", 88, 91], ["T cells", "PROBLEM", 94, 101], ["potential autoreactive T cells", "PROBLEM", 181, 211], ["apoptosis", "TEST", 215, 224], ["thymocytes", "ANATOMY", 114, 124], ["autoreactive T cells", "OBSERVATION", 191, 211], ["all thymocytes", "ANATOMY", 316, 330]]], ["Whereas all thymocytes express EMMPRIN, the mean fluorescence intensity was higher on cells that cycled more, particularly during the DN3-DN4 transition, where TCR-b-selected cells undergo a proliferative burst [45] .", [["thymocytes", "ANATOMY", 12, 22], ["cells", "ANATOMY", 86, 91], ["cells", "ANATOMY", 175, 180], ["TCR", "CHEMICAL", 160, 163], ["thymocytes", "CELL", 12, 22], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 31, 38], ["cells", "CELL", 86, 91], ["TCR", "GENE_OR_GENE_PRODUCT", 160, 163], ["cells", "CELL", 175, 180], ["thymocytes", "CELL_TYPE", 12, 22], ["EMMPRIN", "PROTEIN", 31, 38], ["TCR", "PROTEIN", 160, 163], ["b-selected cells", "CELL_LINE", 164, 180], ["the mean fluorescence intensity", "TEST", 40, 71], ["TCR", "TEST", 160, 163], ["thymocytes", "ANATOMY", 12, 22]]], ["The presence of an anti-EMMPRIN antibody (clone RL73.2) halted murine thymocyte development by largely reducing levels of the DN4 (CD44 2 CD25 2 ) stage, as well as the DP (CD4 + CD8 + ) and CD4 + SP populations [45] .", [["thymocyte", "ANATOMY", 70, 79], ["CD4 + CD8 + )", "ANATOMY", 173, 186], ["CD4 + SP populations", "ANATOMY", 191, 211], ["anti-EMMPRIN antibody", "GENE_OR_GENE_PRODUCT", 19, 40], ["murine", "ORGANISM", 63, 69], ["thymocyte", "CELL", 70, 79], ["CD44 2 CD25 2", "GENE_OR_GENE_PRODUCT", 131, 144], ["DP", "GENE_OR_GENE_PRODUCT", 169, 171], ["CD4", "GENE_OR_GENE_PRODUCT", 173, 176], ["CD8", "GENE_OR_GENE_PRODUCT", 179, 182], ["CD4", "GENE_OR_GENE_PRODUCT", 191, 194], ["anti-EMMPRIN antibody", "PROTEIN", 19, 40], ["clone RL73.2", "PROTEIN", 42, 54], ["DN4", "PROTEIN", 126, 129], ["CD44", "PROTEIN", 131, 135], ["CD4", "PROTEIN", 173, 176], ["CD8", "PROTEIN", 179, 182], ["CD4", "PROTEIN", 191, 194], ["murine", "SPECIES", 63, 69], ["an anti-EMMPRIN antibody", "TEST", 16, 40], ["the DN4", "TEST", 122, 129], ["CD44", "TEST", 131, 135], ["the DP", "TEST", 165, 171], ["CD4", "TEST", 173, 176], ["CD8", "TEST", 179, 182], ["CD4", "TEST", 191, 194], ["DP", "ANATOMY", 169, 171]]], ["These results were corroborated by the newly generated EMMPRIN-floxed mice, where EMMPRIN was conditionally ablated in T cells by use of the Lck-cre promoter [46] .", [["T cells", "ANATOMY", 119, 126], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 55, 62], ["mice", "ORGANISM", 70, 74], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 82, 89], ["T cells", "CELL", 119, 126], ["Lck", "GENE_OR_GENE_PRODUCT", 141, 144], ["cre", "GENE_OR_GENE_PRODUCT", 145, 148], ["EMMPRIN", "PROTEIN", 55, 62], ["EMMPRIN", "PROTEIN", 82, 89], ["T cells", "CELL_TYPE", 119, 126], ["Lck", "PROTEIN", 141, 144], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["the Lck-cre promoter", "TREATMENT", 137, 157]]], ["The conditional deletion of EMMPRIN in Lck-creexpressing T cells, similar to the addition of anti-EMMPRIN antibodies, resulted in a decrease in DP (CD4 + CD8 + ; not a result of enhanced apoptosis) and CD4 + SP cells.", [["Lck-creexpressing T cells", "ANATOMY", 39, 64], ["CD4 + CD8 +", "ANATOMY", 148, 159], ["CD4 + SP cells", "ANATOMY", 202, 216], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 28, 35], ["Lck", "GENE_OR_GENE_PRODUCT", 39, 42], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 93, 116], ["DP", "GENE_OR_GENE_PRODUCT", 144, 146], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD4", "GENE_OR_GENE_PRODUCT", 202, 205], ["EMMPRIN", "PROTEIN", 28, 35], ["Lck", "PROTEIN", 39, 42], ["creexpressing T cells", "CELL_TYPE", 43, 64], ["anti-EMMPRIN antibodies", "PROTEIN", 93, 116], ["CD4", "PROTEIN", 148, 151], ["CD8", "PROTEIN", 154, 157], ["CD4", "PROTEIN", 202, 205], ["SP cells", "CELL_TYPE", 208, 216], ["EMMPRIN in Lck", "TEST", 28, 42], ["creexpressing T cells", "PROBLEM", 43, 64], ["anti-EMMPRIN antibodies", "TREATMENT", 93, 116], ["a decrease in DP", "PROBLEM", 130, 146], ["CD4", "TEST", 148, 151], ["enhanced apoptosis", "PROBLEM", 178, 196], ["CD4 + SP cells", "PROBLEM", 202, 216], ["decrease", "OBSERVATION_MODIFIER", 132, 140], ["DP", "ANATOMY", 144, 146], ["SP cells", "OBSERVATION", 208, 216]]], ["A significant drop in thymus weight and cell number was also apparent.", [["thymus", "ANATOMY", 22, 28], ["cell", "ANATOMY", 40, 44], ["thymus", "ORGAN", 22, 28], ["cell", "CELL", 40, 44], ["A significant drop in thymus weight", "PROBLEM", 0, 35], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["drop", "OBSERVATION", 14, 18], ["thymus", "ANATOMY", 22, 28], ["cell number", "OBSERVATION", 40, 51]]], ["Although the DN phase as a whole showed no alterations in EMMPRIN 2/2 thymocytes, the 4 DN stages were not assessed separately to analyze if there were any differences at the DN4 stage [46] .", [["EMMPRIN 2/2 thymocytes", "ANATOMY", 58, 80], ["EMMPRIN 2/2", "GENE_OR_GENE_PRODUCT", 58, 69], ["EMMPRIN", "PROTEIN", 58, 65], ["thymocytes", "CELL_TYPE", 70, 80], ["the DN phase", "TEST", 9, 21], ["EMMPRIN 2/2 thymocytes", "TREATMENT", 58, 80]]], ["As the cycling ability of thymocytes was suggested to correlate with EMMPRIN-expression levels, it is reasonable to assume that EMMPRIN plays a role in the dramatic expansion of the DN4 phase.", [["thymocytes", "ANATOMY", 26, 36], ["thymocytes", "CELL", 26, 36], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 69, 76], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 128, 135], ["thymocytes", "CELL_TYPE", 26, 36], ["EMMPRIN", "PROTEIN", 69, 76], ["EMMPRIN", "PROTEIN", 128, 135], ["EMMPRIN-expression levels", "TEST", 69, 94], ["the DN4 phase", "TEST", 178, 191]]], ["The rapid proliferation of thymocytes likely undergoes glycolysis to meet energy demands, thus leading to the buildup of toxic intracellular lactate levels [47] .", [["thymocytes", "ANATOMY", 27, 37], ["intracellular", "ANATOMY", 127, 140], ["lactate", "CHEMICAL", 141, 148], ["lactate", "CHEMICAL", 141, 148], ["thymocytes", "CELL", 27, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 140], ["lactate", "SIMPLE_CHEMICAL", 141, 148], ["thymocytes", "CELL_TYPE", 27, 37], ["The rapid proliferation of thymocytes", "PROBLEM", 0, 37], ["toxic intracellular lactate levels", "TEST", 121, 155], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["proliferation", "OBSERVATION", 10, 23], ["thymocytes", "OBSERVATION", 27, 37], ["likely", "UNCERTAINTY", 38, 44], ["toxic", "OBSERVATION_MODIFIER", 121, 126]]], ["In this way, it is possible that EMMPRIN is needed as a chaperone to shuttle MCTs up to the surface to export the toxic lactate build-up out of the cells.", [["surface", "ANATOMY", 92, 99], ["cells", "ANATOMY", 148, 153], ["lactate", "CHEMICAL", 120, 127], ["lactate", "CHEMICAL", 120, 127], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 33, 40], ["MCTs", "GENE_OR_GENE_PRODUCT", 77, 81], ["surface", "CELLULAR_COMPONENT", 92, 99], ["lactate", "SIMPLE_CHEMICAL", 120, 127], ["cells", "CELL", 148, 153], ["EMMPRIN", "PROTEIN", 33, 40], ["the toxic lactate", "TEST", 110, 127], ["toxic", "OBSERVATION_MODIFIER", 114, 119], ["cells", "ANATOMY", 148, 153]]], ["The absence of EMMPRIN would hinder this export, possibly leading to cell death or alternate metabolic pathways.EMMPRIN in T cell activation and proliferationEvidence illustrates that EMMPRIN plays a role in T cell activation and proliferation; however, it seems to display different functional responses at particular phases of T cell activity.", [["cell", "ANATOMY", 69, 73], ["T cell", "ANATOMY", 123, 129], ["T cell", "ANATOMY", 208, 214], ["T cell", "ANATOMY", 329, 335], ["death", "DISEASE", 74, 79], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 15, 22], ["cell", "CELL", 69, 73], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 112, 119], ["T cell", "CELL", 123, 129], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 184, 191], ["T cell", "CELL", 208, 214], ["T cell", "CELL", 329, 335], ["EMMPRIN", "PROTEIN", 15, 22], ["EMMPRIN", "PROTEIN", 112, 119], ["EMMPRIN", "PROTEIN", 184, 191], ["cell death", "PROBLEM", 69, 79], ["EMMPRIN in T cell activation", "TREATMENT", 112, 140], ["cell", "OBSERVATION", 125, 129], ["cell activity", "OBSERVATION", 331, 344]]], ["As EMMPRIN levels are high in thymocytes ( Fig. 2A) , its levels in the periphery of resting T cells are low (Fig. 2B ) [44] and become up-regulated upon T cell activation (Fig. 2C) [44, 48, 49] .", [["thymocytes", "ANATOMY", 30, 40], ["periphery", "ANATOMY", 72, 81], ["T cells", "ANATOMY", 93, 100], ["T cell", "ANATOMY", 154, 160], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 3, 10], ["thymocytes", "CELL", 30, 40], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 43, 50], ["T cells", "CELL", 93, 100], ["T cell", "CELL", 154, 160], ["EMMPRIN", "PROTEIN", 3, 10], ["thymocytes", "CELL_TYPE", 30, 40], ["resting T cells", "CELL_TYPE", 85, 100], ["EMMPRIN levels", "TEST", 3, 17], ["its levels", "TEST", 54, 64], ["resting T cells", "TEST", 85, 100], ["high", "OBSERVATION_MODIFIER", 22, 26], ["periphery", "ANATOMY_MODIFIER", 72, 81]]], ["It was demonstrated that EMMPRIN negatively regulates/inhibits T cell proliferation in a MLR, where splenocytes from EMMPRIN 2/2 animals exhibited an enhanced, proliferative response compared with wild-type splenocytes when cocultured with irradiated BALB/c splenocytes [30] .", [["T cell", "ANATOMY", 63, 69], ["splenocytes", "ANATOMY", 100, 111], ["splenocytes", "ANATOMY", 207, 218], ["BALB/c splenocytes", "ANATOMY", 251, 269], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 25, 32], ["T cell", "CELL", 63, 69], ["splenocytes", "CELL", 100, 111], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 117, 124], ["splenocytes", "CELL", 207, 218], ["BALB/c splenocytes", "ORGANISM", 251, 269], ["EMMPRIN", "PROTEIN", 25, 32], ["splenocytes", "CELL_TYPE", 100, 111], ["EMMPRIN", "PROTEIN", 117, 124], ["wild-type splenocytes", "CELL_TYPE", 197, 218], ["irradiated BALB/c splenocytes", "CELL_LINE", 240, 269], ["T cell proliferation", "PROBLEM", 63, 83], ["a MLR", "TEST", 87, 92], ["splenocytes", "TEST", 100, 111], ["EMMPRIN", "TEST", 117, 124], ["an enhanced, proliferative response", "PROBLEM", 147, 182], ["type splenocytes", "PROBLEM", 202, 218], ["irradiated BALB/c splenocytes", "PROBLEM", 240, 269], ["cell proliferation", "OBSERVATION", 65, 83], ["splenocytes", "ANATOMY", 100, 111], ["proliferative response", "OBSERVATION", 160, 182]]], ["A similar response was observed in anti-CD3/CD28-stimulated, EMMPRIN 2/2 T cells from Lck-Cre; Figure 2 .", [["EMMPRIN 2/2 T cells", "ANATOMY", 61, 80], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 35, 43], ["CD28", "GENE_OR_GENE_PRODUCT", 44, 48], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 61, 68], ["Lck", "GENE_OR_GENE_PRODUCT", 86, 89], ["anti-CD3", "PROTEIN", 35, 43], ["CD28", "PROTEIN", 44, 48], ["EMMPRIN 2/2 T cells", "CELL_LINE", 61, 80], ["Lck", "PROTEIN", 86, 89], ["Cre", "PROTEIN", 90, 93], ["anti-CD3", "TEST", 35, 43], ["CD28", "TEST", 44, 48], ["EMMPRIN", "TEST", 61, 68], ["Lck", "TEST", 86, 89], ["Cre", "TEST", 90, 93]]], ["The role of EMMPRIN in T cell biology.", [["T cell", "ANATOMY", 23, 29], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 12, 19], ["T cell", "CELL", 23, 29], ["EMMPRIN", "PROTEIN", 12, 19]]], ["EMMPRIN is involved in T cell development, activation, proliferation, migration, invasion, adhesion, and energy metabolism.", [["T cell", "ANATOMY", 23, 29], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell", "CELL", 23, 29], ["EMMPRIN", "PROTEIN", 0, 7], ["T cell development", "TREATMENT", 23, 41], ["proliferation", "PROBLEM", 55, 68], ["invasion", "PROBLEM", 81, 89], ["adhesion", "PROBLEM", 91, 99], ["migration", "OBSERVATION_MODIFIER", 70, 79], ["invasion", "OBSERVATION_MODIFIER", 81, 89]]], ["It is highly expressed in thymocytes during T cell development, playing a role in the transition phase from DN3 to DN4, where a proliferative burst occurs (A).", [["thymocytes", "ANATOMY", 26, 36], ["T cell", "ANATOMY", 44, 50], ["thymocytes", "CELL", 26, 36], ["T cell", "CELL", 44, 50], ["DN3", "CELL", 108, 111], ["DN4", "CELL", 115, 118], ["thymocytes", "CELL_TYPE", 26, 36], ["DN3", "CELL_TYPE", 108, 111], ["DN4", "CELL_TYPE", 115, 118], ["thymocytes", "OBSERVATION", 26, 36]]], ["In the periphery, EMMPRIN expression levels are low and localize to the immune synapse upon TCR-mediated T cell activation.", [["immune synapse", "ANATOMY", 72, 86], ["T cell", "ANATOMY", 105, 111], ["TCR", "CHEMICAL", 92, 95], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["immune synapse", "CELLULAR_COMPONENT", 72, 86], ["TCR", "GENE_OR_GENE_PRODUCT", 92, 95], ["T cell", "CELL", 105, 111], ["EMMPRIN", "PROTEIN", 18, 25], ["TCR", "PROTEIN", 92, 95], ["EMMPRIN expression levels", "TEST", 18, 43], ["TCR", "TEST", 92, 95], ["T cell activation", "PROBLEM", 105, 122], ["periphery", "ANATOMY_MODIFIER", 7, 16]]], ["TCR-MHC engagement leads to the up-regulation of CD40 ligand (CD40L; Signal 1), allowing for B7-CD28 costimulation (Signal 2).", [["TCR", "CHEMICAL", 0, 3], ["TCR-MHC", "GENE_OR_GENE_PRODUCT", 0, 7], ["CD40 ligand", "GENE_OR_GENE_PRODUCT", 49, 60], ["CD40L", "GENE_OR_GENE_PRODUCT", 62, 67], ["Signal 1", "GENE_OR_GENE_PRODUCT", 69, 77], ["B7-CD28", "GENE_OR_GENE_PRODUCT", 93, 100], ["Signal 2", "GENE_OR_GENE_PRODUCT", 116, 124], ["TCR", "PROTEIN", 0, 3], ["MHC", "PROTEIN", 4, 7], ["CD40 ligand", "PROTEIN", 49, 60], ["CD40L", "PROTEIN", 62, 67], ["Signal 1", "PROTEIN", 69, 77], ["B7", "PROTEIN", 93, 95], ["CD28", "PROTEIN", 96, 100], ["TCR", "TEST", 0, 3], ["B7-CD28 costimulation", "TREATMENT", 93, 114], ["CD40", "ANATOMY", 49, 53]]], ["APCs also express EMMPRIN, where it may act as an alternate costimulator to provide \"Signal 2\" for T cell activation.", [["APCs", "ANATOMY", 0, 4], ["T cell", "ANATOMY", 99, 105], ["APCs", "CELL", 0, 4], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["Signal 2", "GENE_OR_GENE_PRODUCT", 85, 93], ["T cell", "CELL", 99, 105], ["APCs", "CELL_TYPE", 0, 4], ["EMMPRIN", "PROTEIN", 18, 25], ["T cell activation", "PROBLEM", 99, 116]]], ["EMMPRIN interacts with a number of molecules regulating adhesion (see Fig. 3 ), which could play a role in immune synapse formation (B).", [["immune synapse", "ANATOMY", 107, 121], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["see Fig. 3", "GENE_OR_GENE_PRODUCT", 66, 76], ["immune synapse", "CELLULAR_COMPONENT", 107, 121], ["EMMPRIN", "PROTEIN", 0, 7]]], ["Once T cells are activated, EMMPRIN levels are up-regulated and involved in a number of actions (C; see text for further details).", [["T cells", "ANATOMY", 5, 12], ["T cells", "CELL", 5, 12], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 28, 35], ["T cells", "CELL_TYPE", 5, 12], ["EMMPRIN", "PROTEIN", 28, 35], ["EMMPRIN levels", "TEST", 28, 42]]], ["MHC, major histocompatibility complex.EMMPRIN in T cell activation and proliferationEMMPRIN flox/flox mice, which also revealed elevated CD69 levels, an early T cell activation marker [46] .", [["T cell", "ANATOMY", 49, 55], ["T cell", "ANATOMY", 159, 165], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 5, 37], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 38, 45], ["T cell", "CELL", 49, 55], ["proliferationEMMPRIN flox", "GENE_OR_GENE_PRODUCT", 71, 96], ["flox", "GENE_OR_GENE_PRODUCT", 97, 101], ["CD69", "GENE_OR_GENE_PRODUCT", 137, 141], ["T cell", "CELL", 159, 165], ["MHC", "PROTEIN", 0, 3], ["major histocompatibility complex", "PROTEIN", 5, 37], ["EMMPRIN", "PROTEIN", 38, 45], ["CD69", "PROTEIN", 137, 141], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 102, 106], ["EMMPRIN in T cell activation", "TEST", 38, 66], ["proliferationEMMPRIN flox/flox mice", "TEST", 71, 106], ["elevated CD69 levels", "PROBLEM", 128, 148], ["histocompatibility complex", "OBSERVATION", 11, 37], ["elevated", "OBSERVATION_MODIFIER", 128, 136], ["CD69 levels", "OBSERVATION", 137, 148]]], ["At the resting state, spleen weight and proportions of CD8 and CD4 expression levels were no different between EMMPRIN 2/2 T cells and their controls [46] .", [["spleen", "ANATOMY", 22, 28], ["EMMPRIN 2/2 T cells", "ANATOMY", 111, 130], ["spleen", "ORGAN", 22, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 55, 58], ["CD4", "GENE_OR_GENE_PRODUCT", 63, 66], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 111, 118], ["CD8", "PROTEIN", 55, 58], ["CD4", "PROTEIN", 63, 66], ["EMMPRIN", "PROTEIN", 111, 118], ["T cells", "CELL_TYPE", 123, 130], ["spleen weight", "TEST", 22, 35], ["CD8", "TEST", 55, 58], ["CD4 expression levels", "TEST", 63, 84], ["spleen", "ANATOMY", 22, 28]]], ["In the human system, knockdown of EMMPRIN by use of siRNA in primary cells also increased T cell proliferation (without any changes in CD25 expression) upon activation with PHA, a surface receptor cross-linker [50] .", [["primary cells", "ANATOMY", 61, 74], ["T cell", "ANATOMY", 90, 96], ["surface", "ANATOMY", 180, 187], ["PHA", "CHEMICAL", 173, 176], ["PHA", "CHEMICAL", 173, 176], ["human", "ORGANISM", 7, 12], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 34, 41], ["cells", "CELL", 69, 74], ["T cell", "CELL", 90, 96], ["CD25", "GENE_OR_GENE_PRODUCT", 135, 139], ["PHA", "SIMPLE_CHEMICAL", 173, 176], ["EMMPRIN", "PROTEIN", 34, 41], ["primary cells", "CELL_TYPE", 61, 74], ["CD25", "PROTEIN", 135, 139], ["PHA", "PROTEIN", 173, 176], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["EMMPRIN", "TREATMENT", 34, 41], ["siRNA in primary cells", "PROBLEM", 52, 74], ["increased T cell proliferation", "PROBLEM", 80, 110], ["PHA", "TREATMENT", 173, 176], ["a surface receptor cross-linker", "TREATMENT", 178, 209], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["T cell proliferation", "OBSERVATION", 90, 110]]], ["These results demonstrate EMMPRIN having a negative/inhibitory effect on T cell activation.EMMPRIN in T cell activation and proliferationIn contrast, numerous studies that use antibodies against EMMPRIN (e.g., clone MEM-M6/6, 5A12, or clone 10) have shown that these antibodies suppress T cell proliferation in human PBMCs [48, [51] [52] [53] [54] .", [["T cell", "ANATOMY", 73, 79], ["T cell", "ANATOMY", 102, 108], ["T cell", "ANATOMY", 287, 293], ["PBMCs", "ANATOMY", 317, 322], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 26, 33], ["T cell", "CELL", 73, 79], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 91, 98], ["T cell", "CELL", 102, 108], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 195, 202], ["clone MEM-M6/6", "GENE_OR_GENE_PRODUCT", 210, 224], ["5A12", "GENE_OR_GENE_PRODUCT", 226, 230], ["T cell", "CELL", 287, 293], ["human", "ORGANISM", 311, 316], ["PBMCs", "CELL", 317, 322], ["[51] [52", "SIMPLE_CHEMICAL", 328, 336], ["EMMPRIN", "PROTEIN", 26, 33], ["EMMPRIN", "PROTEIN", 91, 98], ["antibodies", "PROTEIN", 176, 186], ["EMMPRIN", "PROTEIN", 195, 202], ["M6/6", "CELL_LINE", 220, 224], ["5A12", "CELL_LINE", 226, 230], ["clone 10", "CELL_LINE", 235, 243], ["antibodies", "PROTEIN", 267, 277], ["human PBMCs", "CELL_TYPE", 311, 322], ["human", "SPECIES", 311, 316], ["human", "SPECIES", 311, 316], ["T cell activation", "TREATMENT", 73, 90], ["EMMPRIN in T cell activation", "TEST", 91, 119], ["proliferationIn contrast", "TEST", 124, 148], ["numerous studies", "TEST", 150, 166], ["antibodies", "TEST", 176, 186], ["EMMPRIN", "TEST", 195, 202], ["clone MEM", "TEST", 210, 219], ["these antibodies", "TEST", 261, 277], ["human PBMCs", "TEST", 311, 322]]], ["It is suggested that anti-EMMPRIN antibodies may be acting as agonists, mimicking ligand engagement [51, 52] .", [["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 21, 44], ["anti-EMMPRIN antibodies", "PROTEIN", 21, 44], ["anti-EMMPRIN antibodies", "TREATMENT", 21, 44]]], ["Interestingly, EMMPRIN 2/2 T cells or anti-EMMPRIN antibodies only altered the proliferation of T cells when stimulated with anti-CD3/CD28 and not with PMA/ ionomycin (a stimulant that bypasses the need for surface receptors).", [["EMMPRIN 2/2 T cells", "ANATOMY", 15, 34], ["T cells", "ANATOMY", 96, 103], ["surface", "ANATOMY", 207, 214], ["PMA", "CHEMICAL", 152, 155], ["ionomycin", "CHEMICAL", 157, 166], ["PMA", "CHEMICAL", 152, 155], ["ionomycin", "CHEMICAL", 157, 166], ["EMMPRIN 2/2", "GENE_OR_GENE_PRODUCT", 15, 26], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 38, 61], ["T cells", "CELL", 96, 103], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 125, 133], ["CD28", "GENE_OR_GENE_PRODUCT", 134, 138], ["PMA", "SIMPLE_CHEMICAL", 152, 155], ["ionomycin", "SIMPLE_CHEMICAL", 157, 166], ["EMMPRIN", "PROTEIN", 15, 22], ["T cells", "CELL_TYPE", 27, 34], ["anti-EMMPRIN antibodies", "PROTEIN", 38, 61], ["T cells", "CELL_TYPE", 96, 103], ["anti-CD3", "PROTEIN", 125, 133], ["CD28", "PROTEIN", 134, 138], ["surface receptors", "PROTEIN", 207, 224], ["EMMPRIN 2/2 T cells", "TEST", 15, 34], ["anti-EMMPRIN antibodies", "TEST", 38, 61], ["the proliferation of T cells", "PROBLEM", 75, 103], ["anti-CD3/CD28", "TREATMENT", 125, 138], ["PMA", "TREATMENT", 152, 155], ["ionomycin", "TREATMENT", 157, 166], ["surface receptors", "TREATMENT", 207, 224]]], ["This implies that EMMPRIN is involved at the very early stages of T cell activation involving TCRs or costimulators [46, 51] .", [["T cell", "ANATOMY", 66, 72], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["T cell", "CELL", 66, 72], ["TCRs", "GENE_OR_GENE_PRODUCT", 94, 98], ["EMMPRIN", "PROTEIN", 18, 25], ["TCRs", "PROTEIN", 94, 98], ["costimulators", "PROTEIN", 102, 115]]], ["Minutes after TCR-dependent activation, EMMPRIN aggregates to immune synapses ( Fig. 2B) , an area formed upon T cell activation that is densely packed with receptors and signaling molecules pivotal in initiating T cell activation.", [["immune synapses", "ANATOMY", 62, 77], ["area", "ANATOMY", 94, 98], ["T cell", "ANATOMY", 111, 117], ["T cell", "ANATOMY", 213, 219], ["TCR", "CHEMICAL", 14, 17], ["TCR", "GENE_OR_GENE_PRODUCT", 14, 17], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 40, 47], ["immune synapses", "CELLULAR_COMPONENT", 62, 77], ["T cell", "CELL", 111, 117], ["T cell", "CELL", 213, 219], ["TCR", "PROTEIN", 14, 17], ["EMMPRIN", "PROTEIN", 40, 47], ["signaling molecules", "PROTEIN", 171, 190], ["TCR-dependent activation", "TREATMENT", 14, 38], ["EMMPRIN aggregates", "TREATMENT", 40, 58], ["immune synapses", "PROBLEM", 62, 77], ["an area", "PROBLEM", 91, 98], ["T cell activation", "TREATMENT", 111, 128], ["receptors", "TREATMENT", 157, 166], ["signaling molecules pivotal", "PROBLEM", 171, 198], ["T cell activation", "TREATMENT", 213, 230], ["T cell activation", "OBSERVATION", 111, 128], ["densely packed", "OBSERVATION_MODIFIER", 137, 151], ["cell activation", "OBSERVATION", 215, 230]]], ["EMMPRIN colocalized with immune synapse markers, including CD4, CD8, CD48, and GM1 [51, 52] , whereas the presence of anti-EMMPRIN antibodies (both clone MEM-M6/6 and 5A12) altered the formation of these immune synapses [51, 52] .", [["immune synapse", "ANATOMY", 25, 39], ["immune synapses", "ANATOMY", 204, 219], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["CD48", "GENE_OR_GENE_PRODUCT", 69, 73], ["GM1", "GENE_OR_GENE_PRODUCT", 79, 82], ["anti-EMMPRIN", "GENE_OR_GENE_PRODUCT", 118, 130], ["5A12", "GENE_OR_GENE_PRODUCT", 167, 171], ["EMMPRIN", "PROTEIN", 0, 7], ["immune synapse markers", "PROTEIN", 25, 47], ["CD4", "PROTEIN", 59, 62], ["CD8", "PROTEIN", 64, 67], ["CD48", "PROTEIN", 69, 73], ["GM1", "PROTEIN", 79, 82], ["anti-EMMPRIN antibodies", "PROTEIN", 118, 141], ["5A12", "PROTEIN", 167, 171], ["immune synapse markers", "TEST", 25, 47], ["CD4", "TEST", 59, 62], ["CD8", "TEST", 64, 67], ["CD48", "TEST", 69, 73], ["GM1", "TEST", 79, 82], ["anti-EMMPRIN antibodies", "TEST", 118, 141], ["clone MEM", "TEST", 148, 157], ["these immune synapses", "PROBLEM", 198, 219], ["immune synapses", "OBSERVATION", 204, 219]]], ["Administration of the MEM-M6/6 clone upon TCR-mediated activation displaced the T cell coreceptors CD48 and CD59 from lipid rafts, leading to reduced expression of the T cell activation marker CD25 and hence, reduced T cell proliferation.", [["T cell", "ANATOMY", 80, 86], ["lipid rafts", "ANATOMY", 118, 129], ["T cell", "ANATOMY", 168, 174], ["T cell", "ANATOMY", 217, 223], ["TCR", "CHEMICAL", 42, 45], ["MEM-M6/6 clone", "CELL", 22, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 42, 45], ["T cell", "CELL", 80, 86], ["CD48", "GENE_OR_GENE_PRODUCT", 99, 103], ["CD59", "GENE_OR_GENE_PRODUCT", 108, 112], ["lipid rafts", "CELLULAR_COMPONENT", 118, 129], ["T cell", "CELL", 168, 174], ["CD25", "GENE_OR_GENE_PRODUCT", 193, 197], ["T cell", "CELL", 217, 223], ["TCR", "PROTEIN", 42, 45], ["T cell coreceptors", "PROTEIN", 80, 98], ["CD48", "PROTEIN", 99, 103], ["CD59", "PROTEIN", 108, 112], ["T cell activation marker", "PROTEIN", 168, 192], ["CD25", "PROTEIN", 193, 197], ["the MEM", "TREATMENT", 18, 25], ["TCR", "TEST", 42, 45], ["CD59 from lipid rafts", "TEST", 108, 129], ["reduced T cell proliferation", "PROBLEM", 209, 237], ["reduced", "OBSERVATION_MODIFIER", 209, 216], ["T cell proliferation", "OBSERVATION", 217, 237]]], ["Transcripts for IFN-g, IL-15, IL-4, and IL-10, among other cytokines (12 hours after activation), were also diminished.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL-15", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-4", "GENE_OR_GENE_PRODUCT", 30, 34], ["IL-10", "GENE_OR_GENE_PRODUCT", 40, 45], ["IFN", "PROTEIN", 16, 19], ["IL", "PROTEIN", 40, 42], ["cytokines", "PROTEIN", 59, 68], ["IFN", "TEST", 16, 19], ["IL", "TEST", 23, 25], ["IL", "TEST", 30, 32], ["IL", "TEST", 40, 42], ["diminished", "OBSERVATION_MODIFIER", 108, 118]]], ["However, not all microdomains were affected by this antibody, as the distribution pattern of Lck did not change nor did tyrosine phosphorylation levels (5 minutes after activation), as well as IL-2 levels (24 hours after activation) [51] .", [["microdomains", "ANATOMY", 17, 29], ["tyrosine", "CHEMICAL", 120, 128], ["tyrosine", "CHEMICAL", 120, 128], ["Lck", "GENE_OR_GENE_PRODUCT", 93, 96], ["tyrosine", "AMINO_ACID", 120, 128], ["IL-2", "GENE_OR_GENE_PRODUCT", 193, 197], ["Lck", "PROTEIN", 93, 96], ["IL", "PROTEIN", 193, 195], ["all microdomains", "PROBLEM", 13, 29], ["this antibody", "TEST", 47, 60], ["tyrosine phosphorylation levels", "TEST", 120, 151], ["Lck", "OBSERVATION", 93, 96]]], ["Another EMMPRIN antibody, 5A12 clone (which docks to the EC1 domain of EMMPRIN), had similar and contrasting effects from that of the MEM-M6/6 clone (which recognizes the EC2 domain) upon TCR-mediated activation of human T cells.", [["T cells", "ANATOMY", 221, 228], ["TCR", "CHEMICAL", 188, 191], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 8, 15], ["5A12 clone", "GENE_OR_GENE_PRODUCT", 26, 36], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 71, 78], ["MEM-M6/6 clone", "CELL", 134, 148], ["TCR", "GENE_OR_GENE_PRODUCT", 188, 191], ["human", "ORGANISM", 215, 220], ["T cells", "CELL", 221, 228], ["EMMPRIN antibody", "PROTEIN", 8, 24], ["5A12 clone", "PROTEIN", 26, 36], ["EC1 domain", "PROTEIN", 57, 67], ["EMMPRIN", "PROTEIN", 71, 78], ["MEM-M6/6 clone", "CELL_LINE", 134, 148], ["EC2 domain", "PROTEIN", 171, 181], ["TCR", "PROTEIN", 188, 191], ["human T cells", "CELL_TYPE", 215, 228], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["Another EMMPRIN antibody", "TEST", 0, 24], ["the MEM", "TEST", 130, 137], ["TCR", "TEST", 188, 191], ["human T cells", "PROBLEM", 215, 228]]], ["The 5A12 clone demonstrated reduced CD25 and IL-4 protein levels; however, the 5A12 clone also decreased tyrosine phosphorylation (2 hours after activation), EC calcium influx, and IL-2 protein levels, in addition to increased IFN-g protein levels (72 hours after activation) [52] .", [["5A12 clone", "ANATOMY", 4, 14], ["EC", "ANATOMY", 158, 160], ["tyrosine", "CHEMICAL", 105, 113], ["calcium", "CHEMICAL", 161, 168], ["tyrosine", "CHEMICAL", 105, 113], ["calcium", "CHEMICAL", 161, 168], ["5A12 clone", "CELL", 4, 14], ["CD25", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-4", "GENE_OR_GENE_PRODUCT", 45, 49], ["5A12 clone", "CELL", 79, 89], ["tyrosine", "AMINO_ACID", 105, 113], ["EC", "CELL", 158, 160], ["calcium", "SIMPLE_CHEMICAL", 161, 168], ["IL-2", "GENE_OR_GENE_PRODUCT", 181, 185], ["IFN-g", "GENE_OR_GENE_PRODUCT", 227, 232], ["5A12 clone", "CELL_LINE", 4, 14], ["CD25", "PROTEIN", 36, 40], ["5A12 clone", "CELL_LINE", 79, 89], ["EC", "CELL_TYPE", 158, 160], ["IFN", "PROTEIN", 227, 230], ["The 5A12 clone", "TEST", 0, 14], ["IL", "TEST", 45, 47], ["protein levels", "TEST", 50, 64], ["tyrosine phosphorylation", "TREATMENT", 105, 129], ["EC calcium influx", "TEST", 158, 175], ["IL", "TEST", 181, 183], ["protein levels", "TEST", 186, 200], ["increased IFN", "PROBLEM", 217, 230], ["protein levels", "TEST", 233, 247], ["reduced", "OBSERVATION_MODIFIER", 28, 35], ["CD25", "OBSERVATION", 36, 40], ["increased", "OBSERVATION_MODIFIER", 217, 226]]], ["The differences in antibody responses could be a result of differences in experimental methods (e.g., the time analyzed after T cell activation) or perhaps a result of the different functional domains/epitopes of EMMPRIN that the antibodies recognize and to which they bind ( Table 1) .", [["T cell", "ANATOMY", 126, 132], ["T cell", "CELL", 126, 132], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 213, 220], ["epitopes", "PROTEIN", 201, 209], ["EMMPRIN", "PROTEIN", 213, 220], ["antibodies", "PROTEIN", 230, 240], ["experimental methods", "TEST", 74, 94], ["T cell activation", "PROBLEM", 126, 143], ["EMMPRIN", "TREATMENT", 213, 220]]], ["If these antibodies act as agonists, this suggests that the inhibitory effect of EMMPRIN upon TCR-dependent activation works to trigger the dissociation of certain molecules from microdomains to help shut down T cell responses.", [["microdomains", "ANATOMY", 179, 191], ["T cell", "ANATOMY", 210, 216], ["TCR", "CHEMICAL", 94, 97], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 81, 88], ["TCR", "GENE_OR_GENE_PRODUCT", 94, 97], ["T cell", "CELL", 210, 216], ["antibodies", "PROTEIN", 9, 19], ["EMMPRIN", "PROTEIN", 81, 88], ["TCR", "PROTEIN", 94, 97], ["EMMPRIN upon TCR", "TREATMENT", 81, 97]]], ["The mechanism behind the involvement of EMMPRIN in T cell activation still needs to be defined clearly. mAbs toward EMMPRIN demonstrate additional differences.", [["T cell", "ANATOMY", 51, 57], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 40, 47], ["T cell", "CELL", 51, 57], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 116, 123], ["EMMPRIN", "PROTEIN", 40, 47], ["mAbs", "PROTEIN", 104, 108], ["EMMPRIN", "PROTEIN", 116, 123], ["EMMPRIN in T cell activation", "TREATMENT", 40, 68]]], ["In the mouse, the anti-EMMPRIN mAb (RL73.2 clone) was able to inhibit the migration of T cells and monocytes toward CyPA and reduce disease severity of mouse models of RA and lung inflammation (see section below) [61] [62] [63] ; however, the antibody was unable to inhibit the proliferation of MOG-primed T cells [64] or inhibit the release of MMP-9 in a coculture of fibroblasts and mouse macrophages.", [["T cells", "ANATOMY", 87, 94], ["monocytes", "ANATOMY", 99, 108], ["RA", "ANATOMY", 168, 170], ["lung", "ANATOMY", 175, 179], ["T cells", "ANATOMY", 306, 313], ["fibroblasts", "ANATOMY", 369, 380], ["macrophages", "ANATOMY", 391, 402], ["RA", "DISEASE", 168, 170], ["lung inflammation", "DISEASE", 175, 192], ["mouse", "ORGANISM", 7, 12], ["anti-EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 18, 34], ["RL73.2 clone", "CELL", 36, 48], ["T cells", "CELL", 87, 94], ["monocytes", "CELL", 99, 108], ["CyPA", "GENE_OR_GENE_PRODUCT", 116, 120], ["mouse", "ORGANISM", 152, 157], ["lung", "ORGAN", 175, 179], ["MOG", "GENE_OR_GENE_PRODUCT", 295, 298], ["T cells", "CELL", 306, 313], ["MMP-9", "GENE_OR_GENE_PRODUCT", 345, 350], ["fibroblasts", "CELL", 369, 380], ["mouse", "ORGANISM", 385, 390], ["macrophages", "CELL", 391, 402], ["anti-EMMPRIN mAb", "PROTEIN", 18, 34], ["RL73.2 clone", "CELL_LINE", 36, 48], ["T cells", "CELL_TYPE", 87, 94], ["monocytes", "CELL_TYPE", 99, 108], ["MOG-primed T cells", "CELL_LINE", 295, 313], ["MMP-9", "PROTEIN", 345, 350], ["fibroblasts", "CELL_TYPE", 369, 380], ["mouse macrophages", "CELL_TYPE", 385, 402], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 385, 390], ["mouse", "SPECIES", 7, 12], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 385, 390], ["the anti-EMMPRIN mAb", "TREATMENT", 14, 34], ["CyPA", "TEST", 116, 120], ["reduce disease severity of mouse models of RA", "PROBLEM", 125, 170], ["lung inflammation", "PROBLEM", 175, 192], ["the antibody", "TEST", 239, 251], ["MOG", "TEST", 295, 298], ["MMP", "TEST", 345, 348], ["RA", "ANATOMY", 168, 170], ["lung", "ANATOMY", 175, 179], ["inflammation", "OBSERVATION", 180, 192], ["mouse macrophages", "OBSERVATION", 385, 402]]], ["In contrast, the anti-EMMPRIN clone UM-8D6 was able to inhibit MMP-9 secretion by 90% [61] .", [["UM-8D6", "CHEMICAL", 36, 42], ["UM-8D6", "CHEMICAL", 36, 42], ["MMP-9", "GENE_OR_GENE_PRODUCT", 63, 68], ["MMP", "PROTEIN", 63, 66], ["the anti-EMMPRIN clone UM", "TREATMENT", 13, 38], ["MMP", "TEST", 63, 66]]], ["A novel anti-EMMPRIN antibody, clone 10, suppressed EAE disease activity and inhibited T cell proliferation, as well as MMP-9 production [53] .", [["T cell", "ANATOMY", 87, 93], ["EAE", "DISEASE", 52, 55], ["T cell", "CELL", 87, 93], ["MMP-9", "GENE_OR_GENE_PRODUCT", 120, 125], ["anti-EMMPRIN antibody", "PROTEIN", 8, 29], ["clone 10", "CELL_LINE", 31, 39], ["MMP", "PROTEIN", 120, 123], ["A novel anti-EMMPRIN antibody", "TEST", 0, 29], ["clone", "TEST", 31, 36], ["suppressed EAE disease activity", "PROBLEM", 41, 72], ["inhibited T cell proliferation", "PROBLEM", 77, 107], ["MMP", "TEST", 120, 123], ["cell proliferation", "OBSERVATION", 89, 107]]], ["It was also observed that EMMPRIN mAbs, which induced cell aggregation (e.g., M6-1F3) of U937 cells, were not able to inhibit cell proliferation of human T cells and vice versa (e.g., M6-1B9) [54] .", [["cell", "ANATOMY", 54, 58], ["U937 cells", "ANATOMY", 89, 99], ["cell", "ANATOMY", 126, 130], ["T cells", "ANATOMY", 154, 161], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 26, 38], ["cell", "CELL", 54, 58], ["U937 cells", "CELL", 89, 99], ["cell", "CELL", 126, 130], ["human", "ORGANISM", 148, 153], ["T cells", "CELL", 154, 161], ["EMMPRIN mAbs", "PROTEIN", 26, 38], ["U937 cells", "CELL_LINE", 89, 99], ["human T cells", "CELL_TYPE", 148, 161], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["EMMPRIN mAbs", "TEST", 26, 38], ["cell aggregation", "TEST", 54, 70], ["M6", "TEST", 78, 80], ["U937 cells", "PROBLEM", 89, 99], ["cell aggregation", "OBSERVATION", 54, 70]]], ["A summary of the different antibodies discussed in this review and their affects on the activities of EMMPRIN are outlined (Table 1) .EMMPRIN in T cell activation and proliferationEvidence also suggests that EMMPRIN may act as an alternate costimulatory molecule.", [["T cell", "ANATOMY", 145, 151], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 102, 109], ["T cell", "CELL", 145, 151], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 208, 215], ["antibodies", "PROTEIN", 27, 37], ["EMMPRIN", "PROTEIN", 102, 109], ["EMMPRIN", "PROTEIN", 208, 215], ["costimulatory molecule", "PROTEIN", 240, 262], ["the different antibodies", "TREATMENT", 13, 37], ["EMMPRIN", "TREATMENT", 208, 215]]], ["T cell activation and proliferation require an initiation event (Signal 1, provided by TCR engagement) and a costimulatory event (Signal 2; Fig. 2B ).", [["T cell", "ANATOMY", 0, 6], ["T cell", "CELL", 0, 6], ["Signal 1", "GENE_OR_GENE_PRODUCT", 65, 73], ["TCR", "GENE_OR_GENE_PRODUCT", 87, 90], ["Signal 1", "PROTEIN", 65, 73], ["TCR", "PROTEIN", 87, 90], ["T cell activation", "PROBLEM", 0, 17], ["cell activation", "OBSERVATION", 2, 17], ["proliferation", "OBSERVATION_MODIFIER", 22, 35]]], ["Studies suggest that EMMPRIN expression on APCs, rather than on T cells, may be what is important in allowing for T cells to proliferate [58, 67, 68] .", [["APCs", "ANATOMY", 43, 47], ["T cells", "ANATOMY", 64, 71], ["T cells", "ANATOMY", 114, 121], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 21, 28], ["APCs", "CELL", 43, 47], ["T cells", "CELL", 64, 71], ["T cells", "CELL", 114, 121], ["EMMPRIN", "PROTEIN", 21, 28], ["APCs", "CELL_TYPE", 43, 47], ["T cells", "CELL_TYPE", 64, 71], ["T cells", "CELL_TYPE", 114, 121], ["EMMPRIN expression", "PROBLEM", 21, 39], ["APCs", "TEST", 43, 47]]], ["This was demonstrated when \"Signal 1\" provided by anti-CD3 stimulation did not proliferate T cells when mixed with irradiated Signal 2-supplying U937 cells, prepulsed with an anti-EMMPRIN antibody (clone HI197).", [["T cells", "ANATOMY", 91, 98], ["U937 cells", "ANATOMY", 145, 155], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 50, 58], ["T cells", "CELL", 91, 98], ["U937 cells", "CELL", 145, 155], ["anti-CD3", "PROTEIN", 50, 58], ["T cells", "CELL_TYPE", 91, 98], ["U937 cells", "CELL_LINE", 145, 155], ["anti-EMMPRIN antibody", "PROTEIN", 175, 196], ["clone HI197", "PROTEIN", 198, 209], ["anti-CD3 stimulation", "TEST", 50, 70], ["irradiated Signal", "TEST", 115, 132], ["U937 cells", "PROBLEM", 145, 155], ["an anti-EMMPRIN antibody", "TEST", 172, 196], ["U937 cells", "OBSERVATION", 145, 155]]], ["U937 cells are a human monoblastoid cell line that lacks B7 (Fig. 2B) ; thus, they depend on alternate costimulatory pathways to provide Signal 2 [58] .", [["U937 cells", "ANATOMY", 0, 10], ["monoblastoid cell line", "ANATOMY", 23, 45], ["U937 cells", "CELL", 0, 10], ["human", "ORGANISM", 17, 22], ["monoblastoid cell line", "CELL", 23, 45], ["B7", "GENE_OR_GENE_PRODUCT", 57, 59], ["Fig. 2B", "GENE_OR_GENE_PRODUCT", 61, 68], ["U937 cells", "CELL_LINE", 0, 10], ["human monoblastoid cell line", "CELL_LINE", 17, 45], ["B7", "PROTEIN", 57, 59], ["Fig. 2B", "PROTEIN", 61, 68], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["U937 cells", "PROBLEM", 0, 10], ["a human monoblastoid cell line", "TREATMENT", 15, 45], ["monoblastoid cell line", "OBSERVATION", 23, 45]]], ["This result was confirmed by identifying EMMPRIN as one of the candidate genes involved in Chinese hamster ovary [67] or dendritic cell [68] -mediated costimulation of T cells.", [["hamster ovary", "ANATOMY", 99, 112], ["dendritic cell", "ANATOMY", 121, 135], ["T cells", "ANATOMY", 168, 175], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 41, 48], ["hamster ovary", "ORGANISM", 99, 112], ["dendritic cell", "CELL", 121, 135], ["T cells", "CELL", 168, 175], ["EMMPRIN", "PROTEIN", 41, 48], ["T cells", "CELL_TYPE", 168, 175], ["Chinese hamster", "SPECIES", 91, 106], ["dendritic cell", "PROBLEM", 121, 135]]], ["This implicates that EMMPRIN on APCs, and not T cells, may be acting as an important costimulatory molecule for T cell activation.", [["APCs", "ANATOMY", 32, 36], ["T cells", "ANATOMY", 46, 53], ["T cell", "ANATOMY", 112, 118], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 21, 28], ["APCs", "CELL", 32, 36], ["T cells", "CELL", 46, 53], ["T cell", "CELL", 112, 118], ["EMMPRIN", "PROTEIN", 21, 28], ["APCs", "CELL_TYPE", 32, 36], ["T cells", "CELL_TYPE", 46, 53], ["APCs", "TEST", 32, 36], ["T cells", "PROBLEM", 46, 53], ["T cell activation", "PROBLEM", 112, 129]]], ["Yet, studies have also demonstrated proliferative inhibition by anti-EMMPRIN antibodies (by use of clone 5A12 and MEM-M6/6) on purified T cells, as well as PBMCs [51, 52] .", [["T cells", "ANATOMY", 136, 143], ["PBMCs", "ANATOMY", 156, 161], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 64, 87], ["clone 5A12", "CELL", 99, 109], ["MEM-M6/6", "CELL", 114, 122], ["T cells", "CELL", 136, 143], ["PBMCs", "CELL", 156, 161], ["anti-EMMPRIN antibodies", "PROTEIN", 64, 87], ["clone 5A12", "CELL_LINE", 99, 109], ["MEM-M6/6", "CELL_LINE", 114, 122], ["purified T cells", "CELL_TYPE", 127, 143], ["PBMCs", "CELL_TYPE", 156, 161], ["proliferative inhibition", "PROBLEM", 36, 60], ["anti-EMMPRIN antibodies", "PROBLEM", 64, 87], ["MEM", "TEST", 114, 117], ["PBMCs", "TEST", 156, 161], ["proliferative inhibition", "OBSERVATION", 36, 60]]], ["This implies that EMMPRIN expression on APCs as well as T cells has important implications for T cell activation.EMMPRIN in T cell activation and proliferationOnce a T cell is activated, and EMMPRIN levels are elevated, EMMPRIN evolves to have positive/inducing T cell actions.", [["APCs", "ANATOMY", 40, 44], ["T cells", "ANATOMY", 56, 63], ["T cell", "ANATOMY", 95, 101], ["T cell", "ANATOMY", 124, 130], ["T cell", "ANATOMY", 166, 172], ["T cell", "ANATOMY", 262, 268], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["APCs", "CELL", 40, 44], ["T cells", "CELL", 56, 63], ["T cell", "CELL", 95, 101], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 113, 120], ["T cell", "CELL", 124, 130], ["T cell", "CELL", 166, 172], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 191, 198], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 220, 227], ["T cell", "CELL", 262, 268], ["EMMPRIN", "PROTEIN", 18, 25], ["APCs", "CELL_TYPE", 40, 44], ["T cells", "CELL_TYPE", 56, 63], ["EMMPRIN", "PROTEIN", 113, 120], ["T cell", "CELL_TYPE", 166, 172], ["EMMPRIN", "PROTEIN", 191, 198], ["EMMPRIN", "PROTEIN", 220, 227], ["T cell activation", "PROBLEM", 95, 112], ["EMMPRIN in T cell activation", "TREATMENT", 113, 141], ["proliferation", "TEST", 146, 159], ["EMMPRIN levels", "TEST", 191, 205], ["elevated", "PROBLEM", 210, 218], ["T cell actions", "TREATMENT", 262, 276], ["T cell", "OBSERVATION", 124, 130], ["proliferation", "OBSERVATION_MODIFIER", 146, 159]]], ["Actions, such as migration, MMP induction, adhesion, and energy metabolism (activities discussed in the sections below), are reduced in the absence of EMMPRIN and even upon the administration of certain antibodies against EMMPRIN (Fig. 2C) .EMMPRIN in T cell migrationEMMPRIN plays a role in the recruitment of cells into inflamed tissue.", [["sections", "ANATOMY", 104, 112], ["T cell", "ANATOMY", 252, 258], ["cells", "ANATOMY", 311, 316], ["tissue", "ANATOMY", 331, 337], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 151, 158], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 222, 229], ["T cell", "CELL", 252, 258], ["cells", "CELL", 311, 316], ["tissue", "TISSUE", 331, 337], ["MMP", "PROTEIN", 28, 31], ["EMMPRIN", "PROTEIN", 151, 158], ["antibodies", "PROTEIN", 203, 213], ["EMMPRIN", "PROTEIN", 222, 229], ["Fig. 2C) .EMMPRIN", "PROTEIN", 231, 248], ["MMP induction", "TREATMENT", 28, 41], ["adhesion", "PROBLEM", 43, 51], ["energy metabolism", "PROBLEM", 57, 74], ["EMMPRIN", "TREATMENT", 151, 158], ["certain antibodies", "TREATMENT", 195, 213], ["EMMPRIN (Fig. 2C", "TREATMENT", 222, 238], ["T cell migrationEMMPRIN", "TREATMENT", 252, 275], ["inflamed tissue", "PROBLEM", 322, 337], ["inflamed tissue", "OBSERVATION", 322, 337]]], ["EMMPRIN has been identified as the main receptor for EC CyPA, a chemotactic factor for leukocytes (Fig. 2C ) [69] .", [["EC", "ANATOMY", 53, 55], ["leukocytes", "ANATOMY", 87, 97], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["EC", "CELL", 53, 55], ["CyPA", "GENE_OR_GENE_PRODUCT", 56, 60], ["leukocytes", "CELL", 87, 97], ["EMMPRIN", "PROTEIN", 0, 7], ["EC", "CELL_TYPE", 53, 55], ["CyPA", "PROTEIN", 56, 60], ["chemotactic factor", "PROTEIN", 64, 82], ["leukocytes", "CELL_TYPE", 87, 97], ["EMMPRIN", "TREATMENT", 0, 7], ["EC CyPA", "TEST", 53, 60], ["a chemotactic factor", "TEST", 62, 82], ["leukocytes", "TEST", 87, 97]]], ["Cyclophilins are abundant intracellular proteins known for their binding to the immunosuppressive drug, cyclosporine A; however, it has been reported that cyclophilins are released into the EC space of inflamed tissue, such as the synovial fluid of patients with RA [70] , sepsis [71] , and vascular smooth muscle cell disease [72] .", [["intracellular", "ANATOMY", 26, 39], ["EC space", "ANATOMY", 190, 198], ["tissue", "ANATOMY", 211, 217], ["synovial fluid", "ANATOMY", 231, 245], ["vascular smooth muscle cell", "ANATOMY", 291, 318], ["cyclosporine A", "CHEMICAL", 104, 118], ["RA", "DISEASE", 263, 265], ["sepsis", "DISEASE", 273, 279], ["vascular smooth muscle cell disease", "DISEASE", 291, 326], ["Cyclophilins", "CHEMICAL", 0, 12], ["cyclosporine A", "CHEMICAL", 104, 118], ["cyclophilins", "CHEMICAL", 155, 167], ["Cyclophilins", "SIMPLE_CHEMICAL", 0, 12], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 26, 39], ["cyclosporine A", "SIMPLE_CHEMICAL", 104, 118], ["cyclophilins", "SIMPLE_CHEMICAL", 155, 167], ["EC", "CELL", 190, 192], ["tissue", "TISSUE", 211, 217], ["synovial fluid", "TISSUE", 231, 245], ["patients", "ORGANISM", 249, 257], ["vascular smooth muscle cell", "CELL", 291, 318], ["Cyclophilins", "PROTEIN", 0, 12], ["intracellular proteins", "PROTEIN", 26, 48], ["cyclophilins", "PROTEIN", 155, 167], ["patients", "SPECIES", 249, 257], ["Cyclophilins", "TREATMENT", 0, 12], ["intracellular proteins", "PROBLEM", 26, 48], ["the immunosuppressive drug", "TREATMENT", 76, 102], ["cyclosporine", "TREATMENT", 104, 116], ["cyclophilins", "TREATMENT", 155, 167], ["inflamed tissue", "PROBLEM", 202, 217], ["the synovial fluid", "TEST", 227, 245], ["RA", "TEST", 263, 265], ["sepsis", "PROBLEM", 273, 279], ["vascular smooth muscle cell disease", "PROBLEM", 291, 326], ["intracellular proteins", "OBSERVATION", 26, 48], ["inflamed tissue", "OBSERVATION", 202, 217], ["synovial", "ANATOMY", 231, 239], ["fluid", "OBSERVATION", 240, 245], ["sepsis", "OBSERVATION", 273, 279], ["vascular", "ANATOMY", 291, 299], ["smooth muscle cell disease", "OBSERVATION", 300, 326]]], ["The importance of CyPA-EMMPRIN interactions in recruiting leukocytes (neutrophils, eosinophils, Human MEM-M6/6 (IgG1) EC2EMMPRIN in T cell migration\u2022Altered immune synapse formation upon TCR-mediated activation of T cells [48] , [51] , [55] , [56] \u2022Decreased proliferation of PBMCs and purified T cells \u2022Decreased CD25, cytokine expression upon TCR-mediated activation of T cells (no effect on tyrosine phosphorylation and IL-2 levels) \u2022Prevented pathogenic invasion (meningitis, malaria) 5A12 (IgG1) EC1EMMPRIN in T cell migration\u2022Altered immune synapse formation upon TCR-mediated activation of T cells [52] \u2022Decreased proliferation of purified T cells \u2022Reduced CD25, IL-4, tyrosine phosphorylation, calcium influx, IL-2 levels; increased IFN-g MEM-M6/1 (IgG1) EC1EMMPRIN in T cell migration\u2022Reduced tyrosine phosphorylation levels in TCR-stimulated T cells from SLE patients (not healthy patients) [23] , [51] , [57] \u2022Did not affect MMP activity \u2022Did not inhibit T cell proliferation \u2022Did not induce cell aggregation HI197 (IgG1) ?EMMPRIN in T cell migration\u2022Decreased TCR-mediated proliferation of T cells when pre-exposed to U937 myeloid cells before coculture [58] MEM-M6/8 (IgG1) EC1EMMPRIN in T cell migration\u2022Induced cell aggregation and adhesion in Jurkat T cells [23] HAb18 (IgG1) EC1EMMPRIN in T cell migration\u2022Did not inhibit proliferation of purified T cells [52] , [59] , [60] \u2022 ) and/or the nonimmunosuppressive cyclosporine A analog in mouse models of acute lung inflammation [62] , asthmatic inflammation [63] , and RA (via CIA) [61] .", [["leukocytes", "ANATOMY", 58, 68], ["neutrophils", "ANATOMY", 70, 81], ["eosinophils", "ANATOMY", 83, 94], ["T cell", "ANATOMY", 132, 138], ["immune synapse", "ANATOMY", 157, 171], ["T cells", "ANATOMY", 214, 221], ["PBMCs", "ANATOMY", 276, 281], ["T cells", "ANATOMY", 295, 302], ["T cells", "ANATOMY", 372, 379], ["T cell", "ANATOMY", 515, 521], ["immune synapse", "ANATOMY", 540, 554], ["T cells", "ANATOMY", 597, 604], ["T cells", "ANATOMY", 647, 654], ["T cell", "ANATOMY", 777, 783], ["T cells", "ANATOMY", 852, 859], ["T cell", "ANATOMY", 966, 972], ["cell", "ANATOMY", 1003, 1007], ["T cell", "ANATOMY", 1045, 1051], ["T cells", "ANATOMY", 1102, 1109], ["U937 myeloid cells", "ANATOMY", 1130, 1148], ["T cell", "ANATOMY", 1201, 1207], ["cell", "ANATOMY", 1226, 1230], ["Jurkat T cells", "ANATOMY", 1259, 1273], ["T cell", "ANATOMY", 1306, 1312], ["T cells", "ANATOMY", 1365, 1372], ["lung", "ANATOMY", 1475, 1479], ["TCR", "CHEMICAL", 187, 190], ["TCR", "CHEMICAL", 345, 348], ["tyrosine", "CHEMICAL", 394, 402], ["meningitis", "DISEASE", 468, 478], ["malaria", "DISEASE", 480, 487], ["TCR", "CHEMICAL", 570, 573], ["tyrosine", "CHEMICAL", 676, 684], ["calcium", "CHEMICAL", 702, 709], ["tyrosine", "CHEMICAL", 802, 810], ["TCR", "CHEMICAL", 837, 840], ["SLE", "DISEASE", 865, 868], ["TCR", "CHEMICAL", 1072, 1075], ["cyclosporine A", "CHEMICAL", 1428, 1442], ["acute lung inflammation", "DISEASE", 1469, 1492], ["asthmatic inflammation", "DISEASE", 1500, 1522], ["RA", "DISEASE", 1534, 1536], ["tyrosine", "CHEMICAL", 394, 402], ["tyrosine", "CHEMICAL", 676, 684], ["calcium", "CHEMICAL", 702, 709], ["tyrosine", "CHEMICAL", 802, 810], ["cyclosporine A", "CHEMICAL", 1428, 1442], ["CyPA-EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 30], ["leukocytes", "CELL", 58, 68], ["neutrophils", "CELL", 70, 81], ["eosinophils", "CELL", 83, 94], ["Human", "ORGANISM", 96, 101], ["MEM-M6/6", "GENE_OR_GENE_PRODUCT", 102, 110], ["IgG1", "GENE_OR_GENE_PRODUCT", 112, 116], ["T cell", "CELL", 132, 138], ["immune synapse", "CELLULAR_COMPONENT", 157, 171], ["TCR", "GENE_OR_GENE_PRODUCT", 187, 190], ["T cells", "CELL", 214, 221], ["[56] \u2022", "SIMPLE_CHEMICAL", 243, 249], ["PBMCs", "CELL", 276, 281], ["T cells", "CELL", 295, 302], ["CD25", "GENE_OR_GENE_PRODUCT", 314, 318], ["TCR", "GENE_OR_GENE_PRODUCT", 345, 348], ["T cells", "CELL", 372, 379], ["tyrosine", "AMINO_ACID", 394, 402], ["IL-2", "GENE_OR_GENE_PRODUCT", 423, 427], ["IgG1", "GENE_OR_GENE_PRODUCT", 495, 499], ["T cell", "CELL", 515, 521], ["immune synapse", "CELLULAR_COMPONENT", 540, 554], ["TCR", "GENE_OR_GENE_PRODUCT", 570, 573], ["T cells", "CELL", 597, 604], ["T cells", "CELL", 647, 654], ["CD25", "GENE_OR_GENE_PRODUCT", 664, 668], ["IL-4", "GENE_OR_GENE_PRODUCT", 670, 674], ["tyrosine", "AMINO_ACID", 676, 684], ["calcium", "SIMPLE_CHEMICAL", 702, 709], ["IL-2", "GENE_OR_GENE_PRODUCT", 718, 722], ["MEM-M6/1", "GENE_OR_GENE_PRODUCT", 747, 755], ["IgG1", "GENE_OR_GENE_PRODUCT", 757, 761], ["T cell", "CELL", 777, 783], ["tyrosine", "AMINO_ACID", 802, 810], ["TCR", "GENE_OR_GENE_PRODUCT", 837, 840], ["T cells", "CELL", 852, 859], ["patients", "ORGANISM", 869, 877], ["patients", "ORGANISM", 891, 899], ["[51] , [57] \u2022Did", "SIMPLE_CHEMICAL", 908, 924], ["MMP", "GENE_OR_GENE_PRODUCT", 936, 939], ["T cell", "CELL", 966, 972], ["cell", "CELL", 1003, 1007], ["HI197", "GENE_OR_GENE_PRODUCT", 1020, 1025], ["IgG1", "GENE_OR_GENE_PRODUCT", 1027, 1031], ["T cell", "CELL", 1045, 1051], ["TCR", "GENE_OR_GENE_PRODUCT", 1072, 1075], ["T cells", "CELL", 1102, 1109], ["U937 myeloid cells", "CELL", 1130, 1148], ["MEM-M6/8", "CELL", 1171, 1179], ["IgG1", "GENE_OR_GENE_PRODUCT", 1181, 1185], ["T cell", "CELL", 1201, 1207], ["cell", "CELL", 1226, 1230], ["Jurkat T cells", "CELL", 1259, 1273], ["IgG1", "GENE_OR_GENE_PRODUCT", 1286, 1290], ["T cell", "CELL", 1306, 1312], ["T cells", "CELL", 1365, 1372], ["[60] \u2022", "SIMPLE_CHEMICAL", 1387, 1393], ["cyclosporine A", "SIMPLE_CHEMICAL", 1428, 1442], ["mouse", "ORGANISM", 1453, 1458], ["lung", "ORGAN", 1475, 1479], ["CyPA-EMMPRIN", "PROTEIN", 18, 30], ["leukocytes", "CELL_TYPE", 58, 68], ["neutrophils", "CELL_TYPE", 70, 81], ["eosinophils", "CELL_TYPE", 83, 94], ["Human MEM-M6/6 (IgG1) EC2EMMPRIN", "PROTEIN", 96, 128], ["TCR", "PROTEIN", 187, 190], ["T cells", "CELL_TYPE", 214, 221], ["PBMCs", "CELL_TYPE", 276, 281], ["purified T cells", "CELL_TYPE", 286, 302], ["CD25", "PROTEIN", 314, 318], ["cytokine", "PROTEIN", 320, 328], ["TCR", "PROTEIN", 345, 348], ["T cells", "CELL_TYPE", 372, 379], ["IL", "PROTEIN", 423, 425], ["IgG1", "PROTEIN", 495, 499], ["TCR", "PROTEIN", 570, 573], ["T cells", "CELL_TYPE", 597, 604], ["purified T cells", "CELL_TYPE", 638, 654], ["CD25", "PROTEIN", 664, 668], ["IFN", "PROTEIN", 741, 744], ["M6/1 (IgG1) EC1EMMPRIN", "PROTEIN", 751, 773], ["TCR", "PROTEIN", 837, 840], ["T cells", "CELL_TYPE", 852, 859], ["MMP", "PROTEIN", 936, 939], ["HI197 (IgG1) ?EMMPRIN", "PROTEIN", 1020, 1041], ["TCR", "PROTEIN", 1072, 1075], ["T cells", "CELL_TYPE", 1102, 1109], ["U937 myeloid cells", "CELL_LINE", 1130, 1148], ["IgG1", "PROTEIN", 1181, 1185], ["Jurkat T cells", "CELL_LINE", 1259, 1273], ["IgG1", "PROTEIN", 1286, 1290], ["purified T cells", "CELL_TYPE", 1356, 1372], ["Human", "SPECIES", 96, 101], ["patients", "SPECIES", 869, 877], ["patients", "SPECIES", 891, 899], ["mouse", "SPECIES", 1453, 1458], ["mouse", "SPECIES", 1453, 1458], ["leukocytes", "TEST", 58, 68], ["neutrophils", "TEST", 70, 81], ["eosinophils", "TEST", 83, 94], ["Human MEM", "TEST", 96, 105], ["IgG1", "TEST", 112, 116], ["EC2EMMPRIN", "TEST", 118, 128], ["Altered immune synapse formation", "PROBLEM", 149, 181], ["TCR", "TEST", 187, 190], ["activation of T cells", "PROBLEM", 200, 221], ["Decreased proliferation of PBMCs", "PROBLEM", 249, 281], ["purified T cells", "TEST", 286, 302], ["Decreased CD25", "PROBLEM", 304, 318], ["cytokine expression", "TEST", 320, 339], ["TCR", "TEST", 345, 348], ["activation of T cells", "PROBLEM", 358, 379], ["tyrosine phosphorylation", "TREATMENT", 394, 418], ["IL", "TEST", 423, 425], ["pathogenic invasion", "PROBLEM", 447, 466], ["meningitis", "PROBLEM", 468, 478], ["malaria", "PROBLEM", 480, 487], ["Altered immune synapse formation", "PROBLEM", 532, 564], ["TCR", "TEST", 570, 573], ["T cells", "PROBLEM", 597, 604], ["Decreased proliferation of purified T cells", "PROBLEM", 611, 654], ["CD25", "TEST", 664, 668], ["IL", "TEST", 670, 672], ["tyrosine phosphorylation", "TEST", 676, 700], ["calcium influx", "TEST", 702, 716], ["IL", "TEST", 718, 720], ["IFN", "TEST", 741, 744], ["MEM", "TEST", 747, 750], ["Reduced tyrosine phosphorylation levels", "TEST", 794, 833], ["TCR", "TEST", 837, 840], ["MMP activity", "TEST", 936, 948], ["T cell proliferation", "PROBLEM", 966, 986], ["cell aggregation", "PROBLEM", 1003, 1019], ["T cell migration", "TREATMENT", 1045, 1061], ["Decreased TCR", "PROBLEM", 1062, 1075], ["mediated proliferation of T cells", "PROBLEM", 1076, 1109], ["myeloid cells", "TEST", 1135, 1148], ["coculture", "TEST", 1156, 1165], ["MEM", "TEST", 1171, 1174], ["IgG1", "TEST", 1181, 1185], ["EC1EMMPRIN", "TEST", 1187, 1197], ["Induced cell aggregation", "PROBLEM", 1218, 1242], ["adhesion in Jurkat T cells", "TEST", 1247, 1273], ["HAb18", "TEST", 1279, 1284], ["IgG1", "TEST", 1286, 1290], ["EC1EMMPRIN", "TEST", 1292, 1302], ["T cell migration", "TREATMENT", 1306, 1322], ["purified T cells", "TREATMENT", 1356, 1372], ["the nonimmunosuppressive cyclosporine", "TREATMENT", 1403, 1440], ["acute lung inflammation", "PROBLEM", 1469, 1492], ["asthmatic inflammation", "PROBLEM", 1500, 1522], ["cell migration", "OBSERVATION", 134, 148], ["immune synapse", "OBSERVATION", 157, 171], ["pathogenic", "OBSERVATION_MODIFIER", 447, 457], ["invasion", "OBSERVATION", 458, 466], ["meningitis", "OBSERVATION", 468, 478], ["cell migration", "OBSERVATION", 517, 531], ["immune synapse", "OBSERVATION", 540, 554], ["proliferation", "OBSERVATION_MODIFIER", 1085, 1098], ["cell aggregation", "OBSERVATION", 1226, 1242], ["adhesion", "OBSERVATION_MODIFIER", 1247, 1255], ["acute", "OBSERVATION_MODIFIER", 1469, 1474], ["lung", "ANATOMY", 1475, 1479], ["inflammation", "OBSERVATION", 1480, 1492], ["RA", "ANATOMY", 1534, 1536], ["CIA", "ANATOMY", 1542, 1545]]], ["EMMPRIN-dependent migration of activated T cells was also demonstrated in the human system when anti-EMMPRIN antibodies (UM-8D6) inhibited CyPA-mediated migration and not migration stimulated by RANTES [49] .", [["T cells", "ANATOMY", 41, 48], ["UM-8D6", "CHEMICAL", 121, 127], ["CyPA", "CHEMICAL", 139, 143], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cells", "CELL", 41, 48], ["human", "ORGANISM", 78, 83], ["anti-EMMPRIN", "GENE_OR_GENE_PRODUCT", 96, 108], ["UM-8D6", "SIMPLE_CHEMICAL", 121, 127], ["CyPA", "SIMPLE_CHEMICAL", 139, 143], ["RANTES", "GENE_OR_GENE_PRODUCT", 195, 201], ["EMMPRIN", "PROTEIN", 0, 7], ["activated T cells", "CELL_TYPE", 31, 48], ["anti-EMMPRIN antibodies", "PROTEIN", 96, 119], ["8D6", "PROTEIN", 124, 127], ["CyPA", "PROTEIN", 139, 143], ["RANTES", "PROTEIN", 195, 201], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["activated T cells", "PROBLEM", 31, 48], ["anti-EMMPRIN antibodies", "TEST", 96, 119], ["CyPA-mediated migration", "TREATMENT", 139, 162], ["dependent", "OBSERVATION_MODIFIER", 8, 17], ["migration", "OBSERVATION_MODIFIER", 18, 27], ["migration", "OBSERVATION", 153, 162]]], ["In addition to CyPA, EMMPRIN is a receptor for CyPB [73] , which induces chemotaxis of T cells in vitro comparable to RANTES [63] .", [["T cells", "ANATOMY", 87, 94], ["CyPA", "GENE_OR_GENE_PRODUCT", 15, 19], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 21, 28], ["CyPB", "GENE_OR_GENE_PRODUCT", 47, 51], ["T cells", "CELL", 87, 94], ["RANTES", "GENE_OR_GENE_PRODUCT", 118, 124], ["CyPA", "PROTEIN", 15, 19], ["EMMPRIN", "PROTEIN", 21, 28], ["T cells", "CELL_TYPE", 87, 94], ["RANTES", "PROTEIN", 118, 124], ["CyPB", "TEST", 47, 51], ["RANTES", "TEST", 118, 124], ["CyPA", "ANATOMY", 15, 19]]], ["Thus, therapeutic targeting of cyclophilin-EMMPRIN interactions in inflammatory diseases may be a future possibility.EMMPRIN in T cell invasionMMP induction is required for T cells to invade through the basement membrane and drive disease pathogenesis [74] ; thus, ways to inhibit MMP production are critical.", [["T cell", "ANATOMY", 128, 134], ["T cells", "ANATOMY", 173, 180], ["basement membrane", "ANATOMY", 203, 220], ["inflammatory diseases", "DISEASE", 67, 88], ["cyclophilin-EMMPRIN", "GENE_OR_GENE_PRODUCT", 31, 50], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 117, 124], ["T cell", "CELL", 128, 134], ["T cells", "CELL", 173, 180], ["basement membrane", "CELLULAR_COMPONENT", 203, 220], ["MMP", "GENE_OR_GENE_PRODUCT", 281, 284], ["cyclophilin", "PROTEIN", 31, 42], ["EMMPRIN", "PROTEIN", 43, 50], ["EMMPRIN", "PROTEIN", 117, 124], ["MMP", "PROTEIN", 143, 146], ["T cells", "CELL_TYPE", 173, 180], ["MMP", "PROTEIN", 281, 284], ["cyclophilin", "TREATMENT", 31, 42], ["inflammatory diseases", "PROBLEM", 67, 88], ["EMMPRIN in T cell invasionMMP induction", "TREATMENT", 117, 156], ["T cells", "PROBLEM", 173, 180], ["drive disease pathogenesis", "PROBLEM", 225, 251], ["inflammatory diseases", "OBSERVATION", 67, 88], ["may be a future possibility", "UNCERTAINTY", 89, 116]]], ["It was shown that the MMP-9 produced from a PBMC culture upon T cell activation was suppressed by the administration of an EMMPRIN mAb (clone 10) [53] .", [["PBMC", "ANATOMY", 44, 48], ["T cell", "ANATOMY", 62, 68], ["MMP-9", "GENE_OR_GENE_PRODUCT", 22, 27], ["PBMC", "CELL", 44, 48], ["T cell", "CELL", 62, 68], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 123, 130], ["MMP-9", "PROTEIN", 22, 27], ["PBMC culture", "CELL_LINE", 44, 56], ["EMMPRIN mAb", "PROTEIN", 123, 134], ["the MMP", "TEST", 18, 25], ["a PBMC culture", "TEST", 42, 56], ["an EMMPRIN mAb", "TREATMENT", 120, 134]]], ["In patients with T cell lymphomas, EMMPRIN was found highly expressed on peripheral blood T cells compared with healthy controls, and biopsies of skin invasions demonstrated that infiltrating T cell lymphomas were in regions of MMP-2 + fibroblasts [75] .", [["T cell lymphomas", "ANATOMY", 17, 33], ["peripheral blood T cells", "ANATOMY", 73, 97], ["biopsies", "ANATOMY", 134, 142], ["skin", "ANATOMY", 146, 150], ["infiltrating T cell lymphomas", "ANATOMY", 179, 208], ["MMP-2 + fibroblasts", "ANATOMY", 228, 247], ["T cell lymphomas", "DISEASE", 17, 33], ["infiltrating T cell lymphomas", "DISEASE", 179, 208], ["patients", "ORGANISM", 3, 11], ["T cell lymphomas", "CANCER", 17, 33], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 35, 42], ["peripheral blood T cells", "CELL", 73, 97], ["skin", "ORGAN", 146, 150], ["T cell lymphomas", "CANCER", 192, 208], ["MMP-2", "GENE_OR_GENE_PRODUCT", 228, 233], ["EMMPRIN", "PROTEIN", 35, 42], ["peripheral blood T cells", "CELL_TYPE", 73, 97], ["MMP", "PROTEIN", 228, 231], ["fibroblasts", "CELL_TYPE", 236, 247], ["patients", "SPECIES", 3, 11], ["T cell lymphomas", "PROBLEM", 17, 33], ["peripheral blood T cells", "TREATMENT", 73, 97], ["biopsies of skin invasions", "TEST", 134, 160], ["infiltrating T cell lymphomas", "PROBLEM", 179, 208], ["MMP", "TEST", 228, 231], ["cell lymphomas", "OBSERVATION", 19, 33], ["skin", "ANATOMY", 146, 150], ["invasions", "OBSERVATION", 151, 160], ["infiltrating", "OBSERVATION_MODIFIER", 179, 191], ["cell lymphomas", "OBSERVATION", 194, 208]]], ["Moreover, an activity-blocking peptide against EMMPRIN (corresponding to the EC1 domain) inhibited the production of MMP-2 in an experiment by use of transformed lymphocytes (MT2) cocultured with EMMPRINnegative fibroblasts [75] .", [["lymphocytes", "ANATOMY", 162, 173], ["MT2", "ANATOMY", 175, 178], ["fibroblasts", "ANATOMY", 212, 223], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 47, 54], ["MMP-2", "GENE_OR_GENE_PRODUCT", 117, 122], ["lymphocytes", "CELL", 162, 173], ["MT2", "CELL", 175, 178], ["EMMPRINnegative fibroblasts", "CELL", 196, 223], ["EMMPRIN", "PROTEIN", 47, 54], ["EC1 domain", "PROTEIN", 77, 87], ["MMP-2", "PROTEIN", 117, 122], ["transformed lymphocytes", "CELL_LINE", 150, 173], ["MT2", "CELL_LINE", 175, 178], ["EMMPRINnegative fibroblasts", "CELL_LINE", 196, 223], ["EMMPRIN", "PROBLEM", 47, 54], ["MMP", "TEST", 117, 120], ["transformed lymphocytes (MT2)", "TREATMENT", 150, 179]]], ["Another group also demonstrated increased MMP expression by human T cell lines in the presence of fibronectin [76] .", [["T cell lines", "ANATOMY", 66, 78], ["MMP", "GENE_OR_GENE_PRODUCT", 42, 45], ["human", "ORGANISM", 60, 65], ["T cell lines", "CELL", 66, 78], ["fibronectin", "GENE_OR_GENE_PRODUCT", 98, 109], ["MMP", "PROTEIN", 42, 45], ["human T cell lines", "CELL_LINE", 60, 78], ["fibronectin", "PROTEIN", 98, 109], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["increased MMP expression", "PROBLEM", 32, 56], ["human T cell lines", "TREATMENT", 60, 78], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["MMP expression", "OBSERVATION", 42, 56], ["cell lines", "OBSERVATION", 68, 78]]], ["Thus, T cells with high levels of EMMPRIN may facilitate invasion via MMP induction through contact with fibroblasts or other substrates (Fig. 2C) .EMMPRIN in T cell adhesionA number of adhesion molecules associate with EMMPRIN on the cell surface, important for cell-cell contact for events, such as antigen presentation, or to enter sites of inflammation.", [["T cells", "ANATOMY", 6, 13], ["fibroblasts", "ANATOMY", 105, 116], ["T cell", "ANATOMY", 159, 165], ["cell surface", "ANATOMY", 235, 247], ["cell", "ANATOMY", 263, 267], ["cell", "ANATOMY", 268, 272], ["sites", "ANATOMY", 335, 340], ["inflammation", "DISEASE", 344, 356], ["T cells", "CELL", 6, 13], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 34, 41], ["MMP", "GENE_OR_GENE_PRODUCT", 70, 73], ["fibroblasts", "CELL", 105, 116], ["T cell", "CELL", 159, 165], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 220, 227], ["cell surface", "CELLULAR_COMPONENT", 235, 247], ["cell", "CELL", 263, 267], ["cell", "CELL", 268, 272], ["T cells", "CELL_TYPE", 6, 13], ["EMMPRIN", "PROTEIN", 34, 41], ["MMP", "PROTEIN", 70, 73], ["fibroblasts", "CELL_TYPE", 105, 116], ["adhesion molecules", "PROTEIN", 186, 204], ["EMMPRIN", "PROTEIN", 220, 227], ["T cells", "PROBLEM", 6, 13], ["EMMPRIN", "TREATMENT", 34, 41], ["invasion via MMP induction", "TREATMENT", 57, 83], ["other substrates (Fig", "TREATMENT", 120, 141], ["adhesion molecules", "PROBLEM", 186, 204], ["EMMPRIN on the cell surface", "TREATMENT", 220, 247], ["inflammation", "PROBLEM", 344, 356], ["inflammation", "OBSERVATION", 344, 356]]], ["In erythrocytes, EMMPRIN appears to function as an adhesion molecule, as administration of F(ab9) 2 fragments of the anti-EMMPRIN antibody (clone RL73.2) inhibited the migration of murine erythrocytes out of the spleen and into the circulation causing anemia [38] .", [["erythrocytes", "ANATOMY", 3, 15], ["erythrocytes", "ANATOMY", 188, 200], ["spleen", "ANATOMY", 212, 218], ["RL73.2", "CHEMICAL", 146, 152], ["anemia", "DISEASE", 252, 258], ["erythrocytes", "CELL", 3, 15], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 17, 24], ["F(ab9) 2", "GENE_OR_GENE_PRODUCT", 91, 99], ["anti-EMMPRIN antibody", "GENE_OR_GENE_PRODUCT", 117, 138], ["murine", "ORGANISM", 181, 187], ["erythrocytes", "CELL", 188, 200], ["spleen", "ORGAN", 212, 218], ["erythrocytes", "CELL_TYPE", 3, 15], ["EMMPRIN", "PROTEIN", 17, 24], ["F(ab9) 2 fragments", "DNA", 91, 109], ["anti-EMMPRIN antibody", "PROTEIN", 117, 138], ["clone RL73.2", "PROTEIN", 140, 152], ["murine erythrocytes", "CELL_TYPE", 181, 200], ["murine", "SPECIES", 181, 187], ["EMMPRIN", "TREATMENT", 17, 24], ["an adhesion molecule", "PROBLEM", 48, 68], ["F(ab9)", "TREATMENT", 91, 97], ["the anti-EMMPRIN antibody", "TEST", 113, 138], ["murine erythrocytes", "TEST", 181, 200], ["anemia", "PROBLEM", 252, 258], ["erythrocytes", "ANATOMY", 3, 15], ["murine erythrocytes", "OBSERVATION", 181, 200], ["spleen", "ANATOMY", 212, 218], ["circulation", "ANATOMY", 232, 243], ["anemia", "OBSERVATION", 252, 258]]], ["In platelets, EMMPRIN interactions were shown to be involved in their rolling [39] .", [["platelets", "ANATOMY", 3, 12], ["platelets", "CELL", 3, 12], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 14, 21], ["platelets", "CELL_TYPE", 3, 12], ["EMMPRIN", "PROTEIN", 14, 21]]], ["Likewise, in Jurkat cells, a T-lymphoma cell line, siRNA-mediated knockdown of EMMPRIN reduced their adhesion to fibronectin [77] .", [["Jurkat cells", "ANATOMY", 13, 25], ["T-lymphoma cell line", "ANATOMY", 29, 49], ["Jurkat cells", "CELL", 13, 25], ["T-lymphoma cell line", "CELL", 29, 49], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 79, 86], ["fibronectin", "GENE_OR_GENE_PRODUCT", 113, 124], ["Jurkat cells", "CELL_LINE", 13, 25], ["T-lymphoma cell line", "CELL_LINE", 29, 49], ["EMMPRIN", "PROTEIN", 79, 86], ["fibronectin", "PROTEIN", 113, 124], ["a T-lymphoma cell line", "TREATMENT", 27, 49], ["siRNA", "PROBLEM", 51, 56], ["EMMPRIN", "TREATMENT", 79, 86], ["fibronectin", "TEST", 113, 124], ["Jurkat cells", "OBSERVATION", 13, 25], ["lymphoma cell line", "OBSERVATION", 31, 49]]], ["It is noteworthy that EMMPRIN oligomerization is important in increasing the avidity of EMMPRIN interactions with other molecules and with itself for its various functional purposes (Fig. 3A ) [3, 5, 66, 75] .", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 22, 29], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 88, 95], ["EMMPRIN", "PROTEIN", 22, 29], ["EMMPRIN", "PROTEIN", 88, 95], ["EMMPRIN oligomerization", "TREATMENT", 22, 45], ["EMMPRIN interactions", "TREATMENT", 88, 108]]], ["Coimmunoprecipitation and immunofluorescence experiments demonstrated the interaction of EMMPRIN (likely in a lateral fashion) with a 3 b 1 and a 6 b 1 integrins but not a 2 b 1 or a 5 b 1 integrins in the membrane at sites of cell-cell contact in cell lines [78] (Fig. 3B) .", [["membrane", "ANATOMY", 206, 214], ["sites", "ANATOMY", 218, 223], ["cell", "ANATOMY", 227, 231], ["cell", "ANATOMY", 232, 236], ["cell lines", "ANATOMY", 248, 258], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 89, 96], ["b 1 integrins", "GENE_OR_GENE_PRODUCT", 185, 198], ["membrane", "CELLULAR_COMPONENT", 206, 214], ["cell", "CELL", 227, 231], ["cell", "CELL", 232, 236], ["cell lines", "CELL", 248, 258], ["Fig. 3B", "CELL", 265, 272], ["EMMPRIN", "PROTEIN", 89, 96], ["6 b 1 integrins", "PROTEIN", 146, 161], ["2 b 1", "PROTEIN", 172, 177], ["5 b 1 integrins", "PROTEIN", 183, 198], ["Coimmunoprecipitation", "TEST", 0, 21], ["immunofluorescence experiments", "TEST", 26, 56], ["EMMPRIN", "TREATMENT", 89, 96], ["cell-cell contact", "OBSERVATION", 227, 244], ["cell lines", "OBSERVATION", 248, 258]]], ["CyPB, an EMMPRIN ligand, along with glycosaminoglycans, was shown to play a role in the adhesion of human PBMCs (mainly of the CD4 + CD45RO + phenotype) to the ECM [79] .", [["PBMCs", "ANATOMY", 106, 111], ["CD4 + CD45RO + phenotype", "ANATOMY", 127, 151], ["ECM", "ANATOMY", 160, 163], ["CyPB", "CHEMICAL", 0, 4], ["CyPB", "SIMPLE_CHEMICAL", 0, 4], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 9, 16], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 36, 54], ["human", "ORGANISM", 100, 105], ["PBMCs", "CELL", 106, 111], ["CD4", "GENE_OR_GENE_PRODUCT", 127, 130], ["CD45RO", "GENE_OR_GENE_PRODUCT", 133, 139], ["ECM", "CELLULAR_COMPONENT", 160, 163], ["CyPB", "PROTEIN", 0, 4], ["EMMPRIN ligand", "PROTEIN", 9, 23], ["human PBMCs", "CELL_TYPE", 100, 111], ["CD4", "PROTEIN", 127, 130], ["CD45RO", "PROTEIN", 133, 139], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["an EMMPRIN ligand", "TEST", 6, 23], ["glycosaminoglycans", "TREATMENT", 36, 54], ["human PBMCs", "TEST", 100, 111], ["the CD4", "TEST", 123, 130]]], ["Furthermore, syndecan-1, a HSPG present on the cell surface of T cells, also associates with EMMPRIN (likely in the TM region) and is involved in adhesion to fibronectin via CyPB-induced MAPK activation [24] (Fig. 3C) .", [["cell surface", "ANATOMY", 47, 59], ["T cells", "ANATOMY", 63, 70], ["TM region", "ANATOMY", 116, 125], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 13, 23], ["HSPG", "GENE_OR_GENE_PRODUCT", 27, 31], ["cell surface", "CELLULAR_COMPONENT", 47, 59], ["T cells", "CELL", 63, 70], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 93, 100], ["fibronectin", "GENE_OR_GENE_PRODUCT", 158, 169], ["CyPB", "GENE_OR_GENE_PRODUCT", 174, 178], ["MAPK", "GENE_OR_GENE_PRODUCT", 187, 191], ["syndecan-1", "PROTEIN", 13, 23], ["HSPG", "PROTEIN", 27, 31], ["T cells", "CELL_TYPE", 63, 70], ["EMMPRIN", "PROTEIN", 93, 100], ["TM region", "PROTEIN", 116, 125], ["fibronectin", "PROTEIN", 158, 169], ["CyPB", "PROTEIN", 174, 178], ["MAPK", "PROTEIN", 187, 191], ["a HSPG", "PROBLEM", 25, 31], ["EMMPRIN", "TREATMENT", 93, 100], ["fibronectin via CyPB", "TREATMENT", 158, 178], ["MAPK activation", "PROBLEM", 187, 202]]], ["Another report identified EMMPRIN in a complex with CD98, b1 integrins, and CyPB in a human promonocytic leukemia THP-1 cell line that mediated cell adhesion to fibronectin [81] (Fig. 3D) .", [["promonocytic leukemia THP-1 cell line", "ANATOMY", 92, 129], ["cell", "ANATOMY", 144, 148], ["promonocytic leukemia", "DISEASE", 92, 113], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 26, 33], ["CD98", "GENE_OR_GENE_PRODUCT", 52, 56], ["b1 integrins", "GENE_OR_GENE_PRODUCT", 58, 70], ["CyPB", "GENE_OR_GENE_PRODUCT", 76, 80], ["human", "ORGANISM", 86, 91], ["promonocytic leukemia THP-1 cell line", "CELL", 92, 129], ["cell", "CELL", 144, 148], ["fibronectin", "GENE_OR_GENE_PRODUCT", 161, 172], ["EMMPRIN", "PROTEIN", 26, 33], ["CD98", "PROTEIN", 52, 56], ["b1 integrins", "PROTEIN", 58, 70], ["CyPB", "PROTEIN", 76, 80], ["human promonocytic leukemia THP-1 cell line", "CELL_LINE", 86, 129], ["fibronectin", "PROTEIN", 161, 172], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["b1 integrins", "TREATMENT", 58, 70], ["CyPB", "PROBLEM", 76, 80], ["a human promonocytic leukemia THP", "TREATMENT", 84, 117], ["1 cell line", "TREATMENT", 118, 129], ["fibronectin", "TEST", 161, 172], ["human promonocytic leukemia", "OBSERVATION", 86, 113], ["cell line", "OBSERVATION", 120, 129], ["cell adhesion", "OBSERVATION", 144, 157]]], ["The binding of CyPB is thought to catalyze peptidylprolyl cis-trans isomerase activity in EMMPRIN, triggering intracellular signaling events that induce cell aggregation or integrin-mediated adhesion through a PI3K-protein kinase Cd-MAPK pathway.", [["intracellular", "ANATOMY", 110, 123], ["cell", "ANATOMY", 153, 157], ["CyPB", "CHEMICAL", 15, 19], ["peptidylprolyl", "CHEMICAL", 43, 57], ["Cd", "CHEMICAL", 230, 232], ["peptidylprolyl", "CHEMICAL", 43, 57], ["Cd", "CHEMICAL", 230, 232], ["CyPB", "GENE_OR_GENE_PRODUCT", 15, 19], ["peptidylprolyl cis-trans isomerase", "GENE_OR_GENE_PRODUCT", 43, 77], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 90, 97], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 123], ["cell", "CELL", 153, 157], ["integrin", "GENE_OR_GENE_PRODUCT", 173, 181], ["PI3K", "GENE_OR_GENE_PRODUCT", 210, 214], ["MAPK", "GENE_OR_GENE_PRODUCT", 233, 237], ["CyPB", "PROTEIN", 15, 19], ["peptidylprolyl cis-trans isomerase", "PROTEIN", 43, 77], ["EMMPRIN", "PROTEIN", 90, 97], ["integrin", "PROTEIN", 173, 181], ["PI3K", "PROTEIN", 210, 214], ["MAPK", "PROTEIN", 233, 237], ["intracellular signaling events", "PROBLEM", 110, 140], ["cell aggregation", "PROBLEM", 153, 169], ["integrin-mediated adhesion", "TREATMENT", 173, 199], ["a PI3K", "TEST", 208, 214], ["cell aggregation", "OBSERVATION", 153, 169]]], ["It is proposed that CD98 can regulate b1 integrin affinity and was reported to coimmunoprecipitate with a 4 b 1 integrins in PBMCs [81] .", [["PBMCs", "ANATOMY", 125, 130], ["CD98", "GENE_OR_GENE_PRODUCT", 20, 24], ["b1 integrin", "GENE_OR_GENE_PRODUCT", 38, 49], ["b 1 integrins", "GENE_OR_GENE_PRODUCT", 108, 121], ["PBMCs", "CELL", 125, 130], ["CD98", "PROTEIN", 20, 24], ["b1 integrin", "PROTEIN", 38, 49], ["4 b 1 integrins", "PROTEIN", 106, 121], ["PBMCs", "CELL_TYPE", 125, 130]]], ["Hyaluronan-CD44-MCT-EMMPRIN complexes were also shown to exist in human breast adenocarcinoma cell lines [83] (Fig. 3G) .", [["breast adenocarcinoma cell lines", "ANATOMY", 72, 104], ["breast adenocarcinoma", "DISEASE", 72, 93], ["Hyaluronan-CD44", "GENE_OR_GENE_PRODUCT", 0, 15], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 20, 27], ["human", "ORGANISM", 66, 71], ["breast adenocarcinoma cell lines [83", "CELL", 72, 108], ["Fig. 3G", "CELL", 111, 118], ["Hyaluronan-CD44", "PROTEIN", 0, 15], ["MCT-EMMPRIN complexes", "PROTEIN", 16, 37], ["human breast adenocarcinoma cell lines", "CELL_LINE", 66, 104], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["Hyaluronan-CD44", "TREATMENT", 0, 15], ["MCT-EMMPRIN complexes", "TREATMENT", 16, 37], ["breast", "ANATOMY", 72, 78], ["adenocarcinoma", "OBSERVATION", 79, 93], ["cell lines", "OBSERVATION", 94, 104]]], ["Besides its metabolic roles, in T cells, the best established function of CD44 is its adhesive capabilities [86] .", [["T cells", "ANATOMY", 32, 39], ["T cells", "CELL", 32, 39], ["CD44", "GENE_OR_GENE_PRODUCT", 74, 78], ["T cells", "CELL_TYPE", 32, 39], ["CD44", "PROTEIN", 74, 78], ["metabolic roles", "OBSERVATION", 12, 27]]], ["In addition, the presence of a mAb toward EMMPRIN (clone 10) on activated human PBMCs was reported to reduce a4 integrin and NF-kB signaling, leaving Akt and MAPK signaling unaffected, and clone 10 decreased T cell adhesion to endothelial cells [66] .", [["PBMCs", "ANATOMY", 80, 85], ["T cell", "ANATOMY", 208, 214], ["endothelial cells", "ANATOMY", 227, 244], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 42, 49], ["human", "ORGANISM", 74, 79], ["PBMCs", "CELL", 80, 85], ["a4 integrin", "GENE_OR_GENE_PRODUCT", 109, 120], ["NF-kB", "GENE_OR_GENE_PRODUCT", 125, 130], ["Akt", "GENE_OR_GENE_PRODUCT", 150, 153], ["MAPK", "GENE_OR_GENE_PRODUCT", 158, 162], ["T cell", "CELL", 208, 214], ["endothelial cells", "CELL", 227, 244], ["mAb", "PROTEIN", 31, 34], ["EMMPRIN", "PROTEIN", 42, 49], ["clone 10", "PROTEIN", 51, 59], ["activated human PBMCs", "CELL_TYPE", 64, 85], ["a4 integrin", "PROTEIN", 109, 120], ["NF-kB", "PROTEIN", 125, 130], ["Akt", "PROTEIN", 150, 153], ["MAPK", "PROTEIN", 158, 162], ["clone 10", "CELL_LINE", 189, 197], ["endothelial cells", "CELL_TYPE", 227, 244], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["a mAb", "TREATMENT", 29, 34], ["EMMPRIN (clone", "TREATMENT", 42, 56], ["activated human PBMCs", "TEST", 64, 85], ["Akt", "TEST", 150, 153], ["MAPK signaling", "TEST", 158, 172], ["clone", "TEST", 189, 194], ["endothelial cells", "TEST", 227, 244]]], ["The addition of various EMMPRIN mAbs alone to the U937 monocytic cell line would initiate homotypic cell aggregation via LFA-1, a b2 integrin [54, 87] .", [["U937 monocytic cell line", "ANATOMY", 50, 74], ["cell", "ANATOMY", 100, 104], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 24, 31], ["U937 monocytic cell line", "CELL", 50, 74], ["cell", "CELL", 100, 104], ["LFA-1", "GENE_OR_GENE_PRODUCT", 121, 126], ["b2 integrin", "GENE_OR_GENE_PRODUCT", 130, 141], ["EMMPRIN mAbs", "PROTEIN", 24, 36], ["U937 monocytic cell line", "CELL_LINE", 50, 74], ["LFA", "PROTEIN", 121, 124], ["b2 integrin", "PROTEIN", 130, 141], ["various EMMPRIN mAbs", "TREATMENT", 16, 36], ["the U937 monocytic cell line", "TREATMENT", 46, 74], ["homotypic cell aggregation", "TREATMENT", 90, 116], ["LFA", "TEST", 121, 124], ["a b2 integrin", "TEST", 128, 141], ["monocytic cell line", "OBSERVATION", 55, 74], ["homotypic cell aggregation", "OBSERVATION", 90, 116]]], ["In the human Jurkat T cell leukemia cell line, EMMPRIN mAbs (MEM-M6/8 and/or HAb18) also induced homotypic aggregation [23, 59] and adhesion to the LFA-1 ligand, ICAM-1; this adhesion was also regulated by the presence of CD43 [23] .", [["Jurkat T cell leukemia cell line", "ANATOMY", 13, 45], ["human", "ORGANISM", 7, 12], ["Jurkat T cell leukemia cell line", "CELL", 13, 45], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 47, 59], ["HAb18", "GENE_OR_GENE_PRODUCT", 77, 82], ["LFA-1", "GENE_OR_GENE_PRODUCT", 148, 153], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 162, 168], ["CD43", "GENE_OR_GENE_PRODUCT", 222, 226], ["human Jurkat T cell leukemia cell line", "CELL_LINE", 7, 45], ["EMMPRIN mAbs", "PROTEIN", 47, 59], ["M6", "PROTEIN", 65, 67], ["HAb18", "PROTEIN", 77, 82], ["LFA-1 ligand", "PROTEIN", 148, 160], ["ICAM-1", "PROTEIN", 162, 168], ["CD43", "PROTEIN", 222, 226], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["cell line", "TEST", 36, 45], ["EMMPRIN mAbs", "TEST", 47, 59], ["MEM", "TEST", 61, 64], ["M6", "TEST", 65, 67], ["homotypic aggregation", "PROBLEM", 97, 118], ["adhesion", "TEST", 132, 140], ["the LFA", "TEST", 144, 151], ["ICAM", "TEST", 162, 166], ["this adhesion", "PROBLEM", 170, 183], ["CD43", "TEST", 222, 226], ["human Jurkat", "ANATOMY", 7, 19], ["cell leukemia cell line", "OBSERVATION", 22, 45], ["homotypic aggregation", "OBSERVATION", 97, 118], ["LFA", "ANATOMY", 148, 151]]], ["All 3 adhesion molecules, CD18 (representing LFA-1), CD43, and EMMPRIN, colocalized together at sites of cell-cell contact; however, 2 distinct CD43 complexes with EMMPRIN or LFA-1 existed based on coimmunoprecipitation experiments [23] (Fig. 3F ).", [["sites", "ANATOMY", 96, 101], ["cell", "ANATOMY", 105, 109], ["cell", "ANATOMY", 110, 114], ["CD18", "GENE_OR_GENE_PRODUCT", 26, 30], ["LFA-1", "GENE_OR_GENE_PRODUCT", 45, 50], ["CD43", "GENE_OR_GENE_PRODUCT", 53, 57], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 63, 70], ["cell", "CELL", 105, 109], ["cell", "CELL", 110, 114], ["CD43", "GENE_OR_GENE_PRODUCT", 144, 148], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 164, 171], ["LFA-1", "GENE_OR_GENE_PRODUCT", 175, 180], ["adhesion molecules", "PROTEIN", 6, 24], ["CD18", "PROTEIN", 26, 30], ["LFA", "PROTEIN", 45, 48], ["CD43", "PROTEIN", 53, 57], ["EMMPRIN", "PROTEIN", 63, 70], ["CD43 complexes", "PROTEIN", 144, 158], ["EMMPRIN", "PROTEIN", 164, 171], ["LFA", "PROTEIN", 175, 178], ["All 3 adhesion molecules", "TEST", 0, 24], ["CD18", "TEST", 26, 30], ["LFA", "TEST", 45, 48], ["CD43", "TEST", 53, 57], ["EMMPRIN", "TEST", 63, 70], ["EMMPRIN", "TEST", 164, 171], ["LFA", "TEST", 175, 178], ["coimmunoprecipitation experiments", "TEST", 198, 231], ["CD43", "ANATOMY", 53, 57], ["cell contact", "OBSERVATION", 110, 122]]], ["CD43 is a sialoglycoprotein that is highly glycosylated containing a net negative charge; thus, it likely is able to repulse cell contacts, which is important for cell migration, but can still permit cell contacts in the first place.", [["cell contacts", "ANATOMY", 125, 138], ["cell", "ANATOMY", 163, 167], ["cell", "ANATOMY", 200, 204], ["CD43", "GENE_OR_GENE_PRODUCT", 0, 4], ["sialoglycoprotein", "GENE_OR_GENE_PRODUCT", 10, 27], ["cell", "CELL", 125, 129], ["cell", "CELL", 163, 167], ["cell", "CELL", 200, 204], ["CD43", "PROTEIN", 0, 4], ["sialoglycoprotein", "PROTEIN", 10, 27], ["CD43", "TEST", 0, 4], ["a sialoglycoprotein", "PROBLEM", 8, 27], ["cell migration", "TREATMENT", 163, 177], ["cell migration", "OBSERVATION", 163, 177]]], ["It is probable that CD43 interactions with EMMPRIN or LFA-1 may inhibit their adhesive capabilities.", [["CD43", "GENE_OR_GENE_PRODUCT", 20, 24], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 43, 50], ["LFA-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["CD43", "PROTEIN", 20, 24], ["EMMPRIN", "PROTEIN", 43, 50], ["LFA-1", "PROTEIN", 54, 59], ["EMMPRIN or LFA", "TREATMENT", 43, 57], ["probable", "UNCERTAINTY", 6, 14], ["CD43", "OBSERVATION", 20, 24]]], ["Moreover, it was shown recently that in the presence of an anti-EMMPRIN antibody (HAb18), alone, in Jurkat cells or CD4 + primary cells, cell aggregation increased with time, whereas CyPA-induced chemotaxis decreased; these results imply a functional trade-off for EMMPRIN [59] .", [["Jurkat cells", "ANATOMY", 100, 112], ["CD4 + primary cells", "ANATOMY", 116, 135], ["cell", "ANATOMY", 137, 141], ["CyPA", "CHEMICAL", 183, 187], ["CyPA", "CHEMICAL", 183, 187], ["anti-EMMPRIN antibody", "GENE_OR_GENE_PRODUCT", 59, 80], ["HAb18", "GENE_OR_GENE_PRODUCT", 82, 87], ["Jurkat cells", "CELL", 100, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 116, 119], ["cells", "CELL", 130, 135], ["cell", "CELL", 137, 141], ["CyPA", "SIMPLE_CHEMICAL", 183, 187], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 265, 272], ["anti-EMMPRIN antibody", "PROTEIN", 59, 80], ["HAb18", "PROTEIN", 82, 87], ["Jurkat cells", "CELL_LINE", 100, 112], ["CD4", "PROTEIN", 116, 119], ["primary cells", "CELL_TYPE", 122, 135], ["CyPA", "PROTEIN", 183, 187], ["EMMPRIN", "PROTEIN", 265, 272], ["an anti-EMMPRIN antibody", "TEST", 56, 80], ["CD4", "TEST", 116, 119], ["primary cells", "PROBLEM", 122, 135], ["cell aggregation", "PROBLEM", 137, 153], ["CyPA", "TEST", 183, 187], ["induced chemotaxis", "PROBLEM", 188, 206], ["primary cells", "OBSERVATION", 122, 135], ["cell aggregation", "OBSERVATION", 137, 153], ["increased", "OBSERVATION_MODIFIER", 154, 163]]], ["Interestingly, knocking down EMMPRIN in Jurkat cells by RNA interference also induced cell aggregation and decreased levels of CD98 [59] .", [["Jurkat cells", "ANATOMY", 40, 52], ["cell", "ANATOMY", 86, 90], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 29, 36], ["Jurkat cells", "CELL", 40, 52], ["cell", "CELL", 86, 90], ["CD98", "GENE_OR_GENE_PRODUCT", 127, 131], ["EMMPRIN", "PROTEIN", 29, 36], ["Jurkat cells", "CELL_LINE", 40, 52], ["CD98", "PROTEIN", 127, 131], ["EMMPRIN in Jurkat cells", "TREATMENT", 29, 52], ["RNA interference", "PROBLEM", 56, 72], ["induced cell aggregation", "PROBLEM", 78, 102], ["decreased levels of CD98", "PROBLEM", 107, 131], ["cell aggregation", "OBSERVATION", 86, 102], ["decreased", "OBSERVATION_MODIFIER", 107, 116]]], ["This is surprising, as EMMPRIN and CD98 are thought to mediate adhesion.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 23, 30], ["CD98", "GENE_OR_GENE_PRODUCT", 35, 39], ["EMMPRIN", "PROTEIN", 23, 30], ["CD98", "PROTEIN", 35, 39], ["thought to", "UNCERTAINTY", 44, 54], ["adhesion", "OBSERVATION", 63, 71]]], ["Clearly, EMMPRIN and CD98 expression levels are linked.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 9, 16], ["CD98", "GENE_OR_GENE_PRODUCT", 21, 25], ["EMMPRIN", "PROTEIN", 9, 16], ["CD98", "PROTEIN", 21, 25], ["EMMPRIN and CD98 expression levels", "TEST", 9, 43]]], ["It is speculated that EMMPRIN may inhibit cell aggregation and that the addition of an anti-EMMPRIN antibody may work to inhibit EMMPRIN in carrying out this particular negative role (thus acting as an antagonist instead of an agonist) [59] .", [["cell", "ANATOMY", 42, 46], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 22, 29], ["cell", "CELL", 42, 46], ["anti-EMMPRIN antibody", "GENE_OR_GENE_PRODUCT", 87, 108], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 129, 136], ["EMMPRIN", "PROTEIN", 22, 29], ["anti-EMMPRIN antibody", "PROTEIN", 87, 108], ["EMMPRIN", "PROTEIN", 129, 136], ["cell aggregation", "PROBLEM", 42, 58], ["an anti-EMMPRIN antibody", "TREATMENT", 84, 108], ["EMMPRIN", "TREATMENT", 129, 136], ["cell aggregation", "OBSERVATION", 42, 58]]], ["Even though EMMPRIN is shown to be involved in adhesion (as demonstrated in the paragraphs above), different adhesion complexes likely exist, and treatment with EMMPRIN mAbs may cause rearrangement of these adhesion complexes.EMMPRIN in T cell adhesionEMMPRIN seems to influence the adhesive ability of 2 prominent T cell integrins, a 4 b 1 as well as LFA-1, which are important in antigen presentation and the adhesion of T cells to endothelial cells upon entry into sites of inflammation (Fig. 2B Figure 3 .", [["T cell", "ANATOMY", 237, 243], ["T cell", "ANATOMY", 315, 321], ["T cells", "ANATOMY", 423, 430], ["endothelial cells", "ANATOMY", 434, 451], ["sites", "ANATOMY", 468, 473], ["inflammation", "DISEASE", 477, 489], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 12, 19], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 161, 173], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 226, 233], ["T cell", "CELL", 237, 243], ["T cell integrins", "CELL", 315, 331], ["4 b 1", "GENE_OR_GENE_PRODUCT", 335, 340], ["LFA-1", "GENE_OR_GENE_PRODUCT", 352, 357], ["T cells", "CELL", 423, 430], ["endothelial cells", "CELL", 434, 451], ["EMMPRIN", "PROTEIN", 12, 19], ["adhesion complexes", "PROTEIN", 109, 127], ["EMMPRIN mAbs", "PROTEIN", 161, 173], ["adhesion complexes", "PROTEIN", 207, 225], ["EMMPRIN", "PROTEIN", 226, 233], ["T cell integrins", "PROTEIN", 315, 331], ["4 b 1", "PROTEIN", 335, 340], ["LFA", "PROTEIN", 352, 355], ["T cells", "CELL_TYPE", 423, 430], ["endothelial cells", "CELL_TYPE", 434, 451], ["adhesion", "PROBLEM", 47, 55], ["different adhesion complexes", "TREATMENT", 99, 127], ["EMMPRIN mAbs", "TREATMENT", 161, 173], ["these adhesion complexes", "PROBLEM", 201, 225], ["EMMPRIN in T cell adhesionEMMPRIN", "TREATMENT", 226, 259], ["2 prominent T cell integrins", "PROBLEM", 303, 331], ["LFA", "TEST", 352, 355], ["T cells", "PROBLEM", 423, 430], ["endothelial cells", "PROBLEM", 434, 451], ["inflammation", "PROBLEM", 477, 489], ["adhesion complexes", "OBSERVATION", 207, 225], ["cell integrins", "OBSERVATION", 317, 331], ["inflammation", "OBSERVATION", 477, 489]]], ["EMMPRIN interactions.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["EMMPRIN", "PROTEIN", 0, 7]]], ["EMMPRIN can interact with a wide range of binding partners, such as itself forming oligomers (increasing its avidity for other interacting partners) and/or through homotypic interactions between cells, allowing for MMP induction (A).", [["cells", "ANATOMY", 195, 200], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["cells", "CELL", 195, 200], ["MMP", "GENE_OR_GENE_PRODUCT", 215, 218], ["EMMPRIN", "PROTEIN", 0, 7], ["MMP", "PROTEIN", 215, 218], ["MMP induction", "TREATMENT", 215, 228]]], ["EMMPRIN interacts with b1 integrins (B).", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["b1 integrins", "GENE_OR_GENE_PRODUCT", 23, 35], ["B", "GENE_OR_GENE_PRODUCT", 37, 38], ["EMMPRIN", "PROTEIN", 0, 7], ["b1 integrins", "PROTEIN", 23, 35], ["B", "PROTEIN", 37, 38]]], ["EC cyclophilin (CyPA/B) may bind and isomerize EMMPRIN in an HSPG-dependent fashion, likely triggering intracellular signaling events, allowing for migration and/or integrin-mediated adhesion.", [["intracellular", "ANATOMY", 103, 116], ["EC cyclophilin", "GENE_OR_GENE_PRODUCT", 0, 14], ["CyPA/B", "GENE_OR_GENE_PRODUCT", 16, 22], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 47, 54], ["HSPG", "GENE_OR_GENE_PRODUCT", 61, 65], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["EC cyclophilin", "PROTEIN", 0, 14], ["CyPA", "PROTEIN", 16, 20], ["B", "PROTEIN", 21, 22], ["EMMPRIN", "PROTEIN", 47, 54], ["HSPG", "PROTEIN", 61, 65], ["EC cyclophilin (CyPA/B)", "TREATMENT", 0, 23], ["isomerize EMMPRIN", "TREATMENT", 37, 54], ["intracellular signaling events", "PROBLEM", 103, 133], ["integrin-mediated adhesion", "PROBLEM", 165, 191], ["intracellular signaling", "OBSERVATION", 103, 126]]], ["Upon T cell activation, increased EMMPRIN oligomerization allows CyPA to bind without the need for HSPGs.", [["T cell", "ANATOMY", 5, 11], ["T cell", "CELL", 5, 11], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 34, 41], ["CyPA", "GENE_OR_GENE_PRODUCT", 65, 69], ["HSPGs", "GENE_OR_GENE_PRODUCT", 99, 104], ["EMMPRIN", "PROTEIN", 34, 41], ["CyPA", "PROTEIN", 65, 69], ["HSPGs", "PROTEIN", 99, 104], ["T cell activation", "TREATMENT", 5, 22], ["increased EMMPRIN oligomerization", "TREATMENT", 24, 57], ["CyPA to bind", "TREATMENT", 65, 77], ["HSPGs", "TREATMENT", 99, 104], ["cell activation", "OBSERVATION", 7, 22]]], ["CyPB associates by interacting with the heparin sulfates on syndecan-1 and the EC regions of EMMPRIN (C).", [["EC", "ANATOMY", 79, 81], ["CyPB", "CHEMICAL", 0, 4], ["heparin", "CHEMICAL", 40, 47], ["sulfates", "CHEMICAL", 48, 56], ["CyPB", "GENE_OR_GENE_PRODUCT", 0, 4], ["heparin sulfates", "SIMPLE_CHEMICAL", 40, 56], ["syndecan-1", "GENE_OR_GENE_PRODUCT", 60, 70], ["EC", "CELL", 79, 81], ["EMMPRIN (C)", "GENE_OR_GENE_PRODUCT", 93, 104], ["CyPB", "PROTEIN", 0, 4], ["syndecan-1", "PROTEIN", 60, 70], ["EC regions", "PROTEIN", 79, 89], ["EMMPRIN (C)", "PROTEIN", 93, 104], ["the heparin sulfates", "TREATMENT", 36, 56], ["syndecan", "TREATMENT", 60, 68], ["EMMPRIN (C)", "TREATMENT", 93, 104]]], ["EMMPRIN also interacts with CD98 (likely via the EC region of EMMPRIN) and b1 integrins (D).", [["EC region", "ANATOMY", 49, 58], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["CD98", "GENE_OR_GENE_PRODUCT", 28, 32], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 62, 69], ["b1 integrins", "GENE_OR_GENE_PRODUCT", 75, 87], ["D", "GENE_OR_GENE_PRODUCT", 89, 90], ["EMMPRIN", "PROTEIN", 0, 7], ["CD98", "PROTEIN", 28, 32], ["EC region", "PROTEIN", 49, 58], ["EMMPRIN", "PROTEIN", 62, 69], ["b1 integrins", "PROTEIN", 75, 87], ["D", "PROTEIN", 89, 90]]], ["Interestingly, a MCT-EMMPRIN-CD98-LAT1-ASCT2 supercomplex exists, demonstrating that CD98 is involved in regulating EMMPRIN-mediated adhesion and energy metabolism (E).", [["CD98-LAT1", "GENE_OR_GENE_PRODUCT", 29, 38], ["ASCT2", "GENE_OR_GENE_PRODUCT", 39, 44], ["CD98", "GENE_OR_GENE_PRODUCT", 85, 89], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 116, 123], ["CD98-LAT1", "PROTEIN", 29, 38], ["ASCT2 supercomplex", "PROTEIN", 39, 57], ["CD98", "PROTEIN", 85, 89], ["EMMPRIN", "PROTEIN", 116, 123], ["a MCT-EMMPRIN-CD98-LAT1", "TEST", 15, 38], ["CD98", "OBSERVATION", 85, 89], ["adhesion", "OBSERVATION_MODIFIER", 133, 141], ["energy metabolism", "OBSERVATION", 146, 163]]], ["Competitive binding of EMMPRIN for CD43 with LFA-1 affects the adhesive capability of T cells (F).", [["T cells", "ANATOMY", 86, 93], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 23, 30], ["CD43", "GENE_OR_GENE_PRODUCT", 35, 39], ["LFA-1", "GENE_OR_GENE_PRODUCT", 45, 50], ["T cells", "CELL", 86, 93], ["F", "CELL", 95, 96], ["EMMPRIN", "PROTEIN", 23, 30], ["CD43", "PROTEIN", 35, 39], ["LFA-1", "PROTEIN", 45, 50], ["T cells", "CELL_TYPE", 86, 93], ["CD43", "TEST", 35, 39], ["LFA", "TEST", 45, 48]]], ["Lastly, a hyaluronan-CD44-MCT-EMMPRIN supercomplex is shown, important in energy metabolism and drug resistance; in T cells, hyaluronan-CD44 is important in adhesion and migration (G). and C).", [["T cells", "ANATOMY", 116, 123], ["CD44", "GENE_OR_GENE_PRODUCT", 21, 25], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 30, 37], ["T cells", "CELL", 116, 123], ["hyaluronan-CD44", "GENE_OR_GENE_PRODUCT", 125, 140], ["CD44", "PROTEIN", 21, 25], ["MCT-EMMPRIN supercomplex", "PROTEIN", 26, 50], ["T cells", "CELL_TYPE", 116, 123], ["hyaluronan", "PROTEIN", 125, 135], ["CD44", "PROTEIN", 136, 140], ["a hyaluronan-CD44-MCT-EMMPRIN supercomplex", "TREATMENT", 8, 50], ["drug resistance", "PROBLEM", 96, 111], ["hyaluronan-CD44", "TREATMENT", 125, 140], ["drug resistance", "OBSERVATION", 96, 111]]], ["Distinct complexes of adhesion molecules may have a positive or negative role in T cell adhesion.", [["T cell", "ANATOMY", 81, 87], ["T cell", "CELL", 81, 87], ["adhesion molecules", "PROTEIN", 22, 40], ["Distinct complexes of adhesion molecules", "PROBLEM", 0, 40], ["T cell adhesion", "PROBLEM", 81, 96], ["complexes", "OBSERVATION", 9, 18], ["adhesion molecules", "OBSERVATION", 22, 40], ["positive", "OBSERVATION_MODIFIER", 52, 60], ["T cell adhesion", "OBSERVATION", 81, 96]]], ["Clarity is still needed to understand the role of EMMPRIN in cellular adhesion and what its influences are.EMMPRIN in energy metabolismThe rapid rate of T cell proliferation requires cells to undergo glycolysis (instead of oxidative phosphorylation) to meet their fast-paced energy demands [47] .", [["cellular", "ANATOMY", 61, 69], ["T cell", "ANATOMY", 153, 159], ["cells", "ANATOMY", 183, 188], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 50, 57], ["cellular", "CELL", 61, 69], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 107, 114], ["T cell", "CELL", 153, 159], ["cells", "CELL", 183, 188], ["EMMPRIN", "PROTEIN", 50, 57], ["EMMPRIN", "PROTEIN", 107, 114], ["EMMPRIN in cellular adhesion", "TREATMENT", 50, 78], ["T cell proliferation", "PROBLEM", 153, 173], ["glycolysis", "TREATMENT", 200, 210], ["oxidative phosphorylation)", "TREATMENT", 223, 249], ["metabolism", "OBSERVATION", 125, 135], ["rapid", "OBSERVATION_MODIFIER", 139, 144], ["T cell proliferation", "OBSERVATION", 153, 173]]], ["Although glycolysis generates energy faster than oxidative phosphorylation, it is a less efficient approach and leads to the accumulation of lactic acid byproducts.", [["lactic acid", "CHEMICAL", 141, 152], ["lactic acid", "CHEMICAL", 141, 152], ["lactic acid byproducts", "SIMPLE_CHEMICAL", 141, 163], ["oxidative phosphorylation", "TREATMENT", 49, 74], ["lactic acid byproducts", "TREATMENT", 141, 163], ["lactic acid byproducts", "OBSERVATION", 141, 163]]], ["In cancer, this altered energy metabolism is known as the Warburg effect, an effect that EMMPRIN appears to regulate.", [["cancer", "ANATOMY", 3, 9], ["cancer", "DISEASE", 3, 9], ["cancer", "CANCER", 3, 9], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 89, 96], ["EMMPRIN", "PROTEIN", 89, 96], ["this altered energy metabolism", "PROBLEM", 11, 41], ["EMMPRIN", "TREATMENT", 89, 96], ["cancer", "OBSERVATION", 3, 9], ["energy metabolism", "OBSERVATION", 24, 41]]], ["As mentioned previously, EMMPRIN is an important player in alleviating the toxic build-up of lactic acid in cancers by shuttling lactate transporters-MCTs-up to the plasma membrane [14, 25, 88] .", [["cancers", "ANATOMY", 108, 115], ["plasma membrane", "ANATOMY", 165, 180], ["lactic acid", "CHEMICAL", 93, 104], ["cancers", "DISEASE", 108, 115], ["lactate", "CHEMICAL", 129, 136], ["lactic acid", "CHEMICAL", 93, 104], ["lactate", "CHEMICAL", 129, 136], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 25, 32], ["lactic acid", "SIMPLE_CHEMICAL", 93, 104], ["cancers", "CANCER", 108, 115], ["lactate", "SIMPLE_CHEMICAL", 129, 136], ["MCTs", "GENE_OR_GENE_PRODUCT", 150, 154], ["plasma membrane", "CELLULAR_COMPONENT", 165, 180], ["EMMPRIN", "PROTEIN", 25, 32], ["lactic acid in cancers", "PROBLEM", 93, 115], ["lactate transporters", "TEST", 129, 149], ["MCTs", "TEST", 150, 154], ["the plasma membrane", "TEST", 161, 180]]], ["The silencing of EMMPRIN in pancreatic or breast cancer cells inhibited MCT1 and MCT4 expression, reduced their growth, and decreased their glycolytic rate and lactate efflux [83, 89] .", [["pancreatic", "ANATOMY", 28, 38], ["breast cancer cells", "ANATOMY", 42, 61], ["breast cancer", "DISEASE", 42, 55], ["lactate", "CHEMICAL", 160, 167], ["lactate", "CHEMICAL", 160, 167], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 17, 24], ["pancreatic", "CELL", 28, 38], ["breast cancer cells", "CELL", 42, 61], ["MCT1", "GENE_OR_GENE_PRODUCT", 72, 76], ["MCT4", "GENE_OR_GENE_PRODUCT", 81, 85], ["lactate", "SIMPLE_CHEMICAL", 160, 167], ["EMMPRIN", "PROTEIN", 17, 24], ["pancreatic or breast cancer cells", "CELL_TYPE", 28, 61], ["MCT1", "PROTEIN", 72, 76], ["MCT4", "PROTEIN", 81, 85], ["EMMPRIN in pancreatic or breast cancer cells", "PROBLEM", 17, 61], ["MCT1", "TEST", 72, 76], ["MCT4 expression", "TEST", 81, 96], ["lactate efflux", "TEST", 160, 174], ["pancreatic", "ANATOMY", 28, 38], ["breast", "ANATOMY", 42, 48], ["cancer", "OBSERVATION", 49, 55], ["MCT4 expression", "OBSERVATION", 81, 96], ["growth", "OBSERVATION_MODIFIER", 112, 118]]], ["An MCT-EMMPRIN-CD98-LAT1 supercomplex with a neutral amino acid transporter (ASCT2) was shown to exist in human fibrosarcoma, colorectal adenocarcinoma, and breast adenocarcinoma cell lines, demonstrating importance in cellular metabolism [82] (Fig. 3E) .", [["fibrosarcoma", "ANATOMY", 112, 124], ["colorectal adenocarcinoma", "ANATOMY", 126, 151], ["breast adenocarcinoma cell lines", "ANATOMY", 157, 189], ["cellular", "ANATOMY", 219, 227], ["amino acid", "CHEMICAL", 53, 63], ["fibrosarcoma", "DISEASE", 112, 124], ["colorectal adenocarcinoma", "DISEASE", 126, 151], ["breast adenocarcinoma", "DISEASE", 157, 178], ["amino acid", "CHEMICAL", 53, 63], ["LAT1", "GENE_OR_GENE_PRODUCT", 20, 24], ["amino acid", "AMINO_ACID", 53, 63], ["ASCT2", "GENE_OR_GENE_PRODUCT", 77, 82], ["human", "ORGANISM", 106, 111], ["fibrosarcoma", "CANCER", 112, 124], ["colorectal adenocarcinoma", "CANCER", 126, 151], ["breast adenocarcinoma cell lines", "CELL", 157, 189], ["cellular", "CELL", 219, 227], ["MCT-EMMPRIN-CD98", "PROTEIN", 3, 19], ["LAT1 supercomplex", "PROTEIN", 20, 37], ["neutral amino acid transporter", "PROTEIN", 45, 75], ["ASCT2", "PROTEIN", 77, 82], ["human fibrosarcoma, colorectal adenocarcinoma, and breast adenocarcinoma cell lines", "CELL_LINE", 106, 189], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["An MCT-EMMPRIN-CD98", "TEST", 0, 19], ["a neutral amino acid transporter (ASCT2)", "PROBLEM", 43, 83], ["human fibrosarcoma", "PROBLEM", 106, 124], ["colorectal adenocarcinoma", "PROBLEM", 126, 151], ["breast adenocarcinoma cell lines", "PROBLEM", 157, 189], ["human", "ANATOMY", 106, 111], ["fibrosarcoma", "OBSERVATION", 112, 124], ["colorectal adenocarcinoma", "OBSERVATION", 126, 151], ["breast", "ANATOMY", 157, 163], ["adenocarcinoma cell lines", "OBSERVATION", 164, 189], ["cellular metabolism", "OBSERVATION", 219, 238]]], ["Moreover, hyaluronan-CD44-MCT-EMMPRIN complexes exist in human breast adenocarcinoma cell lines [83] (Fig. 3G) .", [["breast adenocarcinoma cell lines", "ANATOMY", 63, 95], ["breast adenocarcinoma", "DISEASE", 63, 84], ["hyaluronan-CD44", "GENE_OR_GENE_PRODUCT", 10, 25], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 30, 37], ["human", "ORGANISM", 57, 62], ["breast adenocarcinoma cell lines [83]", "CELL", 63, 100], ["Fig. 3G", "CELL", 102, 109], ["hyaluronan", "PROTEIN", 10, 20], ["CD44", "PROTEIN", 21, 25], ["MCT-EMMPRIN complexes", "PROTEIN", 26, 47], ["human breast adenocarcinoma cell lines", "CELL_LINE", 57, 95], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["hyaluronan", "TEST", 10, 20], ["CD44-MCT-EMMPRIN complexes", "TREATMENT", 21, 47], ["human breast adenocarcinoma cell lines", "TREATMENT", 57, 95], ["breast", "ANATOMY", 63, 69], ["adenocarcinoma", "OBSERVATION", 70, 84], ["cell lines", "OBSERVATION", 85, 95]]], ["That being said, lactate transport is also important in lymphocyte activation [47] , where inhibition of MCT1 (an interacting partner of EMMPRIN) during T cell activation inhibited T cell proliferation and lactate efflux [90] .", [["lymphocyte", "ANATOMY", 56, 66], ["T cell", "ANATOMY", 153, 159], ["T cell", "ANATOMY", 181, 187], ["lactate", "CHEMICAL", 17, 24], ["lactate", "CHEMICAL", 206, 213], ["lactate", "CHEMICAL", 17, 24], ["lactate", "CHEMICAL", 206, 213], ["lactate", "SIMPLE_CHEMICAL", 17, 24], ["lymphocyte", "CELL", 56, 66], ["MCT1", "GENE_OR_GENE_PRODUCT", 105, 109], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 137, 144], ["T cell", "CELL", 153, 159], ["T cell", "CELL", 181, 187], ["lactate", "SIMPLE_CHEMICAL", 206, 213], ["MCT1", "PROTEIN", 105, 109], ["EMMPRIN", "PROTEIN", 137, 144], ["lactate transport", "TEST", 17, 34], ["MCT1", "TEST", 105, 109], ["T cell activation", "TEST", 153, 170], ["T cell proliferation", "PROBLEM", 181, 201], ["lactate efflux", "TEST", 206, 220]]], ["Thus, EMMPRIN may play a role in alleviating toxic lactic acid byproducts during the rapid proliferation of T cells (Fig. 2C) , an area requiring investigation.Cancer/lymphomaEMMPRIN is up-regulated in a number of different cancers, in which its levels correlate with a poor prognosis in cancer patients [21, [91] [92] [93] [94] .", [["T cells", "ANATOMY", 108, 115], ["Cancer", "ANATOMY", 160, 166], ["cancers", "ANATOMY", 224, 231], ["cancer", "ANATOMY", 288, 294], ["lactic acid", "CHEMICAL", 51, 62], ["Cancer", "DISEASE", 160, 166], ["cancers", "DISEASE", 224, 231], ["cancer", "DISEASE", 288, 294], ["lactic acid", "CHEMICAL", 51, 62], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 6, 13], ["lactic acid", "SIMPLE_CHEMICAL", 51, 62], ["T cells", "CELL", 108, 115], ["Fig. 2C", "CELL", 117, 124], ["Cancer", "CANCER", 160, 166], ["lymphomaEMMPRIN", "GENE_OR_GENE_PRODUCT", 167, 182], ["cancers", "CANCER", 224, 231], ["cancer", "CANCER", 288, 294], ["patients", "ORGANISM", 295, 303], ["[91] [92] [93", "SIMPLE_CHEMICAL", 309, 322], ["EMMPRIN", "PROTEIN", 6, 13], ["T cells", "CELL_TYPE", 108, 115], ["lymphomaEMMPRIN", "PROTEIN", 167, 182], ["patients", "SPECIES", 295, 303], ["alleviating toxic lactic acid byproducts", "PROBLEM", 33, 73], ["the rapid proliferation of T cells", "PROBLEM", 81, 115], ["investigation", "TEST", 146, 159], ["Cancer/lymphomaEMMPRIN", "PROBLEM", 160, 182], ["different cancers", "PROBLEM", 214, 231], ["different", "OBSERVATION_MODIFIER", 214, 223], ["cancers", "OBSERVATION", 224, 231]]], ["MMPs have been identified as potential therapeutic targets in cancers for a long time [95] [96] [97] ; thus, EMMPRIN, an MMP-inducer, is becoming recognized as a suitable candidate for therapeutic intervention.", [["cancers", "ANATOMY", 62, 69], ["cancers", "DISEASE", 62, 69], ["MMPs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancers", "CANCER", 62, 69], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 109, 116], ["MMP", "GENE_OR_GENE_PRODUCT", 121, 124], ["MMPs", "PROTEIN", 0, 4], ["EMMPRIN", "PROTEIN", 109, 116], ["MMP", "PROTEIN", 121, 124], ["EMMPRIN", "TREATMENT", 109, 116], ["an MMP", "TEST", 118, 124], ["therapeutic intervention", "TREATMENT", 185, 209]]], ["EMMPRIN has been shown to promote multiple stages of tumor progression, such as tumor cell proliferation, invasiveness, and metastasis, via MMP induction [98, 99] ; angiogenesis by stimulating VEGF production via the PI3K pathway [100, 101] ; anchorage-independent growth [84] ; chemoresistance [85] ; and lactate efflux (see section above on energy metabolism) [2, 82, 83, 89] .", [["tumor", "ANATOMY", 53, 58], ["tumor cell", "ANATOMY", 80, 90], ["tumor", "DISEASE", 53, 58], ["tumor", "DISEASE", 80, 85], ["lactate", "CHEMICAL", 306, 313], ["lactate", "CHEMICAL", 306, 313], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["tumor", "CANCER", 53, 58], ["tumor cell", "CELL", 80, 90], ["VEGF", "GENE_OR_GENE_PRODUCT", 193, 197], ["PI3K", "GENE_OR_GENE_PRODUCT", 217, 221], ["lactate", "SIMPLE_CHEMICAL", 306, 313], ["EMMPRIN", "PROTEIN", 0, 7], ["MMP", "PROTEIN", 140, 143], ["VEGF", "PROTEIN", 193, 197], ["PI3K", "PROTEIN", 217, 221], ["tumor progression", "PROBLEM", 53, 70], ["tumor cell proliferation", "PROBLEM", 80, 104], ["invasiveness", "PROBLEM", 106, 118], ["metastasis", "PROBLEM", 124, 134], ["MMP induction", "TEST", 140, 153], ["angiogenesis", "PROBLEM", 165, 177], ["stimulating VEGF production", "TEST", 181, 208], ["the PI3K pathway", "TEST", 213, 229], ["chemoresistance", "TEST", 279, 294], ["lactate efflux", "TEST", 306, 320], ["energy metabolism", "TEST", 343, 360], ["multiple stages", "OBSERVATION_MODIFIER", 34, 49], ["tumor", "OBSERVATION", 53, 58], ["tumor cell proliferation", "OBSERVATION", 80, 104], ["invasiveness", "OBSERVATION_MODIFIER", 106, 118], ["metastasis", "OBSERVATION", 124, 134]]], ["With all of these positive roles for EMMRIN in tumor growth and biology, more and more groups are exploring and understanding the benefit of the use of anti-EMMPRIN antibodies as a potential tumor therapy, including HCC (HAb18 and Licartin) [102] and head and neck cancer (CNTO 3899 clone) [103] .Cancer/lymphomaIn relation to T cell biology, glycosylated EMMPRIN is highly expressed in Jurkat cells compared with normal human PBMCs [77, 104] .", [["tumor", "ANATOMY", 47, 52], ["tumor", "ANATOMY", 191, 196], ["HCC", "ANATOMY", 216, 219], ["head and neck cancer", "ANATOMY", 251, 271], ["Cancer", "ANATOMY", 297, 303], ["T cell", "ANATOMY", 327, 333], ["Jurkat cells", "ANATOMY", 387, 399], ["PBMCs", "ANATOMY", 427, 432], ["tumor", "DISEASE", 47, 52], ["tumor", "DISEASE", 191, 196], ["HCC", "DISEASE", 216, 219], ["head and neck cancer", "DISEASE", 251, 271], ["Cancer", "DISEASE", 297, 303], ["EMMRIN", "GENE_OR_GENE_PRODUCT", 37, 43], ["tumor", "CANCER", 47, 52], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 152, 175], ["tumor", "CANCER", 191, 196], ["HCC", "CANCER", 216, 219], ["HAb18", "CANCER", 221, 226], ["head and neck cancer", "CANCER", 251, 271], ["CNTO 3899 clone", "CELL", 273, 288], ["Cancer", "CANCER", 297, 303], ["lymphomaIn", "CANCER", 304, 314], ["T cell", "CELL", 327, 333], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 356, 363], ["Jurkat cells", "CELL", 387, 399], ["human", "ORGANISM", 421, 426], ["PBMCs", "CELL", 427, 432], ["EMMRIN", "PROTEIN", 37, 43], ["anti-EMMPRIN antibodies", "PROTEIN", 152, 175], ["EMMPRIN", "PROTEIN", 356, 363], ["Jurkat cells", "CELL_LINE", 387, 399], ["normal human PBMCs", "CELL_TYPE", 414, 432], ["human", "SPECIES", 421, 426], ["human", "SPECIES", 421, 426], ["EMMRIN in tumor growth", "PROBLEM", 37, 59], ["anti-EMMPRIN antibodies", "TREATMENT", 152, 175], ["a potential tumor therapy", "TREATMENT", 179, 204], ["HCC (HAb18 and Licartin)", "TREATMENT", 216, 240], ["head and neck cancer", "PROBLEM", 251, 271], ["Cancer", "PROBLEM", 297, 303], ["glycosylated EMMPRIN", "PROBLEM", 343, 363], ["tumor", "OBSERVATION", 47, 52], ["tumor", "OBSERVATION", 191, 196], ["head", "ANATOMY", 251, 255], ["neck", "ANATOMY", 260, 264], ["cancer", "OBSERVATION", 265, 271], ["Jurkat cells", "OBSERVATION", 387, 399]]], ["The silencing of EMMPRIN in Jurkat cells decreased its proliferation, migration, and adhesion to fibronectin; this emphasizes the importance of EMMPRIN in the survival and growth of cancer cells.", [["Jurkat cells", "ANATOMY", 28, 40], ["cancer cells", "ANATOMY", 182, 194], ["cancer", "DISEASE", 182, 188], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 17, 24], ["Jurkat cells", "CELL", 28, 40], ["fibronectin", "GENE_OR_GENE_PRODUCT", 97, 108], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 144, 151], ["cancer cells", "CELL", 182, 194], ["EMMPRIN", "PROTEIN", 17, 24], ["Jurkat cells", "CELL_LINE", 28, 40], ["fibronectin", "PROTEIN", 97, 108], ["EMMPRIN", "PROTEIN", 144, 151], ["cancer cells", "CELL_TYPE", 182, 194], ["EMMPRIN in Jurkat cells", "TREATMENT", 17, 40], ["its proliferation", "PROBLEM", 51, 68], ["adhesion to fibronectin", "TREATMENT", 85, 108], ["EMMPRIN", "TREATMENT", 144, 151], ["cancer cells", "PROBLEM", 182, 194], ["Jurkat cells", "OBSERVATION", 28, 40], ["proliferation", "OBSERVATION_MODIFIER", 55, 68], ["migration", "OBSERVATION_MODIFIER", 70, 79], ["cancer cells", "OBSERVATION", 182, 194]]], ["As noted before, the absence of EMMPRIN in primary T cells led to their hyperproliferation [30, 46, 50] .", [["primary T cells", "ANATOMY", 43, 58], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 32, 39], ["T cells", "CELL", 51, 58], ["EMMPRIN", "PROTEIN", 32, 39], ["primary T cells", "CELL_TYPE", 43, 58], ["their hyperproliferation", "PROBLEM", 66, 90], ["hyperproliferation", "OBSERVATION_MODIFIER", 72, 90]]], ["The contradictory results can be explained by the proliferation of cancer cells acting through a mechanism not dependent on TCR-mediated signaling events, as is the case in primary T cells.", [["cancer cells", "ANATOMY", 67, 79], ["primary T cells", "ANATOMY", 173, 188], ["cancer", "DISEASE", 67, 73], ["TCR", "CHEMICAL", 124, 127], ["cancer cells", "CELL", 67, 79], ["TCR", "GENE_OR_GENE_PRODUCT", 124, 127], ["T cells", "CELL", 181, 188], ["cancer cells", "CELL_TYPE", 67, 79], ["TCR", "PROTEIN", 124, 127], ["primary T cells", "CELL_TYPE", 173, 188], ["cancer cells", "PROBLEM", 67, 79], ["cancer", "OBSERVATION", 67, 73]]], ["When Jurkat cells were cocultured with superantigen-loaded Raji B cells, thus subjected to conjugate formation, EMMPRIN aggregated at T cell immune synapses.", [["Jurkat cells", "ANATOMY", 5, 17], ["Raji B cells", "ANATOMY", 59, 71], ["T cell", "ANATOMY", 134, 140], ["Jurkat cells", "CELL", 5, 17], ["Raji B cells", "CELL", 59, 71], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 112, 119], ["T cell", "CELL", 134, 140], ["Jurkat cells", "CELL_LINE", 5, 17], ["superantigen", "PROTEIN", 39, 51], ["Raji B cells", "CELL_LINE", 59, 71], ["EMMPRIN", "PROTEIN", 112, 119], ["Jurkat cells", "PROBLEM", 5, 17], ["superantigen-loaded Raji B cells", "TREATMENT", 39, 71], ["conjugate formation", "PROBLEM", 91, 110], ["EMMPRIN", "PROBLEM", 112, 119]]], ["When Jurkat cells were also stimulated with anti-CD3 antibodies to initiate TCR-dependent signaling events, contrary to TCRindependent mechanisms [77] , EMMPRIN overexpression inhibited T cell activity, as demonstrated by NFAT inhibition (an essential transcription factor in T cell activation), whereas EMMPRIN knockdown promoted NFAT signaling activity (events umpired by the intracellular domain of EMMPRIN) [104] .", [["Jurkat cells", "ANATOMY", 5, 17], ["T cell", "ANATOMY", 186, 192], ["T cell", "ANATOMY", 276, 282], ["intracellular", "ANATOMY", 378, 391], ["TCR", "CHEMICAL", 76, 79], ["Jurkat cells", "CELL", 5, 17], ["anti-CD3 antibodies", "GENE_OR_GENE_PRODUCT", 44, 63], ["TCR", "GENE_OR_GENE_PRODUCT", 76, 79], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 153, 160], ["T cell", "CELL", 186, 192], ["NFAT", "GENE_OR_GENE_PRODUCT", 222, 226], ["T cell", "CELL", 276, 282], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 304, 311], ["NFAT", "GENE_OR_GENE_PRODUCT", 331, 335], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 378, 391], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 402, 409], ["Jurkat cells", "CELL_LINE", 5, 17], ["anti-CD3 antibodies", "PROTEIN", 44, 63], ["TCR", "PROTEIN", 76, 79], ["EMMPRIN", "PROTEIN", 153, 160], ["NFAT", "PROTEIN", 222, 226], ["transcription factor", "PROTEIN", 252, 272], ["EMMPRIN", "PROTEIN", 304, 311], ["NFAT", "PROTEIN", 331, 335], ["intracellular domain", "PROTEIN", 378, 398], ["EMMPRIN", "PROTEIN", 402, 409], ["Jurkat cells", "PROBLEM", 5, 17], ["anti-CD3 antibodies", "TREATMENT", 44, 63], ["dependent signaling events", "PROBLEM", 80, 106], ["EMMPRIN overexpression", "TREATMENT", 153, 175], ["T cell activity", "PROBLEM", 186, 201], ["T cell activation", "TREATMENT", 276, 293], ["EMMPRIN knockdown", "TREATMENT", 304, 321], ["cell activity", "OBSERVATION", 188, 201]]], ["The inhibitory effect of EMMPRIN on TCR-mediated activation in Jurkat cells occurred downstream of the Vav1 (a guanine nucleotide exchange factor for Ras-related C3 botulinum toxin substrate 1) signaling pathway and upstream of the JNK and serine/threonine-protein kinase 1 pathway; ERK signaling remained unaffected.", [["Jurkat cells", "ANATOMY", 63, 75], ["TCR", "CHEMICAL", 36, 39], ["guanine nucleotide", "CHEMICAL", 111, 129], ["guanine nucleotide", "CHEMICAL", 111, 129], ["serine", "CHEMICAL", 240, 246], ["threonine", "CHEMICAL", 247, 256], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 25, 32], ["TCR", "GENE_OR_GENE_PRODUCT", 36, 39], ["Jurkat cells", "CELL", 63, 75], ["Vav1", "GENE_OR_GENE_PRODUCT", 103, 107], ["guanine nucleotide exchange factor", "GENE_OR_GENE_PRODUCT", 111, 145], ["Ras-related C3 botulinum toxin substrate 1", "GENE_OR_GENE_PRODUCT", 150, 192], ["JNK", "GENE_OR_GENE_PRODUCT", 232, 235], ["serine/threonine-protein kinase 1", "GENE_OR_GENE_PRODUCT", 240, 273], ["ERK", "GENE_OR_GENE_PRODUCT", 283, 286], ["EMMPRIN", "PROTEIN", 25, 32], ["TCR", "PROTEIN", 36, 39], ["Jurkat cells", "CELL_LINE", 63, 75], ["Vav1", "PROTEIN", 103, 107], ["guanine nucleotide exchange factor", "PROTEIN", 111, 145], ["Ras-related C3 botulinum toxin substrate 1", "PROTEIN", 150, 192], ["JNK", "PROTEIN", 232, 235], ["protein kinase 1", "PROTEIN", 257, 273], ["ERK", "PROTEIN", 283, 286], ["EMMPRIN", "TREATMENT", 25, 32], ["TCR", "TEST", 36, 39], ["Jurkat cells", "PROBLEM", 63, 75], ["a guanine nucleotide exchange factor", "TREATMENT", 109, 145], ["Ras-related C3 botulinum toxin substrate", "TREATMENT", 150, 190], ["the JNK", "TEST", 228, 235], ["serine/threonine-protein kinase", "TEST", 240, 271], ["ERK signaling", "TEST", 283, 296], ["Jurkat cells", "OBSERVATION", 63, 75], ["Vav1", "ANATOMY", 103, 107], ["JNK", "ANATOMY", 232, 235]]], ["Besides signaling, functional activities, such as proliferation, however, was not assessed [104] .", [["functional activities", "OBSERVATION", 19, 40]]], ["This supports that TCR-mediated activation brings out a regulatory/ inhibitory effect of EMMPRIN at the early stages of T cell activity.", [["T cell", "ANATOMY", 120, 126], ["TCR", "CHEMICAL", 19, 22], ["TCR", "GENE_OR_GENE_PRODUCT", 19, 22], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 89, 96], ["T cell", "CELL", 120, 126], ["TCR", "PROTEIN", 19, 22], ["EMMPRIN", "PROTEIN", 89, 96], ["EMMPRIN", "TREATMENT", 89, 96], ["cell activity", "OBSERVATION", 122, 135]]], ["However, in TCR-independent activation/proliferation, as found in cancer cells (such as lymphomas) or in activated autoimmune T cells (such as in SLE), EMMPRIN (highly up-regulated compared with resting primary T cells) may act in a positive or stimulatory manner for activities, such as adhesion, invasion, migration, or aiding, in the Warburg effect.SLESLE is a systemic autoimmune disease associated with abnormal T and B cell functions leading to the dysfunction of a number of organs [105] .", [["cancer cells", "ANATOMY", 66, 78], ["lymphomas", "ANATOMY", 88, 97], ["autoimmune T cells", "ANATOMY", 115, 133], ["primary T cells", "ANATOMY", 203, 218], ["B cell", "ANATOMY", 423, 429], ["organs", "ANATOMY", 482, 488], ["TCR", "CHEMICAL", 12, 15], ["cancer", "DISEASE", 66, 72], ["lymphomas", "DISEASE", 88, 97], ["SLE", "DISEASE", 146, 149], ["SLESLE", "DISEASE", 352, 358], ["autoimmune disease", "DISEASE", 373, 391], ["TCR", "GENE_OR_GENE_PRODUCT", 12, 15], ["cancer cells", "CELL", 66, 78], ["lymphomas", "CANCER", 88, 97], ["autoimmune T cells", "CELL", 115, 133], ["SLE", "CANCER", 146, 149], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 152, 159], ["T cells", "CELL", 211, 218], ["T", "CELL", 417, 418], ["B cell", "CELL", 423, 429], ["organs", "ORGAN", 482, 488], ["TCR", "PROTEIN", 12, 15], ["cancer cells", "CELL_TYPE", 66, 78], ["activated autoimmune T cells", "CELL_TYPE", 105, 133], ["EMMPRIN", "PROTEIN", 152, 159], ["resting primary T cells", "CELL_TYPE", 195, 218], ["proliferation", "PROBLEM", 39, 52], ["cancer cells", "PROBLEM", 66, 78], ["lymphomas", "PROBLEM", 88, 97], ["activated autoimmune T cells", "PROBLEM", 105, 133], ["EMMPRIN", "TEST", 152, 159], ["adhesion", "PROBLEM", 288, 296], ["invasion", "PROBLEM", 298, 306], ["a systemic autoimmune disease", "PROBLEM", 362, 391], ["abnormal T and B cell functions", "PROBLEM", 408, 439], ["the dysfunction", "PROBLEM", 451, 466], ["cancer cells", "OBSERVATION", 66, 78], ["systemic", "OBSERVATION_MODIFIER", 364, 372], ["autoimmune", "OBSERVATION", 373, 383], ["cell functions", "OBSERVATION", 425, 439], ["dysfunction", "OBSERVATION", 455, 466]]], ["It is reported that T cells from PBMCs of SLE patients are hyperactivated and secrete enhanced levels of MMP-9 compared with healthy controls [106] .", [["T cells", "ANATOMY", 20, 27], ["PBMCs", "ANATOMY", 33, 38], ["SLE", "DISEASE", 42, 45], ["T cells", "CELL", 20, 27], ["PBMCs", "CELL", 33, 38], ["patients", "ORGANISM", 46, 54], ["MMP-9", "GENE_OR_GENE_PRODUCT", 105, 110], ["T cells", "CELL_TYPE", 20, 27], ["PBMCs", "CELL_TYPE", 33, 38], ["MMP-9", "PROTEIN", 105, 110], ["patients", "SPECIES", 46, 54], ["T cells", "PROBLEM", 20, 27], ["hyperactivated", "PROBLEM", 59, 73], ["secrete enhanced levels", "TEST", 78, 101], ["MMP", "TEST", 105, 108]]], ["It was later shown that the enhanced, secreted MMP-9 activity correlated with enhanced EMMPRIN expression on CD3 + T cells in these patients [57] .", [["CD3 + T cells", "ANATOMY", 109, 122], ["MMP-9", "GENE_OR_GENE_PRODUCT", 47, 52], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 87, 94], ["CD3", "GENE_OR_GENE_PRODUCT", 109, 112], ["patients", "ORGANISM", 132, 140], ["MMP", "PROTEIN", 47, 50], ["EMMPRIN", "PROTEIN", 87, 94], ["CD3", "PROTEIN", 109, 112], ["T cells", "CELL_TYPE", 115, 122], ["patients", "SPECIES", 132, 140], ["secreted MMP", "TEST", 38, 50], ["CD3", "TEST", 109, 112]]], ["The application of the anti-EMMPRIN antibody (clone MEM-M6/1) reduced tyrosine phosphorylation levels in anti-CD3/anti-CD28-stimulated T cells from SLE patients, although this did not affect MMP activity [57] .", [["T cells", "ANATOMY", 135, 142], ["tyrosine", "CHEMICAL", 70, 78], ["SLE", "DISEASE", 148, 151], ["tyrosine", "CHEMICAL", 70, 78], ["tyrosine", "AMINO_ACID", 70, 78], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 105, 113], ["CD28", "GENE_OR_GENE_PRODUCT", 119, 123], ["T cells", "CELL", 135, 142], ["patients", "ORGANISM", 152, 160], ["MMP", "GENE_OR_GENE_PRODUCT", 191, 194], ["anti-EMMPRIN antibody", "PROTEIN", 23, 44], ["M6", "PROTEIN", 56, 58], ["anti-CD3", "PROTEIN", 105, 113], ["CD28", "PROTEIN", 119, 123], ["T cells", "CELL_TYPE", 135, 142], ["MMP", "PROTEIN", 191, 194], ["patients", "SPECIES", 152, 160], ["the anti-EMMPRIN antibody", "TEST", 19, 44], ["clone MEM", "TEST", 46, 55], ["tyrosine phosphorylation levels", "TEST", 70, 101], ["anti-CD3", "TEST", 105, 113], ["anti", "TEST", 114, 118], ["MMP activity", "TEST", 191, 203]]], ["It is possible that the administration of other anti-EMMPRIN antibody clones could reduce MMP activity.", [["MMP", "GENE_OR_GENE_PRODUCT", 90, 93], ["anti-EMMPRIN antibody clones", "CELL_LINE", 48, 76], ["MMP", "PROTEIN", 90, 93], ["other anti-EMMPRIN antibody clones", "TREATMENT", 42, 76], ["MMP activity", "PROBLEM", 90, 102]]], ["All in all, the dampening of T cell responses with EMMPRIN mAbs could be a useful therapeutic strategy in SLE; however, further studies are required to validate this approach.GVHDWhen an individual requires the transplantation of stem cells, bone marrow cells, or other forms of tissue grafts, therapies to suppress the immune system are taken to prevent the transplanted donor cells from attacking the recipient, a complication known as GVHD.", [["T cell", "ANATOMY", 29, 35], ["stem cells", "ANATOMY", 230, 240], ["bone marrow cells", "ANATOMY", 242, 259], ["tissue grafts", "ANATOMY", 279, 292], ["immune system", "ANATOMY", 320, 333], ["cells", "ANATOMY", 378, 383], ["SLE", "DISEASE", 106, 109], ["GVHD", "DISEASE", 438, 442], ["T cell", "CELL", 29, 35], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 51, 63], ["stem cells", "CELL", 230, 240], ["bone marrow cells", "CELL", 242, 259], ["tissue grafts", "TISSUE", 279, 292], ["donor cells", "CELL", 372, 383], ["EMMPRIN mAbs", "PROTEIN", 51, 63], ["stem cells", "CELL_TYPE", 230, 240], ["bone marrow cells", "CELL_TYPE", 242, 259], ["transplanted donor cells", "CELL_TYPE", 359, 383], ["EMMPRIN mAbs", "TREATMENT", 51, 63], ["a useful therapeutic strategy in SLE", "PROBLEM", 73, 109], ["further studies", "TEST", 120, 135], ["the transplantation of stem cells", "TREATMENT", 207, 240], ["bone marrow cells", "PROBLEM", 242, 259], ["tissue grafts", "TREATMENT", 279, 292], ["therapies", "TREATMENT", 294, 303], ["the immune system", "PROBLEM", 316, 333], ["the transplanted donor cells", "TREATMENT", 355, 383], ["a complication", "PROBLEM", 414, 428], ["GVHD", "PROBLEM", 438, 442], ["dampening", "OBSERVATION_MODIFIER", 16, 25], ["stem cells", "OBSERVATION", 230, 240], ["bone", "ANATOMY", 242, 246], ["marrow cells", "OBSERVATION", 247, 259], ["tissue", "ANATOMY", 279, 285], ["grafts", "OBSERVATION", 286, 292], ["donor cells", "OBSERVATION", 372, 383]]], ["Despite these immunotherapies (with steroids usually being the first-line treatment), acute GVHD still persists in a fair percentage of cases and many die, frequently of infections, thus the need for alternate secondary therapies [107, 108] .", [["steroids", "CHEMICAL", 36, 44], ["GVHD", "DISEASE", 92, 96], ["infections", "DISEASE", 170, 180], ["steroids", "CHEMICAL", 36, 44], ["these immunotherapies", "TREATMENT", 8, 29], ["steroids", "TREATMENT", 36, 44], ["the first-line treatment", "TREATMENT", 59, 83], ["acute GVHD", "PROBLEM", 86, 96], ["infections", "PROBLEM", 170, 180], ["alternate secondary therapies", "TREATMENT", 200, 229], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["GVHD", "OBSERVATION", 92, 96], ["infections", "OBSERVATION", 170, 180]]], ["A phase 1/2 clinical trial that uses ABX-CBL (also known as gavilimomab), an IgM mAb that recognizes EMMPRIN, for the treatment of steroid-resistant acute GVHD had shown encouraging results [109] .", [["ABX-CBL", "CHEMICAL", 37, 44], ["gavilimomab", "CHEMICAL", 60, 71], ["steroid", "CHEMICAL", 131, 138], ["GVHD", "DISEASE", 155, 159], ["ABX-CBL", "CHEMICAL", 37, 44], ["gavilimomab", "CHEMICAL", 60, 71], ["steroid", "CHEMICAL", 131, 138], ["ABX-CBL", "SIMPLE_CHEMICAL", 37, 44], ["gavilimomab", "SIMPLE_CHEMICAL", 60, 71], ["IgM mAb", "GENE_OR_GENE_PRODUCT", 77, 84], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 101, 108], ["steroid", "SIMPLE_CHEMICAL", 131, 138], ["ABX", "PROTEIN", 37, 40], ["CBL", "PROTEIN", 41, 44], ["gavilimomab", "PROTEIN", 60, 71], ["IgM mAb", "PROTEIN", 77, 84], ["EMMPRIN", "PROTEIN", 101, 108], ["ABX", "TREATMENT", 37, 40], ["an IgM mAb", "TEST", 74, 84], ["EMMPRIN", "TREATMENT", 101, 108], ["steroid", "TREATMENT", 131, 138], ["resistant acute GVHD", "PROBLEM", 139, 159], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["GVHD", "OBSERVATION", 155, 159]]], ["ABX-CBL recognizes EMMPRIN, upregulated on activated T and B cells, as well as on resting and activated monocytes and dendritic cells, and depletes these cell populations though complement-mediated mechanisms.", [["T", "ANATOMY", 53, 54], ["B cells", "ANATOMY", 59, 66], ["monocytes", "ANATOMY", 104, 113], ["dendritic cells", "ANATOMY", 118, 133], ["cell", "ANATOMY", 154, 158], ["ABX-CBL", "GENE_OR_GENE_PRODUCT", 0, 7], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 19, 26], ["T", "CELL", 53, 54], ["B cells", "CELL", 59, 66], ["monocytes", "CELL", 104, 113], ["dendritic cells", "CELL", 118, 133], ["cell populations", "CELL", 154, 170], ["ABX", "PROTEIN", 0, 3], ["CBL", "PROTEIN", 4, 7], ["EMMPRIN", "PROTEIN", 19, 26], ["activated T and B cells", "CELL_TYPE", 43, 66], ["resting and activated monocytes", "CELL_TYPE", 82, 113], ["dendritic cells", "CELL_TYPE", 118, 133], ["ABX", "TREATMENT", 0, 3], ["activated T and B cells", "TREATMENT", 43, 66], ["dendritic cells", "PROBLEM", 118, 133], ["these cell populations", "PROBLEM", 148, 170], ["dendritic cells", "OBSERVATION", 118, 133], ["cell populations", "OBSERVATION", 154, 170]]], ["Resting lymphocytes that express low levels of EMMPRIN were shown to remain unaffected in vitro [109] .", [["lymphocytes", "ANATOMY", 8, 19], ["Resting lymphocytes", "CELL", 0, 19], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 47, 54], ["Resting lymphocytes", "CELL_TYPE", 0, 19], ["EMMPRIN", "PROTEIN", 47, 54], ["Resting lymphocytes", "TEST", 0, 19], ["low levels of EMMPRIN", "PROBLEM", 33, 54], ["low levels", "OBSERVATION_MODIFIER", 33, 43]]], ["It was reported that patients did experience myalgia, but this was manageable with narcotics.", [["myalgia", "DISEASE", 45, 52], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["myalgia", "PROBLEM", 45, 52], ["narcotics", "TREATMENT", 83, 92], ["myalgia", "OBSERVATION", 45, 52]]], ["An additional phase 2/3 multicenter-randomized clinical trial of ABX-CBL was completed for steroid-resistant acute GVHD; this again showed that ABX-CBL was well tolerated with a similar response rate as before but did not gain Food and Drug Administration approval, as its response was not improved compared with antithymocyte globulin, an alternate, second-line therapy [110] .", [["ABX-CBL", "CHEMICAL", 65, 72], ["steroid", "CHEMICAL", 91, 98], ["GVHD", "DISEASE", 115, 119], ["ABX-CBL", "CHEMICAL", 144, 151], ["antithymocyte globulin", "CHEMICAL", 313, 335], ["steroid", "CHEMICAL", 91, 98], ["ABX-CBL", "SIMPLE_CHEMICAL", 65, 72], ["steroid", "SIMPLE_CHEMICAL", 91, 98], ["ABX-CBL", "SIMPLE_CHEMICAL", 144, 151], ["antithymocyte globulin", "SIMPLE_CHEMICAL", 313, 335], ["CBL", "PROTEIN", 69, 72], ["CBL", "PROTEIN", 148, 151], ["antithymocyte globulin", "PROTEIN", 313, 335], ["ABX", "TREATMENT", 65, 68], ["CBL", "TEST", 69, 72], ["steroid", "TREATMENT", 91, 98], ["resistant acute GVHD", "PROBLEM", 99, 119], ["ABX", "TREATMENT", 144, 147], ["antithymocyte globulin", "TREATMENT", 313, 335], ["second-line therapy", "TREATMENT", 351, 370], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["GVHD", "OBSERVATION", 115, 119]]], ["Indeed, ABX-CBL did show activity and good tolerance, thus has potential as a future treatment for other inflammatory diseases or in combination with other treatments.RAAs EMMPRIN can induce MMP production, factors that can lead to cartilage and bone destruction [111] , its role was investigated in RA.", [["cartilage", "ANATOMY", 232, 241], ["bone", "ANATOMY", 246, 250], ["ABX", "CHEMICAL", 8, 11], ["inflammatory diseases", "DISEASE", 105, 126], ["RA", "DISEASE", 300, 302], ["ABX-CBL", "GENE_OR_GENE_PRODUCT", 8, 15], ["RAAs", "GENE_OR_GENE_PRODUCT", 167, 171], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 172, 179], ["MMP", "GENE_OR_GENE_PRODUCT", 191, 194], ["cartilage", "TISSUE", 232, 241], ["bone", "TISSUE", 246, 250], ["ABX", "PROTEIN", 8, 11], ["CBL", "PROTEIN", 12, 15], ["RAAs", "PROTEIN", 167, 171], ["EMMPRIN", "PROTEIN", 172, 179], ["MMP", "PROTEIN", 191, 194], ["ABX", "TREATMENT", 8, 11], ["a future treatment", "TREATMENT", 76, 94], ["other inflammatory diseases", "PROBLEM", 99, 126], ["other treatments", "TREATMENT", 150, 166], ["RAAs EMMPRIN", "TREATMENT", 167, 179], ["MMP production", "PROBLEM", 191, 205], ["cartilage and bone destruction", "PROBLEM", 232, 262], ["good tolerance", "OBSERVATION", 38, 52], ["inflammatory", "OBSERVATION", 105, 117], ["bone", "ANATOMY", 246, 250], ["destruction", "OBSERVATION", 251, 262], ["RA", "ANATOMY", 300, 302]]], ["EMMPRIN is up-regulated in the rheumatoid synovial membrane [112] , where its expression was found to correlate to MMP-1 and MMP-3 production in the synovial tissue [113] .", [["rheumatoid synovial membrane", "ANATOMY", 31, 59], ["synovial tissue", "ANATOMY", 149, 164], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["synovial membrane", "CELLULAR_COMPONENT", 42, 59], ["MMP-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["MMP-3", "GENE_OR_GENE_PRODUCT", 125, 130], ["synovial tissue", "TISSUE", 149, 164], ["EMMPRIN", "PROTEIN", 0, 7], ["MMP", "PROTEIN", 115, 118], ["MMP-3", "PROTEIN", 125, 130], ["MMP", "TEST", 115, 118], ["MMP", "TEST", 125, 128], ["rheumatoid synovial", "ANATOMY", 31, 50], ["synovial tissue", "ANATOMY", 149, 164]]], ["Indeed, EMMPRIN is involved in the pathogenesis of RA, as administration of the anti-EMMPRIN antibody (RL73.2 clone) in its animal model suppressed the development of CIA by reducing joint inflammation by .75% [61] .RAIn the peripheral blood of RA patients, monocytes/ macrophages showed increased expression of EMMPRIN compared with healthy controls and a further increase in the synovial fluid.", [["joint", "ANATOMY", 183, 188], ["peripheral blood", "ANATOMY", 225, 241], ["monocytes", "ANATOMY", 258, 267], ["macrophages", "ANATOMY", 269, 280], ["synovial fluid", "ANATOMY", 381, 395], ["RA", "DISEASE", 51, 53], ["CIA", "DISEASE", 167, 170], ["inflammation", "DISEASE", 189, 201], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 8, 15], ["anti-EMMPRIN antibody", "GENE_OR_GENE_PRODUCT", 80, 101], ["RL73.2 clone", "CELL", 103, 115], ["joint", "MULTI-TISSUE_STRUCTURE", 183, 188], ["peripheral blood", "ORGANISM_SUBSTANCE", 225, 241], ["patients", "ORGANISM", 248, 256], ["monocytes", "CELL", 258, 267], ["macrophages", "CELL", 269, 280], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 312, 319], ["synovial fluid", "ORGANISM_SUBSTANCE", 381, 395], ["EMMPRIN", "PROTEIN", 8, 15], ["anti-EMMPRIN antibody", "PROTEIN", 80, 101], ["RL73.2 clone", "CELL_LINE", 103, 115], ["monocytes", "CELL_TYPE", 258, 267], ["macrophages", "CELL_TYPE", 269, 280], ["EMMPRIN", "PROTEIN", 312, 319], ["patients", "SPECIES", 248, 256], ["the anti-EMMPRIN antibody", "TREATMENT", 76, 101], ["CIA", "PROBLEM", 167, 170], ["reducing joint inflammation", "PROBLEM", 174, 201], ["monocytes/ macrophages", "TEST", 258, 280], ["increased expression of EMMPRIN", "PROBLEM", 288, 319], ["a further increase in the synovial fluid", "PROBLEM", 355, 395], ["RA", "ANATOMY", 51, 53], ["CIA", "ANATOMY", 167, 170], ["joint", "ANATOMY", 183, 188], ["peripheral", "ANATOMY_MODIFIER", 225, 235], ["blood", "ANATOMY", 236, 241], ["RA", "ANATOMY", 245, 247], ["monocytes", "ANATOMY", 258, 267], ["macrophages", "ANATOMY", 269, 280], ["increased", "OBSERVATION_MODIFIER", 288, 297], ["increase", "OBSERVATION_MODIFIER", 365, 373], ["synovial", "ANATOMY", 381, 389], ["fluid", "OBSERVATION", 390, 395]]], ["Anti-EMMPRIN antibodies and EMMPRIN antagonistic peptides prevented the CyPA-mediated chemotaxis of mononuclear cells, as well as MMP-9 and MMP-2 production and invasive properties of human fibroblasts cocultured with monocytes [114] .", [["mononuclear cells", "ANATOMY", 100, 117], ["fibroblasts", "ANATOMY", 190, 201], ["monocytes", "ANATOMY", 218, 227], ["CyPA", "CHEMICAL", 72, 76], ["Anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 0, 23], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 28, 35], ["CyPA", "SIMPLE_CHEMICAL", 72, 76], ["mononuclear cells", "CELL", 100, 117], ["MMP-9", "GENE_OR_GENE_PRODUCT", 130, 135], ["MMP-2", "GENE_OR_GENE_PRODUCT", 140, 145], ["human", "ORGANISM", 184, 189], ["fibroblasts", "CELL", 190, 201], ["monocytes", "CELL", 218, 227], ["Anti-EMMPRIN antibodies", "PROTEIN", 0, 23], ["EMMPRIN", "PROTEIN", 28, 35], ["CyPA", "PROTEIN", 72, 76], ["mononuclear cells", "CELL_TYPE", 100, 117], ["MMP", "PROTEIN", 130, 133], ["human fibroblasts", "CELL_TYPE", 184, 201], ["monocytes", "CELL_TYPE", 218, 227], ["human", "SPECIES", 184, 189], ["human", "SPECIES", 184, 189], ["Anti-EMMPRIN antibodies", "TREATMENT", 0, 23], ["EMMPRIN antagonistic peptides", "TREATMENT", 28, 57], ["the CyPA", "TEST", 68, 76], ["mononuclear cells", "TEST", 100, 117], ["MMP", "TEST", 130, 133], ["MMP", "TEST", 140, 143], ["monocytes", "TEST", 218, 227], ["mononuclear cells", "OBSERVATION", 100, 117]]], ["FLS from RA patients also possessed high EMMPRIN expression levels, where EMMPRIN antagonistic peptides inhibited their production and activation of MMPs, as well as their invasive potential in a coculture with human monocytic THP-1 cells [115] .", [["FLS", "ANATOMY", 0, 3], ["monocytic THP-1 cells", "ANATOMY", 217, 238], ["FLS", "CELL", 0, 3], ["patients", "ORGANISM", 12, 20], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 41, 48], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 74, 81], ["MMPs", "GENE_OR_GENE_PRODUCT", 149, 153], ["human", "ORGANISM", 211, 216], ["monocytic THP-1 cells [115]", "CELL", 217, 244], ["FLS", "CELL_TYPE", 0, 3], ["EMMPRIN", "PROTEIN", 41, 48], ["EMMPRIN", "PROTEIN", 74, 81], ["MMPs", "PROTEIN", 149, 153], ["human monocytic THP-1 cells", "CELL_LINE", 211, 238], ["patients", "SPECIES", 12, 20], ["human", "SPECIES", 211, 216], ["human", "SPECIES", 211, 216], ["high EMMPRIN expression levels", "PROBLEM", 36, 66], ["EMMPRIN antagonistic peptides", "TREATMENT", 74, 103], ["MMPs", "PROBLEM", 149, 153], ["RA", "ANATOMY", 9, 11]]], ["This demonstrates a potential therapeutic role for anti-EMMPRIN antibodies in preventing RA progression.RAThe elevated expression of EMMPRIN found on neutrophils in the peripheral blood of RA patients compared with controls was also shown to play a role in neutrophil chemotaxis via CyPA.", [["neutrophils", "ANATOMY", 150, 161], ["peripheral blood", "ANATOMY", 169, 185], ["neutrophil", "ANATOMY", 257, 267], ["RA", "DISEASE", 89, 91], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 51, 74], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 133, 140], ["neutrophils", "CELL", 150, 161], ["peripheral blood", "ORGANISM_SUBSTANCE", 169, 185], ["patients", "ORGANISM", 192, 200], ["neutrophil", "CELL", 257, 267], ["CyPA", "GENE_OR_GENE_PRODUCT", 283, 287], ["anti-EMMPRIN antibodies", "PROTEIN", 51, 74], ["EMMPRIN", "PROTEIN", 133, 140], ["neutrophils", "CELL_TYPE", 150, 161], ["neutrophil", "CELL_TYPE", 257, 267], ["CyPA", "PROTEIN", 283, 287], ["patients", "SPECIES", 192, 200], ["anti-EMMPRIN antibodies", "TREATMENT", 51, 74], ["RA progression", "PROBLEM", 89, 103], ["EMMPRIN", "PROBLEM", 133, 140], ["neutrophils", "TEST", 150, 161], ["RA", "ANATOMY", 89, 91], ["peripheral", "ANATOMY_MODIFIER", 169, 179], ["blood", "ANATOMY", 180, 185], ["RA", "ANATOMY", 189, 191]]], ["Anti-EMMPRIN antibodies (HAb18) prevented MMP production and activation and invasive capabilities of RA FLS, when cocultured with RA neutrophils [60] .", [["RA FLS", "ANATOMY", 101, 107], ["RA neutrophils", "ANATOMY", 130, 144], ["Anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 0, 23], ["HAb18", "SIMPLE_CHEMICAL", 25, 30], ["MMP", "GENE_OR_GENE_PRODUCT", 42, 45], ["RA FLS", "CELL", 101, 107], ["RA neutrophils", "CELL", 130, 144], ["Anti-EMMPRIN antibodies", "PROTEIN", 0, 23], ["HAb18", "PROTEIN", 25, 30], ["MMP", "PROTEIN", 42, 45], ["RA FLS", "CELL_LINE", 101, 107], ["RA neutrophils", "CELL_TYPE", 130, 144], ["Anti-EMMPRIN antibodies (HAb18", "TREATMENT", 0, 30], ["MMP production", "PROBLEM", 42, 56], ["invasive capabilities", "TEST", 76, 97], ["RA FLS", "TEST", 101, 107], ["RA neutrophils", "TEST", 130, 144], ["RA", "ANATOMY", 101, 103]]], ["In addition to MMP induction, this same group demonstrated the involvement of EMMPRIN in the induction of VEGF and HIF-1a in human RA FLS, thus contributing to angiogenesis and disease progression.", [["RA FLS", "ANATOMY", 131, 137], ["MMP", "GENE_OR_GENE_PRODUCT", 15, 18], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 78, 85], ["VEGF", "GENE_OR_GENE_PRODUCT", 106, 110], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 115, 121], ["human", "ORGANISM", 125, 130], ["RA FLS", "CELL", 131, 137], ["MMP", "PROTEIN", 15, 18], ["EMMPRIN", "PROTEIN", 78, 85], ["VEGF", "PROTEIN", 106, 110], ["HIF-1a", "PROTEIN", 115, 121], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["MMP induction", "TREATMENT", 15, 28], ["EMMPRIN", "TREATMENT", 78, 85], ["VEGF", "TEST", 106, 110], ["HIF", "TEST", 115, 118], ["angiogenesis", "PROBLEM", 160, 172], ["disease progression", "PROBLEM", 177, 196], ["angiogenesis", "OBSERVATION", 160, 172], ["disease", "OBSERVATION", 177, 184]]], ["Anti-EMMPRIN antibody treatment of a severe combined immunodeficiency mouse model of RA decreased expression of VEGF and HIF-1a, improving outcomes [116, 117] .", [["immunodeficiency", "DISEASE", 53, 69], ["RA", "DISEASE", 85, 87], ["mouse", "ORGANISM", 70, 75], ["RA", "CANCER", 85, 87], ["VEGF", "GENE_OR_GENE_PRODUCT", 112, 116], ["HIF-1a", "GENE_OR_GENE_PRODUCT", 121, 127], ["Anti-EMMPRIN antibody", "PROTEIN", 0, 21], ["VEGF", "PROTEIN", 112, 116], ["HIF", "PROTEIN", 121, 124], ["mouse", "SPECIES", 70, 75], ["mouse", "SPECIES", 70, 75], ["Anti-EMMPRIN antibody treatment", "TREATMENT", 0, 31], ["a severe combined immunodeficiency mouse model of RA", "PROBLEM", 35, 87], ["VEGF", "TEST", 112, 116], ["severe", "OBSERVATION_MODIFIER", 37, 43]]], ["With its involvement in MMP induction and angiogenesis in RA, EMMPRIN mAbs seem like a promising therapy.", [["MMP", "GENE_OR_GENE_PRODUCT", 24, 27], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 62, 74], ["MMP", "PROTEIN", 24, 27], ["EMMPRIN mAbs", "PROTEIN", 62, 74], ["MMP induction", "TREATMENT", 24, 37], ["angiogenesis in RA", "TREATMENT", 42, 60], ["EMMPRIN mAbs", "TREATMENT", 62, 74], ["a promising therapy", "TREATMENT", 85, 104], ["RA", "ANATOMY", 58, 60]]], ["It is even reported to have stronger antiangiogenic effects than infliximab, an agent approved for RA treatment [116] .MSMS is an immune-mediated disorder of the CNS characterized by the generation of autoreactive T cells, demyelination, and axonal degeneration, where the standard disease-modifying treatments are immunomodulators [118] .", [["CNS", "ANATOMY", 162, 165], ["autoreactive T cells", "ANATOMY", 201, 221], ["axonal", "ANATOMY", 242, 248], ["infliximab", "CHEMICAL", 65, 75], ["RA", "DISEASE", 99, 101], ["MSMS", "DISEASE", 119, 123], ["disorder of the CNS", "DISEASE", 146, 165], ["demyelination", "DISEASE", 223, 236], ["axonal degeneration", "DISEASE", 242, 261], ["infliximab", "SIMPLE_CHEMICAL", 65, 75], ["CNS", "ANATOMICAL_SYSTEM", 162, 165], ["autoreactive T cells", "CELL", 201, 221], ["autoreactive T cells", "CELL_TYPE", 201, 221], ["infliximab", "TREATMENT", 65, 75], ["an agent", "TREATMENT", 77, 85], ["RA treatment", "TREATMENT", 99, 111], ["an immune-mediated disorder of the CNS", "PROBLEM", 127, 165], ["autoreactive T cells", "PROBLEM", 201, 221], ["demyelination", "PROBLEM", 223, 236], ["axonal degeneration", "PROBLEM", 242, 261], ["the standard disease", "PROBLEM", 269, 289], ["modifying treatments", "TREATMENT", 290, 310], ["immunomodulators", "TREATMENT", 315, 331], ["CNS", "ANATOMY", 162, 165], ["autoreactive T cells", "OBSERVATION", 201, 221], ["demyelination", "OBSERVATION", 223, 236], ["axonal degeneration", "OBSERVATION", 242, 261]]], ["EMMPRIN was found upregulated in leukocytes in active lesions in MS and its animal model, EAE.", [["leukocytes", "ANATOMY", 33, 43], ["lesions", "ANATOMY", 54, 61], ["MS", "DISEASE", 65, 67], ["EAE", "DISEASE", 90, 93], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["leukocytes", "CELL", 33, 43], ["lesions", "PATHOLOGICAL_FORMATION", 54, 61], ["EMMPRIN", "PROTEIN", 0, 7], ["leukocytes", "CELL_TYPE", 33, 43], ["leukocytes", "PROBLEM", 33, 43], ["active lesions in MS", "PROBLEM", 47, 67], ["upregulated", "OBSERVATION_MODIFIER", 18, 29], ["leukocytes", "OBSERVATION_MODIFIER", 33, 43], ["active", "OBSERVATION_MODIFIER", 47, 53], ["lesions", "OBSERVATION", 54, 61], ["animal model", "OBSERVATION_MODIFIER", 76, 88]]], ["EMMPRIN colocalized with T cells, macrophages, and astrocytes in inflammatory perivascular cuffs of EAE and MS, where its up-regulation was associated with increased MMP activity [66] .", [["T cells", "ANATOMY", 25, 32], ["macrophages", "ANATOMY", 34, 45], ["astrocytes", "ANATOMY", 51, 61], ["perivascular cuffs", "ANATOMY", 78, 96], ["EAE", "DISEASE", 100, 103], ["MS", "DISEASE", 108, 110], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cells", "CELL", 25, 32], ["macrophages", "CELL", 34, 45], ["astrocytes", "CELL", 51, 61], ["perivascular cuffs", "PATHOLOGICAL_FORMATION", 78, 96], ["MMP", "GENE_OR_GENE_PRODUCT", 166, 169], ["EMMPRIN", "PROTEIN", 0, 7], ["T cells", "CELL_TYPE", 25, 32], ["macrophages", "CELL_TYPE", 34, 45], ["astrocytes", "CELL_TYPE", 51, 61], ["MMP", "PROTEIN", 166, 169], ["macrophages", "PROBLEM", 34, 45], ["astrocytes in inflammatory perivascular cuffs of EAE", "PROBLEM", 51, 103], ["MS", "PROBLEM", 108, 110], ["increased MMP activity", "PROBLEM", 156, 178], ["astrocytes", "ANATOMY", 51, 61], ["inflammatory", "OBSERVATION_MODIFIER", 65, 77], ["perivascular cuffs", "OBSERVATION", 78, 96]]], ["Furthermore, administration of anti-EMMPRIN antibodies (RL73.2 clone or clone 10) reduced the severity of EAE [53, 64] , emphasizing its role in MS pathogenesis.", [["EAE", "DISEASE", 106, 109], ["MS", "DISEASE", 145, 147], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 31, 54], ["RL73.2 clone", "CELL", 56, 68], ["anti-EMMPRIN antibodies", "PROTEIN", 31, 54], ["RL73.2 clone", "PROTEIN", 56, 68], ["clone 10", "CELL_LINE", 72, 80], ["anti-EMMPRIN antibodies", "TREATMENT", 31, 54], ["MS pathogenesis", "PROBLEM", 145, 160]]], ["Anti-EMMPRIN antibody treatments reduced CNS infiltrates, the number of perivascular cuffs, and MMP activity [64] .", [["CNS infiltrates", "ANATOMY", 41, 56], ["perivascular cuffs", "ANATOMY", 72, 90], ["CNS infiltrates", "PATHOLOGICAL_FORMATION", 41, 56], ["perivascular cuffs", "TISSUE", 72, 90], ["Anti-EMMPRIN antibody", "PROTEIN", 0, 21], ["MMP", "PROTEIN", 96, 99], ["Anti-EMMPRIN antibody treatments", "TREATMENT", 0, 32], ["CNS infiltrates", "PROBLEM", 41, 56], ["perivascular cuffs", "TREATMENT", 72, 90], ["MMP activity", "TEST", 96, 108], ["CNS", "ANATOMY", 41, 44], ["infiltrates", "OBSERVATION", 45, 56], ["perivascular cuffs", "ANATOMY", 72, 90]]], ["In vitro, treatments reduced the adhesion and migration of leukocytes across the BBB endothelial cell [66] , as well as T cell neurotoxicity, demonstrating reduced granzyme B levels compared with the isotype control [53] .", [["leukocytes", "ANATOMY", 59, 69], ["BBB endothelial cell", "ANATOMY", 81, 101], ["T cell", "ANATOMY", 120, 126], ["neurotoxicity", "DISEASE", 127, 140], ["leukocytes", "CELL", 59, 69], ["BBB endothelial cell", "CELL", 81, 101], ["T cell", "CELL", 120, 126], ["granzyme B", "GENE_OR_GENE_PRODUCT", 164, 174], ["leukocytes", "CELL_TYPE", 59, 69], ["granzyme B", "PROTEIN", 164, 174], ["treatments", "TREATMENT", 10, 20], ["the adhesion", "PROBLEM", 29, 41], ["leukocytes", "TEST", 59, 69], ["the BBB endothelial cell", "TEST", 77, 101], ["T cell neurotoxicity", "PROBLEM", 120, 140], ["reduced granzyme B levels", "PROBLEM", 156, 181], ["the isotype control", "TREATMENT", 196, 215], ["BBB endothelial", "ANATOMY", 81, 96]]], ["As EMMPRIN is involved in all critical stages of MS disease, including T cell activation and proliferation; chemotaxis of leukocytes, adhesion, and migration across the BBB; MMP induction, which is essential to enter into the brain parenchyma; and neurotoxicity, its multifunctional nature would make for an excellent therapeutic target.Atherosclerosis and acute myocardial infarctionAtherosclerosis is an inflammatory disease of the vascular wall that may lead to acute myocardial infarction (diminished blood supply to the heart) or stroke (diminished blood supply to the brain) as a result of the build-up and/or rupture of plaques inside arteries.", [["T cell", "ANATOMY", 71, 77], ["leukocytes", "ANATOMY", 122, 132], ["BBB", "ANATOMY", 169, 172], ["brain parenchyma", "ANATOMY", 226, 242], ["myocardial", "ANATOMY", 363, 373], ["vascular wall", "ANATOMY", 434, 447], ["myocardial", "ANATOMY", 471, 481], ["blood", "ANATOMY", 505, 510], ["heart", "ANATOMY", 525, 530], ["blood", "ANATOMY", 554, 559], ["brain", "ANATOMY", 574, 579], ["plaques", "ANATOMY", 627, 634], ["arteries", "ANATOMY", 642, 650], ["MS", "DISEASE", 49, 51], ["neurotoxicity", "DISEASE", 248, 261], ["Atherosclerosis", "DISEASE", 337, 352], ["acute myocardial infarction", "DISEASE", 357, 384], ["Atherosclerosis", "DISEASE", 384, 399], ["acute myocardial infarction", "DISEASE", 465, 492], ["stroke", "DISEASE", 535, 541], ["rupture", "DISEASE", 616, 623], ["plaques", "DISEASE", 627, 634], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 3, 10], ["T cell", "CELL", 71, 77], ["leukocytes", "CELL", 122, 132], ["BBB", "MULTI-TISSUE_STRUCTURE", 169, 172], ["MMP", "GENE_OR_GENE_PRODUCT", 174, 177], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 226, 242], ["myocardial", "MULTI-TISSUE_STRUCTURE", 363, 373], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 434, 447], ["myocardial", "MULTI-TISSUE_STRUCTURE", 471, 481], ["blood", "ORGANISM_SUBSTANCE", 505, 510], ["heart", "ORGAN", 525, 530], ["blood", "ORGANISM_SUBSTANCE", 554, 559], ["brain", "ORGAN", 574, 579], ["arteries", "MULTI-TISSUE_STRUCTURE", 642, 650], ["EMMPRIN", "PROTEIN", 3, 10], ["leukocytes", "CELL_TYPE", 122, 132], ["MMP", "PROTEIN", 174, 177], ["MS disease", "PROBLEM", 49, 59], ["T cell activation", "PROBLEM", 71, 88], ["proliferation", "PROBLEM", 93, 106], ["leukocytes", "PROBLEM", 122, 132], ["adhesion", "PROBLEM", 134, 142], ["migration across the BBB", "PROBLEM", 148, 172], ["MMP induction", "TREATMENT", 174, 187], ["neurotoxicity", "PROBLEM", 248, 261], ["Atherosclerosis", "PROBLEM", 337, 352], ["acute myocardial infarctionAtherosclerosis", "PROBLEM", 357, 399], ["an inflammatory disease of the vascular wall", "PROBLEM", 403, 447], ["acute myocardial infarction", "PROBLEM", 465, 492], ["diminished blood supply to the heart)", "PROBLEM", 494, 531], ["stroke", "PROBLEM", 535, 541], ["diminished blood supply to the brain", "PROBLEM", 543, 579], ["rupture of plaques inside arteries", "PROBLEM", 616, 650], ["cell", "OBSERVATION", 73, 77], ["BBB", "ANATOMY", 169, 172], ["brain", "ANATOMY", 226, 231], ["parenchyma", "ANATOMY_MODIFIER", 232, 242], ["acute", "OBSERVATION_MODIFIER", 357, 362], ["myocardial", "ANATOMY", 363, 373], ["infarction", "OBSERVATION", 374, 384], ["inflammatory", "OBSERVATION_MODIFIER", 406, 418], ["vascular wall", "ANATOMY", 434, 447], ["may lead to", "UNCERTAINTY", 453, 464], ["acute", "OBSERVATION_MODIFIER", 465, 470], ["myocardial", "ANATOMY", 471, 481], ["infarction", "OBSERVATION", 482, 492], ["diminished", "OBSERVATION_MODIFIER", 494, 504], ["heart", "ANATOMY", 525, 530], ["stroke", "OBSERVATION", 535, 541], ["diminished", "OBSERVATION_MODIFIER", 543, 553], ["brain", "ANATOMY", 574, 579], ["rupture", "OBSERVATION", 616, 623], ["plaques", "OBSERVATION", 627, 634], ["arteries", "ANATOMY", 642, 650]]], ["Plaques consist of an accumulation of inflammatory cells and subsequent production of MMPs, which may lead to plaque breakdown and surrounding cell death, thereby worsening the disease progress [119] [120] [121] [122] .", [["Plaques", "ANATOMY", 0, 7], ["inflammatory cells", "ANATOMY", 38, 56], ["plaque", "ANATOMY", 110, 116], ["cell", "ANATOMY", 143, 147], ["Plaques", "DISEASE", 0, 7], ["death", "DISEASE", 148, 153], ["inflammatory cells", "CELL", 38, 56], ["MMPs", "GENE_OR_GENE_PRODUCT", 86, 90], ["plaque", "PATHOLOGICAL_FORMATION", 110, 116], ["cell", "CELL", 143, 147], ["inflammatory cells", "CELL_TYPE", 38, 56], ["MMPs", "PROTEIN", 86, 90], ["Plaques", "PROBLEM", 0, 7], ["inflammatory cells", "PROBLEM", 38, 56], ["MMPs", "PROBLEM", 86, 90], ["plaque breakdown", "PROBLEM", 110, 126], ["surrounding cell death", "PROBLEM", 131, 153], ["worsening the disease progress", "PROBLEM", 163, 193], ["accumulation", "OBSERVATION_MODIFIER", 22, 34], ["inflammatory cells", "OBSERVATION", 38, 56], ["production", "OBSERVATION_MODIFIER", 72, 82], ["may lead to", "UNCERTAINTY", 98, 109], ["plaque", "OBSERVATION", 110, 116], ["cell death", "OBSERVATION", 143, 153], ["worsening", "OBSERVATION_MODIFIER", 163, 172]]], ["EMMPRIN expression in patients with acute myocardial infarction was found upregulated on circulating monocytes and correlated with monocytic MT1-MMP levels and MMP-9 plasma activity [123] .", [["myocardial", "ANATOMY", 42, 52], ["monocytes", "ANATOMY", 101, 110], ["monocytic", "ANATOMY", 131, 140], ["acute myocardial infarction", "DISEASE", 36, 63], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["patients", "ORGANISM", 22, 30], ["myocardial", "MULTI-TISSUE_STRUCTURE", 42, 52], ["monocytes", "CELL", 101, 110], ["MT1-MMP", "GENE_OR_GENE_PRODUCT", 141, 148], ["MMP-9", "GENE_OR_GENE_PRODUCT", 160, 165], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["EMMPRIN", "PROTEIN", 0, 7], ["circulating monocytes", "CELL_TYPE", 89, 110], ["MT1", "PROTEIN", 141, 144], ["MMP", "PROTEIN", 145, 148], ["MMP", "PROTEIN", 160, 163], ["patients", "SPECIES", 22, 30], ["acute myocardial infarction", "PROBLEM", 36, 63], ["circulating monocytes", "TEST", 89, 110], ["monocytic MT1", "TEST", 131, 144], ["MMP levels", "TEST", 145, 155], ["MMP", "TEST", 160, 163], ["plasma activity", "TEST", 166, 181], ["myocardial", "ANATOMY", 42, 52], ["infarction", "OBSERVATION", 53, 63]]], ["As platelets and monocytes play a pathogenic role in atherosclerosis, it was demonstrated that EMMPRIN-EMMPRIN interactions in a coculture of platelets with monocytes induced the secretion of MMPs, proinflammatory (IL-6 and TNF-a), and antiinflammatory (IL-10) cytokines in monocytes via an NF-kBmediated pathway [39] .", [["platelets", "ANATOMY", 3, 12], ["monocytes", "ANATOMY", 17, 26], ["platelets", "ANATOMY", 142, 151], ["monocytes", "ANATOMY", 157, 166], ["monocytes", "ANATOMY", 274, 283], ["atherosclerosis", "DISEASE", 53, 68], ["platelets", "CELL", 3, 12], ["monocytes", "CELL", 17, 26], ["EMMPRIN-EMMPRIN", "GENE_OR_GENE_PRODUCT", 95, 110], ["platelets", "CELL", 142, 151], ["monocytes", "CELL", 157, 166], ["MMPs", "GENE_OR_GENE_PRODUCT", 192, 196], ["IL-6", "GENE_OR_GENE_PRODUCT", 215, 219], ["TNF-a", "GENE_OR_GENE_PRODUCT", 224, 229], ["IL-10", "GENE_OR_GENE_PRODUCT", 254, 259], ["monocytes", "CELL", 274, 283], ["NF-kBmediated", "GENE_OR_GENE_PRODUCT", 291, 304], ["platelets", "CELL_TYPE", 3, 12], ["monocytes", "CELL_TYPE", 17, 26], ["EMMPRIN", "PROTEIN", 103, 110], ["platelets", "CELL_TYPE", 142, 151], ["monocytes", "CELL_TYPE", 157, 166], ["MMPs", "PROTEIN", 192, 196], ["proinflammatory (IL-6", "PROTEIN", 198, 219], ["TNF", "PROTEIN", 224, 227], ["antiinflammatory (IL-10) cytokines", "PROTEIN", 236, 270], ["monocytes", "CELL_TYPE", 274, 283], ["platelets", "TEST", 3, 12], ["monocytes", "PROBLEM", 17, 26], ["atherosclerosis", "PROBLEM", 53, 68], ["platelets", "TEST", 142, 151], ["monocytes", "PROBLEM", 157, 166], ["MMPs", "PROBLEM", 192, 196], ["proinflammatory (IL", "TEST", 198, 217], ["TNF", "TEST", 224, 227], ["antiinflammatory (IL", "TREATMENT", 236, 256], ["monocytes", "OBSERVATION_MODIFIER", 17, 26], ["pathogenic", "OBSERVATION_MODIFIER", 34, 44], ["atherosclerosis", "OBSERVATION", 53, 68]]], ["In addition, a mouse model of myocardial infarction demonstrated that EMMPRIN +/2 mice, mice treated with an anti-EMMPRIN antibody (RL73.2 clone), or CyPA 2/2 mice exhibited a reduced infarct size compared with controls; this is likely a consequence of impaired CyPA-mediated recruitment and adhesion of monocytes and neutrophils to the injured site [65] .", [["myocardial", "ANATOMY", 30, 40], ["infarct", "ANATOMY", 184, 191], ["monocytes", "ANATOMY", 304, 313], ["neutrophils", "ANATOMY", 318, 329], ["site", "ANATOMY", 345, 349], ["myocardial infarction", "DISEASE", 30, 51], ["infarct", "DISEASE", 184, 191], ["CyPA", "CHEMICAL", 262, 266], ["mouse", "ORGANISM", 15, 20], ["myocardial", "MULTI-TISSUE_STRUCTURE", 30, 40], ["EMMPRIN +/2", "GENE_OR_GENE_PRODUCT", 70, 81], ["mice", "ORGANISM", 88, 92], ["RL73.2 clone", "CELL", 132, 144], ["CyPA 2/2 mice", "ORGANISM", 150, 163], ["CyPA", "GENE_OR_GENE_PRODUCT", 262, 266], ["monocytes", "CELL", 304, 313], ["neutrophils", "CELL", 318, 329], ["EMMPRIN", "PROTEIN", 70, 77], ["anti-EMMPRIN antibody", "PROTEIN", 109, 130], ["RL73.2 clone", "CELL_LINE", 132, 144], ["CyPA", "PROTEIN", 262, 266], ["monocytes", "CELL_TYPE", 304, 313], ["neutrophils", "CELL_TYPE", 318, 329], ["mouse", "SPECIES", 15, 20], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 159, 163], ["mouse", "SPECIES", 15, 20], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 159, 163], ["myocardial infarction", "PROBLEM", 30, 51], ["EMMPRIN +/2 mice", "TREATMENT", 70, 86], ["an anti-EMMPRIN antibody", "TEST", 106, 130], ["CyPA", "TEST", 150, 154], ["a reduced infarct size", "PROBLEM", 174, 196], ["impaired CyPA", "PROBLEM", 253, 266], ["monocytes", "TEST", 304, 313], ["neutrophils", "TEST", 318, 329], ["myocardial", "ANATOMY", 30, 40], ["infarction", "OBSERVATION", 41, 51], ["reduced", "OBSERVATION_MODIFIER", 176, 183], ["infarct", "OBSERVATION", 184, 191], ["size", "OBSERVATION_MODIFIER", 192, 196], ["likely a consequence", "UNCERTAINTY", 229, 249], ["impaired", "OBSERVATION_MODIFIER", 253, 261], ["CyPA", "OBSERVATION", 262, 266], ["recruitment", "OBSERVATION_MODIFIER", 276, 287]]], ["This suggests that EMMPRIN plays a role in leukocyte recruitment and MMP induction in cardiovascular disease, and thus, the targeting of cyclophilin-EMMPRIN interactions may be of a therapeutic benefit.", [["leukocyte", "ANATOMY", 43, 52], ["cardiovascular", "ANATOMY", 86, 100], ["cardiovascular disease", "DISEASE", 86, 108], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 19, 26], ["leukocyte", "CELL", 43, 52], ["MMP", "GENE_OR_GENE_PRODUCT", 69, 72], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["cyclophilin-EMMPRIN", "GENE_OR_GENE_PRODUCT", 137, 156], ["EMMPRIN", "PROTEIN", 19, 26], ["MMP", "PROTEIN", 69, 72], ["cyclophilin", "PROTEIN", 137, 148], ["EMMPRIN", "PROTEIN", 149, 156], ["leukocyte recruitment", "TREATMENT", 43, 64], ["MMP induction", "TREATMENT", 69, 82], ["cardiovascular disease", "PROBLEM", 86, 108], ["cyclophilin", "TREATMENT", 137, 148], ["EMMPRIN interactions", "TREATMENT", 149, 169], ["leukocyte recruitment", "OBSERVATION", 43, 64]]], ["However, a balance between harmful inflammatory monocytes and beneficial reparative monocytes involved in MMP-dependent remodeling and the development of scar tissue must be considered [124] .Lung interstitial fibrosisLung interstitial fibrosis is a chronic lung disease, as a result of excessive accumulation of the ECM, resulting in scarring and thickening of the lung.", [["monocytes", "ANATOMY", 48, 57], ["monocytes", "ANATOMY", 84, 93], ["scar tissue", "ANATOMY", 154, 165], ["Lung interstitial", "ANATOMY", 192, 209], ["Lung interstitial", "ANATOMY", 218, 235], ["lung", "ANATOMY", 258, 262], ["ECM", "ANATOMY", 317, 320], ["lung", "ANATOMY", 366, 370], ["scar", "DISEASE", 154, 158], ["fibrosis", "DISEASE", 210, 218], ["interstitial fibrosis", "DISEASE", 223, 244], ["chronic lung disease", "DISEASE", 250, 270], ["scarring", "DISEASE", 335, 343], ["monocytes", "CELL", 48, 57], ["monocytes", "CELL", 84, 93], ["MMP", "GENE_OR_GENE_PRODUCT", 106, 109], ["scar tissue", "TISSUE", 154, 165], ["Lung interstitial", "MULTI-TISSUE_STRUCTURE", 192, 209], ["Lung interstitial", "MULTI-TISSUE_STRUCTURE", 218, 235], ["lung", "ORGAN", 258, 262], ["ECM", "CELLULAR_COMPONENT", 317, 320], ["lung", "ORGAN", 366, 370], ["inflammatory monocytes", "CELL_TYPE", 35, 57], ["reparative monocytes", "CELL_TYPE", 73, 93], ["MMP", "PROTEIN", 106, 109], ["a balance between harmful inflammatory monocytes", "PROBLEM", 9, 57], ["beneficial reparative monocytes", "PROBLEM", 62, 93], ["MMP", "PROBLEM", 106, 109], ["dependent remodeling", "PROBLEM", 110, 130], ["scar tissue", "PROBLEM", 154, 165], ["Lung interstitial fibrosis", "PROBLEM", 192, 218], ["Lung interstitial fibrosis", "PROBLEM", 218, 244], ["a chronic lung disease", "PROBLEM", 248, 270], ["excessive accumulation of the ECM", "PROBLEM", 287, 320], ["scarring", "PROBLEM", 335, 343], ["thickening of the lung", "PROBLEM", 348, 370], ["inflammatory monocytes", "OBSERVATION", 35, 57], ["reparative monocytes", "OBSERVATION", 73, 93], ["dependent remodeling", "OBSERVATION_MODIFIER", 110, 130], ["scar", "OBSERVATION", 154, 158], ["interstitial", "ANATOMY_MODIFIER", 197, 209], ["fibrosis", "OBSERVATION", 210, 218], ["Lung", "ANATOMY", 218, 222], ["interstitial", "ANATOMY_MODIFIER", 223, 235], ["fibrosis", "OBSERVATION", 236, 244], ["chronic", "OBSERVATION_MODIFIER", 250, 257], ["lung", "ANATOMY", 258, 262], ["disease", "OBSERVATION", 263, 270], ["excessive", "OBSERVATION_MODIFIER", 287, 296], ["accumulation", "OBSERVATION_MODIFIER", 297, 309], ["ECM", "OBSERVATION_MODIFIER", 317, 320], ["scarring", "OBSERVATION", 335, 343], ["thickening", "OBSERVATION", 348, 358], ["lung", "ANATOMY", 366, 370]]], ["EMMPRIN expression was found increased in murine and human lung fibrosis in alveolar macrophages and epithelial cells [126, 127] .", [["lung", "ANATOMY", 59, 63], ["alveolar macrophages", "ANATOMY", 76, 96], ["epithelial cells", "ANATOMY", 101, 117], ["fibrosis", "DISEASE", 64, 72], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["murine", "ORGANISM", 42, 48], ["human", "ORGANISM", 53, 58], ["lung", "ORGAN", 59, 63], ["alveolar macrophages", "CELL", 76, 96], ["epithelial cells", "CELL", 101, 117], ["EMMPRIN", "PROTEIN", 0, 7], ["alveolar macrophages", "CELL_TYPE", 76, 96], ["epithelial cells", "CELL_TYPE", 101, 117], ["murine", "SPECIES", 42, 48], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["EMMPRIN expression", "TEST", 0, 18], ["human lung fibrosis in alveolar macrophages", "PROBLEM", 53, 96], ["epithelial cells", "TEST", 101, 117], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["lung", "ANATOMY", 59, 63], ["fibrosis", "OBSERVATION", 64, 72], ["alveolar macrophages", "OBSERVATION", 76, 96], ["epithelial cells", "OBSERVATION", 101, 117]]], ["Treatment with anti-EMMPRIN mAbs (HAb18) in a mouse model of lung interstitial fibrosis reduced clinical symptoms and decreased M1 macrophage and Th17 infiltration [128] .", [["lung interstitial", "ANATOMY", 61, 78], ["M1 macrophage", "ANATOMY", 128, 141], ["interstitial fibrosis", "DISEASE", 66, 87], ["anti-EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 15, 32], ["HAb18", "GENE_OR_GENE_PRODUCT", 34, 39], ["mouse", "ORGANISM", 46, 51], ["lung interstitial", "MULTI-TISSUE_STRUCTURE", 61, 78], ["M1 macrophage", "CELL", 128, 141], ["Th17", "CELL", 146, 150], ["anti-EMMPRIN mAbs", "PROTEIN", 15, 32], ["HAb18", "PROTEIN", 34, 39], ["mouse", "SPECIES", 46, 51], ["mouse", "SPECIES", 46, 51], ["anti-EMMPRIN mAbs", "TREATMENT", 15, 32], ["lung interstitial fibrosis", "PROBLEM", 61, 87], ["clinical symptoms", "PROBLEM", 96, 113], ["decreased M1 macrophage", "PROBLEM", 118, 141], ["Th17 infiltration", "PROBLEM", 146, 163], ["lung", "ANATOMY", 61, 65], ["interstitial", "ANATOMY_MODIFIER", 66, 78], ["fibrosis", "OBSERVATION", 79, 87], ["decreased", "OBSERVATION_MODIFIER", 118, 127], ["M1 macrophage", "OBSERVATION", 128, 141], ["Th17 infiltration", "OBSERVATION", 146, 163]]], ["It was also discovered that M1 macrophages induced Th17 differentiation in an EMMPRINdependent manner [128] .", [["M1 macrophages", "ANATOMY", 28, 42], ["M1 macrophages", "CELL", 28, 42], ["Th17", "CELL", 51, 55], ["M1 macrophages", "CELL_TYPE", 28, 42], ["M1 macrophages", "OBSERVATION", 28, 42], ["Th17 differentiation", "OBSERVATION", 51, 71]]], ["The cellular mechanism behind this is currently unknown and may involve cytokine regulation.", [["cellular", "ANATOMY", 4, 12], ["cellular", "CELL", 4, 12], ["cytokine", "PROTEIN", 72, 80], ["cytokine regulation", "TREATMENT", 72, 91], ["cellular mechanism", "OBSERVATION", 4, 22]]], ["The understanding of whether EMMPRIN is involved in the regulation of Th17 cells in other inflammatory diseases, such as MS or RA, would be of significance.Pathogenic invasionEMMPRIN was identified recently as a receptor for the invasion of bacterial, parasitic, and viral strains.", [["Th17 cells", "ANATOMY", 70, 80], ["inflammatory diseases", "DISEASE", 90, 111], ["MS", "DISEASE", 121, 123], ["RA", "DISEASE", 127, 129], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 29, 36], ["Th17 cells", "CELL", 70, 80], ["EMMPRIN", "PROTEIN", 29, 36], ["Th17 cells", "CELL_TYPE", 70, 80], ["invasionEMMPRIN", "PROTEIN", 167, 182], ["Th17 cells", "PROBLEM", 70, 80], ["other inflammatory diseases", "PROBLEM", 84, 111], ["Pathogenic invasionEMMPRIN", "PROBLEM", 156, 182], ["a receptor", "TREATMENT", 210, 220], ["bacterial, parasitic", "PROBLEM", 241, 261], ["viral strains", "PROBLEM", 267, 280], ["Th17 cells", "OBSERVATION", 70, 80], ["inflammatory", "OBSERVATION_MODIFIER", 90, 102], ["RA", "ANATOMY", 127, 129], ["bacterial", "OBSERVATION_MODIFIER", 241, 250], ["parasitic", "OBSERVATION_MODIFIER", 252, 261], ["viral strains", "OBSERVATION", 267, 280]]], ["Meningitis is an infection that leads to inflammation of the membranes surrounding the CNS and can cause associated vascular dysfunction.", [["membranes", "ANATOMY", 61, 70], ["CNS", "ANATOMY", 87, 90], ["vascular", "ANATOMY", 116, 124], ["Meningitis", "DISEASE", 0, 10], ["infection", "DISEASE", 17, 26], ["inflammation", "DISEASE", 41, 53], ["vascular dysfunction", "DISEASE", 116, 136], ["membranes", "CELLULAR_COMPONENT", 61, 70], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["vascular", "MULTI-TISSUE_STRUCTURE", 116, 124], ["Meningitis", "PROBLEM", 0, 10], ["an infection", "PROBLEM", 14, 26], ["inflammation of the membranes", "PROBLEM", 41, 70], ["associated vascular dysfunction", "PROBLEM", 105, 136], ["infection", "OBSERVATION", 17, 26], ["inflammation", "OBSERVATION", 41, 53], ["membranes", "ANATOMY_MODIFIER", 61, 70], ["CNS", "ANATOMY", 87, 90], ["vascular", "ANATOMY", 116, 124], ["dysfunction", "OBSERVATION", 125, 136]]], ["EMMPRIN expression on peripheral and brain endothelial cells was identified as an important receptor for the initial invasion of blood-borne meningococci (particularly the meningococcal type IV pilus components PilE and PilV) [55] .", [["peripheral", "ANATOMY", 22, 32], ["brain endothelial cells", "ANATOMY", 37, 60], ["blood", "ANATOMY", 129, 134], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["peripheral", "CELL", 22, 32], ["brain endothelial cells", "CELL", 37, 60], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["meningococci", "ORGANISM", 141, 153], ["type IV pilus components PilE", "GENE_OR_GENE_PRODUCT", 186, 215], ["EMMPRIN", "PROTEIN", 0, 7], ["peripheral and brain endothelial cells", "CELL_TYPE", 22, 60], ["meningococcal type IV pilus components", "PROTEIN", 172, 210], ["PilE", "PROTEIN", 211, 215], ["PilV", "PROTEIN", 220, 224], ["EMMPRIN expression on peripheral and brain endothelial cells", "PROBLEM", 0, 60], ["blood-borne meningococci", "PROBLEM", 129, 153], ["the meningococcal type IV pilus components", "TREATMENT", 168, 210], ["peripheral", "ANATOMY_MODIFIER", 22, 32], ["brain endothelial", "ANATOMY", 37, 54]]], ["The expression of EMMPRIN on erythrocytes also mediated the erythrocyte invasion of Plasmodium falciparum, a malaria parasite [56] .", [["erythrocytes", "ANATOMY", 29, 41], ["erythrocyte", "ANATOMY", 60, 71], ["Plasmodium falciparum", "DISEASE", 84, 105], ["malaria parasite", "DISEASE", 109, 125], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["erythrocytes", "CELL", 29, 41], ["erythrocyte", "CELL", 60, 71], ["Plasmodium falciparum", "ORGANISM", 84, 105], ["EMMPRIN", "PROTEIN", 18, 25], ["erythrocytes", "CELL_TYPE", 29, 41], ["Plasmodium falciparum", "SPECIES", 84, 105], ["Plasmodium falciparum", "SPECIES", 84, 105], ["EMMPRIN on erythrocytes", "PROBLEM", 18, 41], ["the erythrocyte invasion", "PROBLEM", 56, 80], ["Plasmodium falciparum", "PROBLEM", 84, 105], ["a malaria parasite", "PROBLEM", 107, 125], ["erythrocyte invasion", "OBSERVATION", 60, 80], ["Plasmodium falciparum", "OBSERVATION", 84, 105]]], ["Interference that uses soluble EMMPRIN, knockdown, or anti-EMMPRIN antibodies (MEM-M6/6) successfully prevented pathogenic colonization [55, 56] .", [["MEM-M6/6", "CHEMICAL", 79, 87], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 31, 38], ["anti-EMMPRIN antibodies", "GENE_OR_GENE_PRODUCT", 54, 77], ["EMMPRIN", "PROTEIN", 31, 38], ["anti-EMMPRIN antibodies", "PROTEIN", 54, 77], ["M6", "PROTEIN", 83, 85], ["soluble EMMPRIN", "TREATMENT", 23, 38], ["anti-EMMPRIN antibodies", "TEST", 54, 77], ["MEM", "TEST", 79, 82], ["pathogenic colonization", "PROBLEM", 112, 135]]], ["Furthermore, EMMPRIN was also discovered to play a role in the host entry of CyPA-associated HIV1 [129] and CyPA-bound severe acute respiratory syndrome coronavirus [130] , in addition to a role in viral oncogenesis [131] .CONCLUDING REMARKSAnti-EMMPRIN antibodies showed efficacy in treatment of GVHD, tumorigenesis, models of RA, MS, acute myocardial infarction, and lung inflammation, disease states involving various inflammatory mediators.", [["myocardial", "ANATOMY", 342, 352], ["lung", "ANATOMY", 369, 373], ["CyPA", "CHEMICAL", 77, 81], ["acute respiratory syndrome coronavirus", "DISEASE", 126, 164], ["GVHD", "DISEASE", 297, 301], ["RA", "DISEASE", 328, 330], ["MS", "DISEASE", 332, 334], ["acute myocardial infarction", "DISEASE", 336, 363], ["lung inflammation", "DISEASE", 369, 386], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 13, 20], ["CyPA", "GENE_OR_GENE_PRODUCT", 77, 81], ["HIV1", "GENE_OR_GENE_PRODUCT", 93, 97], ["CyPA", "GENE_OR_GENE_PRODUCT", 108, 112], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 119, 164], ["myocardial", "MULTI-TISSUE_STRUCTURE", 342, 352], ["lung", "ORGAN", 369, 373], ["EMMPRIN", "PROTEIN", 13, 20], ["CyPA", "PROTEIN", 77, 81], ["CyPA", "PROTEIN", 108, 112], ["REMARKSAnti-EMMPRIN antibodies", "PROTEIN", 234, 264], ["inflammatory mediators", "PROTEIN", 421, 443], ["severe acute respiratory syndrome coronavirus", "SPECIES", 119, 164], ["CyPA", "TEST", 77, 81], ["HIV1", "TEST", 93, 97], ["CyPA", "TEST", 108, 112], ["bound severe acute respiratory syndrome coronavirus", "PROBLEM", 113, 164], ["viral oncogenesis", "PROBLEM", 198, 215], ["REMARKSAnti-EMMPRIN antibodies", "TEST", 234, 264], ["GVHD", "PROBLEM", 297, 301], ["tumorigenesis", "PROBLEM", 303, 316], ["models of RA", "PROBLEM", 318, 330], ["MS", "PROBLEM", 332, 334], ["acute myocardial infarction", "PROBLEM", 336, 363], ["lung inflammation", "PROBLEM", 369, 386], ["disease states", "PROBLEM", 388, 402], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["respiratory syndrome", "OBSERVATION", 132, 152], ["GVHD", "OBSERVATION", 297, 301], ["RA", "ANATOMY", 328, 330], ["acute", "OBSERVATION_MODIFIER", 336, 341], ["myocardial", "ANATOMY", 342, 352], ["infarction", "OBSERVATION", 353, 363], ["lung", "ANATOMY", 369, 373], ["inflammation", "OBSERVATION", 374, 386], ["various", "OBSERVATION_MODIFIER", 413, 420], ["inflammatory", "OBSERVATION_MODIFIER", 421, 433]]], ["These results highlight the important but still uncertain roles of dysregulated EMMPRIN on immune cells in disease pathogenesis.", [["immune cells", "ANATOMY", 91, 103], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 80, 87], ["immune cells", "CELL", 91, 103], ["EMMPRIN", "PROTEIN", 80, 87], ["immune cells", "CELL_TYPE", 91, 103], ["dysregulated EMMPRIN", "PROBLEM", 67, 87], ["immune cells", "TREATMENT", 91, 103], ["disease pathogenesis", "PROBLEM", 107, 127], ["immune cells", "OBSERVATION", 91, 103]]], ["EMMPRIN could also be regarded as a potential diagnostic marker for early-stage disease or for disease monitoring [40, 41, 91, [132] [133] [134] [135] [136] .", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["EMMPRIN", "PROTEIN", 0, 7], ["early-stage disease", "PROBLEM", 68, 87], ["disease monitoring", "TEST", 95, 113]]], ["T cell-mediated inflammation relies on a cascade of events, including its development, activation, proliferation, migration, and adhesion; all of these steps have been shown to be influenced by EMMPRIN in complex ways ( Table 2) .", [["T cell", "ANATOMY", 0, 6], ["inflammation", "DISEASE", 16, 28], ["T cell", "CELL", 0, 6], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 194, 201], ["EMMPRIN", "PROTEIN", 194, 201], ["T cell-mediated inflammation", "PROBLEM", 0, 28], ["proliferation", "PROBLEM", 99, 112], ["adhesion", "PROBLEM", 129, 137], ["inflammation", "OBSERVATION", 16, 28], ["proliferation", "OBSERVATION_MODIFIER", 99, 112], ["migration", "OBSERVATION_MODIFIER", 114, 123]]], ["Administration of most mAbs dampens these T cell functional responses (Tables 1 and 2 ), in which different EMMPRIN antibodies may target specific T cell activities, likely depending on its recognized epitope (e.g., antibodies that inhibited T cell proliferation did not induce cell aggregation and vice versa; Table 1 ) [54] .", [["T cell", "ANATOMY", 42, 48], ["T cell", "ANATOMY", 147, 153], ["T cell", "ANATOMY", 242, 248], ["cell", "ANATOMY", 278, 282], ["T cell", "CELL", 42, 48], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 108, 115], ["T cell", "CELL", 147, 153], ["T cell", "CELL", 242, 248], ["cell", "CELL", 278, 282], ["mAbs", "PROTEIN", 23, 27], ["EMMPRIN antibodies", "PROTEIN", 108, 126], ["epitope", "PROTEIN", 201, 208], ["antibodies", "PROTEIN", 216, 226], ["EMMPRIN antibodies", "TEST", 108, 126], ["target specific T cell activities", "PROBLEM", 131, 164], ["its recognized epitope (e.g., antibodies", "PROBLEM", 186, 226], ["T cell proliferation", "PROBLEM", 242, 262], ["cell aggregation", "PROBLEM", 278, 294]]], ["This targeted approach will likely result in less toxic side-effects when used as a therapy, but it requires an improved understanding of EMMPRIN biology in relation to the epitope that the various antibodies recognize for therapeutic implications.CONCLUDING REMARKSIt appears that EMMPRIN mAbs can behave as agonists (have stimulatory roles) for some functions and antagonists (have inhibitory or function-blocking roles) for other functions.", [["EMMPRIN", "GENE_OR_GENE_PRODUCT", 138, 145], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 282, 294], ["EMMPRIN", "PROTEIN", 138, 145], ["antibodies", "PROTEIN", 198, 208], ["EMMPRIN mAbs", "PROTEIN", 282, 294], ["a therapy", "TREATMENT", 82, 91], ["EMMPRIN mAbs", "TREATMENT", 282, 294], ["antagonists", "TREATMENT", 366, 377]]], ["For example, knocking out EMMPRIN in primary T cells led to increased proliferation upon TCR-mediated activation ( Table 2) , implying that EMMPRIN functions to shut down these responses.", [["primary T cells", "ANATOMY", 37, 52], ["TCR", "CHEMICAL", 89, 92], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 26, 33], ["T cells", "CELL", 45, 52], ["TCR", "GENE_OR_GENE_PRODUCT", 89, 92], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 140, 147], ["EMMPRIN", "PROTEIN", 26, 33], ["primary T cells", "CELL_TYPE", 37, 52], ["TCR", "PROTEIN", 89, 92], ["EMMPRIN", "PROTEIN", 140, 147], ["knocking out EMMPRIN in primary T cells", "PROBLEM", 13, 52], ["increased proliferation", "PROBLEM", 60, 83], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["proliferation", "OBSERVATION_MODIFIER", 70, 83]]], ["On the other hand, the application of EMMPRIN mAbs decreased TCR-mediated proliferation ( Table 2 ); this indicates that these antibodies work in an agonistic fashion for that particular task.", [["TCR", "CHEMICAL", 61, 64], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 38, 50], ["TCR", "GENE_OR_GENE_PRODUCT", 61, 64], ["EMMPRIN mAbs", "PROTEIN", 38, 50], ["TCR", "PROTEIN", 61, 64], ["antibodies", "PROTEIN", 127, 137], ["EMMPRIN mAbs", "TREATMENT", 38, 50], ["these antibodies", "TEST", 121, 137]]], ["Alternatively, the reduction of EMMPRIN expression by RNA interference in cancer cells or the application of EMMPRIN mAbs led to a reduction in migration, adhesion, energy metabolism, and proliferation (via TCR-independent mechanisms) yet an increase in cell aggregation.", [["cancer cells", "ANATOMY", 74, 86], ["cell", "ANATOMY", 254, 258], ["cancer", "DISEASE", 74, 80], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 32, 39], ["cancer cells", "CELL", 74, 86], ["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 109, 121], ["TCR", "GENE_OR_GENE_PRODUCT", 207, 210], ["cell", "CELL", 254, 258], ["EMMPRIN", "PROTEIN", 32, 39], ["cancer cells", "CELL_TYPE", 74, 86], ["EMMPRIN mAbs", "PROTEIN", 109, 121], ["TCR", "PROTEIN", 207, 210], ["EMMPRIN expression", "TREATMENT", 32, 50], ["RNA interference in cancer cells", "PROBLEM", 54, 86], ["EMMPRIN mAbs", "TREATMENT", 109, 121], ["a reduction in migration", "TREATMENT", 129, 153], ["adhesion", "PROBLEM", 155, 163], ["energy metabolism", "PROBLEM", 165, 182], ["proliferation", "PROBLEM", 188, 201], ["an increase in cell aggregation", "PROBLEM", 239, 270], ["reduction", "OBSERVATION_MODIFIER", 19, 28], ["cancer cells", "OBSERVATION", 74, 86], ["reduction", "OBSERVATION_MODIFIER", 131, 140], ["migration", "OBSERVATION_MODIFIER", 144, 153], ["increase", "OBSERVATION_MODIFIER", 242, 250], ["cell aggregation", "OBSERVATION", 254, 270]]], ["This likely demonstrates that EMMPRIN works to promote the migration, adhesion, and energy metabolism of cells and TCR-independent proliferation of cancer cells but functions to impede cell aggregation.", [["cells", "ANATOMY", 105, 110], ["cancer cells", "ANATOMY", 148, 160], ["cell", "ANATOMY", 185, 189], ["TCR", "CHEMICAL", 115, 118], ["cancer", "DISEASE", 148, 154], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 30, 37], ["cells", "CELL", 105, 110], ["TCR", "GENE_OR_GENE_PRODUCT", 115, 118], ["cancer cells", "CELL", 148, 160], ["cell", "CELL", 185, 189], ["EMMPRIN", "PROTEIN", 30, 37], ["TCR", "PROTEIN", 115, 118], ["cancer cells", "CELL_TYPE", 148, 160], ["the migration", "PROBLEM", 55, 68], ["adhesion", "PROBLEM", 70, 78], ["energy metabolism of cells", "PROBLEM", 84, 110], ["TCR", "PROBLEM", 115, 118], ["cancer cells", "PROBLEM", 148, 160], ["cell aggregation", "PROBLEM", 185, 201], ["proliferation", "OBSERVATION_MODIFIER", 131, 144], ["cancer cells", "OBSERVATION", 148, 160], ["cell aggregation", "OBSERVATION", 185, 201]]], ["In these circumstances, EMMPRIN mAbs appear to have function-blocking attributes.", [["EMMPRIN mAbs", "GENE_OR_GENE_PRODUCT", 24, 36], ["EMMPRIN mAbs", "PROTEIN", 24, 36], ["EMMPRIN mAbs", "TREATMENT", 24, 36]]], ["How EMMPRIN is involved in inhibiting cell aggregation or inducing adhesion, migration, and proliferation of cancer cells is not clearly understood.CONCLUDING REMARKSIt is also demonstrated that mAbs that recognize the EC1 (e.g., 5A12) or the EC2 (e.g., MEM-M6/6) domain have similar effects in dampening down T cell proliferation (Table 1) .", [["cell", "ANATOMY", 38, 42], ["cancer cells", "ANATOMY", 109, 121], ["T cell", "ANATOMY", 310, 316], ["cancer", "DISEASE", 109, 115], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 4, 11], ["cell", "CELL", 38, 42], ["cancer cells", "CELL", 109, 121], ["mAbs", "GENE_OR_GENE_PRODUCT", 195, 199], ["EC1", "GENE_OR_GENE_PRODUCT", 219, 222], ["5A12", "GENE_OR_GENE_PRODUCT", 230, 234], ["EC2", "GENE_OR_GENE_PRODUCT", 243, 246], ["T cell", "CELL", 310, 316], ["EMMPRIN", "PROTEIN", 4, 11], ["cancer cells", "CELL_TYPE", 109, 121], ["REMARKSIt", "PROTEIN", 159, 168], ["mAbs", "PROTEIN", 195, 199], ["EC1", "PROTEIN", 219, 222], ["5A12", "PROTEIN", 230, 234], ["EC2", "PROTEIN", 243, 246], ["MEM-M6/6) domain", "PROTEIN", 254, 270], ["inhibiting cell aggregation", "PROBLEM", 27, 54], ["adhesion", "PROBLEM", 67, 75], ["proliferation of cancer cells", "PROBLEM", 92, 121], ["the EC2", "TEST", 239, 246], ["MEM", "TEST", 254, 257], ["dampening down T cell proliferation", "PROBLEM", 295, 330], ["adhesion", "OBSERVATION_MODIFIER", 67, 75], ["cancer", "OBSERVATION", 109, 115], ["dampening", "OBSERVATION_MODIFIER", 295, 304], ["cell proliferation", "OBSERVATION", 312, 330]]], ["Interestingly, MEM-M6/1 (which also recognizes the EC1 domain of EMM-PRIN) seems to behave as a functionally inactive antibody; however, it does have an effect on T cells of diseased patients with SLE (Table 1) .", [["T cells", "ANATOMY", 163, 170], ["SLE", "DISEASE", 197, 200], ["MEM-M6/1", "GENE_OR_GENE_PRODUCT", 15, 23], ["EMM-PRIN", "GENE_OR_GENE_PRODUCT", 65, 73], ["T cells", "CELL", 163, 170], ["patients", "ORGANISM", 183, 191], ["M6/1", "PROTEIN", 19, 23], ["EC1 domain", "PROTEIN", 51, 61], ["EMM", "PROTEIN", 65, 68], ["PRIN", "PROTEIN", 69, 73], ["inactive antibody", "PROTEIN", 109, 126], ["T cells", "CELL_TYPE", 163, 170], ["patients", "SPECIES", 183, 191], ["a functionally inactive antibody", "PROBLEM", 94, 126], ["SLE", "PROBLEM", 197, 200]]], ["Thus, antibody affinity also plays a role in functionality.", [["antibody affinity", "PROBLEM", 6, 23]]], ["For example, as mentioned before, disparity in epitope recognition, antibody affinity, and the density of EMMPRIN on the cell surface could all influence antibody functionality.", [["cell surface", "ANATOMY", 121, 133], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 106, 113], ["cell surface", "CELLULAR_COMPONENT", 121, 133], ["EMMPRIN", "PROTEIN", 106, 113], ["disparity in epitope recognition", "PROBLEM", 34, 66], ["antibody affinity", "PROBLEM", 68, 85], ["the cell surface", "TREATMENT", 117, 133], ["antibody functionality", "OBSERVATION", 154, 176]]], ["How the structure of EMMPRIN may be oriented upon binding with various interacting partners may also have an influence; there is a flexible linker between the EC1 and EC2 domain of EMMPRIN, allowing for conformational changes [8] .CONCLUDING REMARKSThe observation that EMMPRIN seems to exhibit functional duality in T cells is not clearly understood.", [["T cells", "ANATOMY", 317, 324], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 21, 28], ["EC1", "GENE_OR_GENE_PRODUCT", 159, 162], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 181, 188], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 270, 277], ["T cells", "CELL", 317, 324], ["EMMPRIN", "PROTEIN", 21, 28], ["EC1", "PROTEIN", 159, 162], ["EC2 domain", "PROTEIN", 167, 177], ["EMMPRIN", "PROTEIN", 181, 188], ["EMMPRIN", "PROTEIN", 270, 277], ["T cells", "CELL_TYPE", 317, 324]]], ["As already described, it acts as a regulatory molecule upon the initial stages of TCRmediated activation and proliferation and likely for cell aggregation via a TCR-independent mechanism; however, once T cells are activated or during T cell development when EMMPRIN expression levels are high, positive/facilitatory roles are displayed for activities, such as chemotaxis, MMP induction, adhesion, and likely, the shuttling of lactate in proliferating cells.", [["cell", "ANATOMY", 138, 142], ["T cells", "ANATOMY", 202, 209], ["T cell", "ANATOMY", 234, 240], ["cells", "ANATOMY", 451, 456], ["lactate", "CHEMICAL", 426, 433], ["lactate", "CHEMICAL", 426, 433], ["cell", "CELL", 138, 142], ["TCR", "GENE_OR_GENE_PRODUCT", 161, 164], ["T cells", "CELL", 202, 209], ["T cell", "CELL", 234, 240], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 258, 265], ["MMP", "GENE_OR_GENE_PRODUCT", 372, 375], ["lactate", "SIMPLE_CHEMICAL", 426, 433], ["cells", "CELL", 451, 456], ["regulatory molecule", "PROTEIN", 35, 54], ["TCR", "PROTEIN", 161, 164], ["T cells", "CELL_TYPE", 202, 209], ["EMMPRIN", "PROTEIN", 258, 265], ["MMP", "PROTEIN", 372, 375], ["proliferating cells", "CELL_TYPE", 437, 456], ["TCRmediated activation", "PROBLEM", 82, 104], ["proliferation", "PROBLEM", 109, 122], ["cell aggregation", "PROBLEM", 138, 154], ["EMMPRIN expression levels", "TEST", 258, 283], ["positive/facilitatory roles", "PROBLEM", 294, 321], ["MMP induction", "TREATMENT", 372, 385], ["adhesion", "PROBLEM", 387, 395], ["the shuttling of lactate in proliferating cells", "PROBLEM", 409, 456], ["likely for", "UNCERTAINTY", 127, 137], ["cell aggregation", "OBSERVATION", 138, 154], ["proliferating cells", "OBSERVATION", 437, 456]]], ["One reconciling factor for the positive or negative effects of EMMPRIN on T cells appears to be its levels on these leukocytes; when levels of EMMPRIN are high, such as in thymocytes or on T cells in the periphery during disease states, EMMPRIN facilitates several T cell phenotypes (Table 2 ).", [["T cells", "ANATOMY", 74, 81], ["leukocytes", "ANATOMY", 116, 126], ["thymocytes", "ANATOMY", 172, 182], ["T cells", "ANATOMY", 189, 196], ["T cell", "ANATOMY", 265, 271], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 63, 70], ["T cells", "CELL", 74, 81], ["leukocytes", "CELL", 116, 126], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 143, 150], ["thymocytes", "CELL", 172, 182], ["T cells", "CELL", 189, 196], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 237, 244], ["T cell", "CELL", 265, 271], ["EMMPRIN", "PROTEIN", 63, 70], ["T cells", "CELL_TYPE", 74, 81], ["leukocytes", "CELL_TYPE", 116, 126], ["EMMPRIN", "PROTEIN", 143, 150], ["thymocytes", "CELL_TYPE", 172, 182], ["T cells", "CELL_TYPE", 189, 196], ["EMMPRIN", "PROTEIN", 237, 244], ["EMMPRIN on T cells", "PROBLEM", 63, 81], ["these leukocytes", "TEST", 110, 126], ["EMMPRIN", "TEST", 143, 150], ["thymocytes", "PROBLEM", 172, 182], ["T cells in the periphery during disease states", "PROBLEM", 189, 235], ["EMMPRIN", "TREATMENT", 237, 244], ["several T cell phenotypes", "TREATMENT", 257, 282], ["thymocytes", "ANATOMY", 172, 182], ["periphery", "ANATOMY_MODIFIER", 204, 213]]], ["In contrast, when EMMPRIN levels are low, such as on circulating T cells in the periphery in normal homeostasis, EMMPRIN appears to have an inhibitory role on T cell activation and proliferation; an [45] Decreased DN4, DP, CD4 + SP populations Lck-cre; EMMPRIN flox/flox thymocytes [46] Decreased DP, CD4 + SP populations (DN4 not assessed) Periphery Negative/inhibitory role for EMMPRIN Low EMMPRIN levels T cell activation TCR-mediated activation of human T cells [51, 52] Identified EMMPRIN at immune synapses EMMPRIN mAb (MEM-M6/6, 5A12) on human T cells upon TCR-mediated activation [51, 52] Altered immune synapse formation CD48 and CD59 displaced from lipid rafts Decreased CD25, tyrosine phosphorylation, cytokines Proliferation EMMPRIN 2/2 splenocytes in a MLR [30] Increased proliferation Lck-cre; EMMPRIN flox/flox T cells upon anti-CD3/CD28 stimulation [46] Increased proliferation EMMPRIN siRNA KD in human T cells and PHA activation [50] Increased proliferation EMMPRIN mAb (MEM-M6/6, 5A12, clone 10, M6-1B9, UM-8D6, HI197) on human PBMCs and/or purified T cells upon TCR-mediated activation [48, [51] [52] [53] [54] 58] Decreased proliferation Periphery Positive/facilitatory role for EMMPRIN High EMMPRIN levels Migration EMMPRIN mAb (UM-8D6) on human T cells [49] Decreased CyPA-mediated migration EMMPRIN mAb (RL73.2) in the mouse system [61] [62] [63] Decreased CyPA-mediated migration EMMPRIN KD or EMMPRIN mAb (HAb18) in/on Jurkat cells [59, 77] Decreased transendothelial migration and CyPA-mediated migration Invasion EMMPRIN mAb (UM-8D6, clone 10) in cocultures of mouse mf or fibroblasts with human T cells [53, 61] Inhibited MMP-9 secretion EMMPRIN activity-blocking peptide in cocultures of transformed human T cells and fibroblasts [75] Decreased MMP-2 stimulation Adhesion Immunoprecipitation and co-localization experiments in cell lines [78] Identified EMMPRIN to interact with b1 integrins EMMPRIN mAb (HIM6) on human PBMCs and THP-1 cells [24, 79, 81] Reduced CyPB-induced P-ERK and adhesion to fibronectin Identified EMMPRIN-CyPB-CD98-b1 integrin complexes EMMPRIN mAb (clone 10) upon TCR-mediated activation of human PBMCs [66] Decreased a4 integrin levels Decreased adhesion to endothelial cells EMMPRIN mAb (MEM-M6/8, HAb18) on Jurkat cells [23, 59] Induced homotypic cell aggregation and adhesion to a LFA-1 ligand Identified CD43-EMMPRIN complexes EMMPRIN KD in Jurkat cells [59, 77] Reduced adhesion to ECM fibronectin Induced homotypic cell aggregation, decreased CD98 expression Energy metabolism EMMPRIN siRNA KD in human cell lines [25, 82, 83, 89] Decreased MCT1/4 expression and efflux of toxic lactic acid byproducts Identified MCT-EMMPRIN complexes MCT1 inhibition in human PBMCs [90] Decreased T cell proliferation and lactate efflux Proliferation EMMPRIN siRNA KD in Jurkat cells or other cell lines [77, 89] Decreased proliferation A positive/facilitatory role for EMMPRIN exists when EMMPRIN expression levels are high and a negative/inhibitory role when EMMPRIN expression levels are low.", [["T cells", "ANATOMY", 65, 72], ["T cell", "ANATOMY", 159, 165], ["CD4 + SP populations", "ANATOMY", 301, 321], ["T cell", "ANATOMY", 407, 413], ["T cells", "ANATOMY", 458, 465], ["immune synapses", "ANATOMY", 497, 512], ["T cells", "ANATOMY", 551, 558], ["immune synapse", "ANATOMY", 605, 619], ["lipid rafts", "ANATOMY", 659, 670], ["splenocytes", "ANATOMY", 749, 760], ["flox/flox T cells", "ANATOMY", 816, 833], ["T cells", "ANATOMY", 920, 927], ["UM-8D6", "ANATOMY", 1023, 1029], ["PBMCs", "ANATOMY", 1047, 1052], ["T cells", "ANATOMY", 1069, 1076], ["T cells", "ANATOMY", 1268, 1275], ["Jurkat cells", "ANATOMY", 1445, 1457], ["transendothelial", "ANATOMY", 1477, 1493], ["UM-8D6", "ANATOMY", 1554, 1560], ["mf", "ANATOMY", 1595, 1597], ["fibroblasts", "ANATOMY", 1601, 1612], ["T cells", "ANATOMY", 1624, 1631], ["T cells", "ANATOMY", 1736, 1743], ["fibroblasts", "ANATOMY", 1748, 1759], ["cell lines", "ANATOMY", 1857, 1867], ["PBMCs", "ANATOMY", 1950, 1955], ["THP-1 cells", "ANATOMY", 1960, 1971], ["PBMCs", "ANATOMY", 2152, 2157], ["endothelial cells", "ANATOMY", 2214, 2231], ["Jurkat cells", "ANATOMY", 2265, 2277], ["cell", "ANATOMY", 2305, 2309], ["Jurkat cells", "ANATOMY", 2401, 2413], ["ECM", "ANATOMY", 2443, 2446], ["cell", "ANATOMY", 2477, 2481], ["cell lines", "ANATOMY", 2565, 2575], ["PBMCs", "ANATOMY", 2722, 2727], ["T cell", "ANATOMY", 2743, 2749], ["Jurkat cells", "ANATOMY", 2817, 2829], ["cell lines", "ANATOMY", 2839, 2849], ["TCR", "CHEMICAL", 425, 428], ["TCR", "CHEMICAL", 564, 567], ["tyrosine", "CHEMICAL", 687, 695], ["TCR", "CHEMICAL", 1082, 1085], ["UM-8D6", "CHEMICAL", 1251, 1257], ["CyPA", "CHEMICAL", 1381, 1385], ["TCR", "CHEMICAL", 2119, 2122], ["lactic acid", "CHEMICAL", 2641, 2652], ["lactate", "CHEMICAL", 2768, 2775], ["tyrosine", "CHEMICAL", 687, 695], ["lactic acid", "CHEMICAL", 2641, 2652], ["lactate", "CHEMICAL", 2768, 2775], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 18, 25], ["T cells", "CELL", 65, 72], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 113, 120], ["T cell", "CELL", 159, 165], ["DN4", "GENE_OR_GENE_PRODUCT", 214, 217], ["DP", "GENE_OR_GENE_PRODUCT", 219, 221], ["CD4", "GENE_OR_GENE_PRODUCT", 223, 226], ["Lck", "GENE_OR_GENE_PRODUCT", 244, 247], ["cre", "GENE_OR_GENE_PRODUCT", 248, 251], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 253, 260], ["CD4", "GENE_OR_GENE_PRODUCT", 301, 304], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 380, 387], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 392, 399], ["T cell", "GENE_OR_GENE_PRODUCT", 407, 413], ["TCR", "GENE_OR_GENE_PRODUCT", 425, 428], ["human", "ORGANISM", 452, 457], ["T cells", "CELL", 458, 465], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 486, 493], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 513, 520], ["MEM-M6/6", "GENE_OR_GENE_PRODUCT", 526, 534], ["human", "ORGANISM", 545, 550], ["T cells", "CELL", 551, 558], ["TCR", "GENE_OR_GENE_PRODUCT", 564, 567], ["immune synapse", "CELLULAR_COMPONENT", 605, 619], ["CD48", "GENE_OR_GENE_PRODUCT", 630, 634], ["CD59", "GENE_OR_GENE_PRODUCT", 639, 643], ["lipid rafts", "CELLULAR_COMPONENT", 659, 670], ["CD25", "GENE_OR_GENE_PRODUCT", 681, 685], ["tyrosine", "AMINO_ACID", 687, 695], ["Lck", "GENE_OR_GENE_PRODUCT", 799, 802], ["cre", "GENE_OR_GENE_PRODUCT", 803, 806], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 808, 815], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 839, 847], ["CD28", "GENE_OR_GENE_PRODUCT", 848, 852], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 894, 901], ["human", "ORGANISM", 914, 919], ["T cells", "CELL", 920, 927], ["PHA", "CELL", 932, 935], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 976, 987], ["M6-1B9", "CELL", 1015, 1021], ["UM-8D6", "CELL", 1023, 1029], ["HI197", "CELL", 1031, 1036], ["human", "ORGANISM", 1041, 1046], ["PBMCs", "CELL", 1047, 1052], ["T cells", "CELL", 1069, 1076], ["TCR", "GENE_OR_GENE_PRODUCT", 1082, 1085], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1200, 1207], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1213, 1220], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1238, 1245], ["UM-8D6", "SIMPLE_CHEMICAL", 1251, 1257], ["human", "ORGANISM", 1262, 1267], ["T cells", "CELL", 1268, 1275], ["CyPA", "GENE_OR_GENE_PRODUCT", 1291, 1295], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 1315, 1326], ["mouse", "ORGANISM", 1343, 1348], ["CyPA", "SIMPLE_CHEMICAL", 1381, 1385], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1405, 1412], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 1419, 1430], ["Jurkat cells", "CELL", 1445, 1457], ["transendothelial", "CELL", 1477, 1493], ["CyPA", "SIMPLE_CHEMICAL", 1508, 1512], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 1541, 1552], ["mouse", "ORGANISM", 1589, 1594], ["mf", "CELL", 1595, 1597], ["fibroblasts", "CELL", 1601, 1612], ["human", "ORGANISM", 1618, 1623], ["T cells", "CELL", 1624, 1631], ["MMP-9", "GENE_OR_GENE_PRODUCT", 1651, 1656], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1667, 1674], ["human", "ORGANISM", 1730, 1735], ["T cells", "CELL", 1736, 1743], ["fibroblasts", "CELL", 1748, 1759], ["MMP-2", "GENE_OR_GENE_PRODUCT", 1775, 1780], ["cell lines", "CELL", 1857, 1867], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 1884, 1891], ["b1 integrins", "GENE_OR_GENE_PRODUCT", 1909, 1921], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 1922, 1933], ["HIM6", "GENE_OR_GENE_PRODUCT", 1935, 1939], ["human", "ORGANISM", 1944, 1949], ["PBMCs", "CELL", 1950, 1955], ["THP-1 cells", "CELL", 1960, 1971], ["CyPB", "SIMPLE_CHEMICAL", 1993, 1997], ["ERK", "GENE_OR_GENE_PRODUCT", 2008, 2011], ["fibronectin", "GENE_OR_GENE_PRODUCT", 2028, 2039], ["EMMPRIN-CyPB-CD98-b1 integrin", "GENE_OR_GENE_PRODUCT", 2051, 2080], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 2091, 2102], ["TCR", "GENE_OR_GENE_PRODUCT", 2119, 2122], ["human", "ORGANISM", 2146, 2151], ["PBMCs", "CELL", 2152, 2157], ["a4 integrin", "GENE_OR_GENE_PRODUCT", 2173, 2184], ["endothelial cells", "CELL", 2214, 2231], ["EMMPRIN mAb", "GENE_OR_GENE_PRODUCT", 2232, 2243], ["MEM-M6/8", "GENE_OR_GENE_PRODUCT", 2245, 2253], ["HAb18", "GENE_OR_GENE_PRODUCT", 2255, 2260], ["Jurkat cells", "CELL", 2265, 2277], ["cell", "CELL", 2305, 2309], ["LFA-1", "GENE_OR_GENE_PRODUCT", 2340, 2345], ["CD43", "GENE_OR_GENE_PRODUCT", 2364, 2368], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2369, 2376], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2387, 2394], ["Jurkat cells", "CELL", 2401, 2413], ["ECM fibronectin", "GENE_OR_GENE_PRODUCT", 2443, 2458], ["cell", "CELL", 2477, 2481], ["CD98", "GENE_OR_GENE_PRODUCT", 2505, 2509], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2539, 2546], ["human", "ORGANISM", 2559, 2564], ["cell lines", "CELL", 2565, 2575], ["MCT1", "GENE_OR_GENE_PRODUCT", 2603, 2607], ["4", "GENE_OR_GENE_PRODUCT", 2608, 2609], ["lactic acid byproducts", "SIMPLE_CHEMICAL", 2641, 2663], ["MCT-EMMPRIN", "SIMPLE_CHEMICAL", 2675, 2686], ["MCT1", "GENE_OR_GENE_PRODUCT", 2697, 2701], ["human", "ORGANISM", 2716, 2721], ["PBMCs", "CELL", 2722, 2727], ["T cell", "CELL", 2743, 2749], ["lactate", "SIMPLE_CHEMICAL", 2768, 2775], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2797, 2804], ["Jurkat cells", "CELL", 2817, 2829], ["cell lines", "CELL", 2839, 2849], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2916, 2923], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 2936, 2943], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 3007, 3014], ["EMMPRIN", "PROTEIN", 18, 25], ["circulating T cells", "CELL_TYPE", 53, 72], ["EMMPRIN", "PROTEIN", 113, 120], ["DN4", "PROTEIN", 214, 217], ["DP", "PROTEIN", 219, 221], ["CD4", "PROTEIN", 223, 226], ["Lck", "PROTEIN", 244, 247], ["EMMPRIN", "PROTEIN", 253, 260], ["flox thymocytes", "CELL_TYPE", 266, 281], ["CD4", "PROTEIN", 301, 304], ["SP populations", "CELL_TYPE", 307, 321], ["DN4", "CELL_TYPE", 323, 326], ["EMMPRIN", "PROTEIN", 380, 387], ["EMMPRIN", "PROTEIN", 392, 399], ["TCR", "PROTEIN", 425, 428], ["human T cells", "CELL_TYPE", 452, 465], ["EMMPRIN", "PROTEIN", 486, 493], ["EMMPRIN mAb", "PROTEIN", 513, 524], ["M6/6", "PROTEIN", 530, 534], ["5A12", "PROTEIN", 536, 540], ["human T cells", "CELL_TYPE", 545, 558], ["TCR", "PROTEIN", 564, 567], ["CD48", "PROTEIN", 630, 634], ["CD59", "PROTEIN", 639, 643], ["CD25", "PROTEIN", 681, 685], ["cytokines", "PROTEIN", 713, 722], ["EMMPRIN", "PROTEIN", 737, 744], ["Lck", "PROTEIN", 799, 802], ["EMMPRIN flox/flox T cells", "CELL_LINE", 808, 833], ["anti-CD3", "PROTEIN", 839, 847], ["CD28", "PROTEIN", 848, 852], ["EMMPRIN", "PROTEIN", 894, 901], ["human T cells", "CELL_TYPE", 914, 927], ["PHA", "PROTEIN", 932, 935], ["EMMPRIN mAb", "PROTEIN", 976, 987], ["5A12", "PROTEIN", 999, 1003], ["M6", "PROTEIN", 1015, 1017], ["8D6", "CELL_LINE", 1026, 1029], ["HI197", "CELL_LINE", 1031, 1036], ["human PBMCs", "CELL_TYPE", 1041, 1052], ["purified T cells", "CELL_TYPE", 1060, 1076], ["TCR", "PROTEIN", 1082, 1085], ["EMMPRIN", "PROTEIN", 1200, 1207], ["EMMPRIN", "PROTEIN", 1213, 1220], ["EMMPRIN mAb", "PROTEIN", 1238, 1249], ["UM", "PROTEIN", 1251, 1253], ["8D6", "PROTEIN", 1254, 1257], ["human T cells", "CELL_TYPE", 1262, 1275], ["CyPA", "PROTEIN", 1291, 1295], ["EMMPRIN mAb", "PROTEIN", 1315, 1326], ["RL73.2", "PROTEIN", 1328, 1334], ["CyPA", "PROTEIN", 1381, 1385], ["EMMPRIN KD", "PROTEIN", 1405, 1415], ["EMMPRIN mAb", "PROTEIN", 1419, 1430], ["HAb18", "PROTEIN", 1432, 1437], ["Jurkat cells", "CELL_LINE", 1445, 1457], ["CyPA", "PROTEIN", 1508, 1512], ["EMMPRIN mAb", "PROTEIN", 1541, 1552], ["UM", "PROTEIN", 1554, 1556], ["8D6", "PROTEIN", 1557, 1560], ["clone 10", "CELL_LINE", 1562, 1570], ["fibroblasts", "CELL_TYPE", 1601, 1612], ["human T cells", "CELL_TYPE", 1618, 1631], ["MMP", "PROTEIN", 1651, 1654], ["EMMPRIN", "PROTEIN", 1667, 1674], ["transformed human T cells", "CELL_LINE", 1718, 1743], ["fibroblasts", "CELL_TYPE", 1748, 1759], ["MMP", "PROTEIN", 1775, 1778], ["cell lines", "CELL_LINE", 1857, 1867], ["EMMPRIN", "PROTEIN", 1884, 1891], ["b1 integrins", "PROTEIN", 1909, 1921], ["EMMPRIN mAb", "PROTEIN", 1922, 1933], ["HIM6", "PROTEIN", 1935, 1939], ["human PBMCs", "CELL_TYPE", 1944, 1955], ["THP-1 cells", "CELL_LINE", 1960, 1971], ["CyPB", "PROTEIN", 1993, 1997], ["P", "DNA", 2006, 2007], ["ERK", "PROTEIN", 2008, 2011], ["fibronectin", "PROTEIN", 2028, 2039], ["EMMPRIN", "PROTEIN", 2051, 2058], ["CyPB", "PROTEIN", 2059, 2063], ["CD98", "PROTEIN", 2064, 2068], ["b1 integrin complexes", "PROTEIN", 2069, 2090], ["EMMPRIN mAb", "PROTEIN", 2091, 2102], ["clone 10", "PROTEIN", 2104, 2112], ["TCR", "PROTEIN", 2119, 2122], ["human PBMCs", "CELL_TYPE", 2146, 2157], ["a4 integrin", "PROTEIN", 2173, 2184], ["endothelial cells", "CELL_TYPE", 2214, 2231], ["EMMPRIN mAb", "PROTEIN", 2232, 2243], ["MEM", "PROTEIN", 2245, 2248], ["M6/8", "PROTEIN", 2249, 2253], ["HAb18", "PROTEIN", 2255, 2260], ["Jurkat cells", "CELL_LINE", 2265, 2277], ["LFA-1 ligand", "PROTEIN", 2340, 2352], ["CD43", "PROTEIN", 2364, 2368], ["EMMPRIN complexes", "PROTEIN", 2369, 2386], ["EMMPRIN", "PROTEIN", 2387, 2394], ["Jurkat cells", "CELL_LINE", 2401, 2413], ["ECM fibronectin", "PROTEIN", 2443, 2458], ["CD98", "PROTEIN", 2505, 2509], ["EMMPRIN", "PROTEIN", 2539, 2546], ["human cell lines", "CELL_LINE", 2559, 2575], ["MCT1", "PROTEIN", 2603, 2607], ["MCT-EMMPRIN complexes", "PROTEIN", 2675, 2696], ["MCT1", "PROTEIN", 2697, 2701], ["human PBMCs", "CELL_TYPE", 2716, 2727], ["EMMPRIN", "PROTEIN", 2797, 2804], ["Jurkat cells", "CELL_LINE", 2817, 2829], ["EMMPRIN", "PROTEIN", 2916, 2923], ["EMMPRIN", "PROTEIN", 2936, 2943], ["EMMPRIN", "PROTEIN", 3007, 3014], ["human", "SPECIES", 452, 457], ["human", "SPECIES", 545, 550], ["human", "SPECIES", 914, 919], ["human", "SPECIES", 1041, 1046], ["human", "SPECIES", 1262, 1267], ["mouse", "SPECIES", 1343, 1348], ["mouse", "SPECIES", 1589, 1594], ["human", "SPECIES", 1618, 1623], ["human", "SPECIES", 1730, 1735], ["human", "SPECIES", 1944, 1949], ["human", "SPECIES", 2146, 2151], ["human", "SPECIES", 2559, 2564], ["human", "SPECIES", 2716, 2721], ["human", "SPECIES", 452, 457], ["human", "SPECIES", 545, 550], ["human", "SPECIES", 914, 919], ["human", "SPECIES", 1041, 1046], ["human", "SPECIES", 1262, 1267], ["mouse", "SPECIES", 1343, 1348], ["mouse", "SPECIES", 1589, 1594], ["human", "SPECIES", 1618, 1623], ["human", "SPECIES", 1730, 1735], ["human", "SPECIES", 1944, 1949], ["human", "SPECIES", 2146, 2151], ["human", "SPECIES", 2559, 2564], ["human", "SPECIES", 2716, 2721], ["EMMPRIN levels", "TEST", 18, 32], ["proliferation", "TEST", 181, 194], ["DP", "TEST", 219, 221], ["CD4", "TEST", 223, 226], ["SP populations", "TEST", 229, 243], ["Lck", "TEST", 244, 247], ["cre", "TEST", 248, 251], ["EMMPRIN flox", "TEST", 253, 265], ["thymocytes", "TEST", 271, 281], ["DP", "TEST", 297, 299], ["CD4", "TEST", 301, 304], ["EMMPRIN Low EMMPRIN levels", "TEST", 380, 406], ["T cell activation", "TEST", 407, 424], ["TCR", "TEST", 425, 428], ["human T cells", "TEST", 452, 465], ["EMMPRIN", "TEST", 486, 493], ["EMMPRIN mAb", "TEST", 513, 524], ["MEM", "TEST", 526, 529], ["Altered immune synapse", "PROBLEM", 597, 619], ["CD48", "TEST", 630, 634], ["CD59", "TEST", 639, 643], ["lipid rafts", "TEST", 659, 670], ["CD25", "TEST", 681, 685], ["tyrosine phosphorylation", "TREATMENT", 687, 711], ["cytokines Proliferation", "TEST", 713, 736], ["EMMPRIN", "TEST", 737, 744], ["splenocytes", "TEST", 749, 760], ["a MLR", "TEST", 764, 769], ["Increased proliferation", "PROBLEM", 775, 798], ["Lck", "TEST", 799, 802], ["cre", "TEST", 803, 806], ["EMMPRIN flox/flox T cells", "TREATMENT", 808, 833], ["anti-CD3/CD28 stimulation", "TREATMENT", 839, 864], ["Increased proliferation EMMPRIN siRNA KD in human T cells", "TREATMENT", 870, 927], ["PHA activation", "TEST", 932, 946], ["EMMPRIN mAb", "TEST", 976, 987], ["MEM", "TEST", 989, 992], ["clone", "TEST", 1005, 1010], ["M6", "TEST", 1015, 1017], ["UM", "TEST", 1023, 1025], ["human PBMCs", "TEST", 1041, 1052], ["TCR", "TEST", 1082, 1085], ["Decreased proliferation Periphery Positive/facilitatory role", "PROBLEM", 1135, 1195], ["EMMPRIN High EMMPRIN levels", "TREATMENT", 1200, 1227], ["Migration", "TEST", 1228, 1237], ["EMMPRIN mAb", "TEST", 1238, 1249], ["UM", "TEST", 1251, 1253], ["human T cells", "TEST", 1262, 1275], ["Decreased CyPA-mediated migration", "TREATMENT", 1281, 1314], ["EMMPRIN mAb", "TEST", 1315, 1326], ["CyPA", "TEST", 1381, 1385], ["EMMPRIN KD", "TEST", 1405, 1415], ["EMMPRIN mAb", "TEST", 1419, 1430], ["HAb18", "TEST", 1432, 1437], ["Jurkat cells", "TEST", 1445, 1457], ["Decreased transendothelial migration", "TREATMENT", 1467, 1503], ["CyPA", "TEST", 1508, 1512], ["mediated migration Invasion", "TREATMENT", 1513, 1540], ["EMMPRIN mAb", "TEST", 1541, 1552], ["UM", "TEST", 1554, 1556], ["fibroblasts", "PROBLEM", 1601, 1612], ["human T cells", "TEST", 1618, 1631], ["MMP", "TEST", 1651, 1654], ["EMMPRIN activity", "TEST", 1667, 1683], ["blocking peptide", "TREATMENT", 1684, 1700], ["transformed human T cells", "PROBLEM", 1718, 1743], ["fibroblasts", "TEST", 1748, 1759], ["Decreased MMP-2 stimulation Adhesion Immunoprecipitation", "TREATMENT", 1765, 1821], ["co-localization experiments in cell lines", "TREATMENT", 1826, 1867], ["EMMPRIN", "TREATMENT", 1884, 1891], ["b1 integrins", "TREATMENT", 1909, 1921], ["EMMPRIN mAb", "TEST", 1922, 1933], ["HIM6", "TEST", 1935, 1939], ["human PBMCs", "TEST", 1944, 1955], ["THP", "TEST", 1960, 1963], ["CyPB", "TEST", 1993, 1997], ["adhesion", "TEST", 2016, 2024], ["fibronectin", "TEST", 2028, 2039], ["EMMPRIN", "TEST", 2051, 2058], ["CyPB", "TEST", 2059, 2063], ["CD98", "TEST", 2064, 2068], ["b1 integrin complexes EMMPRIN mAb (clone", "TREATMENT", 2069, 2109], ["TCR", "TEST", 2119, 2122], ["human PBMCs", "TEST", 2146, 2157], ["Decreased a4 integrin levels", "PROBLEM", 2163, 2191], ["Decreased adhesion", "PROBLEM", 2192, 2210], ["endothelial cells", "TEST", 2214, 2231], ["EMMPRIN", "TEST", 2232, 2239], ["mAb", "TEST", 2240, 2243], ["MEM", "TEST", 2245, 2248], ["Jurkat cells", "TEST", 2265, 2277], ["homotypic cell aggregation", "PROBLEM", 2295, 2321], ["a LFA", "TEST", 2338, 2343], ["CD43", "TEST", 2364, 2368], ["EMMPRIN complexes EMMPRIN", "TREATMENT", 2369, 2394], ["KD", "TEST", 2395, 2397], ["Jurkat cells", "TEST", 2401, 2413], ["Reduced adhesion", "PROBLEM", 2423, 2439], ["fibronectin", "TEST", 2447, 2458], ["homotypic cell aggregation", "PROBLEM", 2467, 2493], ["decreased CD98 expression Energy", "TREATMENT", 2495, 2527], ["EMMPRIN siRNA KD in human cell lines", "TREATMENT", 2539, 2575], ["toxic lactic acid byproducts", "TREATMENT", 2635, 2663], ["MCT1 inhibition", "TEST", 2697, 2712], ["PBMCs", "TEST", 2722, 2727], ["Decreased T cell proliferation", "TREATMENT", 2733, 2763], ["lactate efflux Proliferation", "TREATMENT", 2768, 2796], ["EMMPRIN siRNA KD in Jurkat cells", "TREATMENT", 2797, 2829], ["other cell lines", "TEST", 2833, 2849], ["Decreased proliferation A positive/facilitatory role", "PROBLEM", 2859, 2911], ["EMMPRIN exists", "TEST", 2916, 2930], ["EMMPRIN expression levels", "TEST", 2936, 2961], ["EMMPRIN expression levels", "TEST", 3007, 3032], ["low", "OBSERVATION_MODIFIER", 37, 40], ["periphery", "ANATOMY_MODIFIER", 80, 89], ["normal homeostasis", "OBSERVATION", 93, 111], ["Negative", "OBSERVATION", 351, 359], ["immune synapse", "OBSERVATION", 605, 619], ["transendothelial migration", "OBSERVATION", 1477, 1503], ["cell lines", "OBSERVATION", 1857, 1867], ["endothelial", "ANATOMY", 2214, 2225], ["homotypic cell aggregation", "OBSERVATION", 2295, 2321], ["LFA", "ANATOMY", 2340, 2343], ["homotypic cell aggregation", "OBSERVATION", 2467, 2493], ["cell proliferation", "OBSERVATION", 2745, 2763], ["cell lines", "OBSERVATION", 2839, 2849]]], ["KD, Knockdown; mf, macrophages; P-ERK, phosphorylated ERK. inhibitory role for EMMPRIN is consistent when activated under TCR-mediated mechanisms.CONCLUDING REMARKSIn conclusion, clarity on how EMMPRIN expression levels are controlled, what signaling pathways EMMPRIN activates, its binding partners, and an understanding of how it carries out its functions is necessary.", [["macrophages", "ANATOMY", 19, 30], ["TCR", "CHEMICAL", 122, 125], ["macrophages", "CELL", 19, 30], ["P-ERK", "GENE_OR_GENE_PRODUCT", 32, 37], ["ERK", "GENE_OR_GENE_PRODUCT", 54, 57], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 79, 86], ["TCR", "GENE_OR_GENE_PRODUCT", 122, 125], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 194, 201], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 260, 267], ["macrophages", "CELL_TYPE", 19, 30], ["ERK", "PROTEIN", 34, 37], ["phosphorylated ERK", "PROTEIN", 39, 57], ["EMMPRIN", "PROTEIN", 79, 86], ["TCR", "PROTEIN", 122, 125], ["EMMPRIN", "PROTEIN", 194, 201], ["EMMPRIN", "PROTEIN", 260, 267], ["EMMPRIN expression levels", "TEST", 194, 219], ["macrophages", "ANATOMY", 19, 30]]], ["The understanding of the importance of EMMPRIN on APCs versus T cells in initiating TCR-mediated cell activation also requires further clarification.", [["APCs", "ANATOMY", 50, 54], ["T cells", "ANATOMY", 62, 69], ["cell", "ANATOMY", 97, 101], ["TCR", "CHEMICAL", 84, 87], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 39, 46], ["APCs", "CELL", 50, 54], ["T cells", "CELL", 62, 69], ["TCR", "GENE_OR_GENE_PRODUCT", 84, 87], ["cell", "CELL", 97, 101], ["EMMPRIN", "PROTEIN", 39, 46], ["APCs", "CELL_TYPE", 50, 54], ["T cells", "CELL_TYPE", 62, 69], ["TCR", "PROTEIN", 84, 87], ["EMMPRIN on APCs versus T cells", "TREATMENT", 39, 69], ["TCR-mediated cell activation", "TREATMENT", 84, 112], ["cell activation", "OBSERVATION", 97, 112]]], ["EMMPRIN could be acting through an unidentified coreceptor or be a novel costimulator for T cell activation.", [["T cell", "ANATOMY", 90, 96], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cell", "CELL", 90, 96], ["EMMPRIN", "PROTEIN", 0, 7], ["coreceptor", "PROTEIN", 48, 58], ["EMMPRIN", "TREATMENT", 0, 7], ["a novel costimulator", "TREATMENT", 65, 85], ["T cell activation", "TREATMENT", 90, 107]]], ["Many more lessons are to be learned in understanding the involvement of EMMPRIN in T cell activities.", [["T cell", "ANATOMY", 83, 89], ["EMMPRIN", "GENE_OR_GENE_PRODUCT", 72, 79], ["T cell", "CELL", 83, 89], ["EMMPRIN", "PROTEIN", 72, 79], ["EMMPRIN in T cell activities", "TREATMENT", 72, 100]]]], "5496499f43b6133a6aed88453436013d4437278b": [["BackgroundThe Coronavirus Disease 2019 (COVID-19) pandemic originated in China in late 2019 and continues to spread globally.", [["COVID-19", "CHEMICAL", 40, 48], ["COVID-19", "ORGANISM", 40, 48], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 14, 48], ["The Coronavirus Disease", "PROBLEM", 10, 33], ["COVID", "TEST", 40, 45], ["pandemic", "PROBLEM", 50, 58], ["Coronavirus Disease", "OBSERVATION", 14, 33]]], ["1 At the time of writing, there were over 260,000 COVID-19 cases causing close to 12,000 deaths across more than 185 affected countries and territories.", [["deaths", "DISEASE", 89, 95]]], ["2 As healthcare systems like those in Northern Italy approach collapse, there is a pressing need for tools modeling the capacity of acute and critical care systems during the COVID-19 pandemic.", [["collapse", "PROBLEM", 62, 70], ["the COVID", "TEST", 171, 180], ["pandemic", "PROBLEM", 184, 192], ["collapse", "OBSERVATION", 62, 70], ["acute", "OBSERVATION_MODIFIER", 132, 137]]], ["3ObjectiveTo develop an online tool capable of estimating the maximum daily number of incident COVID-19 cases that a healthcare system could manage given age-based case distribution and severity.MethodsWe modeled steady-state patient-flow dynamics for acute care beds, critical care beds, and mechanical ventilators during the COVID-19 pandemic.", [["patient", "ORGANISM", 226, 233], ["patient", "SPECIES", 226, 233], ["a healthcare system", "TREATMENT", 115, 134], ["severity", "PROBLEM", 186, 194], ["acute care beds", "TREATMENT", 252, 267], ["critical care beds", "TREATMENT", 269, 287], ["mechanical ventilators", "TREATMENT", 293, 315], ["the COVID", "TEST", 323, 332], ["pandemic", "PROBLEM", 336, 344]]], ["4 Parameters for patient-flow dynamics were extracted from evolving data on COVID-19 and assumptions based on expert guidance, but were left modifiable in the tool for users to adjust based upon local experience.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["patient-flow dynamics", "TEST", 17, 38], ["COVID", "TEST", 76, 81], ["expert guidance", "TEST", 110, 125]]], ["We used the package shiny within R (version 3.5.3) to create the interactive tool.MethodsThe tool determines the maximum daily number of incident COVID-19 cases (\"patients in\") which would equal the maximum daily turnover of acute care beds, critical care beds, and mechanical ventilators available and/or used for COVID-19 patients (\"patients out\")-this is the steady state which could be maximally managed by a healthcare system.", [["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 324, 332], ["patients", "ORGANISM", 335, 343], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 324, 332], ["patients", "SPECIES", 335, 343], ["COVID", "TEST", 146, 151], ["acute care beds", "TREATMENT", 225, 240], ["critical care beds", "TREATMENT", 242, 260], ["mechanical ventilators", "TREATMENT", 266, 288]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)MethodsThe copyright holder for this preprint this version posted March 25, 2020. . https://doi.org/10.1101/2020.03.25.20043711 doi: medRxiv preprint COVID-19 patients include the proportion of existing resources that could be made maximally available to support COVID-19 patients plus any additional surge capacity.MethodsThe tool first calculates the daily turnover of acute care beds, critical care beds and mechanical ventilators available for COVID-19 patients by taking the maximally available number of those resources and dividing it by the expected duration of use for COVID-19 patients.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 361, 369], ["patients", "ORGANISM", 474, 482], ["patients", "ORGANISM", 659, 667], ["patients", "ORGANISM", 789, 797], ["patients", "SPECIES", 361, 369], ["patients", "SPECIES", 474, 482], ["patients", "SPECIES", 659, 667], ["patients", "SPECIES", 789, 797], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 209, 229], ["medRxiv preprint COVID", "TREATMENT", 335, 357], ["COVID", "TEST", 465, 470], ["any additional surge capacity", "PROBLEM", 488, 517], ["acute care beds", "TREATMENT", 573, 588], ["critical care beds", "TREATMENT", 590, 608], ["mechanical ventilators", "TREATMENT", 613, 635], ["COVID", "TREATMENT", 650, 655], ["med", "ANATOMY", 105, 108]]], ["Based on published data, the average length of stay in acute care was set at 11 days, the average length of stay in critical care was set at 20 days, and the average length of time for mechanical ventilation was set at 20 days.", [["mechanical ventilation", "TREATMENT", 185, 207], ["length", "OBSERVATION_MODIFIER", 37, 43], ["acute", "OBSERVATION_MODIFIER", 55, 60]]], ["1, 5 The tool then calculates the population-weighted expected probabilities of acute care hospitalization and critical care admissions for COVID-19 infections; we assumed that 50% of critical care patients would require mechanical ventilation.", [["infections", "DISEASE", 149, 159], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 198, 206], ["acute care hospitalization", "TREATMENT", 80, 106], ["COVID-19 infections", "PROBLEM", 140, 159], ["mechanical ventilation", "TREATMENT", 221, 243], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["mechanical ventilation", "OBSERVATION", 221, 243]]], ["5, 6 Finally, the maximum daily number of incident COVID-19 cases that a healthcare system could manage is calculated by dividing the daily turnover of maximally available acute care beds, critical care beds or mechanical ventilators by the probability of those resources being used among COVID-19 cases.MethodsWhile the tool can be used in any region, default parameters for age-based case distribution and severity were set using data from the United States, while parameters for acute and critical care resource availability were set for Canada's most populous province of Ontario (see Appendix 1).", [["acute care beds", "TREATMENT", 172, 187], ["critical care beds", "TREATMENT", 189, 207], ["mechanical ventilators", "TREATMENT", 211, 233], ["those resources", "TREATMENT", 256, 271], ["Methods", "TREATMENT", 304, 311], ["severity", "PROBLEM", 408, 416]]], ["6FindingsThe COVID-19 Acute and Intensive Care Resource Tool (CAIC-RT) is open-access and published online, available at https://caic-rt.shinyapps.io/CAIC-RT.", [["The COVID", "TEST", 9, 18], ["Tool (CAIC-RT)", "TREATMENT", 56, 70], ["Acute", "OBSERVATION_MODIFIER", 22, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)FindingsThe copyright holder for this preprint this version posted March 25, 2020. . https://doi.org/10.1101/2020.03.25.20043711 doi: medRxiv preprint maximum daily number of incident COVID-19 cases which could be managed by the Ontario healthcare system is detailed in Figure 1 .DiscussionUsing an online tool, healthcare systems can estimate the maximum daily number of incident COVID-19 cases which could be managed based on age-based case distribution and severity and the number of maximally available acute and critical care resources.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 210, 230], ["medRxiv", "TREATMENT", 336, 343], ["COVID", "TEST", 386, 391], ["med", "ANATOMY", 105, 108]]], ["Unlike forecasting tools, our tool has the advantage of determining a sustainable threshold for resource utilization during the COVID-19 pandemic rather than forecasting when resources might become depleted based on assumptions about reporting, epidemic growth and reproduction numbers. .", [["resource utilization", "TREATMENT", 96, 116], ["the COVID", "TREATMENT", 124, 133], ["epidemic growth", "PROBLEM", 245, 260]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 25, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Outputs from the tool will allow planners to examine how increases in acute and critical resources available for COVID-19 patients can impact healthcare system sustainability.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["COVID", "TREATMENT", 113, 118], ["acute", "OBSERVATION_MODIFIER", 70, 75]]], ["Further, the tool can inform the required intensity for non-pharmaceutical societal interventions like physical distancing based on a healthcare system's proximity to the sustainable threshold.(which was not certified by peer review)Finally, the tool allows for customization of age-based case distribution and severity which is essential for countries with differing population demographics and healthcare systems.(which was not certified by peer review)Limitations of this tool include the assumption that COVID-19 cases become instantaneously hospitalized and the application of Canadian, Chinese and US data for default parameters which may not generalizable to all healthcare systems.", [["non-pharmaceutical societal interventions", "TREATMENT", 56, 97], ["COVID", "TEST", 508, 513], ["US data", "TEST", 604, 611], ["default parameters", "TEST", 616, 634]]], ["Though we intentionally left the tool modifiable, we will update the default values as new data emerges, in order to account for the ramp-up of diagnostic testing in countries like the United States with the understanding that most of those tested will not be hospitalized.Age-Based Case Distribution and SeverityThe age-based case distribution and severity parameters took the midpoint of the lower and upper bound of ranges for hospitalization and ICU admission in the above table. .", [["diagnostic testing", "TEST", 144, 162], ["severity parameters", "PROBLEM", 349, 368], ["Severity", "OBSERVATION_MODIFIER", 305, 313], ["lower", "ANATOMY_MODIFIER", 394, 399], ["upper", "ANATOMY_MODIFIER", 404, 409]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 25, 2020. .Province of Ontario, Canada:In Canada's most populous province of Ontario with nearly 15-million residents, there are approximately 33,511 acute care beds, 2053 ICU beds, and 1311 mechanical ventilators.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["mechanical ventilators", "TREATMENT", 457, 479], ["med", "ANATOMY", 105, 108], ["mechanical ventilators", "OBSERVATION", 457, 479]]], ["Assuming 75% baseline occupancy rates of these resources for non-COVID-19 patients, there are 8,378 available acute care beds, 513 available ICU beds, and 328 available mechanical ventilators. .", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["mechanical ventilators", "TREATMENT", 169, 191]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted March 25, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["For example, suppose the hospital can handle 100 patients, 50% of beds are usually occupied by non-COVID-19 patients and 50% are available for or occupied by COVID-19 patients.", [["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 167, 175]]], ["Further, suppose the average length-of-stay for COVID-19 patients is 10 days.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["COVID", "TREATMENT", 48, 53]]], ["We can calculate the rate of COVID-19 patients leaving the hospital as: Therefore, given that there are 50 beds available for COVID-19 patients, and each patient stays 10 days on average, the expected rate of COVID-19 patients leaving the hospital is 5 patients per day.Step 2: Calculate the proportion of COVID-19 cases that get hospitalizedThe next step is to determine the proportion of COVID-19 patients that become hospitalized.", [["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 135, 143], ["patient", "ORGANISM", 154, 161], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 253, 261], ["patients", "ORGANISM", 399, 407], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 135, 143], ["patient", "SPECIES", 154, 161], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 253, 261], ["patients", "SPECIES", 399, 407], ["COVID", "TEST", 126, 131], ["COVID", "TEST", 306, 311]]], ["Referring to Appendix 2 Figure 1 we determined what proportion of the incident cases (mid-blue circle) are hospitalized (dark-blue circle).", [["Appendix", "ANATOMY", 13, 21]]], ["The probability of being hospitalized given someone is a COVID-19 case is highly dependent on the age distribution of the case population.", [["highly dependent", "OBSERVATION_MODIFIER", 74, 90]]], ["To perform this calculation, among cases we multiply the probability of being within an age-group by the probability of being hospitalized if someone is in that age group.", [["this calculation", "TEST", 11, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Therefore, we expect 22.5% of the cases in this population to be hospitalized.Step 3: Calculate the maximum daily number of COVID-19 cases sustainable by a healthcare systemThe final step is to calculate the maximum daily cases of COVID-19 that can occur within the population such that the hospital can run at full-capacity with no patient over-flow (i.e. steady-state at full capacity).", [["patient", "ORGANISM", 333, 340], ["patient", "SPECIES", 333, 340], ["COVID", "TEST", 124, 129], ["COVID", "TEST", 231, 236]]], ["Given what we calculated in Step 1 and Step 2, for the system to be steady-state: per day, of which 5 will be admitted to hospital, and 5 COVID-19 patients leaving the hospital either through discharge or death.Extension to other resourcesIn this example we have demonstrated the application using acute care hospitalizations.", [["death", "DISEASE", 205, 210], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["death", "PROBLEM", 205, 210], ["acute care hospitalizations", "TREATMENT", 298, 325]]], ["This methodology can be applied to any resource of interest.", [["This methodology", "TREATMENT", 0, 16]]], ["In our online tool we apply it to acute care beds, critical care beds, and mechanical ventilators.", [["acute care beds", "TREATMENT", 34, 49], ["critical care beds", "TREATMENT", 51, 69], ["mechanical ventilators", "TREATMENT", 75, 97], ["mechanical ventilators", "OBSERVATION", 75, 97]]], ["For each resource one must know the average length-of-use per admitted COVID-19 patient (for the cases).", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87]]], ["For example, a patient is admitted to hospital, spends the first 5 days in acute care, 6 days in critical care (no intubation), followed by another 6 days in critical care intubated, another 2 days in critical care (no intubation), and 5 more days in acute care.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["intubation", "TREATMENT", 115, 125], ["intubation", "TREATMENT", 219, 229], ["acute care", "TREATMENT", 251, 261], ["acute", "OBSERVATION_MODIFIER", 251, 256]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Extension to other resourcesThe copyright holder for this preprint this version posted March 25, 2020. . https://doi.org/10.1101/2020.03.25.20043711 doi: medRxiv preprint the length-of-stay in acute care is 10 days, the length-of-stay in critical care is 14 days, and length of mechanical ventilation is 6 days.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 230, 250], ["mechanical ventilation", "TREATMENT", 480, 502], ["med", "ANATOMY", 105, 108]]], ["In our tool it is assumed that a ventilated patient is de facto in critical care.", [["patient", "ORGANISM", 44, 51], ["patient", "SPECIES", 44, 51]]], ["Therefore the number of ventilators should not exceed the number of critical care beds.Extension to other resources.", [["ventilators", "TREATMENT", 24, 35]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Extension to other resourcesThe copyright holder for this preprint this version posted March 25, 2020. . https://doi.org/10.1101/2020.03.25.20043711 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 230, 250], ["medRxiv", "TREATMENT", 356, 363], ["med", "ANATOMY", 105, 108]]]], "36878ef3cdf585376c19d3f19f3a50a1bd466615": [["Patients' demographic and clinical profiles are shown in online Technical Appendix Table 1 (http://wwwnc.cdc. gov/EID/article/21/12/15-1421-Techapp1.pdf).", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["clinical profiles", "TEST", 26, 43], ["Appendix", "ANATOMY", 74, 82]]], ["Of the 17 patients, 9 had severe disease (4 required mechanical ventilation, 4 required supplemental oxygen; 1 died) and 8 had mild disease.", [["oxygen", "CHEMICAL", 101, 107], ["oxygen", "CHEMICAL", 101, 107], ["patients", "ORGANISM", 10, 18], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["patients", "SPECIES", 10, 18], ["severe disease", "PROBLEM", 26, 40], ["mechanical ventilation", "TREATMENT", 53, 75], ["supplemental oxygen", "TREATMENT", 88, 107], ["mild disease", "PROBLEM", 127, 139], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["disease", "OBSERVATION", 33, 40], ["mechanical ventilation", "OBSERVATION", 53, 75], ["mild", "OBSERVATION_MODIFIER", 127, 131], ["disease", "OBSERVATION", 132, 139]]], ["Serial serum samples were collected and analyzed.", [["serum samples", "ANATOMY", 7, 20], ["serum samples", "ORGANISM_SUBSTANCE", 7, 20], ["Serial serum samples", "TEST", 0, 20]]], ["The study was approved by the SNU Institutional Review Board.", [["The study", "TEST", 0, 9]]]], "PMC7166602": [["IntroductionHepatitis B virus (HBV) infection is a significant cause of liver\u2010related morbidity and mortality, particularly in regions of high endemicity [1].", [["IntroductionHepatitis B virus (HBV) infection", "DISEASE", 0, 45], ["IntroductionHepatitis B virus", "ORGANISM", 0, 29], ["HBV", "ORGANISM", 31, 34], ["B virus (HBV", "SPECIES", 22, 34], ["IntroductionHepatitis B virus", "SPECIES", 0, 29], ["HBV", "SPECIES", 31, 34], ["IntroductionHepatitis B virus (HBV) infection", "PROBLEM", 0, 45], ["liver\u2010related morbidity", "PROBLEM", 72, 95], ["virus", "OBSERVATION", 24, 29], ["liver\u2010related", "OBSERVATION_MODIFIER", 72, 85], ["morbidity", "OBSERVATION", 86, 95], ["high", "OBSERVATION_MODIFIER", 138, 142], ["endemicity", "OBSERVATION", 143, 153]]], ["The natural course and clinical outcome of HBV infection is mediated by a complex interaction between the virus and the host\u2019s immune response.", [["HBV infection", "DISEASE", 43, 56], ["HBV", "ORGANISM", 43, 46], ["HBV", "SPECIES", 43, 46], ["HBV infection", "PROBLEM", 43, 56], ["a complex interaction between the virus", "PROBLEM", 72, 111], ["natural", "OBSERVATION_MODIFIER", 4, 11], ["course", "OBSERVATION_MODIFIER", 12, 18], ["infection", "OBSERVATION", 47, 56]]], ["Successful control of HBV replication is associated with a strong, multi\u2010specific CD4+ and CD8+ T\u2010cell response in conjunction with a humoral immune response [2, 3, 4, 5].", [["HBV", "ORGANISM", 22, 25], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["CD8", "GENE_OR_GENE_PRODUCT", 91, 94], ["CD4", "PROTEIN", 82, 85], ["CD8", "PROTEIN", 91, 94], ["HBV", "SPECIES", 22, 25], ["HBV replication", "TREATMENT", 22, 37], ["multi\u2010specific CD4", "TEST", 67, 85], ["HBV", "OBSERVATION", 22, 25]]], ["Based on current understanding of host\u2013virus interactions and the natural course of HBV infection, management strategies have focussed on enhancement of the host\u2019s HBV\u2010specific T\u2010cell response and direct suppression of HBV replication to attain sustained viral control and remission of liver disease [6, 7].", [["liver", "ANATOMY", 286, 291], ["HBV infection", "DISEASE", 84, 97], ["liver disease", "DISEASE", 286, 299], ["HBV", "ORGANISM", 84, 87], ["HBV", "ORGANISM", 164, 167], ["T\u2010cell", "CELL", 177, 183], ["HBV", "ORGANISM", 219, 222], ["liver", "ORGAN", 286, 291], ["HBV", "SPECIES", 84, 87], ["HBV", "SPECIES", 164, 167], ["HBV", "SPECIES", 219, 222], ["host\u2013virus interactions", "PROBLEM", 34, 57], ["HBV infection", "PROBLEM", 84, 97], ["management strategies", "TREATMENT", 99, 120], ["HBV", "PROBLEM", 164, 167], ["HBV replication", "TREATMENT", 219, 234], ["sustained viral control", "TREATMENT", 245, 268], ["liver disease", "PROBLEM", 286, 299], ["liver", "ANATOMY", 286, 291]]], ["Of the currently available anti\u2010HBV therapies, only interferon (IFN)\u2010\u03b1 and pegylated IFN\u2010\u03b1 have demonstrated an immunomodulatory effect on HBV [8].", [["pegylated IFN\u2010\u03b1", "CHEMICAL", 75, 90], ["anti\u2010HBV", "ORGANISM", 27, 35], ["interferon (IFN)\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 52, 70], ["pegylated IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 75, 90], ["HBV", "ORGANISM", 139, 142], ["interferon (IFN)\u2010\u03b1", "PROTEIN", 52, 70], ["pegylated IFN\u2010\u03b1", "PROTEIN", 75, 90], ["HBV", "SPECIES", 32, 35], ["HBV", "SPECIES", 139, 142], ["anti\u2010HBV therapies", "TREATMENT", 27, 45], ["interferon (IFN)", "TREATMENT", 52, 68], ["pegylated IFN\u2010\u03b1", "PROBLEM", 75, 90], ["an immunomodulatory effect", "PROBLEM", 109, 135], ["HBV", "PROBLEM", 139, 142]]], ["The immunomodulatory effect has been reported with the nucleoside ribavirin; the mechanisms of action are considered to be Th1 cell differentiation and upregulation of activity of double\u2010stranded (ds) RNA\u2010activated protein kinase [9, 10, 11].", [["Th1 cell", "ANATOMY", 123, 131], ["nucleoside", "CHEMICAL", 55, 65], ["ribavirin", "CHEMICAL", 66, 75], ["nucleoside ribavirin", "CHEMICAL", 55, 75], ["nucleoside ribavirin", "SIMPLE_CHEMICAL", 55, 75], ["Th1 cell", "CELL", 123, 131], ["double\u2010stranded (ds) RNA\u2010activated protein kinase", "GENE_OR_GENE_PRODUCT", 180, 229], ["double\u2010stranded (ds) RNA\u2010activated protein kinase", "PROTEIN", 180, 229], ["the nucleoside ribavirin", "TREATMENT", 51, 75], ["Th1 cell differentiation", "PROBLEM", 123, 147], ["RNA\u2010activated protein kinase", "TEST", 201, 229], ["immunomodulatory effect", "OBSERVATION", 4, 27], ["Th1 cell differentiation", "OBSERVATION", 123, 147]]], ["Very little is known about the influence of newer oral nucleosides on the T\u2010cell\u2010specific immune response.IntroductionTelbivudine, an L\u2010nucleoside analogue of thymidine, is a potent and specific inhibitor of HBV DNA polymerase, and it is approved for the treatment of patients with chronic hepatitis B (CHB) [12, 13, 14, 15, 16].", [["oral", "ANATOMY", 50, 54], ["nucleosides", "CHEMICAL", 55, 66], ["Telbivudine", "CHEMICAL", 118, 129], ["L\u2010nucleoside", "CHEMICAL", 134, 146], ["thymidine", "CHEMICAL", 159, 168], ["chronic hepatitis B", "DISEASE", 282, 301], ["CHB", "DISEASE", 303, 306], ["nucleosides", "CHEMICAL", 55, 66], ["Telbivudine", "CHEMICAL", 118, 129], ["L\u2010nucleoside", "CHEMICAL", 134, 146], ["thymidine", "CHEMICAL", 159, 168], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["nucleosides", "SIMPLE_CHEMICAL", 55, 66], ["Telbivudine", "SIMPLE_CHEMICAL", 118, 129], ["L\u2010nucleoside", "SIMPLE_CHEMICAL", 134, 146], ["thymidine", "SIMPLE_CHEMICAL", 159, 168], ["HBV", "ORGANISM", 208, 211], ["DNA", "CELLULAR_COMPONENT", 212, 215], ["patients", "ORGANISM", 268, 276], ["chronic hepatitis B", "ORGANISM", 282, 301], ["HBV DNA polymerase", "PROTEIN", 208, 226], ["patients", "SPECIES", 268, 276], ["HBV", "SPECIES", 208, 211], ["newer oral nucleosides", "TREATMENT", 44, 66], ["Telbivudine", "TREATMENT", 118, 129], ["an L\u2010nucleoside analogue of thymidine", "TREATMENT", 131, 168], ["HBV DNA polymerase", "PROBLEM", 208, 226], ["chronic hepatitis B", "PROBLEM", 282, 301], ["chronic", "OBSERVATION_MODIFIER", 282, 289], ["hepatitis", "OBSERVATION", 290, 299]]], ["In the 2\u2010year analysis of the GLOBE study, the rate of hepatitis B e antigen (HBeAg) seroconversion during telbivudine administration was higher than during lamivudine administration in patients with serum alanine aminotransferase (ALT) levels greater than two times the upper limit of normal (ULN) [17].", [["serum", "ANATOMY", 200, 205], ["hepatitis B e antigen", "CHEMICAL", 55, 76], ["HBeAg", "CHEMICAL", 78, 83], ["telbivudine", "CHEMICAL", 107, 118], ["lamivudine", "CHEMICAL", 157, 167], ["alanine", "CHEMICAL", 206, 213], ["telbivudine", "CHEMICAL", 107, 118], ["lamivudine", "CHEMICAL", 157, 167], ["alanine", "CHEMICAL", 206, 213], ["hepatitis B e antigen", "GENE_OR_GENE_PRODUCT", 55, 76], ["HBeAg", "GENE_OR_GENE_PRODUCT", 78, 83], ["telbivudine", "SIMPLE_CHEMICAL", 107, 118], ["lamivudine", "SIMPLE_CHEMICAL", 157, 167], ["patients", "ORGANISM", 186, 194], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 206, 230], ["ALT", "SIMPLE_CHEMICAL", 232, 235], ["serum alanine aminotransferase", "PROTEIN", 200, 230], ["ALT", "PROTEIN", 232, 235], ["patients", "SPECIES", 186, 194], ["the GLOBE study", "TEST", 26, 41], ["the rate", "TEST", 43, 51], ["hepatitis B e antigen", "TREATMENT", 55, 76], ["HBeAg", "TEST", 78, 83], ["seroconversion", "TREATMENT", 85, 99], ["telbivudine administration", "TREATMENT", 107, 133], ["lamivudine administration", "TREATMENT", 157, 182], ["serum alanine aminotransferase", "TEST", 200, 230], ["ALT) levels", "TEST", 232, 243], ["GLOBE", "ANATOMY", 30, 35], ["upper limit", "OBSERVATION_MODIFIER", 271, 282], ["normal", "OBSERVATION", 286, 292]]], ["The relatively high HBeAg seroconversion rate attained with telbivudine differs from the rates obtained with other potent anti\u2010HBV agents and suggests that telbivudine potentially has immunomodulatory activities.IntroductionThe aims of the present study were to characterize the effects of telbivudine on cytokine profile and T\u2010cell response in vitro and in vivo using a previously characterized mouse model of viral hepatitis induced by the coronavirus mouse hepatitis virus strain 3 (MHV\u20103) [18, 19].", [["HBeAg", "CHEMICAL", 20, 25], ["telbivudine", "CHEMICAL", 60, 71], ["telbivudine", "CHEMICAL", 156, 167], ["telbivudine", "CHEMICAL", 290, 301], ["viral hepatitis", "DISEASE", 411, 426], ["hepatitis", "DISEASE", 460, 469], ["telbivudine", "CHEMICAL", 60, 71], ["telbivudine", "CHEMICAL", 156, 167], ["telbivudine", "CHEMICAL", 290, 301], ["HBeAg", "GENE_OR_GENE_PRODUCT", 20, 25], ["telbivudine", "SIMPLE_CHEMICAL", 60, 71], ["telbivudine", "SIMPLE_CHEMICAL", 156, 167], ["telbivudine", "SIMPLE_CHEMICAL", 290, 301], ["T\u2010cell", "SIMPLE_CHEMICAL", 326, 332], ["mouse", "ORGANISM", 396, 401], ["coronavirus", "ORGANISM", 442, 453], ["mouse hepatitis virus strain 3", "ORGANISM", 454, 484], ["MHV\u20103", "ORGANISM", 486, 491], ["cytokine", "PROTEIN", 305, 313], ["mouse", "SPECIES", 396, 401], ["coronavirus", "SPECIES", 442, 453], ["mouse", "SPECIES", 454, 459], ["hepatitis virus", "SPECIES", 460, 475], ["HBV", "SPECIES", 127, 130], ["mouse", "SPECIES", 396, 401], ["coronavirus mouse hepatitis virus", "SPECIES", 442, 475], ["MHV", "SPECIES", 486, 489], ["The relatively high HBeAg seroconversion rate", "TREATMENT", 0, 45], ["telbivudine", "TREATMENT", 60, 71], ["other potent anti\u2010HBV agents", "TREATMENT", 109, 137], ["telbivudine", "TREATMENT", 156, 167], ["immunomodulatory activities", "TREATMENT", 184, 211], ["the present study", "TEST", 236, 253], ["telbivudine", "TREATMENT", 290, 301], ["cytokine profile", "TEST", 305, 321], ["vitro", "TREATMENT", 345, 350], ["viral hepatitis", "PROBLEM", 411, 426], ["the coronavirus mouse hepatitis virus strain", "PROBLEM", 438, 482], ["high", "OBSERVATION_MODIFIER", 15, 19], ["HBeAg", "OBSERVATION", 20, 25], ["viral hepatitis", "OBSERVATION", 411, 426], ["coronavirus mouse hepatitis", "OBSERVATION", 442, 469]]], ["The effect of telbivudine on the programmed cell death pathway, a possible mechanism by which CD8+ T\u2010cell function was influenced, was also investigated.Telbivudine and lamivudine ::: Materials and methodsTelbivudine (pure substance) was obtained from Novartis Pharma (Basel, Switzerland) and lamivudine was purchased from Moravek Biochemical (Brea, CA, USA).", [["cell", "ANATOMY", 44, 48], ["T\u2010cell", "ANATOMY", 99, 105], ["telbivudine", "CHEMICAL", 14, 25], ["Telbivudine", "CHEMICAL", 153, 164], ["lamivudine", "CHEMICAL", 169, 179], ["Telbivudine", "CHEMICAL", 205, 216], ["lamivudine", "CHEMICAL", 293, 303], ["telbivudine", "CHEMICAL", 14, 25], ["Telbivudine", "CHEMICAL", 153, 164], ["lamivudine", "CHEMICAL", 169, 179], ["Telbivudine", "CHEMICAL", 205, 216], ["lamivudine", "CHEMICAL", 293, 303], ["telbivudine", "SIMPLE_CHEMICAL", 14, 25], ["cell", "CELL", 44, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 94, 97], ["Telbivudine", "SIMPLE_CHEMICAL", 153, 164], ["lamivudine", "SIMPLE_CHEMICAL", 169, 179], ["Telbivudine", "SIMPLE_CHEMICAL", 205, 216], ["lamivudine", "SIMPLE_CHEMICAL", 293, 303], ["CD8", "PROTEIN", 94, 97], ["telbivudine", "TREATMENT", 14, 25], ["Telbivudine", "TREATMENT", 153, 164], ["lamivudine", "TREATMENT", 169, 179], ["Materials", "TREATMENT", 184, 193], ["methodsTelbivudine (pure substance", "TREATMENT", 198, 232], ["lamivudine", "TREATMENT", 293, 303]]], ["Substance concentrations were determined by high\u2010performance liquid chromatography.Virus ::: Materials and methodsMouse hepatitis virus strain 3 was originally obtained from the American Type Culture Collection (Rockville, MD, USA) and it was plaque purified on monolayers of DBT cells and grown to titres of 2 \u00d7 107 plaque\u2010forming units (p.f.u.)/mL.", [["plaque", "ANATOMY", 243, 249], ["monolayers", "ANATOMY", 262, 272], ["DBT cells", "ANATOMY", 276, 285], ["hepatitis virus", "DISEASE", 120, 135], ["DBT", "CHEMICAL", 276, 279], ["Virus", "ORGANISM", 83, 88], ["Mouse hepatitis virus strain 3", "ORGANISM", 114, 144], ["monolayers", "CELL", 262, 272], ["DBT cells", "CELL", 276, 285], ["DBT cells", "CELL_LINE", 276, 285], ["Mouse hepatitis virus", "SPECIES", 114, 135], ["Mouse hepatitis virus", "SPECIES", 114, 135], ["Substance concentrations", "PROBLEM", 0, 24], ["Materials", "TREATMENT", 93, 102], ["methodsMouse hepatitis virus strain", "PROBLEM", 107, 142], ["plaque", "PROBLEM", 243, 249], ["DBT cells", "TREATMENT", 276, 285], ["titres", "TEST", 299, 305], ["plaque", "OBSERVATION", 243, 249], ["plaque", "OBSERVATION", 317, 323]]], ["Virus was harvested by centrifugation at 4500 g for 1 h at 4 \u00b0C and was assayed on monolayers of L2 cells in a standard plaque assay.Mice ::: Materials and methodsFemale BALB/cJ and C3H mice at 6\u20138 weeks of age were obtained from the Hubei Provincial Institute of Science and Technology (Wuhan, China) and the Vital River Company (Beijing, China), respectively.", [["monolayers", "ANATOMY", 83, 93], ["L2 cells", "ANATOMY", 97, 105], ["plaque", "ANATOMY", 120, 126], ["Virus", "ORGANISM", 0, 5], ["monolayers", "CELL", 83, 93], ["L2 cells", "CELL", 97, 105], ["Mice", "ORGANISM", 133, 137], ["BALB/cJ", "ORGANISM", 170, 177], ["C3H mice", "ORGANISM", 182, 190], ["L2 cells", "CELL_LINE", 97, 105], ["Mice", "SPECIES", 133, 137], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["Virus", "PROBLEM", 0, 5], ["L2 cells", "ANATOMY", 97, 105], ["plaque", "OBSERVATION", 120, 126]]], ["All animal studies were conducted in accordance with the Chinese Council on Animal Care and they were approved by Tongji Hospital (Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China).Macrophage isolation :::In vitro study ::: Materials and methodsPeritoneal macrophages were harvested from BALB/cJ mice 4 days after an intraperitoneal injection of 1.5 mL of 3% thioglycollate, as outlined previously [20].", [["Macrophage", "ANATOMY", 216, 226], ["Peritoneal macrophages", "ANATOMY", 280, 302], ["intraperitoneal", "ANATOMY", 352, 367], ["thioglycollate", "CHEMICAL", 394, 408], ["Macrophage", "CELL", 216, 226], ["Peritoneal macrophages", "CELL", 280, 302], ["BALB/cJ mice", "ORGANISM", 323, 335], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 352, 367], ["thioglycollate", "SIMPLE_CHEMICAL", 394, 408], ["Peritoneal macrophages", "CELL_TYPE", 280, 302], ["mice", "SPECIES", 331, 335], ["mice", "SPECIES", 331, 335], ["All animal studies", "TEST", 0, 18], ["Peritoneal macrophages", "PROBLEM", 280, 302], ["an intraperitoneal injection", "TREATMENT", 349, 377], ["3% thioglycollate", "TREATMENT", 391, 408], ["macrophages", "OBSERVATION", 291, 302]]], ["Macrophages were \u226595% pure, as determined by morphology.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "TEST", 0, 11]]], ["Viability exceeded 95% by Trypan blue exclusion.Effect of telbivudine on the replication of MHV\u20103 in macrophages :::In vitro study ::: Materials and methodsMacrophages were incubated in the presence of indicated concentrations of telbivudine (10, 50 or 100 \u03bcg/mL) with MHV\u20103.", [["macrophages", "ANATOMY", 101, 112], ["Macrophages", "ANATOMY", 156, 167], ["Trypan blue", "CHEMICAL", 26, 37], ["telbivudine", "CHEMICAL", 58, 69], ["telbivudine", "CHEMICAL", 230, 241], ["Trypan blue", "CHEMICAL", 26, 37], ["telbivudine", "CHEMICAL", 58, 69], ["telbivudine", "CHEMICAL", 230, 241], ["Trypan blue", "SIMPLE_CHEMICAL", 26, 37], ["telbivudine", "SIMPLE_CHEMICAL", 58, 69], ["MHV\u20103", "ORGANISM", 92, 97], ["macrophages", "CELL", 101, 112], ["Macrophages", "CELL", 156, 167], ["telbivudine", "SIMPLE_CHEMICAL", 230, 241], ["MHV\u20103", "PROTEIN", 92, 97], ["macrophages", "CELL_TYPE", 101, 112], ["Macrophages", "CELL_TYPE", 156, 167], ["MHV", "SPECIES", 92, 95], ["Viability", "TEST", 0, 9], ["Trypan blue exclusion", "TEST", 26, 47], ["telbivudine", "TREATMENT", 58, 69], ["methodsMacrophages", "TEST", 149, 167], ["telbivudine", "TREATMENT", 230, 241]]], ["Macrophages were harvested 10 h after infection and viral titre was determined in a standard plaque assay.Cytokine level measurement by PCR and enzyme\u2010linked immunosorbent assay :::In vitro study ::: Materials and methodsTo determine the effect of telbivudine on tumour necrosis factor (TNF)\u2010\u03b1 and interleukin (IL)\u201012 cytokine production, one million macrophages from BALB/cJ mice were stimulated with MHV\u20103 (multiplicity of infection, 2.5) and telbivudine was added at indicated concentrations.", [["Macrophages", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 93, 99], ["macrophages", "ANATOMY", 351, 362], ["infection", "DISEASE", 38, 47], ["telbivudine", "CHEMICAL", 248, 259], ["necrosis", "DISEASE", 270, 278], ["infection", "DISEASE", 425, 434], ["telbivudine", "CHEMICAL", 445, 456], ["telbivudine", "CHEMICAL", 248, 259], ["telbivudine", "CHEMICAL", 445, 456], ["Macrophages", "CELL", 0, 11], ["Cytokine", "GENE_OR_GENE_PRODUCT", 106, 114], ["telbivudine", "SIMPLE_CHEMICAL", 248, 259], ["tumour necrosis factor (TNF)\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 263, 293], ["interleukin (IL)\u201012", "GENE_OR_GENE_PRODUCT", 298, 317], ["macrophages", "CELL", 351, 362], ["BALB/cJ mice", "ORGANISM", 368, 380], ["MHV\u20103", "ORGANISM", 402, 407], ["telbivudine", "SIMPLE_CHEMICAL", 445, 456], ["Macrophages", "CELL_TYPE", 0, 11], ["Cytokine", "PROTEIN", 106, 114], ["tumour necrosis factor (TNF)\u2010\u03b1", "PROTEIN", 263, 293], ["interleukin (IL)\u201012", "PROTEIN", 298, 317], ["cytokine", "PROTEIN", 318, 326], ["macrophages", "CELL_TYPE", 351, 362], ["mice", "SPECIES", 376, 380], ["mice", "SPECIES", 376, 380], ["MHV", "SPECIES", 402, 405], ["infection", "PROBLEM", 38, 47], ["viral titre", "PROBLEM", 52, 63], ["Cytokine level measurement", "TEST", 106, 132], ["PCR", "TEST", 136, 139], ["enzyme\u2010linked immunosorbent assay", "TEST", 144, 177], ["telbivudine", "TREATMENT", 248, 259], ["tumour necrosis factor", "PROBLEM", 263, 285], ["interleukin (IL)", "TREATMENT", 298, 314], ["cytokine production", "TREATMENT", 318, 337], ["BALB/cJ mice", "TREATMENT", 368, 380], ["MHV\u20103", "TREATMENT", 402, 407], ["infection", "PROBLEM", 425, 434], ["telbivudine", "TREATMENT", 445, 456], ["plaque", "OBSERVATION", 93, 99], ["tumour", "OBSERVATION_MODIFIER", 263, 269], ["necrosis", "OBSERVATION", 270, 278]]], ["Relative quantitative real\u2010time polymerase chain reaction (PCR) was performed to measure the mRNA levels on a Roche LightCycler\u00ae (Roche Diagnostics, Nutley, NJ, USA) following the manufacturers\u2019 instructions.", [["Relative quantitative real\u2010time polymerase chain reaction", "PROBLEM", 0, 57], ["PCR", "TEST", 59, 62]]], ["Cytokine protein levels were determined in cell supernatants following appropriate dilution using enzyme\u2010linked immunosorbent assay (ELISA) (R&D Systems, Abingdon, UK).", [["cell supernatants", "ANATOMY", 43, 60], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell", "CELL", 43, 47], ["Cytokine protein", "PROTEIN", 0, 16], ["Cytokine protein levels", "TEST", 0, 23], ["appropriate dilution", "TREATMENT", 71, 91], ["enzyme\u2010linked immunosorbent assay", "TEST", 98, 131]]], ["The cytokine levels in lipopolysaccharide (LPS)\u2010stimulated macrophages with or without telbivudine added from the same strain of mice were also investigated.Animal model :::In vivo study ::: Materials and methodsFifteen C3H mice each infected with 10 p.f.u.", [["macrophages", "ANATOMY", 59, 70], ["lipopolysaccharide", "CHEMICAL", 23, 41], ["LPS", "CHEMICAL", 43, 46], ["telbivudine", "CHEMICAL", 87, 98], ["telbivudine", "CHEMICAL", 87, 98], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 23, 41], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["macrophages", "CELL", 59, 70], ["telbivudine", "SIMPLE_CHEMICAL", 87, 98], ["mice", "ORGANISM", 129, 133], ["C3H mice", "ORGANISM", 220, 228], ["cytokine", "PROTEIN", 4, 12], ["lipopolysaccharide (LPS)\u2010stimulated macrophages", "CELL_LINE", 23, 70], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 224, 228], ["The cytokine levels", "TEST", 0, 19], ["lipopolysaccharide", "TEST", 23, 41], ["LPS", "TEST", 43, 46], ["stimulated macrophages", "PROBLEM", 48, 70], ["telbivudine", "TREATMENT", 87, 98]]], ["MHV\u20103 received telbivudine 60 mg/kg in 100 \u03bcL phosphate\u2010buffered saline (PBS) via intraperitoneal injection for 15 days, starting 2 h before infection and daily thereafter.", [["intraperitoneal", "ANATOMY", 82, 97], ["telbivudine", "CHEMICAL", 15, 26], ["phosphate", "CHEMICAL", 46, 55], ["infection", "DISEASE", 141, 150], ["telbivudine", "CHEMICAL", 15, 26], ["phosphate", "CHEMICAL", 46, 55], ["telbivudine", "SIMPLE_CHEMICAL", 15, 26], ["phosphate\u2010buffered saline", "SIMPLE_CHEMICAL", 46, 71], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 97], ["MHV", "SPECIES", 0, 3], ["telbivudine", "TREATMENT", 15, 26], ["phosphate", "TREATMENT", 46, 55], ["buffered saline (PBS", "TREATMENT", 56, 76], ["intraperitoneal injection", "TREATMENT", 82, 107], ["infection", "PROBLEM", 141, 150], ["intraperitoneal", "ANATOMY", 82, 97], ["infection", "OBSERVATION", 141, 150]]], ["An additional 15 MHV\u20103\u2010infected mice in each group received lamivudine 60 mg/kg per day or PBS as a control.", [["lamivudine", "CHEMICAL", 60, 70], ["lamivudine", "CHEMICAL", 60, 70], ["mice", "ORGANISM", 32, 36], ["lamivudine", "SIMPLE_CHEMICAL", 60, 70], ["mice", "SPECIES", 32, 36], ["MHV", "SPECIES", 17, 20], ["mice", "SPECIES", 32, 36], ["MHV\u20103\u2010infected mice", "TREATMENT", 17, 36], ["lamivudine", "TREATMENT", 60, 70], ["PBS", "TREATMENT", 91, 94], ["15 MHV", "OBSERVATION_MODIFIER", 14, 20]]], ["Clinical conditions and survival were observed.", [["Clinical conditions", "PROBLEM", 0, 19], ["survival", "TREATMENT", 24, 32]]], ["Animals were killed on Day 15 after infection, and spleens, livers and blood were collected for experiments.Clinical conditions :::In vivo study ::: Materials and methodsThe effect of treatment with telbivudine on MHV\u20103\u2010induced liver disease was determined by monitoring mice twice daily for changes in clinical signs, including abnormalities of fur texture, increased respiration, and the presence of tremor.", [["spleens", "ANATOMY", 51, 58], ["livers", "ANATOMY", 60, 66], ["blood", "ANATOMY", 71, 76], ["liver", "ANATOMY", 228, 233], ["telbivudine", "CHEMICAL", 199, 210], ["liver disease", "DISEASE", 228, 241], ["tremor", "DISEASE", 402, 408], ["telbivudine", "CHEMICAL", 199, 210], ["Animals", "ORGANISM", 0, 7], ["spleens", "ORGAN", 51, 58], ["livers", "ORGAN", 60, 66], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["telbivudine", "SIMPLE_CHEMICAL", 199, 210], ["MHV\u20103", "ORGANISM", 214, 219], ["liver", "ORGAN", 228, 233], ["mice", "ORGANISM", 271, 275], ["fur", "GENE_OR_GENE_PRODUCT", 346, 349], ["mice", "SPECIES", 271, 275], ["MHV", "SPECIES", 214, 217], ["mice", "SPECIES", 271, 275], ["infection", "PROBLEM", 36, 45], ["treatment", "TREATMENT", 184, 193], ["telbivudine", "TREATMENT", 199, 210], ["MHV\u2010", "TREATMENT", 214, 218], ["liver disease", "PROBLEM", 228, 241], ["changes in clinical signs", "PROBLEM", 292, 317], ["abnormalities of fur texture", "PROBLEM", 329, 357], ["increased respiration", "PROBLEM", 359, 380], ["tremor", "PROBLEM", 402, 408], ["infection", "OBSERVATION", 36, 45], ["spleens", "ANATOMY", 51, 58], ["livers", "ANATOMY", 60, 66], ["blood", "ANATOMY", 71, 76], ["liver", "ANATOMY", 228, 233], ["disease", "OBSERVATION", 234, 241], ["increased respiration", "OBSERVATION", 359, 380], ["tremor", "OBSERVATION", 402, 408]]], ["Conditions were graded on a scale of 1\u20135, with 1 indicating the marked presence of an abnormality and 5 indicating normalcy.", [["a scale", "TEST", 26, 33], ["an abnormality", "PROBLEM", 83, 97], ["abnormality", "OBSERVATION", 86, 97]]], ["A composite score for all parameters was calculated by two independent examiners who were blinded to the treatment regimens to minimize bias.Liver histology :::In vivo study ::: Materials and methodsAt the time the mice were killed, livers were removed, weighed and fixed in 10% buffered formalin for a minimum of 4 h.", [["Liver", "ANATOMY", 141, 146], ["livers", "ANATOMY", 233, 239], ["formalin", "CHEMICAL", 288, 296], ["formalin", "CHEMICAL", 288, 296], ["Liver", "ORGAN", 141, 146], ["mice", "ORGANISM", 215, 219], ["livers", "ORGAN", 233, 239], ["formalin", "SIMPLE_CHEMICAL", 288, 296], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["A composite score", "TEST", 0, 17], ["the treatment regimens", "TREATMENT", 101, 123], ["Liver histology", "TEST", 141, 156], ["histology", "OBSERVATION", 147, 156], ["livers", "ANATOMY", 233, 239]]], ["Tissues were processed and paraffin embedded by routine methods, and they were stained with haematoxylin and eosin.Isolation of splenocytes and CD8+ T cells :::In vivo study ::: Materials and methodsSpleens from each group of mice were harvested 15 days after MHV\u20103 infection.", [["Tissues", "ANATOMY", 0, 7], ["splenocytes", "ANATOMY", 128, 139], ["CD8+", "ANATOMY", 144, 148], ["T cells", "ANATOMY", 149, 156], ["Spleens", "ANATOMY", 199, 206], ["infection", "DISEASE", 266, 275], ["paraffin", "CHEMICAL", 27, 35], ["haematoxylin", "CHEMICAL", 92, 104], ["eosin", "CHEMICAL", 109, 114], ["Tissues", "CANCER", 0, 7], ["haematoxylin", "SIMPLE_CHEMICAL", 92, 104], ["eosin", "SIMPLE_CHEMICAL", 109, 114], ["splenocytes", "CELL", 128, 139], ["CD8", "GENE_OR_GENE_PRODUCT", 144, 147], ["T cells", "CELL", 149, 156], ["Spleens", "ORGAN", 199, 206], ["mice", "ORGANISM", 226, 230], ["splenocytes", "CELL_TYPE", 128, 139], ["CD8", "PROTEIN", 144, 147], ["T cells", "CELL_TYPE", 149, 156], ["mice", "SPECIES", 226, 230], ["mice", "SPECIES", 226, 230], ["MHV", "SPECIES", 260, 263], ["paraffin", "TREATMENT", 27, 35], ["routine methods", "TEST", 48, 63], ["haematoxylin", "TREATMENT", 92, 104], ["MHV\u20103 infection", "PROBLEM", 260, 275], ["splenocytes", "ANATOMY", 128, 139], ["CD8+", "OBSERVATION", 144, 148], ["Spleens", "ANATOMY", 199, 206], ["infection", "OBSERVATION", 266, 275]]], ["Spleens were dissected and single\u2010cell suspensions were made by passage through a nylon cell strainer.", [["Spleens", "ANATOMY", 0, 7], ["cell", "ANATOMY", 88, 92], ["Spleens", "ORGAN", 0, 7], ["nylon cell", "CELL", 82, 92], ["single\u2010cell suspensions", "TREATMENT", 27, 50], ["a nylon cell strainer", "TREATMENT", 80, 101], ["suspensions", "OBSERVATION_MODIFIER", 39, 50], ["nylon cell strainer", "OBSERVATION", 82, 101]]], ["After density gradient centrifugation and lysis of red cells in ammonium chloride solution, cells were prepared for study.", [["red cells", "ANATOMY", 51, 60], ["cells", "ANATOMY", 92, 97], ["ammonium chloride", "CHEMICAL", 64, 81], ["ammonium chloride", "CHEMICAL", 64, 81], ["red cells", "CELL", 51, 60], ["ammonium chloride", "SIMPLE_CHEMICAL", 64, 81], ["cells", "CELL", 92, 97], ["red cells", "CELL_TYPE", 51, 60], ["density gradient centrifugation", "TREATMENT", 6, 37], ["lysis of red cells in ammonium chloride solution", "TREATMENT", 42, 90], ["study", "TEST", 116, 121], ["density", "OBSERVATION_MODIFIER", 6, 13], ["gradient centrifugation", "OBSERVATION", 14, 37], ["lysis", "OBSERVATION_MODIFIER", 42, 47], ["red cells", "OBSERVATION", 51, 60]]], ["CD8+ T cells were purified from single\u2010cell splenocyte suspension using an isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany).Hepatocytes :::In vivo study ::: Materials and methodsMouse hepatitis virus strain 3\u2010infected C3H mice were anaesthetized and their livers were perfused in situ with a Ca2+\u2010free Hank\u2019s balanced salt solution containing 1 mm ethylenediaminetetraacetic acid for 4 min at 37 \u00b0C, followed by a 0.05% collagenase solution (type IV; Sigma\u2010Aldrich, St Louis, MO, USA) for 10 min.", [["CD8+ T cells", "ANATOMY", 0, 12], ["splenocyte", "ANATOMY", 44, 54], ["Hepatocytes", "ANATOMY", 135, 146], ["livers", "ANATOMY", 267, 273], ["hepatitis virus", "DISEASE", 195, 210], ["Ca2", "CHEMICAL", 303, 306], ["ethylenediaminetetraacetic acid", "CHEMICAL", 359, 390], ["Ca2+", "CHEMICAL", 303, 307], ["ethylenediaminetetraacetic acid", "CHEMICAL", 359, 390], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["single\u2010cell splenocyte", "CELL", 32, 54], ["Hepatocytes", "CELL", 135, 146], ["Mouse", "ORGANISM", 189, 194], ["hepatitis virus strain 3", "ORGANISM", 195, 219], ["C3H mice", "ORGANISM", 229, 237], ["livers", "ORGAN", 267, 273], ["Ca2+", "SIMPLE_CHEMICAL", 303, 307], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 359, 390], ["collagenase", "GENE_OR_GENE_PRODUCT", 431, 442], ["CD8", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["single\u2010cell splenocyte suspension", "CELL_LINE", 32, 65], ["Miltenyi Biotec", "PROTEIN", 90, 105], ["Bergisch Gladbach", "PROTEIN", 107, 124], ["Hepatocytes", "CELL_TYPE", 135, 146], ["Mouse hepatitis virus", "SPECIES", 189, 210], ["mice", "SPECIES", 233, 237], ["Mouse hepatitis virus", "SPECIES", 189, 210], ["mice", "SPECIES", 233, 237], ["CD8", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["single\u2010cell splenocyte suspension", "TREATMENT", 32, 65], ["an isolation kit", "TREATMENT", 72, 88], ["Materials", "TREATMENT", 168, 177], ["methodsMouse hepatitis virus strain", "TREATMENT", 182, 217], ["a Ca2", "TEST", 301, 306], ["balanced salt solution", "TREATMENT", 320, 342], ["1 mm ethylenediaminetetraacetic acid", "TREATMENT", 354, 390], ["a 0.05% collagenase solution", "TREATMENT", 423, 451], ["splenocyte suspension", "OBSERVATION", 44, 65], ["isolation kit", "OBSERVATION", 75, 88], ["livers", "ANATOMY", 267, 273]]], ["After digestion, the livers were removed and placed into a sterile Petri dish.", [["livers", "ANATOMY", 21, 27], ["livers", "ORGAN", 21, 27], ["a sterile Petri dish", "TREATMENT", 57, 77], ["livers", "ANATOMY", 21, 27], ["Petri dish", "OBSERVATION", 67, 77]]], ["Single\u2010cell suspensions were prepared.", [["Single\u2010cell suspensions", "TREATMENT", 0, 23]]], ["The viability of hepatocytes both before and after treatment was \u226595%, as assessed by Trypan blue staining.Serum collection and cytokine measurements :::In vivo study ::: Materials and methodsOn the day the mice were killed, sera were collected and assayed for IL\u20104 and IFN\u2010\u03b3 using the appropriate ELISA (R&D Systems).Intracellular staining for cytokines :::In vivo study ::: Materials and methodsMice were sacrificed at the indicated time points.", [["hepatocytes", "ANATOMY", 17, 28], ["Serum", "ANATOMY", 107, 112], ["sera", "ANATOMY", 225, 229], ["Intracellular", "ANATOMY", 318, 331], ["Trypan blue", "CHEMICAL", 86, 97], ["Trypan blue", "CHEMICAL", 86, 97], ["hepatocytes", "CELL", 17, 28], ["Trypan blue", "SIMPLE_CHEMICAL", 86, 97], ["Serum", "ORGANISM_SUBSTANCE", 107, 112], ["mice", "ORGANISM", 207, 211], ["sera", "ORGANISM_SUBSTANCE", 225, 229], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 261, 265], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 270, 275], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 318, 331], ["Mice", "ORGANISM", 397, 401], ["hepatocytes", "CELL_TYPE", 17, 28], ["cytokine", "PROTEIN", 128, 136], ["IL\u20104", "PROTEIN", 261, 265], ["IFN\u2010\u03b3", "PROTEIN", 270, 275], ["cytokines", "PROTEIN", 345, 354], ["mice", "SPECIES", 207, 211], ["Mice", "SPECIES", 397, 401], ["mice", "SPECIES", 207, 211], ["treatment", "TREATMENT", 51, 60], ["Trypan blue staining", "TEST", 86, 106], ["Serum collection", "TEST", 107, 123], ["cytokine measurements", "TEST", 128, 149], ["sera", "TEST", 225, 229], ["Intracellular staining", "TEST", 318, 340], ["cytokines", "PROBLEM", 345, 354], ["methodsMice", "TREATMENT", 390, 401], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["hepatocytes", "ANATOMY", 17, 28], ["both", "OBSERVATION_MODIFIER", 29, 33], ["staining", "OBSERVATION", 332, 340]]], ["Purified cells were cultured at 2 \u00d7 106 cells/mL in the presence of 25 ng/mL phorbol myristate acetate plus 1 \u03bcg/mL ionomycin for 5 h in 24\u2010well plates.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 40, 45], ["phorbol myristate acetate", "CHEMICAL", 77, 102], ["ionomycin", "CHEMICAL", 116, 125], ["phorbol myristate acetate", "CHEMICAL", 77, 102], ["ionomycin", "CHEMICAL", 116, 125], ["cells", "CELL", 9, 14], ["cells", "CELL", 40, 45], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 77, 102], ["ionomycin", "SIMPLE_CHEMICAL", 116, 125], ["Purified cells", "PROBLEM", 0, 14], ["25 ng/mL phorbol myristate acetate", "TREATMENT", 68, 102], ["ionomycin", "TREATMENT", 116, 125]]], ["Cells were then stained with monoclonal antibodies specific for surface markers, permeabilized, and fixed using Cytofix/Cytoperm\u2122 (BD, Franklin Lakes, NJ, USA) according to the manufacturer\u2019s instructions.", [["Cells", "ANATOMY", 0, 5], ["surface", "ANATOMY", 64, 71], ["Cells", "CELL", 0, 5], ["monoclonal antibodies", "PROTEIN", 29, 50], ["surface markers", "PROTEIN", 64, 79], ["monoclonal antibodies", "TEST", 29, 50], ["surface markers", "TEST", 64, 79], ["Cytofix", "TREATMENT", 112, 119], ["Cytoperm", "TREATMENT", 120, 128]]], ["Different cell subsets were identified using antibodies to IL\u20104, IL\u201010, IFN\u2010\u03b3, TNF\u2010\u03b1, perforin, granzyme B (eBioscience, San Diego, CA, USA) and their isotypes.Flow cytometry :::In vivo study ::: Materials and methodsThe antibodies used for staining were anti\u2010CD3 (PE\u2010Cy5.5), anti\u2010CD8 (APC), anti\u2010CD4 [fluorescein isothiocyanate (FITC)], anti\u2010programmed death 1(PD\u20101), anti\u2010programmed death ligand 1 (PDL\u20101), anti\u2010Fas ligand (FasL), anti\u2010perforin, anti\u2010granzyme B, anti\u2010TNF\u2010\u03b1\u2010R1/2, anti\u2010TNF\u2010\u03b1, anti\u2010IFN\u2010\u03b3 (PE), and isotype control (PE) (eBioscience).", [["cell", "ANATOMY", 10, 14], ["fluorescein isothiocyanate", "CHEMICAL", 302, 328], ["fluorescein isothiocyanate", "CHEMICAL", 302, 328], ["FITC", "CHEMICAL", 330, 334], ["cell", "CELL", 10, 14], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 59, 63], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 65, 70], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 72, 77], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 79, 84], ["perforin", "GENE_OR_GENE_PRODUCT", 86, 94], ["granzyme B", "GENE_OR_GENE_PRODUCT", 96, 106], ["anti\u2010CD3", "GENE_OR_GENE_PRODUCT", 255, 263], ["PE\u2010Cy5.5", "GENE_OR_GENE_PRODUCT", 265, 273], ["anti\u2010CD8", "GENE_OR_GENE_PRODUCT", 276, 284], ["APC", "GENE_OR_GENE_PRODUCT", 286, 289], ["anti\u2010CD4", "SIMPLE_CHEMICAL", 292, 300], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 302, 328], ["FITC", "SIMPLE_CHEMICAL", 330, 334], ["anti\u2010programmed death 1", "GENE_OR_GENE_PRODUCT", 338, 361], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 362, 366], ["anti\u2010programmed death ligand 1", "GENE_OR_GENE_PRODUCT", 369, 399], ["PDL\u20101", "GENE_OR_GENE_PRODUCT", 401, 406], ["anti\u2010Fas ligand", "GENE_OR_GENE_PRODUCT", 409, 424], ["FasL", "GENE_OR_GENE_PRODUCT", 426, 430], ["anti\u2010perforin", "GENE_OR_GENE_PRODUCT", 433, 446], ["anti\u2010granzyme B", "GENE_OR_GENE_PRODUCT", 448, 463], ["TNF", "GENE_OR_GENE_PRODUCT", 470, 473], ["\u03b1\u2010R1", "GENE_OR_GENE_PRODUCT", 474, 478], ["2", "GENE_OR_GENE_PRODUCT", 479, 480], ["anti\u2010TNF\u2010\u03b1", "SIMPLE_CHEMICAL", 482, 492], ["anti\u2010IFN\u2010\u03b3", "SIMPLE_CHEMICAL", 494, 504], ["PE", "SIMPLE_CHEMICAL", 506, 508], ["antibodies", "PROTEIN", 45, 55], ["IL\u20104", "PROTEIN", 59, 63], ["IL\u201010", "PROTEIN", 65, 70], ["IFN\u2010\u03b3", "PROTEIN", 72, 77], ["TNF\u2010\u03b1", "PROTEIN", 79, 84], ["perforin", "PROTEIN", 86, 94], ["granzyme B", "PROTEIN", 96, 106], ["eBioscience", "PROTEIN", 108, 119], ["antibodies", "PROTEIN", 221, 231], ["anti\u2010CD3", "PROTEIN", 255, 263], ["PE", "PROTEIN", 265, 267], ["Cy5.5", "PROTEIN", 268, 273], ["anti\u2010CD8", "PROTEIN", 276, 284], ["APC", "PROTEIN", 286, 289], ["anti\u2010CD4", "PROTEIN", 292, 300], ["fluorescein isothiocyanate", "PROTEIN", 302, 328], ["anti\u2010programmed death 1", "PROTEIN", 338, 361], ["anti\u2010programmed death ligand 1", "PROTEIN", 369, 399], ["PDL\u20101", "PROTEIN", 401, 406], ["anti\u2010Fas ligand", "PROTEIN", 409, 424], ["FasL", "PROTEIN", 426, 430], ["anti\u2010perforin", "PROTEIN", 433, 446], ["anti\u2010granzyme B", "PROTEIN", 448, 463], ["TNF", "PROTEIN", 470, 473], ["\u03b1", "PROTEIN", 474, 475], ["R1", "PROTEIN", 476, 478], ["anti\u2010TNF\u2010\u03b1", "PROTEIN", 482, 492], ["anti\u2010IFN\u2010\u03b3", "PROTEIN", 494, 504], ["PE", "PROTEIN", 506, 508], ["eBioscience", "PROTEIN", 537, 548], ["Different cell subsets", "PROBLEM", 0, 22], ["antibodies to IL\u2010", "TREATMENT", 45, 62], ["IL\u2010", "TREATMENT", 65, 68], ["IFN\u2010\u03b3", "TREATMENT", 72, 77], ["TNF", "TEST", 79, 82], ["perforin", "TREATMENT", 86, 94], ["Flow cytometry", "TEST", 160, 174], ["The antibodies", "TEST", 217, 231], ["staining", "TEST", 241, 249], ["anti\u2010CD3 (PE\u2010Cy5.5", "TREATMENT", 255, 273], ["anti\u2010CD8 (APC)", "TREATMENT", 276, 290], ["anti\u2010CD4 [fluorescein isothiocyanate (FITC)", "TREATMENT", 292, 335], ["anti\u2010programmed death", "TREATMENT", 338, 359], ["anti\u2010programmed death ligand", "TREATMENT", 369, 397], ["anti\u2010Fas ligand", "TREATMENT", 409, 424], ["FasL", "TEST", 426, 430], ["anti\u2010perforin", "TREATMENT", 433, 446], ["anti\u2010granzyme B", "TREATMENT", 448, 463], ["anti\u2010TNF", "TREATMENT", 465, 473], ["anti\u2010TNF", "TEST", 482, 490], ["anti\u2010IFN\u2010\u03b3", "TEST", 494, 504], ["PE", "TEST", 506, 508], ["isotype control (PE) (eBioscience)", "PROBLEM", 515, 549], ["cell subsets", "OBSERVATION", 10, 22], ["PE", "OBSERVATION", 506, 508], ["PE", "OBSERVATION", 532, 534]]], ["All analyses were performed on a FACSAria\u2122 cell sorter (BD), and subsequent analysis was performed with FACSDiva software (BD).Cytotoxicity against hepatocytes :::In vivo study ::: Materials and methodsFreshly isolated hepatocytes from MHV\u20103\u2010infected C3H mice were used as target cells and CD8+ T cells as effector cells.", [["cell", "ANATOMY", 43, 47], ["hepatocytes", "ANATOMY", 148, 159], ["hepatocytes", "ANATOMY", 219, 230], ["cells", "ANATOMY", 280, 285], ["CD8+ T cells", "ANATOMY", 290, 302], ["cells", "ANATOMY", 315, 320], ["hepatocytes", "CELL", 148, 159], ["hepatocytes", "CELL", 219, 230], ["MHV\u20103", "ORGANISM", 236, 241], ["C3H mice", "ORGANISM", 251, 259], ["cells", "CELL", 280, 285], ["CD8", "GENE_OR_GENE_PRODUCT", 290, 293], ["effector cells", "CELL", 306, 320], ["FACSAria\u2122 cell sorter", "CELL_LINE", 33, 54], ["BD", "CELL_LINE", 56, 58], ["hepatocytes", "CELL_TYPE", 148, 159], ["hepatocytes", "CELL_TYPE", 219, 230], ["target cells", "CELL_TYPE", 273, 285], ["CD8+ T cells", "CELL_TYPE", 290, 302], ["effector cells", "CELL_TYPE", 306, 320], ["mice", "SPECIES", 255, 259], ["MHV", "SPECIES", 236, 239], ["mice", "SPECIES", 255, 259], ["All analyses", "TEST", 0, 12], ["subsequent analysis", "TEST", 65, 84], ["Cytotoxicity against hepatocytes", "PROBLEM", 127, 159], ["MHV", "TEST", 236, 239], ["CD8", "TEST", 290, 293], ["hepatocytes", "ANATOMY", 219, 230]]], ["Cytolytic activity was determined with the CytoTox 96\u00ae non\u2010radioactive cytotoxicity assay (Promega, Madison, WI, USA).", [["Cytolytic activity", "TEST", 0, 18], ["the CytoTox", "TEST", 39, 50], ["non\u2010radioactive cytotoxicity assay", "TEST", 55, 89]]], ["For each effector:target cell ratio (ranging from 40.0:1 to 2.5:1), specific target cell lysis was calculated as follows: [(experimental release \u2212 spontaneous release)/(maximum release \u2212 spontaneous release)] \u00d7 100.", [["cell", "ANATOMY", 25, 29], ["cell", "ANATOMY", 84, 88], ["cell", "CELL", 25, 29], ["cell", "CELL", 84, 88], ["target cell ratio", "TEST", 18, 35], ["specific target cell lysis", "TREATMENT", 68, 94], ["cell lysis", "OBSERVATION", 84, 94]]], ["Each effector:target cell ratio was measured in quadruplicate.Statistical analysis ::: Materials and methodsStatistical analysis was conducted with a Student\u2019s t\u2010test, and a P\u2010value of \u22640.05 was considered statistically significant.", [["cell", "ANATOMY", 21, 25], ["cell", "CELL", 21, 25], ["target cell ratio", "TEST", 14, 31], ["Statistical analysis", "TEST", 108, 128], ["a P\u2010value", "TEST", 172, 181]]], ["Results were reported as the mean \u00b1 standard deviation for three or more separate experiments, each performed in triplicate.Telbivudine does not affect MHV\u20103 replication in macrophages ::: ResultsFirst, we investigated whether telbivudine has no cytotoxic effect on macrophages.", [["macrophages", "ANATOMY", 173, 184], ["macrophages", "ANATOMY", 266, 277], ["Telbivudine", "CHEMICAL", 124, 135], ["telbivudine", "CHEMICAL", 227, 238], ["Telbivudine", "CHEMICAL", 124, 135], ["telbivudine", "CHEMICAL", 227, 238], ["Telbivudine", "SIMPLE_CHEMICAL", 124, 135], ["MHV\u20103", "ORGANISM", 152, 157], ["macrophages", "CELL", 173, 184], ["telbivudine", "SIMPLE_CHEMICAL", 227, 238], ["macrophages", "CELL", 266, 277], ["macrophages", "CELL_TYPE", 173, 184], ["macrophages", "CELL_TYPE", 266, 277], ["MHV", "SPECIES", 152, 155], ["Telbivudine", "TREATMENT", 124, 135], ["telbivudine", "TREATMENT", 227, 238], ["cytotoxic effect on macrophages", "PROBLEM", 246, 277], ["no", "UNCERTAINTY", 243, 245], ["cytotoxic effect", "OBSERVATION", 246, 262], ["macrophages", "OBSERVATION", 266, 277]]], ["The addition of up to 100 \u03bcg/mL telbivudine to peritoneal macrophages freshly isolated from BALB/cJ mice had no toxic effects, as demonstrated by Trypan blue exclusion (95% viable cells).Telbivudine does not affect MHV\u20103 replication in macrophages ::: ResultsTo examine the efficacy of telbivudine on viral replication directly, isolated macrophages were treated with telbivudine at indicated concentrations.", [["peritoneal macrophages", "ANATOMY", 47, 69], ["cells", "ANATOMY", 180, 185], ["macrophages", "ANATOMY", 236, 247], ["macrophages", "ANATOMY", 338, 349], ["telbivudine", "CHEMICAL", 32, 43], ["Trypan blue", "CHEMICAL", 146, 157], ["Telbivudine", "CHEMICAL", 187, 198], ["telbivudine", "CHEMICAL", 286, 297], ["telbivudine", "CHEMICAL", 368, 379], ["telbivudine", "CHEMICAL", 32, 43], ["Trypan blue", "CHEMICAL", 146, 157], ["Telbivudine", "CHEMICAL", 187, 198], ["telbivudine", "CHEMICAL", 286, 297], ["telbivudine", "CHEMICAL", 368, 379], ["telbivudine", "SIMPLE_CHEMICAL", 32, 43], ["peritoneal macrophages", "CELL", 47, 69], ["BALB/cJ mice", "ORGANISM", 92, 104], ["Trypan blue", "SIMPLE_CHEMICAL", 146, 157], ["cells", "CELL", 180, 185], ["Telbivudine", "SIMPLE_CHEMICAL", 187, 198], ["MHV\u20103", "ORGANISM", 215, 220], ["macrophages", "CELL", 236, 247], ["telbivudine", "SIMPLE_CHEMICAL", 286, 297], ["macrophages", "CELL", 338, 349], ["telbivudine", "SIMPLE_CHEMICAL", 368, 379], ["peritoneal macrophages", "CELL_TYPE", 47, 69], ["macrophages", "CELL_TYPE", 236, 247], ["isolated macrophages", "CELL_TYPE", 329, 349], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 100, 104], ["MHV", "SPECIES", 215, 218], ["telbivudine", "TREATMENT", 32, 43], ["peritoneal macrophages", "TEST", 47, 69], ["toxic effects", "PROBLEM", 112, 125], ["Trypan blue exclusion", "TEST", 146, 167], ["Telbivudine", "TREATMENT", 187, 198], ["telbivudine", "TREATMENT", 286, 297], ["viral replication", "TREATMENT", 301, 318], ["isolated macrophages", "PROBLEM", 329, 349], ["telbivudine", "TREATMENT", 368, 379], ["peritoneal", "ANATOMY", 47, 57], ["macrophages", "OBSERVATION", 58, 69], ["no", "UNCERTAINTY", 109, 111], ["toxic effects", "OBSERVATION", 112, 125], ["macrophages", "OBSERVATION", 338, 349]]], ["The starting concentration (10 \u03bcg/mL) was chosen based on maximal concentration and area under the concentration\u2013time curve from zero to infinity, and it was as close to twice the dose as that for patient administration [21, 22].", [["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["The starting concentration", "TREATMENT", 0, 26]]], ["Telbivudine had no effect on MHV\u20103 replication from the starting dose of 10 \u03bcg/mL to doses as high as 50 and 100 \u03bcg/mL (Fig. 1).Telbivudine enhanced the production of TNF\u2010\u03b1 and IL\u201012 in macrophages after MHV\u20103 infection but not in LPS\u2010induced macrophages ::: ResultsExperiments were performed to test the ability of telbivudine to modulate the immune response of MHV\u20103\u2010infected macrophages.", [["macrophages", "ANATOMY", 186, 197], ["macrophages", "ANATOMY", 243, 254], ["macrophages", "ANATOMY", 378, 389], ["Telbivudine", "CHEMICAL", 0, 11], ["Telbivudine", "CHEMICAL", 128, 139], ["infection", "DISEASE", 210, 219], ["LPS", "CHEMICAL", 231, 234], ["telbivudine", "CHEMICAL", 316, 327], ["Telbivudine", "CHEMICAL", 0, 11], ["Telbivudine", "CHEMICAL", 128, 139], ["telbivudine", "CHEMICAL", 316, 327], ["Telbivudine", "SIMPLE_CHEMICAL", 0, 11], ["MHV\u20103", "ORGANISM", 29, 34], ["Telbivudine", "SIMPLE_CHEMICAL", 128, 139], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 167, 172], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 177, 182], ["macrophages", "CELL", 186, 197], ["MHV\u20103", "ORGANISM", 204, 209], ["LPS", "SIMPLE_CHEMICAL", 231, 234], ["macrophages", "CELL", 243, 254], ["telbivudine", "SIMPLE_CHEMICAL", 316, 327], ["macrophages", "CELL", 378, 389], ["TNF\u2010\u03b1", "PROTEIN", 167, 172], ["IL\u201012", "PROTEIN", 177, 182], ["macrophages", "CELL_TYPE", 186, 197], ["\u2010induced macrophages", "CELL_TYPE", 234, 254], ["MHV\u20103\u2010infected macrophages", "CELL_LINE", 363, 389], ["MHV", "SPECIES", 29, 32], ["MHV", "SPECIES", 204, 207], ["MHV", "SPECIES", 363, 366], ["Telbivudine", "TREATMENT", 0, 11], ["MHV", "TREATMENT", 29, 32], ["Telbivudine", "TREATMENT", 128, 139], ["TNF\u2010\u03b1", "TREATMENT", 167, 172], ["IL\u2010", "TREATMENT", 177, 180], ["MHV\u20103 infection", "PROBLEM", 204, 219], ["telbivudine", "TREATMENT", 316, 327], ["no", "UNCERTAINTY", 16, 18], ["effect", "OBSERVATION_MODIFIER", 19, 25], ["infection", "OBSERVATION", 210, 219]]], ["Macrophages produced significantly higher levels of TNF\u2010\u03b1 and IL\u201012 in response to MHV\u20103 infection in comparison with basal values.", [["Macrophages", "ANATOMY", 0, 11], ["infection", "DISEASE", 89, 98], ["Macrophages", "CELL", 0, 11], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 62, 67], ["MHV\u20103", "ORGANISM", 83, 88], ["Macrophages", "CELL_TYPE", 0, 11], ["TNF\u2010\u03b1", "PROTEIN", 52, 57], ["IL\u201012", "PROTEIN", 62, 67], ["MHV", "SPECIES", 83, 86], ["Macrophages", "PROBLEM", 0, 11], ["TNF\u2010\u03b1", "TREATMENT", 52, 57], ["IL\u2010", "TREATMENT", 62, 65], ["MHV\u20103 infection", "PROBLEM", 83, 98], ["basal values", "TEST", 118, 130], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["higher", "OBSERVATION_MODIFIER", 35, 41], ["levels", "OBSERVATION_MODIFIER", 42, 48], ["MHV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 89, 98]]], ["Telbivudine significantly enhanced the production of TNF\u2010\u03b1 and IL\u201012 in MHV\u20103\u2010infected macrophages compared with controls and this effect occurred in a dose\u2010dependent manner (Figs 2b,d).", [["macrophages", "ANATOMY", 87, 98], ["Telbivudine", "CHEMICAL", 0, 11], ["Telbivudine", "CHEMICAL", 0, 11], ["Telbivudine", "SIMPLE_CHEMICAL", 0, 11], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 63, 68], ["MHV\u20103", "CELL", 72, 77], ["macrophages", "CELL", 87, 98], ["TNF\u2010\u03b1", "PROTEIN", 53, 58], ["IL\u201012", "PROTEIN", 63, 68], ["MHV\u20103\u2010infected macrophages", "CELL_LINE", 72, 98], ["MHV", "SPECIES", 72, 75], ["Telbivudine", "TREATMENT", 0, 11], ["TNF", "TEST", 53, 56], ["IL", "TEST", 63, 65], ["\u2010infected macrophages", "PROBLEM", 77, 98], ["macrophages", "OBSERVATION", 87, 98]]], ["A similar pattern of increase in TNF\u2010\u03b1 and IL\u201012 mRNA production was also observed in response to telbivudine (Figs 2a,c).", [["telbivudine", "CHEMICAL", 98, 109], ["telbivudine", "CHEMICAL", 98, 109], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 33, 38], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 43, 48], ["telbivudine", "SIMPLE_CHEMICAL", 98, 109], ["TNF\u2010\u03b1 and IL\u201012 mRNA", "RNA", 33, 53], ["increase in TNF\u2010\u03b1", "TREATMENT", 21, 38], ["mRNA production", "PROBLEM", 49, 64], ["telbivudine", "TREATMENT", 98, 109], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["pattern", "OBSERVATION_MODIFIER", 10, 17], ["increase", "OBSERVATION_MODIFIER", 21, 29], ["TNF", "OBSERVATION_MODIFIER", 33, 36]]], ["However, telbivudine had no effect on TNF\u2010\u03b1 and IL\u201012 levels or mRNA production in LPS\u2010stimulated macrophages (Figs 2a,b).Telbivudine improves survival and clinical outcome in vivo::: ResultsTelbivudine increased the survival rate in MHV\u20103\u2010infected C3H mice from 18.2% to 63.6% compared with the PBS\u2010treated controls (Fig. 3a).", [["macrophages", "ANATOMY", 98, 109], ["telbivudine", "CHEMICAL", 9, 20], ["LPS", "CHEMICAL", 83, 86], ["Telbivudine", "CHEMICAL", 122, 133], ["Telbivudine", "CHEMICAL", 191, 202], ["telbivudine", "CHEMICAL", 9, 20], ["Telbivudine", "CHEMICAL", 122, 133], ["Telbivudine", "CHEMICAL", 191, 202], ["telbivudine", "SIMPLE_CHEMICAL", 9, 20], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 48, 53], ["LPS", "SIMPLE_CHEMICAL", 83, 86], ["macrophages", "CELL", 98, 109], ["Telbivudine", "SIMPLE_CHEMICAL", 122, 133], ["Telbivudine", "SIMPLE_CHEMICAL", 191, 202], ["MHV\u20103", "ORGANISM", 234, 239], ["C3H mice", "ORGANISM", 249, 257], ["TNF", "PROTEIN", 38, 41], ["LPS\u2010stimulated macrophages", "CELL_LINE", 83, 109], ["mice", "SPECIES", 253, 257], ["MHV", "SPECIES", 234, 237], ["mice", "SPECIES", 253, 257], ["telbivudine", "TREATMENT", 9, 20], ["TNF", "TEST", 38, 41], ["IL", "TEST", 48, 50], ["mRNA production", "TEST", 64, 79], ["Telbivudine", "TREATMENT", 122, 133], ["Telbivudine", "TREATMENT", 191, 202]]], ["A composite clinical score was obtained by combining the clinical scores for all measured symptoms.", [["A composite clinical score", "TEST", 0, 26], ["all measured symptoms", "PROBLEM", 77, 98]]], ["Telbivudine\u2010treated mice maintained improved composite clinical scores in all conditional categories to the end of the study (Fig. 3b).Telbivudine reduces histological lesions in the liver ::: ResultsIn addition to improving overall survival and clinical scores, telbivudine reduced the histological signs associated with MHV\u20103 infection (Fig. 3c).", [["lesions", "ANATOMY", 168, 175], ["liver", "ANATOMY", 183, 188], ["Telbivudine", "CHEMICAL", 135, 146], ["telbivudine", "CHEMICAL", 263, 274], ["MHV\u20103 infection", "DISEASE", 322, 337], ["Telbivudine", "CHEMICAL", 135, 146], ["telbivudine", "CHEMICAL", 263, 274], ["mice", "ORGANISM", 20, 24], ["Telbivudine", "SIMPLE_CHEMICAL", 135, 146], ["histological lesions", "PATHOLOGICAL_FORMATION", 155, 175], ["liver", "ORGAN", 183, 188], ["telbivudine", "SIMPLE_CHEMICAL", 263, 274], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["MHV", "SPECIES", 322, 325], ["the study", "TEST", 115, 124], ["Telbivudine", "TREATMENT", 135, 146], ["histological lesions in the liver", "PROBLEM", 155, 188], ["clinical scores", "TEST", 246, 261], ["telbivudine", "TREATMENT", 263, 274], ["the histological signs", "PROBLEM", 283, 305], ["MHV\u20103 infection", "PROBLEM", 322, 337], ["lesions", "OBSERVATION", 168, 175], ["liver", "ANATOMY", 183, 188], ["infection", "OBSERVATION", 328, 337]]], ["The livers recovered from the PBS\u2010treated mice showed remarkable necrosis by 15 days after infection compared with the livers obtained from the uninfected control mice (the arrows in Fig. 3c indicate necrosis).", [["livers", "ANATOMY", 4, 10], ["livers", "ANATOMY", 119, 125], ["necrosis", "DISEASE", 65, 73], ["infection", "DISEASE", 91, 100], ["necrosis", "DISEASE", 200, 208], ["livers", "ORGAN", 4, 10], ["mice", "ORGANISM", 42, 46], ["livers", "ORGAN", 119, 125], ["mice", "ORGANISM", 163, 167], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 163, 167], ["the PBS\u2010treated mice", "TEST", 26, 46], ["remarkable necrosis", "PROBLEM", 54, 73], ["infection", "PROBLEM", 91, 100], ["necrosis", "PROBLEM", 200, 208], ["livers", "ANATOMY", 4, 10], ["remarkable", "OBSERVATION_MODIFIER", 54, 64], ["necrosis", "OBSERVATION", 65, 73], ["livers", "ANATOMY", 119, 125], ["necrosis", "OBSERVATION", 200, 208]]], ["In contrast, although not completely free of disease, the livers recovered from the telbivudine\u2010treated mice showed a marked reduction in histological evidence of hepatic necrosis (Fig. 3c).Telbivudine promotes IFN\u2010\u03b3 production and inhibits IL\u20104 production in vivo::: ResultsTelbivudine treatment resulted in an additional 1.8\u2010fold increase in IFN\u2010\u03b3 production in sera compared with MHV\u20103\u2010infected controls (Table 1).", [["livers", "ANATOMY", 58, 64], ["hepatic", "ANATOMY", 163, 170], ["sera", "ANATOMY", 364, 368], ["hepatic necrosis", "DISEASE", 163, 179], ["Telbivudine", "CHEMICAL", 190, 201], ["Telbivudine", "CHEMICAL", 275, 286], ["Telbivudine", "CHEMICAL", 190, 201], ["Telbivudine", "CHEMICAL", 275, 286], ["livers", "ORGAN", 58, 64], ["mice", "ORGANISM", 104, 108], ["hepatic", "ORGAN", 163, 170], ["Telbivudine", "SIMPLE_CHEMICAL", 190, 201], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 211, 216], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 241, 245], ["Telbivudine", "SIMPLE_CHEMICAL", 275, 286], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 344, 349], ["sera", "ORGANISM_SUBSTANCE", 364, 368], ["IFN", "PROTEIN", 211, 214], ["IFN\u2010\u03b3", "PROTEIN", 344, 349], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["MHV", "SPECIES", 383, 386], ["disease", "PROBLEM", 45, 52], ["a marked reduction", "PROBLEM", 116, 134], ["hepatic necrosis", "PROBLEM", 163, 179], ["Telbivudine", "TREATMENT", 190, 201], ["Telbivudine treatment", "TREATMENT", 275, 296], ["an additional 1.8\u2010fold increase", "PROBLEM", 309, 340], ["IFN\u2010\u03b3 production in sera", "PROBLEM", 344, 368], ["disease", "OBSERVATION", 45, 52], ["livers", "ANATOMY", 58, 64], ["marked", "OBSERVATION_MODIFIER", 118, 124], ["reduction", "OBSERVATION_MODIFIER", 125, 134], ["histological", "OBSERVATION", 138, 150], ["evidence of", "UNCERTAINTY", 151, 162], ["hepatic", "ANATOMY", 163, 170], ["necrosis", "OBSERVATION", 171, 179], ["increase", "OBSERVATION_MODIFIER", 332, 340]]], ["In contrast, a 1.6\u2010fold inhibition of IL\u20104 production was observed in the telbivudine\u2010treated group compared with the controls.Telbivudine increases the total number of T cells, the percentage of IFN\u2010\u03b3\u2010 and TNF\u2010\u03b1\u2010producing CD4+ T cells, and the percentage of IFN\u2010\u03b3\u2010producing CD8+ T cells ::: ResultsPhenotypic analysis of spleen cells from telbivudine\u2010treated mice revealed an increase in the total number of T cells compared with PBS\u2010 and lamivudine\u2010treated controls (Fig. 4a).", [["T cells", "ANATOMY", 169, 176], ["CD4+ T cells", "ANATOMY", 223, 235], ["\u2010\u03b3\u2010producing CD8+ T cells", "ANATOMY", 262, 287], ["spleen cells", "ANATOMY", 322, 334], ["T cells", "ANATOMY", 409, 416], ["Telbivudine", "CHEMICAL", 127, 138], ["Telbivudine", "CHEMICAL", 127, 138], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 38, 42], ["Telbivudine", "SIMPLE_CHEMICAL", 127, 138], ["T cells", "CELL", 169, 176], ["IFN\u2010\u03b3\u2010", "GENE_OR_GENE_PRODUCT", 196, 202], ["TNF", "GENE_OR_GENE_PRODUCT", 207, 210], ["CD4", "GENE_OR_GENE_PRODUCT", 223, 226], ["CD8", "GENE_OR_GENE_PRODUCT", 275, 278], ["spleen cells", "CELL", 322, 334], ["mice", "ORGANISM", 360, 364], ["T cells", "CELL", 409, 416], ["IL\u20104", "PROTEIN", 38, 42], ["T cells", "CELL_TYPE", 169, 176], ["IFN", "PROTEIN", 196, 199], ["TNF", "PROTEIN", 207, 210], ["CD4", "PROTEIN", 223, 226], ["T cells", "CELL_TYPE", 228, 235], ["IFN\u2010\u03b3\u2010producing CD8+ T cells", "CELL_TYPE", 259, 287], ["spleen cells", "CELL_TYPE", 322, 334], ["T cells", "CELL_TYPE", 409, 416], ["mice", "SPECIES", 360, 364], ["mice", "SPECIES", 360, 364], ["a 1.6\u2010fold inhibition of IL\u2010", "TREATMENT", 13, 41], ["Telbivudine", "TREATMENT", 127, 138], ["IFN", "TEST", 196, 199], ["TNF", "TEST", 207, 210], ["CD4", "TEST", 223, 226], ["IFN", "TEST", 259, 262], ["Phenotypic analysis", "TEST", 299, 318], ["spleen cells", "TEST", 322, 334], ["telbivudine\u2010treated mice", "TEST", 340, 364], ["an increase", "PROBLEM", 374, 385], ["PBS\u2010", "TREATMENT", 431, 435], ["lamivudine\u2010treated controls", "TREATMENT", 440, 467], ["spleen", "ANATOMY", 322, 328], ["increase", "OBSERVATION_MODIFIER", 377, 385]]], ["The frequency of IFN\u2010\u03b3\u2010producing CD4+ and CD8+ T cells in the telbivudine\u2010treated group was significantly increased compared with the PBS\u2010 and lamivudine\u2010treated groups (Figs 4b,c,f).", [["T cells", "ANATOMY", 47, 54], ["IFN", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 42, 45], ["T cells", "CELL", 47, 54], ["IFN", "PROTEIN", 17, 20], ["CD4", "PROTEIN", 33, 36], ["CD8", "PROTEIN", 42, 45], ["T cells", "CELL_TYPE", 47, 54], ["IFN", "TEST", 17, 20], ["CD4", "TEST", 33, 36], ["CD8", "TEST", 42, 45], ["the PBS", "TEST", 130, 137], ["increased", "OBSERVATION_MODIFIER", 106, 115]]], ["The frequency of TNF\u2010\u03b1\u2010producing CD4+ T cells in the telbivudine\u2010treated group was increased significantly compared with the PBS\u2010 and lamivudine\u2010treated groups (Figs 4d,g).", [["CD4+ T cells", "ANATOMY", 33, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD4", "GENE_OR_GENE_PRODUCT", 33, 36], ["TNF", "PROTEIN", 17, 20], ["CD4", "PROTEIN", 33, 36], ["T cells", "CELL_TYPE", 38, 45], ["TNF", "TEST", 17, 20], ["CD4", "TEST", 33, 36], ["T cells", "PROBLEM", 38, 45], ["the PBS", "TREATMENT", 121, 128], ["lamivudine\u2010treated groups", "TREATMENT", 134, 159]]], ["The frequency of the TNF\u2010\u03b1\u2010producing CD8+ T cells was similar among all of the treatment groups (Figs 4e,g).", [["CD8+ T cells", "ANATOMY", 37, 49], ["TNF", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["TNF", "PROTEIN", 21, 24], ["CD8", "PROTEIN", 37, 40], ["T cells", "CELL_TYPE", 42, 49], ["the TNF", "TEST", 17, 24], ["T cells", "PROBLEM", 42, 49], ["the treatment groups", "TREATMENT", 75, 95]]], ["No difference was observed in the frequency of IL\u20104\u2010 and IL\u201010\u2010producing CD4+ and CD8+ T cells (data not shown).Telbivudine has no effect on cytolytic function but downregulates PD\u2010L1 expression on T cells ::: ResultsTo determine whether telbivudine treatment enhanced killer T\u2010cell cytotoxicity, we performed cytotoxicity assays using spleen\u2010isolated CD8+ T cells as effector cells.", [["CD4+ and CD8+ T cells", "ANATOMY", 73, 94], ["T cells", "ANATOMY", 198, 205], ["killer T\u2010cell", "ANATOMY", 269, 282], ["CD8+ T cells", "ANATOMY", 352, 364], ["effector cells", "ANATOMY", 368, 382], ["Telbivudine", "CHEMICAL", 112, 123], ["telbivudine", "CHEMICAL", 238, 249], ["Telbivudine", "CHEMICAL", 112, 123], ["telbivudine", "CHEMICAL", 238, 249], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 47, 51], ["IL\u201010", "GENE_OR_GENE_PRODUCT", 57, 62], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD8", "GENE_OR_GENE_PRODUCT", 82, 85], ["Telbivudine", "SIMPLE_CHEMICAL", 112, 123], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 178, 183], ["T cells", "CELL", 198, 205], ["telbivudine", "SIMPLE_CHEMICAL", 238, 249], ["killer T\u2010cell", "CELL", 269, 282], ["CD8", "GENE_OR_GENE_PRODUCT", 352, 355], ["effector cells", "CELL", 368, 382], ["CD4", "PROTEIN", 73, 76], ["CD8", "PROTEIN", 82, 85], ["T cells", "CELL_TYPE", 87, 94], ["L1", "DNA", 181, 183], ["T cells", "CELL_TYPE", 198, 205], ["spleen\u2010isolated CD8+ T cells", "CELL_TYPE", 336, 364], ["effector cells", "CELL_TYPE", 368, 382], ["IL", "TEST", 47, 49], ["IL", "TEST", 57, 59], ["CD4", "TEST", 73, 76], ["Telbivudine", "TREATMENT", 112, 123], ["cytolytic function", "PROBLEM", 141, 159], ["telbivudine treatment", "TREATMENT", 238, 259], ["cytotoxicity assays", "TEST", 310, 329], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["no", "UNCERTAINTY", 128, 130]]], ["An increase in cytotoxicity (Fig. 5a) was observed in all infected groups, but no differences were observed among groups with or without telbivudine treatment, suggesting that telbivudine has no effect on the cytolytic function of T cells.", [["T cells", "ANATOMY", 231, 238], ["telbivudine", "CHEMICAL", 137, 148], ["telbivudine", "CHEMICAL", 176, 187], ["telbivudine", "CHEMICAL", 137, 148], ["telbivudine", "CHEMICAL", 176, 187], ["telbivudine", "SIMPLE_CHEMICAL", 137, 148], ["telbivudine", "SIMPLE_CHEMICAL", 176, 187], ["T cells", "CELL", 231, 238], ["T cells", "CELL_TYPE", 231, 238], ["An increase in cytotoxicity", "PROBLEM", 0, 27], ["telbivudine treatment", "TREATMENT", 137, 158], ["telbivudine", "TREATMENT", 176, 187], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["cytotoxicity", "OBSERVATION_MODIFIER", 15, 27], ["infected", "OBSERVATION", 58, 66]]], ["PD\u20101 and FasL expression were increased in infected groups compared with the uninfected group, but no differences were observed among infected groups (Fig. 5b).", [["PD\u20101", "GENE_OR_GENE_PRODUCT", 0, 4], ["FasL", "GENE_OR_GENE_PRODUCT", 9, 13], ["FasL", "PROTEIN", 9, 13], ["PD\u2010", "TREATMENT", 0, 3], ["FasL expression", "PROBLEM", 9, 24], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["no", "UNCERTAINTY", 99, 101]]], ["There were no significant differences for tumour necrosis factor receptor (TNFR)\u20101, TNFR\u20102, perforin or granzyme B expression on the CD8+ T cells among infected groups and the uninfected group (Fig. 5c).", [["CD8+ T cells", "ANATOMY", 133, 145], ["necrosis", "DISEASE", 49, 57], ["tumour necrosis factor receptor (TNFR)\u20101", "GENE_OR_GENE_PRODUCT", 42, 82], ["TNFR\u20102", "GENE_OR_GENE_PRODUCT", 84, 90], ["perforin", "GENE_OR_GENE_PRODUCT", 92, 100], ["granzyme B", "GENE_OR_GENE_PRODUCT", 104, 114], ["CD8", "GENE_OR_GENE_PRODUCT", 133, 136], ["tumour necrosis factor receptor", "PROTEIN", 42, 73], ["TNFR", "PROTEIN", 75, 79], ["TNFR\u20102", "PROTEIN", 84, 90], ["perforin", "PROTEIN", 92, 100], ["granzyme B", "PROTEIN", 104, 114], ["CD8", "PROTEIN", 133, 136], ["T cells", "CELL_TYPE", 138, 145], ["tumour necrosis", "PROBLEM", 42, 57], ["TNFR", "TEST", 75, 79], ["TNFR", "TEST", 84, 88], ["perforin", "PROBLEM", 92, 100], ["the CD8", "TEST", 129, 136], ["T cells", "PROBLEM", 138, 145], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["necrosis", "OBSERVATION", 49, 57]]], ["To further understand this phenomenon, we investigated the expression of PD\u2010L1 and found that telbivudine treatment significantly downregulated the expression of PD\u2010L1 on CD3+ and CD8+ T cells compared with PBS and lamivudine treatment (Figs 5d,e).DiscussionThis is the first study to demonstrate, both in vitro and in vivo, that telbivudine has immunomodulatory effects, independent of its potent antiviral activity.", [["CD3+", "ANATOMY", 171, 175], ["CD8+ T cells", "ANATOMY", 180, 192], ["telbivudine", "CHEMICAL", 94, 105], ["lamivudine", "CHEMICAL", 215, 225], ["telbivudine", "CHEMICAL", 330, 341], ["telbivudine", "CHEMICAL", 94, 105], ["lamivudine", "CHEMICAL", 215, 225], ["telbivudine", "CHEMICAL", 330, 341], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 73, 78], ["telbivudine", "SIMPLE_CHEMICAL", 94, 105], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 162, 167], ["CD3", "GENE_OR_GENE_PRODUCT", 171, 174], ["CD8", "GENE_OR_GENE_PRODUCT", 180, 183], ["lamivudine", "SIMPLE_CHEMICAL", 215, 225], ["telbivudine", "SIMPLE_CHEMICAL", 330, 341], ["PD\u2010L1", "DNA", 73, 78], ["PD\u2010L1", "PROTEIN", 162, 167], ["CD3", "PROTEIN", 171, 174], ["CD8", "PROTEIN", 180, 183], ["T cells", "CELL_TYPE", 185, 192], ["this phenomenon", "PROBLEM", 22, 37], ["PD\u2010L1", "TREATMENT", 73, 78], ["telbivudine treatment", "TREATMENT", 94, 115], ["PD", "TEST", 162, 164], ["CD3", "TEST", 171, 174], ["CD8+ T cells", "PROBLEM", 180, 192], ["PBS", "TREATMENT", 207, 210], ["lamivudine treatment", "TREATMENT", 215, 235], ["the first study", "TEST", 266, 281], ["telbivudine", "TREATMENT", 330, 341], ["immunomodulatory effects", "PROBLEM", 346, 370], ["antiviral activity", "OBSERVATION", 398, 416]]], ["Our data show that telbivudine has no inhibitory effects on the replication of MHV\u20103 in macrophages.", [["macrophages", "ANATOMY", 88, 99], ["telbivudine", "CHEMICAL", 19, 30], ["telbivudine", "CHEMICAL", 19, 30], ["telbivudine", "SIMPLE_CHEMICAL", 19, 30], ["MHV\u20103", "GENE_OR_GENE_PRODUCT", 79, 84], ["macrophages", "CELL", 88, 99], ["MHV\u20103", "PROTEIN", 79, 84], ["macrophages", "CELL_TYPE", 88, 99], ["MHV", "SPECIES", 79, 82], ["Our data", "TEST", 0, 8], ["telbivudine", "TREATMENT", 19, 30], ["inhibitory effects", "PROBLEM", 38, 56]]], ["This finding is consistent with the fact that telbivudine is highly selective for HBV and lacks activity against other viruses [12].", [["telbivudine", "CHEMICAL", 46, 57], ["telbivudine", "CHEMICAL", 46, 57], ["telbivudine", "SIMPLE_CHEMICAL", 46, 57], ["HBV", "ORGANISM", 82, 85], ["HBV", "SPECIES", 82, 85], ["telbivudine", "TREATMENT", 46, 57], ["HBV", "PROBLEM", 82, 85], ["other viruses", "PROBLEM", 113, 126], ["consistent with", "UNCERTAINTY", 16, 31]]], ["This study showed that telbivudine, at concentrations that are achieved in vivo, enhanced the production of TNF\u2010\u03b1 and IL\u201012 in BALB/cJ macrophages in vitro when challenged with MHV\u20103.", [["BALB/cJ macrophages", "ANATOMY", 127, 146], ["telbivudine", "CHEMICAL", 23, 34], ["telbivudine", "CHEMICAL", 23, 34], ["telbivudine", "SIMPLE_CHEMICAL", 23, 34], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 108, 113], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 118, 123], ["BALB/cJ macrophages", "CELL", 127, 146], ["MHV\u20103", "ORGANISM", 177, 182], ["TNF\u2010\u03b1", "PROTEIN", 108, 113], ["IL\u201012", "PROTEIN", 118, 123], ["BALB/cJ macrophages", "CELL_LINE", 127, 146], ["MHV", "SPECIES", 177, 180], ["This study", "TEST", 0, 10], ["telbivudine", "TREATMENT", 23, 34], ["TNF\u2010\u03b1", "TREATMENT", 108, 113], ["IL\u2010", "TREATMENT", 118, 121]]], ["Telbivudine was unable to cause a similar effect in LPS\u2010induced inflammatory cytokines.", [["Telbivudine", "CHEMICAL", 0, 11], ["LPS", "CHEMICAL", 52, 55], ["Telbivudine", "CHEMICAL", 0, 11], ["Telbivudine", "SIMPLE_CHEMICAL", 0, 11], ["LPS", "SIMPLE_CHEMICAL", 52, 55], ["inflammatory cytokines", "PROTEIN", 64, 86], ["Telbivudine", "TREATMENT", 0, 11], ["LPS\u2010induced inflammatory cytokines", "PROBLEM", 52, 86], ["inflammatory cytokines", "OBSERVATION", 64, 86]]], ["This may be because the mechanism of induction of TNF\u2010\u03b1 and IL\u201012 by LPS is different from that by virus [23].DiscussionPrevious studies of the immune response during antiviral treatment with nucleoside or nucleotide analogues in patients with CHB have shown that potent suppression of HBV replication is associated with enhanced T\u2010cell reactivity and cytokine production [24, 25, 26].", [["T\u2010cell", "ANATOMY", 330, 336], ["LPS", "CHEMICAL", 69, 72], ["nucleoside", "CHEMICAL", 192, 202], ["nucleotide", "CHEMICAL", 206, 216], ["CHB", "DISEASE", 244, 247], ["nucleoside", "CHEMICAL", 192, 202], ["nucleotide", "CHEMICAL", 206, 216], ["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 50, 55], ["IL\u201012", "GENE_OR_GENE_PRODUCT", 60, 65], ["LPS", "GENE_OR_GENE_PRODUCT", 69, 72], ["nucleoside", "SIMPLE_CHEMICAL", 192, 202], ["nucleotide analogues", "SIMPLE_CHEMICAL", 206, 226], ["patients", "ORGANISM", 230, 238], ["HBV", "ORGANISM", 286, 289], ["TNF\u2010\u03b1", "PROTEIN", 50, 55], ["IL\u201012", "PROTEIN", 60, 65], ["cytokine", "PROTEIN", 352, 360], ["patients", "SPECIES", 230, 238], ["HBV", "SPECIES", 286, 289], ["induction of TNF\u2010\u03b1 and IL\u2010", "TREATMENT", 37, 63], ["DiscussionPrevious studies", "TEST", 110, 136], ["antiviral treatment", "TREATMENT", 167, 186], ["nucleoside", "TREATMENT", 192, 202], ["nucleotide analogues", "TREATMENT", 206, 226], ["CHB", "PROBLEM", 244, 247], ["HBV replication", "PROBLEM", 286, 301], ["enhanced T\u2010cell reactivity", "PROBLEM", 321, 347], ["cytokine production", "TEST", 352, 371], ["HBV", "OBSERVATION", 286, 289]]], ["However, these studies in patients with CHB do not allow dissection of whether the effect on adaptive immunity is due to direct immunomodulatory properties of the antiviral agent or a secondary to reduced viraemia and antigen levels.", [["CHB", "DISEASE", 40, 43], ["viraemia", "DISEASE", 205, 213], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["these studies", "TEST", 9, 22], ["CHB", "TREATMENT", 40, 43], ["dissection", "TREATMENT", 57, 67], ["adaptive immunity", "TREATMENT", 93, 110], ["direct immunomodulatory properties", "TREATMENT", 121, 155], ["the antiviral agent", "TREATMENT", 159, 178], ["reduced viraemia", "PROBLEM", 197, 213], ["antigen levels", "TEST", 218, 232], ["dissection", "OBSERVATION", 57, 67], ["reduced", "OBSERVATION_MODIFIER", 197, 204], ["viraemia", "OBSERVATION", 205, 213]]], ["The advantage of our mouse model is that it allows investigation of potential immunomodulatory effects independent of antiviral activity.", [["mouse", "ORGANISM", 21, 26], ["mouse", "SPECIES", 21, 26], ["mouse", "SPECIES", 21, 26], ["antiviral activity", "TREATMENT", 118, 136], ["antiviral activity", "OBSERVATION", 118, 136]]], ["The use of MHV\u20103, which produces a strain\u2010dependent pattern of viral hepatitis in inbred strains of mice, has brought insights into the pathogenesis of viral hepatitis [27, 28, 29, 30, 31].", [["viral hepatitis", "DISEASE", 63, 78], ["viral hepatitis", "DISEASE", 152, 167], ["MHV\u20103", "ORGANISM", 11, 16], ["mice", "ORGANISM", 100, 104], ["MHV\u20103", "PROTEIN", 11, 16], ["mice", "SPECIES", 100, 104], ["MHV", "SPECIES", 11, 14], ["mice", "SPECIES", 100, 104], ["MHV\u2010", "TREATMENT", 11, 15], ["viral hepatitis in inbred strains of mice", "PROBLEM", 63, 104], ["viral hepatitis", "PROBLEM", 152, 167], ["viral hepatitis", "OBSERVATION", 63, 78], ["viral hepatitis", "OBSERVATION", 152, 167]]], ["A previous study using an MHV\u20103 virus\u2010induced hepatitis model from our group showed that ribavirin preserves Th1 cytokine production but inhibits Th2 cytokine response; the study explored the remarkable increased sustained virological response post interferon and ribavirin combination therapy for hepatitis C patients [9].DiscussionThe results from the in vitro experiments on the MHV\u20103\u2010infected macrophages support a further investigation of the immunomodulatory effect of telbivudine in vivo.", [["macrophages", "ANATOMY", 397, 408], ["hepatitis", "DISEASE", 46, 55], ["ribavirin", "CHEMICAL", 89, 98], ["interferon", "CHEMICAL", 249, 259], ["ribavirin", "CHEMICAL", 264, 273], ["hepatitis C", "DISEASE", 298, 309], ["telbivudine", "CHEMICAL", 475, 486], ["ribavirin", "CHEMICAL", 89, 98], ["ribavirin", "CHEMICAL", 264, 273], ["telbivudine", "CHEMICAL", 475, 486], ["MHV\u20103", "ORGANISM", 26, 31], ["ribavirin", "SIMPLE_CHEMICAL", 89, 98], ["Th1 cytokine", "GENE_OR_GENE_PRODUCT", 109, 121], ["ribavirin", "SIMPLE_CHEMICAL", 264, 273], ["patients", "ORGANISM", 310, 318], ["macrophages", "CELL", 397, 408], ["telbivudine", "SIMPLE_CHEMICAL", 475, 486], ["Th1 cytokine", "PROTEIN", 109, 121], ["Th2 cytokine", "PROTEIN", 146, 158], ["interferon", "PROTEIN", 249, 259], ["MHV\u20103\u2010infected macrophages", "CELL_LINE", 382, 408], ["patients", "SPECIES", 310, 318], ["MHV", "SPECIES", 26, 29], ["MHV", "SPECIES", 382, 385], ["A previous study", "TEST", 0, 16], ["an MHV\u20103 virus\u2010induced hepatitis model", "TEST", 23, 61], ["ribavirin", "TREATMENT", 89, 98], ["Th1 cytokine production", "PROBLEM", 109, 132], ["Th2 cytokine response", "PROBLEM", 146, 167], ["the study", "TEST", 169, 178], ["the remarkable increased sustained virological response", "PROBLEM", 188, 243], ["interferon", "TREATMENT", 249, 259], ["ribavirin combination therapy", "TREATMENT", 264, 293], ["hepatitis C patients", "PROBLEM", 298, 318], ["telbivudine in vivo", "TREATMENT", 475, 494], ["ribavirin", "OBSERVATION", 89, 98], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["sustained", "OBSERVATION_MODIFIER", 213, 222], ["virological response", "OBSERVATION", 223, 243]]], ["Because MHV\u20103 belongs to the coronavirus family of positive\u2010stranded RNA viruses, it is a suitable model with which to study the pure immunomodulatory effect of telbivudine without the influence of its viral inhibitory effect, which in turn may indirectly affect the immune system.", [["immune system", "ANATOMY", 267, 280], ["telbivudine", "CHEMICAL", 161, 172], ["telbivudine", "CHEMICAL", 161, 172], ["MHV\u20103", "ORGANISM", 8, 13], ["coronavirus", "ORGANISM", 29, 40], ["telbivudine", "SIMPLE_CHEMICAL", 161, 172], ["MHV\u20103", "PROTEIN", 8, 13], ["MHV", "SPECIES", 8, 11], ["positive\u2010stranded RNA viruses", "PROBLEM", 51, 80], ["telbivudine", "TREATMENT", 161, 172], ["its viral inhibitory effect", "PROBLEM", 198, 225], ["RNA viruses", "OBSERVATION", 69, 80]]], ["In this study, telbivudine treatment significantly improved survival in MHV\u20103\u2010infected C3H mice and it improved clinical conditions and histological outcomes.", [["telbivudine", "CHEMICAL", 15, 26], ["telbivudine", "CHEMICAL", 15, 26], ["telbivudine", "SIMPLE_CHEMICAL", 15, 26], ["MHV\u20103", "ORGANISM", 72, 77], ["C3H mice", "ORGANISM", 87, 95], ["mice", "SPECIES", 91, 95], ["MHV", "SPECIES", 72, 75], ["mice", "SPECIES", 91, 95], ["this study", "TEST", 3, 13], ["telbivudine treatment", "TREATMENT", 15, 36]]], ["The treatment of MHV\u20103\u2010infected C3H mice with telbivudine resulted in the inhibition of IL\u20104 production, and similar doses of telbivudine enhanced the production of IFN\u2010\u03b3, and furthermore increased total T cell numbers, IFN\u2010\u03b3\u2010producing CD4+ and CD8+ T cells and TNF\u2010\u03b1\u2010producing CD4+ T cells, indicating a predominantly Th1 response post telbivudine treatment.DiscussionOne mechanism of the immune response involves naive CD4+ T cells, which, through the production of cytokines, control the development of immune\u2013effector mechanisms [32].", [["T cell", "ANATOMY", 204, 210], ["CD4+", "ANATOMY", 236, 240], ["CD8+ T cells", "ANATOMY", 245, 257], ["CD4+ T cells", "ANATOMY", 278, 290], ["CD4+ T cells", "ANATOMY", 421, 433], ["telbivudine", "CHEMICAL", 46, 57], ["telbivudine", "CHEMICAL", 126, 137], ["telbivudine", "CHEMICAL", 337, 348], ["telbivudine", "CHEMICAL", 46, 57], ["telbivudine", "CHEMICAL", 126, 137], ["telbivudine", "CHEMICAL", 337, 348], ["MHV\u20103", "ORGANISM", 17, 22], ["C3H mice", "ORGANISM", 32, 40], ["telbivudine", "SIMPLE_CHEMICAL", 46, 57], ["IL\u20104", "GENE_OR_GENE_PRODUCT", 88, 92], ["telbivudine", "SIMPLE_CHEMICAL", 126, 137], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 165, 170], ["T cell", "CELL", 204, 210], ["IFN\u2010", "GENE_OR_GENE_PRODUCT", 220, 224], ["CD4", "GENE_OR_GENE_PRODUCT", 236, 239], ["CD8", "GENE_OR_GENE_PRODUCT", 245, 248], ["TNF", "GENE_OR_GENE_PRODUCT", 262, 265], ["CD4", "GENE_OR_GENE_PRODUCT", 278, 281], ["telbivudine", "SIMPLE_CHEMICAL", 337, 348], ["CD4", "GENE_OR_GENE_PRODUCT", 421, 424], ["IFN\u2010\u03b3", "PROTEIN", 165, 170], ["IFN", "PROTEIN", 220, 223], ["CD4", "PROTEIN", 236, 239], ["CD8+ T cells", "CELL_TYPE", 245, 257], ["TNF", "PROTEIN", 262, 265], ["CD4", "PROTEIN", 278, 281], ["T cells", "CELL_TYPE", 283, 290], ["naive CD4+ T cells", "CELL_TYPE", 415, 433], ["cytokines", "PROTEIN", 468, 477], ["mice", "SPECIES", 36, 40], ["MHV", "SPECIES", 17, 20], ["mice", "SPECIES", 36, 40], ["MHV\u2010", "TREATMENT", 17, 21], ["telbivudine", "TREATMENT", 46, 57], ["telbivudine", "TREATMENT", 126, 137], ["total T cell numbers", "TEST", 198, 218], ["IFN", "TEST", 220, 223], ["CD4", "TEST", 236, 239], ["CD8", "TEST", 245, 248], ["TNF", "TEST", 262, 265], ["CD4+ T cells", "PROBLEM", 278, 290], ["telbivudine treatment", "TREATMENT", 337, 358], ["T cells", "PROBLEM", 426, 433], ["cytokines", "TREATMENT", 468, 477], ["immune\u2013effector mechanisms", "PROBLEM", 506, 532], ["predominantly", "OBSERVATION_MODIFIER", 305, 318], ["Th1 response", "OBSERVATION", 319, 331], ["post telbivudine", "OBSERVATION", 332, 348]]], ["A Th1 response has been associated with host resistance whereas a Th2 response has been associated with susceptibility in murine models of MHV\u20103.", [["Th1", "GENE_OR_GENE_PRODUCT", 2, 5], ["murine", "ORGANISM", 122, 128], ["MHV\u20103", "ORGANISM", 139, 144], ["murine", "SPECIES", 122, 128], ["MHV", "SPECIES", 139, 142], ["host resistance", "PROBLEM", 40, 55], ["Th1 response", "OBSERVATION", 2, 14], ["host resistance", "OBSERVATION", 40, 55], ["Th2 response", "OBSERVATION", 66, 78]]], ["Studies have suggested that resistance to MHV\u20103 is associated with a predominant Th1 response, the production of IFN, and cytotoxic T cells [33, 34].", [["cytotoxic T cells", "ANATOMY", 122, 139], ["MHV\u20103", "ORGANISM", 42, 47], ["IFN", "GENE_OR_GENE_PRODUCT", 113, 116], ["cytotoxic T cells", "CELL", 122, 139], ["IFN", "PROTEIN", 113, 116], ["cytotoxic T cells", "CELL_TYPE", 122, 139], ["MHV", "SPECIES", 42, 45], ["Studies", "TEST", 0, 7], ["resistance to MHV", "PROBLEM", 28, 45], ["a predominant Th1 response", "PROBLEM", 67, 93], ["IFN", "PROBLEM", 113, 116], ["cytotoxic T cells", "TEST", 122, 139], ["resistance", "OBSERVATION", 28, 38], ["predominant", "OBSERVATION_MODIFIER", 69, 80], ["Th1 response", "OBSERVATION", 81, 93]]], ["Cytotoxic lymphocytes kill target cells by two major pathways: one is dependent on the exocytosis of granule effector molecules, including perforin and granzymes A and B; the other is dependent on the engagement of target cell TNFR\u20101 family death receptors (e.g. Fas, TNFR\u20101, TNFR\u20102) by effector cell\u2010expressed FasL, membrane\u2010bound or secreted TNF, or TNF\u2010related apoptosis\u2010inducing ligand [35, 36, 37].", [["lymphocytes", "ANATOMY", 10, 21], ["cells", "ANATOMY", 34, 39], ["granule", "ANATOMY", 101, 108], ["cell", "ANATOMY", 222, 226], ["death", "DISEASE", 241, 246], ["Cytotoxic lymphocytes", "CELL", 0, 21], ["cells", "CELL", 34, 39], ["perforin", "GENE_OR_GENE_PRODUCT", 139, 147], ["granzymes A", "GENE_OR_GENE_PRODUCT", 152, 163], ["B", "GENE_OR_GENE_PRODUCT", 168, 169], ["cell", "CELL", 222, 226], ["TNFR\u20101", "GENE_OR_GENE_PRODUCT", 227, 233], ["Fas", "GENE_OR_GENE_PRODUCT", 263, 266], ["TNFR\u20101", "GENE_OR_GENE_PRODUCT", 268, 274], ["TNFR\u20102", "GENE_OR_GENE_PRODUCT", 276, 282], ["FasL", "GENE_OR_GENE_PRODUCT", 311, 315], ["TNF", "GENE_OR_GENE_PRODUCT", 344, 347], ["TNF\u2010related apoptosis\u2010inducing ligand", "GENE_OR_GENE_PRODUCT", 352, 389], ["Cytotoxic lymphocytes", "CELL_TYPE", 0, 21], ["target cells", "CELL_TYPE", 27, 39], ["granule effector molecules", "PROTEIN", 101, 127], ["perforin", "PROTEIN", 139, 147], ["granzymes A", "PROTEIN", 152, 163], ["B", "PROTEIN", 168, 169], ["target cell TNFR\u20101 family death receptors", "PROTEIN", 215, 256], ["Fas", "PROTEIN", 263, 266], ["TNFR\u20101", "PROTEIN", 268, 274], ["TNFR\u20102", "PROTEIN", 276, 282], ["FasL", "PROTEIN", 311, 315], ["TNF", "PROTEIN", 344, 347], ["TNF", "PROTEIN", 352, 355], ["apoptosis\u2010inducing ligand", "PROTEIN", 364, 389], ["Cytotoxic lymphocytes kill target cells", "PROBLEM", 0, 39], ["granule effector molecules", "PROBLEM", 101, 127], ["death receptors", "TEST", 241, 256], ["Fas", "TEST", 263, 266], ["TNFR", "TEST", 268, 272], ["TNFR", "TEST", 276, 280], ["FasL", "TEST", 311, 315], ["secreted TNF", "PROBLEM", 335, 347], ["granule effector molecules", "OBSERVATION", 101, 127]]], ["Our results demonstrate that FasL plays an important role in cytotoxic T lymphocyte (CTL) cytotoxicity to hepatocytes in MHV\u20103\u2010infected C3H mice.", [["cytotoxic T lymphocyte", "ANATOMY", 61, 83], ["CTL", "ANATOMY", 85, 88], ["hepatocytes", "ANATOMY", 106, 117], ["FasL", "GENE_OR_GENE_PRODUCT", 29, 33], ["cytotoxic T lymphocyte", "CELL", 61, 83], ["CTL", "CELL", 85, 88], ["hepatocytes", "CELL", 106, 117], ["MHV\u20103\u2010infected C3H mice", "ORGANISM", 121, 144], ["FasL", "PROTEIN", 29, 33], ["cytotoxic T lymphocyte", "CELL_TYPE", 61, 83], ["hepatocytes", "CELL_TYPE", 106, 117], ["mice", "SPECIES", 140, 144], ["MHV", "SPECIES", 121, 124], ["mice", "SPECIES", 140, 144], ["cytotoxic T lymphocyte (CTL) cytotoxicity", "TREATMENT", 61, 102], ["hepatocytes", "TEST", 106, 117], ["hepatocytes", "ANATOMY", 106, 117], ["MHV", "ANATOMY", 121, 124]]], ["However, telbivudine treatment did not promote CTL cytotoxicity.", [["telbivudine", "CHEMICAL", 9, 20], ["telbivudine", "CHEMICAL", 9, 20], ["telbivudine", "SIMPLE_CHEMICAL", 9, 20], ["CTL", "CELL", 47, 50], ["telbivudine treatment", "TREATMENT", 9, 30], ["CTL cytotoxicity", "PROBLEM", 47, 63], ["CTL cytotoxicity", "OBSERVATION", 47, 63]]], ["Previous studies have established that TNF\u2010\u03b1 and IFN\u2010\u03b3 are key cytokines for non\u2010cytolytic control of HBV replication [38, 39, 40].", [["TNF\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN\u2010\u03b3", "GENE_OR_GENE_PRODUCT", 49, 54], ["HBV", "ORGANISM", 102, 105], ["TNF\u2010\u03b1", "PROTEIN", 39, 44], ["IFN\u2010\u03b3", "PROTEIN", 49, 54], ["cytokines", "PROTEIN", 63, 72], ["HBV", "SPECIES", 102, 105], ["Previous studies", "TEST", 0, 16], ["TNF\u2010\u03b1", "TEST", 39, 44], ["IFN\u2010\u03b3", "TEST", 49, 54], ["cytokines", "TEST", 63, 72], ["non\u2010cytolytic control", "TREATMENT", 77, 98], ["HBV replication", "PROBLEM", 102, 117]]], ["The release of these cytokines from T cells leads to inactivation of HBV without killing the infected hepatocytes.", [["T cells", "ANATOMY", 36, 43], ["hepatocytes", "ANATOMY", 102, 113], ["T cells", "CELL", 36, 43], ["HBV", "ORGANISM", 69, 72], ["hepatocytes", "CELL", 102, 113], ["cytokines", "PROTEIN", 21, 30], ["T cells", "CELL_TYPE", 36, 43], ["infected hepatocytes", "CELL_TYPE", 93, 113], ["HBV", "SPECIES", 69, 72], ["these cytokines from T cells", "TREATMENT", 15, 43], ["HBV", "PROBLEM", 69, 72], ["killing the infected hepatocytes", "PROBLEM", 81, 113], ["infected", "OBSERVATION", 93, 101], ["hepatocytes", "ANATOMY", 102, 113]]], ["Our results suggest that telbivudine is altering the balance of Th1/Th2 cytokines which is independent of the direct antiviral effect against MHV\u20103.DiscussionProgrammed death\u20101 is a receptor that is expressed on a subset of activated T and B cells and PD\u2010L1 (also known as B7\u2010H1) is expressed on both haematopoietic and parenchymal cells [41, 42].", [["T and B cells", "ANATOMY", 234, 247], ["haematopoietic", "ANATOMY", 301, 315], ["parenchymal cells", "ANATOMY", 320, 337], ["telbivudine", "CHEMICAL", 25, 36], ["telbivudine", "CHEMICAL", 25, 36], ["telbivudine", "SIMPLE_CHEMICAL", 25, 36], ["Th1", "GENE_OR_GENE_PRODUCT", 64, 67], ["Th2", "GENE_OR_GENE_PRODUCT", 68, 71], ["MHV\u20103", "ORGANISM", 142, 147], ["death\u20101", "GENE_OR_GENE_PRODUCT", 169, 176], ["T", "CELL", 234, 235], ["B cells", "CELL", 240, 247], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 252, 257], ["B7\u2010H1", "GENE_OR_GENE_PRODUCT", 273, 278], ["haematopoietic", "CELL", 301, 315], ["parenchymal cells", "CELL", 320, 337], ["Th1/Th2 cytokines", "PROTEIN", 64, 81], ["death\u20101", "PROTEIN", 169, 176], ["activated T and B cells", "CELL_TYPE", 224, 247], ["PD\u2010L1", "PROTEIN", 252, 257], ["B7", "PROTEIN", 273, 275], ["H1", "PROTEIN", 276, 278], ["haematopoietic and parenchymal cells", "CELL_TYPE", 301, 337], ["MHV", "SPECIES", 142, 145], ["telbivudine", "TREATMENT", 25, 36], ["Th1/Th2 cytokines", "TREATMENT", 64, 81], ["activated T and B cells and PD\u2010L1", "TREATMENT", 224, 257], ["L1", "ANATOMY", 255, 257], ["both", "ANATOMY_MODIFIER", 296, 300], ["haematopoietic", "ANATOMY", 301, 315], ["parenchymal", "ANATOMY_MODIFIER", 320, 331]]], ["In chronic viral infection, CD8 T cells express high levels of PD\u20101, but its ligand PD\u2010L1 is also highly upregulated [43].", [["CD8 T cells", "ANATOMY", 28, 39], ["chronic viral infection", "DISEASE", 3, 26], ["CD8 T cells", "CELL", 28, 39], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 63, 67], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 84, 89], ["CD8 T cells", "CELL_TYPE", 28, 39], ["PD\u20101", "PROTEIN", 63, 67], ["L1", "PROTEIN", 87, 89], ["chronic viral infection", "PROBLEM", 3, 26], ["CD8 T cells", "TEST", 28, 39], ["high levels of PD\u20101", "PROBLEM", 48, 67], ["its ligand PD\u2010L1", "TEST", 73, 89], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["viral", "OBSERVATION_MODIFIER", 11, 16], ["infection", "OBSERVATION", 17, 26]]], ["In vivo blockade of the interaction of PD\u20101 with its ligand PD\u2010L1 has been reported to enhance T\u2010cell responses [43].", [["T\u2010cell", "ANATOMY", 95, 101], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 39, 43], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 60, 65], ["T\u2010cell", "CELL", 95, 101], ["PD\u20101", "PROTEIN", 39, 43], ["PD\u20101", "TREATMENT", 39, 43], ["its ligand PD\u2010L1", "TREATMENT", 49, 65], ["blockade", "OBSERVATION_MODIFIER", 8, 16], ["L1", "ANATOMY", 63, 65]]], ["Reduction of PD\u20101 during the treatment of CHB was shown to correlate with reduction of HBV DNA levels [26].", [["CHB", "DISEASE", 42, 45], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 13, 17], ["HBV", "ORGANISM", 87, 90], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["HBV", "SPECIES", 87, 90], ["PD", "TREATMENT", 13, 15], ["the treatment", "TREATMENT", 25, 38], ["CHB", "PROBLEM", 42, 45], ["HBV DNA levels", "PROBLEM", 87, 101], ["PD", "OBSERVATION", 13, 15], ["CHB", "OBSERVATION", 42, 45]]], ["Given the role of PD\u20101/PD\u2010L1 is an important inhibitory pathway in T\u2010cell function, the effect of telbivudine on the expression of PD\u20101 and PD\u2010L1 was investigated to further define the effect of telbivudine on T\u2010cell response.", [["T\u2010cell", "ANATOMY", 67, 73], ["T\u2010cell", "ANATOMY", 210, 216], ["telbivudine", "CHEMICAL", 98, 109], ["telbivudine", "CHEMICAL", 195, 206], ["telbivudine", "CHEMICAL", 98, 109], ["telbivudine", "CHEMICAL", 195, 206], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 18, 22], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 23, 28], ["T\u2010cell", "CANCER", 67, 73], ["telbivudine", "SIMPLE_CHEMICAL", 98, 109], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 131, 135], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 140, 145], ["telbivudine", "SIMPLE_CHEMICAL", 195, 206], ["T\u2010cell", "CELL", 210, 216], ["L1", "DNA", 26, 28], ["PD\u2010L1", "DNA", 140, 145], ["PD\u20101/PD\u2010L1", "TREATMENT", 18, 28], ["telbivudine", "TREATMENT", 98, 109], ["PD\u20101 and PD\u2010L1", "TREATMENT", 131, 145], ["telbivudine", "TREATMENT", 195, 206], ["L1", "ANATOMY", 26, 28]]], ["Although telbivudine does not alter the expression of PD\u20101, of note is that it significantly downregulated PD\u2010L1 expression on T cells in MHV\u20103\u2010infected C3H mice.", [["T cells", "ANATOMY", 127, 134], ["telbivudine", "CHEMICAL", 9, 20], ["telbivudine", "CHEMICAL", 9, 20], ["telbivudine", "SIMPLE_CHEMICAL", 9, 20], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 54, 58], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 107, 112], ["T cells", "CELL", 127, 134], ["MHV\u20103\u2010infected C3H mice", "ORGANISM", 138, 161], ["L1", "DNA", 110, 112], ["T cells", "CELL_TYPE", 127, 134], ["mice", "SPECIES", 157, 161], ["MHV", "SPECIES", 138, 141], ["mice", "SPECIES", 157, 161], ["telbivudine", "TREATMENT", 9, 20], ["MHV", "ANATOMY", 138, 141]]], ["This result provides initial evidence for a role of telbivudine in this inhibitory pathway in regulating T\u2010cell function that may favour the development of immune clearance of virus infection.", [["T\u2010cell", "ANATOMY", 105, 111], ["telbivudine", "CHEMICAL", 52, 63], ["infection", "DISEASE", 182, 191], ["telbivudine", "CHEMICAL", 52, 63], ["telbivudine", "SIMPLE_CHEMICAL", 52, 63], ["T\u2010cell", "CELL", 105, 111], ["telbivudine", "TREATMENT", 52, 63], ["immune clearance", "PROBLEM", 156, 172], ["virus infection", "PROBLEM", 176, 191]]], ["However, the effects of telbivudine on PD\u20101 and PD\u2010L1 expression on other cell types should be clarified in further studies.", [["cell", "ANATOMY", 74, 78], ["telbivudine", "CHEMICAL", 24, 35], ["telbivudine", "CHEMICAL", 24, 35], ["telbivudine", "SIMPLE_CHEMICAL", 24, 35], ["PD\u20101", "GENE_OR_GENE_PRODUCT", 39, 43], ["PD\u2010L1", "GENE_OR_GENE_PRODUCT", 48, 53], ["cell", "CELL", 74, 78], ["telbivudine", "TREATMENT", 24, 35], ["PD\u2010", "TREATMENT", 39, 42], ["PD\u2010L1 expression", "TREATMENT", 48, 64], ["further studies", "TEST", 108, 123]]], ["Also, the underlying molecular mechanism requires further investigation.", [["further investigation", "TEST", 50, 71], ["molecular mechanism", "OBSERVATION", 21, 40]]], ["One of the proposed mechanisms is upregulation of the activity of cellular kinases to facilitate efficient phosphorylation.", [["cellular", "ANATOMY", 66, 74], ["cellular", "CELL", 66, 74], ["cellular kinases", "PROTEIN", 66, 82], ["cellular kinases", "TREATMENT", 66, 82], ["efficient phosphorylation", "TREATMENT", 97, 122], ["upregulation", "OBSERVATION_MODIFIER", 34, 46]]], ["On the other hand, many nucleoside analogue\u2010like substances [e.g. CpG\u2010containing DNA, as found in DNA viruses and bacteria; viral dsRNA; the viral mimic polyinosinic:polycytidylic acid (polyI:C)] can exert immunomodulatory activities via toll\u2010like receptors.", [["nucleoside", "CHEMICAL", 24, 34], ["polyinosinic:polycytidylic acid", "CHEMICAL", 153, 184], ["polyI:C", "CHEMICAL", 186, 193], ["nucleoside", "CHEMICAL", 24, 34], ["polyinosinic:polycytidylic acid", "CHEMICAL", 153, 184], ["polyI:C", "CHEMICAL", 186, 193], ["nucleoside analogue\u2010like substances", "SIMPLE_CHEMICAL", 24, 59], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["polyinosinic:polycytidylic acid", "SIMPLE_CHEMICAL", 153, 184], ["polyI:C", "SIMPLE_CHEMICAL", 186, 193], ["CpG\u2010containing DNA", "DNA", 66, 84], ["toll\u2010like receptors", "PROTEIN", 238, 257], ["many nucleoside analogue\u2010like substances", "TREATMENT", 19, 59], ["CpG\u2010containing DNA", "PROBLEM", 66, 84], ["DNA viruses", "PROBLEM", 98, 109], ["bacteria", "PROBLEM", 114, 122], ["viral dsRNA", "PROBLEM", 124, 135], ["the viral mimic polyinosinic", "TEST", 137, 165], ["polycytidylic acid", "PROBLEM", 166, 184], ["viral dsRNA", "OBSERVATION", 124, 135]]], ["As telbivudine is a thymidine nucleoside analogue, it may exert immunomodulatory activities via toll\u2010like receptors.DiscussionIn summary, the present study demonstrates that the beneficial effects of telbivudine in MHV\u20103\u2010induced hepatitis may be mediated by its effect on the immune response rather than the inhibition of viral replication in this animal model.", [["telbivudine", "CHEMICAL", 3, 14], ["thymidine nucleoside", "CHEMICAL", 20, 40], ["telbivudine", "CHEMICAL", 200, 211], ["hepatitis", "DISEASE", 229, 238], ["telbivudine", "CHEMICAL", 3, 14], ["thymidine nucleoside", "CHEMICAL", 20, 40], ["telbivudine", "CHEMICAL", 200, 211], ["telbivudine", "SIMPLE_CHEMICAL", 3, 14], ["thymidine nucleoside", "SIMPLE_CHEMICAL", 20, 40], ["telbivudine", "SIMPLE_CHEMICAL", 200, 211], ["MHV\u20103\u2010induced hepatitis", "ORGANISM", 215, 238], ["toll\u2010like receptors", "PROTEIN", 96, 115], ["MHV", "SPECIES", 215, 218], ["telbivudine", "TREATMENT", 3, 14], ["a thymidine nucleoside analogue", "TREATMENT", 18, 49], ["the present study", "TEST", 138, 155], ["telbivudine", "TREATMENT", 200, 211], ["MHV\u2010", "TREATMENT", 215, 219], ["hepatitis", "PROBLEM", 229, 238], ["viral replication", "TREATMENT", 322, 339], ["viral replication", "OBSERVATION", 322, 339]]], ["The immunomodulatory effect of telbivudine may be explained partly by a shift in the balance between Th1\u2010 and Th2\u2010like immune responses.", [["telbivudine", "CHEMICAL", 31, 42], ["telbivudine", "CHEMICAL", 31, 42], ["telbivudine", "SIMPLE_CHEMICAL", 31, 42], ["Th1\u2010", "GENE_OR_GENE_PRODUCT", 101, 105], ["Th2\u2010like", "GENE_OR_GENE_PRODUCT", 110, 118], ["telbivudine", "TREATMENT", 31, 42], ["a shift in the balance between Th1\u2010", "PROBLEM", 70, 105]]], ["This in turn may explain the benefit of telbivudine on the amelioration of MHV\u20103 infection and increased survival as well as improvements in clinical scores and liver histology.", [["liver", "ANATOMY", 161, 166], ["telbivudine", "CHEMICAL", 40, 51], ["infection", "DISEASE", 81, 90], ["telbivudine", "CHEMICAL", 40, 51], ["telbivudine", "SIMPLE_CHEMICAL", 40, 51], ["liver", "ORGAN", 161, 166], ["MHV", "SPECIES", 75, 78], ["telbivudine", "TREATMENT", 40, 51], ["MHV\u20103 infection", "PROBLEM", 75, 90], ["increased survival", "PROBLEM", 95, 113], ["clinical scores", "TEST", 141, 156], ["liver histology", "TEST", 161, 176], ["MHV", "OBSERVATION", 75, 78], ["infection", "OBSERVATION", 81, 90], ["liver", "ANATOMY", 161, 166]]], ["These data identify an immunomodulatory mechanism of telbivudine treatment in the MHV\u20103\u2010induced viral hepatitis model and provide an insight into a potential additional mode of action for the management of viral hepatitis infection.Statement of interestsAuthors\u2019 declaration of personal interests: The authors have no financial conflict of interest.Statement of interestsDeclaration of funding interests: This work was funded by the National Key Basic Research Program of China (grant no. 2007CB512900) and the Eleventh 5\u2010Year Plan Key Project (grant no. 2008ZX10002\u2010004).", [["telbivudine", "CHEMICAL", 53, 64], ["viral hepatitis", "DISEASE", 96, 111], ["viral hepatitis infection", "DISEASE", 206, 231], ["telbivudine", "CHEMICAL", 53, 64], ["telbivudine", "SIMPLE_CHEMICAL", 53, 64], ["MHV\u20103", "ORGANISM", 82, 87], ["viral hepatitis", "ORGANISM", 206, 221], ["telbivudine treatment", "TREATMENT", 53, 74], ["the MHV", "TREATMENT", 78, 85], ["viral hepatitis model", "PROBLEM", 96, 117], ["the management", "TREATMENT", 188, 202], ["viral hepatitis infection", "PROBLEM", 206, 231], ["viral hepatitis", "OBSERVATION", 206, 221], ["no", "UNCERTAINTY", 315, 317]]]], "c2fe74df531683b1bcf8c1e7e61612295125422d": [["IntroductionBronchopulmonary dysplasia (BPD) is a chronic lung disease affecting an estimated 10,000-15,000 premature infants annually in the United States [1, 2] .", [["Bronchopulmonary dysplasia", "ANATOMY", 12, 38], ["lung", "ANATOMY", 58, 62], ["Bronchopulmonary dysplasia", "DISEASE", 12, 38], ["BPD", "DISEASE", 40, 43], ["lung disease", "DISEASE", 58, 70], ["Bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 12, 38], ["lung", "ORGAN", 58, 62], ["infants", "ORGANISM", 118, 125], ["infants", "SPECIES", 118, 125], ["Bronchopulmonary dysplasia (BPD)", "PROBLEM", 12, 44], ["a chronic lung disease", "PROBLEM", 48, 70], ["Bronchopulmonary", "ANATOMY", 12, 28], ["dysplasia", "OBSERVATION", 29, 38], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["lung", "ANATOMY", 58, 62], ["disease", "OBSERVATION", 63, 70]]], ["It is associated with long-term lasting effects including small airway dysfunction, re-hospitalization for respiratory symptoms, increased need for respiratory medications into young adulthood, neurologic impairment, and mortality [1, [3] [4] [5] [6] .", [["airway", "ANATOMY", 64, 70], ["respiratory", "ANATOMY", 107, 118], ["respiratory", "ANATOMY", 148, 159], ["neurologic", "ANATOMY", 194, 204], ["airway dysfunction", "DISEASE", 64, 82], ["respiratory symptoms", "DISEASE", 107, 127], ["neurologic impairment", "DISEASE", 194, 215], ["airway", "MULTI-TISSUE_STRUCTURE", 64, 70], ["[3] [4] [5", "SIMPLE_CHEMICAL", 235, 245], ["long-term lasting effects", "PROBLEM", 22, 47], ["small airway dysfunction", "PROBLEM", 58, 82], ["respiratory symptoms", "PROBLEM", 107, 127], ["respiratory medications", "TREATMENT", 148, 171], ["neurologic impairment", "PROBLEM", 194, 215], ["long-term", "OBSERVATION_MODIFIER", 22, 31], ["small", "OBSERVATION_MODIFIER", 58, 63], ["airway dysfunction", "OBSERVATION", 64, 82]]], ["Although no US Food and Drug Administration approved indication exists for the use of bronchodilators in the prevention or treatment of BPD, inhaled bronchodilators (IBs) are widely used in the neonatal intensive care unit (NICU) [7] .IntroductionInhaled bronchodilators are used to relax the smooth muscle in the bronchi and bronchioles, resulting in dilation of the small airways and potentially decreased airway resistance and increased lung compliance in some infants with BPD [8] [9] [10] .", [["smooth muscle", "ANATOMY", 293, 306], ["bronchi", "ANATOMY", 314, 321], ["bronchioles", "ANATOMY", 326, 337], ["small airways", "ANATOMY", 368, 381], ["airway", "ANATOMY", 408, 414], ["lung", "ANATOMY", 440, 444], ["BPD", "DISEASE", 136, 139], ["BPD", "DISEASE", 477, 480], ["smooth muscle", "TISSUE", 293, 306], ["bronchi", "MULTI-TISSUE_STRUCTURE", 314, 321], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 326, 337], ["airways", "MULTI-TISSUE_STRUCTURE", 374, 381], ["airway", "MULTI-TISSUE_STRUCTURE", 408, 414], ["lung", "ORGAN", 440, 444], ["infants", "SPECIES", 464, 471], ["Drug Administration", "TREATMENT", 24, 43], ["bronchodilators", "TREATMENT", 86, 101], ["BPD", "PROBLEM", 136, 139], ["inhaled bronchodilators (IBs", "TREATMENT", 141, 169], ["IntroductionInhaled bronchodilators", "TREATMENT", 235, 270], ["dilation of the small airways", "PROBLEM", 352, 381], ["decreased airway resistance", "PROBLEM", 398, 425], ["increased lung compliance", "PROBLEM", 430, 455], ["BPD", "PROBLEM", 477, 480], ["no", "UNCERTAINTY", 9, 11], ["smooth muscle", "ANATOMY", 293, 306], ["bronchi", "ANATOMY", 314, 321], ["bronchioles", "ANATOMY", 326, 337], ["dilation", "OBSERVATION", 352, 360], ["small", "OBSERVATION_MODIFIER", 368, 373], ["airways", "ANATOMY", 374, 381], ["potentially", "UNCERTAINTY", 386, 397], ["decreased", "OBSERVATION_MODIFIER", 398, 407], ["airway resistance", "OBSERVATION", 408, 425], ["increased", "OBSERVATION_MODIFIER", 430, 439], ["lung", "ANATOMY", 440, 444], ["compliance", "OBSERVATION", 445, 455]]], ["A previous study of IB use in the first 100 days of life demonstrated that in infants with BPD, IB use increases steadily in the first month of life and peaks on day of life 99 when~10% of the population receives an IB [11] .", [["BPD", "DISEASE", 91, 94], ["infants", "ORGANISM", 78, 85], ["infants", "SPECIES", 78, 85], ["A previous study", "TEST", 0, 16], ["BPD", "PROBLEM", 91, 94]]], ["It is not known whether IB use continues to increase after the first 100 days, though it is certainly possible given that the average length of stay for severe BPD is around 4.5 months [12] .", [["BPD", "DISEASE", 160, 163], ["severe BPD", "PROBLEM", 153, 163], ["not known", "UNCERTAINTY", 6, 15]]], ["The only randomized trial assessing albuterol use in subjects with evolving BPD patients was published more than 20 years ago and failed to demonstrate any difference in survival, incidence and severity of BPD, or duration of ventilator support or oxygen therapy [13] .", [["albuterol", "CHEMICAL", 36, 45], ["BPD", "DISEASE", 76, 79], ["BPD", "DISEASE", 206, 209], ["oxygen", "CHEMICAL", 248, 254], ["albuterol", "CHEMICAL", 36, 45], ["oxygen", "CHEMICAL", 248, 254], ["albuterol", "SIMPLE_CHEMICAL", 36, 45], ["patients", "ORGANISM", 80, 88], ["oxygen", "SIMPLE_CHEMICAL", 248, 254], ["patients", "SPECIES", 80, 88], ["albuterol use", "TREATMENT", 36, 49], ["BPD", "PROBLEM", 206, 209], ["ventilator support", "TREATMENT", 226, 244], ["oxygen therapy", "TREATMENT", 248, 262]]], ["More recently, the early use of bronchodilators was shown to have no significant impact on the risk of BPD or death in extremely premature infants [14] .", [["BPD", "DISEASE", 103, 106], ["death", "DISEASE", 110, 115], ["infants", "SPECIES", 139, 146], ["bronchodilators", "TREATMENT", 32, 47], ["BPD", "PROBLEM", 103, 106], ["death", "PROBLEM", 110, 115]]], ["Unfortunately, there is no information on the use of IBs from randomized studies in infants with established BPD [15] .", [["BPD", "DISEASE", 109, 112], ["infants", "ORGANISM", 84, 91], ["IBs", "PROTEIN", 53, 56], ["infants", "SPECIES", 84, 91], ["IBs", "PROBLEM", 53, 56], ["randomized studies", "TEST", 62, 80], ["no", "UNCERTAINTY", 24, 26]]], ["Despite the lack of evidence for long-term benefits, IBs may be beneficial in treating acute symptoms of BPD in those infants that remain ventilator dependent [16] .IntroductionThe paucity of data surrounding the indications, timing of use, and effectiveness of IBs in managing symptoms of BPD, as well as concerns for adverse effects, have likely led to the wide variation in IB exposure in infants with developing or established BPD [11, 17] .", [["BPD", "DISEASE", 105, 108], ["BPD", "DISEASE", 290, 293], ["BPD", "DISEASE", 431, 434], ["IBs", "SIMPLE_CHEMICAL", 53, 56], ["infants", "ORGANISM", 118, 125], ["infants", "ORGANISM", 392, 399], ["infants", "SPECIES", 118, 125], ["infants", "SPECIES", 392, 399], ["long-term benefits", "PROBLEM", 33, 51], ["IBs", "PROBLEM", 53, 56], ["acute symptoms", "PROBLEM", 87, 101], ["BPD", "PROBLEM", 105, 108], ["ventilator dependent", "PROBLEM", 138, 158], ["IBs", "PROBLEM", 262, 265], ["managing symptoms", "PROBLEM", 269, 286], ["BPD", "PROBLEM", 290, 293], ["adverse effects", "PROBLEM", 319, 334]]], ["For those with BPD, and especially severe BPD, the extent of IB use and the factors related to IB use are incompletely understood.", [["BPD", "DISEASE", 15, 18], ["BPD", "DISEASE", 42, 45], ["BPD", "PROBLEM", 15, 18], ["severe BPD", "PROBLEM", 35, 45], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["BPD", "OBSERVATION", 42, 45]]], ["This information is crucial to designing future clinical trials evaluating the safety and effectiveness of IBs.", [["IBs", "ORGANISM_SUBSTANCE", 107, 110], ["IBs", "PROTEIN", 107, 110], ["IBs", "PROBLEM", 107, 110]]], ["The objective of this study was to evaluate the scope of IB exposure, inter-hospital variation in IB exposure, and the clinical and demographic factors associated with IB use in BPD, and severe BPD patients using a national cohort extracted from the Pediatric Health Information System (PHIS) database.MethodsUsing the PHIS database (Lenexa, KS, USA), we conducted a retrospective cohort study of infants born between January 1, 2013 and December 31, 2018.", [["BPD", "DISEASE", 178, 181], ["BPD", "DISEASE", 194, 197], ["patients", "ORGANISM", 198, 206], ["infants", "ORGANISM", 397, 404], ["patients", "SPECIES", 198, 206], ["infants", "SPECIES", 397, 404], ["this study", "TEST", 17, 27], ["IB exposure", "PROBLEM", 57, 68], ["inter-hospital variation in IB exposure", "PROBLEM", 70, 109], ["BPD", "PROBLEM", 178, 181], ["severe BPD patients", "PROBLEM", 187, 206], ["a retrospective cohort study", "TEST", 365, 393], ["severe", "OBSERVATION_MODIFIER", 187, 193]]], ["Inclusion criteria were birth prior to 32 weeks of gestation, birth weight <1500 g, admission to the NICU in the first week of life, and treatment with supplemental oxygen or respiratory support (i.e., nasal cannula (NC), high flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), bi-level positive airway pressure (BiPAP), noninvasive positive pressure ventilation (NIPPV), invasive mechanical ventilation (IMV), or high frequency ventilation (HFV)) at 28 days of life.", [["respiratory", "ANATOMY", 175, 186], ["nasal", "ANATOMY", 202, 207], ["nasal", "ANATOMY", 232, 237], ["airway", "ANATOMY", 274, 280], ["airway", "ANATOMY", 316, 322], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "SIMPLE_CHEMICAL", 165, 171], ["airway", "MULTI-TISSUE_STRUCTURE", 274, 280], ["airway", "MULTI-TISSUE_STRUCTURE", 316, 322], ["HFV", "SPECIES", 462, 465], ["birth weight", "TEST", 62, 74], ["treatment", "TREATMENT", 137, 146], ["supplemental oxygen", "TREATMENT", 152, 171], ["respiratory support", "TREATMENT", 175, 194], ["nasal cannula (NC)", "TREATMENT", 202, 220], ["high flow nasal cannula (HFNC", "TREATMENT", 222, 251], ["continuous positive airway pressure (CPAP", "TREATMENT", 254, 295], ["bi-level positive airway pressure", "TREATMENT", 298, 331], ["BiPAP", "TREATMENT", 333, 338], ["noninvasive positive pressure ventilation", "TREATMENT", 341, 382], ["NIPPV", "TREATMENT", 384, 389], ["invasive mechanical ventilation", "TREATMENT", 392, 423], ["IMV)", "TREATMENT", 425, 429], ["high frequency ventilation", "TREATMENT", 434, 460], ["respiratory support", "OBSERVATION", 175, 194], ["airway pressure", "OBSERVATION", 274, 289], ["airway pressure", "OBSERVATION", 316, 331], ["pressure ventilation", "OBSERVATION", 362, 382], ["mechanical ventilation", "OBSERVATION", 401, 423]]], ["Units that did not care for at least ten infants meeting the inclusion criteria within the study period were excluded.", [["infants", "ORGANISM", 41, 48], ["infants", "SPECIES", 41, 48]]], ["Subjects were followed through the cessation of supplemental oxygen and respiratory support, discharge from the hospital, or the day of death, whichever came first.MethodsInhaled bronchodilator exposure was defined in two ways.", [["respiratory", "ANATOMY", 72, 83], ["oxygen", "CHEMICAL", 61, 67], ["death", "DISEASE", 136, 141], ["oxygen", "CHEMICAL", 61, 67], ["Subjects", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["supplemental oxygen", "TREATMENT", 48, 67], ["respiratory support", "TREATMENT", 72, 91], ["MethodsInhaled bronchodilator exposure", "TREATMENT", 164, 202]]], ["The first was as a continuous variable, defined as the number of days an infant was exposed to any IB between day of life 28 and cessation of supplemental oxygen and respiratory support, discharge from the hospital, or the day of death, whichever came first.", [["oxygen", "CHEMICAL", 155, 161], ["death", "DISEASE", 230, 235], ["oxygen", "CHEMICAL", 155, 161], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["supplemental oxygen", "TREATMENT", 142, 161], ["respiratory support", "TREATMENT", 166, 185]]], ["Secondarily, a binary variable was generated, defined as any exposure between day of life 28 and cessation of supplemental oxygen and respiratory support, discharge from the hospital, or the day of death, whichever came first.", [["oxygen", "CHEMICAL", 123, 129], ["death", "DISEASE", 198, 203], ["oxygen", "CHEMICAL", 123, 129], ["oxygen", "SIMPLE_CHEMICAL", 123, 129], ["supplemental oxygen", "TREATMENT", 110, 129], ["respiratory support", "TREATMENT", 134, 153], ["respiratory support", "OBSERVATION", 134, 153]]], ["BPD was defined using modified 2018 Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop guidelines [18] .", [["BPD", "DISEASE", 0, 3], ["Human", "ORGANISM", 98, 103], ["Human", "SPECIES", 98, 103], ["BPD", "PROBLEM", 0, 3]]], ["Infants were classified by the level of support needed at 36 weeks post-menstrual age (PMA).", [["Infants", "ORGANISM", 0, 7], ["Infants", "SPECIES", 0, 7]]], ["BPD categories were: (1) mild: no supplemental oxygen or respiratory support, (2) moderate: NC, and (3) severe: HFNC, CPAP, BiPAP, NIPPV, IMV, or HFV at 36 weeks PMA.", [["respiratory", "ANATOMY", 57, 68], ["BPD", "DISEASE", 0, 3], ["oxygen", "CHEMICAL", 47, 53], ["HFNC", "DISEASE", 112, 116], ["oxygen", "CHEMICAL", 47, 53], ["CPAP", "CHEMICAL", 118, 122], ["PMA", "CHEMICAL", 162, 165], ["oxygen", "SIMPLE_CHEMICAL", 47, 53], ["PMA", "SIMPLE_CHEMICAL", 162, 165], ["HFV", "SPECIES", 146, 149], ["supplemental oxygen", "TREATMENT", 34, 53], ["respiratory support", "TREATMENT", 57, 76], ["HFNC", "TREATMENT", 112, 116], ["CPAP", "TREATMENT", 118, 122], ["BiPAP", "TREATMENT", 124, 129], ["NIPPV", "TREATMENT", 131, 136], ["IMV", "TREATMENT", 138, 141], ["HFV", "TREATMENT", 146, 149], ["no", "UNCERTAINTY", 31, 33], ["supplemental oxygen", "OBSERVATION", 34, 53], ["respiratory support", "OBSERVATION", 57, 76], ["moderate", "OBSERVATION_MODIFIER", 82, 90]]], ["Those discharged by 36 weeks PMA were considered mild BPD, while those who died prior to 36 weeks PMA were categorized as severe BPD.", [["BPD", "DISEASE", 54, 57], ["BPD", "DISEASE", 129, 132], ["PMA", "CHEMICAL", 29, 32], ["PMA", "CHEMICAL", 98, 101], ["PMA", "SIMPLE_CHEMICAL", 29, 32], ["mild BPD", "PROBLEM", 49, 57], ["severe BPD", "PROBLEM", 122, 132], ["mild", "OBSERVATION_MODIFIER", 49, 53], ["BPD", "OBSERVATION", 54, 57], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["BPD", "OBSERVATION", 129, 132]]], ["Further refinement of BPD based on supplemental oxygens support and x-ray finding is not possible as PHIS does not record FiO 2 data or results of radiological tests performed.Data sourceThe data for this study were obtained from PHIS, an administrative database containing patient billing and clinical data from members of the Children's Hospital Association.", [["BPD", "DISEASE", 22, 25], ["oxygens", "CHEMICAL", 48, 55], ["patient", "ORGANISM", 274, 281], ["patient", "SPECIES", 274, 281], ["Children", "SPECIES", 328, 336], ["BPD", "PROBLEM", 22, 25], ["supplemental oxygens support", "TREATMENT", 35, 63], ["x-ray", "TEST", 68, 73], ["radiological tests", "TEST", 147, 165], ["this study", "TEST", 200, 210], ["BPD", "OBSERVATION", 22, 25]]], ["The PHIS hospitals are 51 of the largest and most advanced children's hospitals in America, and constitute the most demanding standards of pediatric service in America.", [["children", "ORGANISM", 59, 67], ["children", "SPECIES", 59, 67]]], ["Clinical data include patient demographics, diagnoses, level of respiratory support, and medications.", [["respiratory", "ANATOMY", 64, 75], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["respiratory support", "TREATMENT", 64, 83], ["medications", "TREATMENT", 89, 100], ["respiratory support", "OBSERVATION", 64, 83]]], ["Hospitals with <10 qualifying cases in the study period were eliminated, leaving 44 hospitals included in this analysis.", [["this analysis", "TEST", 106, 119]]], ["This protocol was deemed exempt by the Institutional Review Board of the University of Nebraska Medical Center and Children's Hospital & Medical Center.Study variablesThe PHIS database was queried to obtain daily IB administrations, daily respiratory support (NC, HFNC, CPAP, BiPAP, NIPPV, IMV, and HFV), length of stay, daily systemic corticosteroid and diuretic administrations, tracheostomy procedure (ICD-9: 31.Statistical analysisOdds of IB use were compared across all levels of each covariate (gestational age, birth weight, sex, race/ethnicity, payer, average yearly census of BPD patients, level of respiratory support at 36 weeks PMA, total days of respiratory support after age 28 days, days of administration of systemic corticosteroids and diuretics after age 28 days, presence of a co-morbid condition, small for gestational age status, and presence of a tracheostomy).", [["respiratory", "ANATOMY", 239, 250], ["BPD", "DISEASE", 585, 588], ["PMA", "CHEMICAL", 640, 643], ["patients", "ORGANISM", 589, 597], ["patients", "SPECIES", 589, 597], ["HFV", "SPECIES", 299, 302], ["Study variables", "TEST", 152, 167], ["daily IB administrations", "TREATMENT", 207, 231], ["daily respiratory support", "TREATMENT", 233, 258], ["NC", "TREATMENT", 260, 262], ["HFNC", "TREATMENT", 264, 268], ["CPAP", "TREATMENT", 270, 274], ["BiPAP", "TREATMENT", 276, 281], ["NIPPV", "TREATMENT", 283, 288], ["IMV", "TREATMENT", 290, 293], ["HFV", "TREATMENT", 299, 302], ["daily systemic corticosteroid", "TREATMENT", 321, 350], ["diuretic administrations", "TREATMENT", 355, 379], ["tracheostomy procedure (ICD", "TREATMENT", 381, 408], ["IB use", "TREATMENT", 443, 449], ["respiratory support", "TREATMENT", 608, 627], ["respiratory support", "TREATMENT", 659, 678], ["systemic corticosteroids", "TREATMENT", 724, 748], ["diuretics", "TREATMENT", 753, 762], ["a co-morbid condition", "PROBLEM", 794, 815], ["a tracheostomy", "TREATMENT", 867, 881], ["small", "OBSERVATION_MODIFIER", 817, 822], ["tracheostomy", "OBSERVATION", 869, 881]]], ["The proportion of patients given an IB was compared across PMA stratified by severity level using linear regression.", [["PMA", "CHEMICAL", 59, 62], ["patients", "ORGANISM", 18, 26], ["PMA", "SIMPLE_CHEMICAL", 59, 62], ["patients", "SPECIES", 18, 26], ["an IB", "PROBLEM", 33, 38], ["linear regression", "PROBLEM", 98, 115]]], ["The proportion of patients given an IB after 28 days of life and the proportion of patient-days (post 28 days of life) that IB use occurred was compared for each hospital using linear regression to determine if there was a correlation between the two.", [["patients", "ORGANISM", 18, 26], ["patient", "ORGANISM", 83, 90], ["patients", "SPECIES", 18, 26], ["patient", "SPECIES", 83, 90]]], ["All analyses were conducted using R version 3.5.1 (R Core Team, Vienna, Austria).ResultsA total of 4986 infants from 44 hospitals required supplemental oxygen or respiratory support at 28 days of life, and 25% (1224/4986) received at least one dose of an IB between age 28 days and discharge or death.", [["oxygen", "CHEMICAL", 152, 158], ["death", "DISEASE", 295, 300], ["oxygen", "CHEMICAL", 152, 158], ["infants", "ORGANISM", 104, 111], ["oxygen", "SIMPLE_CHEMICAL", 152, 158], ["infants", "SPECIES", 104, 111], ["All analyses", "TEST", 0, 12], ["supplemental oxygen", "TREATMENT", 139, 158], ["respiratory support", "TREATMENT", 162, 181]]], ["For those with severe BPD at 36 weeks PMA, 48% (664/1390) received an IB after 28 days of age.", [["BPD", "DISEASE", 22, 25], ["PMA", "CHEMICAL", 38, 41], ["severe BPD", "PROBLEM", 15, 25]]], ["Increased IB exposure was associated with lower gestational age, lower birth weight, need for respiratory support at 36 weeks PMA, longer duration of respiratory support, need for tracheostomy, longer systemic steroid exposure, more days receiving a diuretic, male gender, and diagnosis with a major co-morbidity of IVH, NEC, or PDA (Tables 1 and 2 ).ResultsThe proportion of those who received an IB at each PMA is shown in Fig. 1 .", [["respiratory", "ANATOMY", 94, 105], ["respiratory", "ANATOMY", 150, 161], ["steroid", "CHEMICAL", 210, 217], ["IVH", "DISEASE", 316, 319], ["NEC", "DISEASE", 321, 324], ["PMA", "CHEMICAL", 409, 412], ["PMA", "CHEMICAL", 126, 129], ["steroid", "CHEMICAL", 210, 217], ["PMA", "CHEMICAL", 409, 412], ["steroid", "SIMPLE_CHEMICAL", 210, 217], ["PMA", "SIMPLE_CHEMICAL", 409, 412], ["Increased IB exposure", "PROBLEM", 0, 21], ["lower gestational age", "PROBLEM", 42, 63], ["lower birth weight", "PROBLEM", 65, 83], ["respiratory support", "TREATMENT", 94, 113], ["respiratory support", "TREATMENT", 150, 169], ["tracheostomy", "TREATMENT", 180, 192], ["longer systemic steroid exposure", "TREATMENT", 194, 226], ["a diuretic", "TREATMENT", 248, 258], ["IVH", "PROBLEM", 316, 319], ["NEC", "PROBLEM", 321, 324], ["PDA", "PROBLEM", 329, 332], ["an IB at each PMA", "TREATMENT", 395, 412], ["IB exposure", "OBSERVATION", 10, 21], ["IVH", "OBSERVATION", 316, 319], ["NEC", "OBSERVATION", 321, 324]]], ["Up until 36 weeks PMA, <5% of infants with BPD received an IB.", [["BPD", "DISEASE", 43, 46], ["PMA", "CHEMICAL", 18, 21], ["infants", "ORGANISM", 30, 37], ["infants", "SPECIES", 30, 37], ["BPD", "PROBLEM", 43, 46]]], ["After this time, the proportion with mild-to-moderate BPD receiving an IB increased steadily until 60 weeks PMA, where the proportion receiving IB reaches 35-50%.", [["BPD", "DISEASE", 54, 57], ["PMA", "CHEMICAL", 108, 111], ["mild-to-moderate BPD", "PROBLEM", 37, 57], ["an IB", "TREATMENT", 68, 73], ["IB", "TREATMENT", 144, 146], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["moderate", "OBSERVATION_MODIFIER", 45, 53], ["BPD", "OBSERVATION", 54, 57]]], ["The prevalence of IB use remains relatively unchanged in this range through 92 weeks PMA or 1 year corrected age for those infants still in the hospital (Fig. 1 ).", [["PMA", "CHEMICAL", 85, 88], ["infants", "ORGANISM", 123, 130], ["infants", "SPECIES", 123, 130], ["unchanged", "OBSERVATION_MODIFIER", 44, 53]]], ["Among infants with severe BPD, IB use rises from 25 weeks to 56 weeks PMA, reaching 35-45% of subjects receiving IBs at that time ( Fig. 1) .", [["BPD", "DISEASE", 26, 29], ["PMA", "CHEMICAL", 70, 73], ["PMA", "CHEMICAL", 70, 73], ["infants", "ORGANISM", 6, 13], ["PMA", "SIMPLE_CHEMICAL", 70, 73], ["infants", "SPECIES", 6, 13], ["severe BPD", "PROBLEM", 19, 29], ["IBs", "TREATMENT", 113, 116], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["BPD", "OBSERVATION", 26, 29]]], ["Those with severe and those with mild or moderate BPD did not differ in their rate of BPD use at baseline (p for severity level = 0.92) or across PMA (p for interaction = 0.18).", [["BPD", "DISEASE", 50, 53], ["BPD", "DISEASE", 86, 89], ["PMA", "CHEMICAL", 146, 149], ["PMA", "SIMPLE_CHEMICAL", 146, 149], ["mild or moderate BPD", "PROBLEM", 33, 53], ["severity level", "TEST", 113, 127], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["BPD", "OBSERVATION", 50, 53]]], ["Because subjects were followed through the cessation of supplemental oxygen and respiratory support, discharge to home, or the day of death, whichever came first, the number of infants studied at each gestational age changed over time peaking at 3286 at 36 weeks PMA for the mild or moderate group and decreasing thereafter as also shown in Fig. 1 .", [["oxygen", "CHEMICAL", 69, 75], ["death", "DISEASE", 134, 139], ["PMA", "CHEMICAL", 263, 266], ["oxygen", "CHEMICAL", 69, 75], ["PMA", "CHEMICAL", 263, 266], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["infants", "ORGANISM", 177, 184], ["PMA", "SIMPLE_CHEMICAL", 263, 266], ["infants", "SPECIES", 177, 184], ["supplemental oxygen", "TREATMENT", 56, 75], ["respiratory support", "TREATMENT", 80, 99], ["the mild or moderate group", "PROBLEM", 271, 297], ["respiratory support", "OBSERVATION", 80, 99], ["mild", "OBSERVATION_MODIFIER", 275, 279], ["moderate", "OBSERVATION_MODIFIER", 283, 291]]], ["While most infants were discharged home from the NICU, 276 (6%) were transferred to the pediatric ICU and remained in the study until one of the above endpoints was met.ResultsPatterns and frequency of IB use were determined for four IBs.", [["infants", "ORGANISM", 11, 18], ["IBs", "PROTEIN", 234, 237], ["infants", "SPECIES", 11, 18], ["the study", "TEST", 118, 127]]], ["Within this cohort of BPD patients, 1147 (23%) received albuterol, 191 (3.8%) received levalbuterol, 169 (3.4%) received ipratropium bromide, and 16 (0.3%) received albuterol/ipratropium combination.", [["BPD", "DISEASE", 22, 25], ["albuterol", "CHEMICAL", 56, 65], ["levalbuterol", "CHEMICAL", 87, 99], ["ipratropium bromide", "CHEMICAL", 121, 140], ["albuterol", "CHEMICAL", 165, 174], ["ipratropium", "CHEMICAL", 175, 186], ["albuterol", "CHEMICAL", 56, 65], ["levalbuterol", "CHEMICAL", 87, 99], ["ipratropium bromide", "CHEMICAL", 121, 140], ["albuterol", "CHEMICAL", 165, 174], ["ipratropium", "CHEMICAL", 175, 186], ["patients", "ORGANISM", 26, 34], ["albuterol", "SIMPLE_CHEMICAL", 56, 65], ["levalbuterol", "SIMPLE_CHEMICAL", 87, 99], ["ipratropium bromide", "SIMPLE_CHEMICAL", 121, 140], ["albuterol", "SIMPLE_CHEMICAL", 165, 174], ["ipratropium", "SIMPLE_CHEMICAL", 175, 186], ["patients", "SPECIES", 26, 34], ["albuterol", "TREATMENT", 56, 65], ["levalbuterol", "TREATMENT", 87, 99], ["ipratropium bromide", "TREATMENT", 121, 140], ["albuterol", "TREATMENT", 165, 174], ["ipratropium combination", "TREATMENT", 175, 198]]], ["Of the BPD patients classified as severe, 621 (45%) received albuterol, 132 (9.5%) received levalbuterol, 128 (9.2%) received ipratropium bromide, and 12 (0.9%) received albuterol/ ipratropium combination.", [["BPD", "DISEASE", 7, 10], ["albuterol", "CHEMICAL", 61, 70], ["levalbuterol", "CHEMICAL", 92, 104], ["ipratropium bromide", "CHEMICAL", 126, 145], ["albuterol", "CHEMICAL", 170, 179], ["ipratropium", "CHEMICAL", 181, 192], ["albuterol", "CHEMICAL", 61, 70], ["levalbuterol", "CHEMICAL", 92, 104], ["ipratropium bromide", "CHEMICAL", 126, 145], ["albuterol", "CHEMICAL", 170, 179], ["ipratropium", "CHEMICAL", 181, 192], ["patients", "ORGANISM", 11, 19], ["albuterol", "SIMPLE_CHEMICAL", 61, 70], ["levalbuterol", "SIMPLE_CHEMICAL", 92, 104], ["ipratropium bromide", "SIMPLE_CHEMICAL", 126, 145], ["albuterol", "SIMPLE_CHEMICAL", 170, 179], ["ipratropium", "SIMPLE_CHEMICAL", 181, 192], ["patients", "SPECIES", 11, 19], ["albuterol", "TREATMENT", 61, 70], ["levalbuterol", "TREATMENT", 92, 104], ["ipratropium bromide", "TREATMENT", 126, 145], ["albuterol", "TREATMENT", 170, 179], ["ipratropium combination", "TREATMENT", 181, 204], ["severe", "OBSERVATION_MODIFIER", 34, 40]]], ["Albuterol was the IB most widely prescribed IB at any point during hospitalization, as well as the IB prescribed most per patient-days among all patients (26,454 (4.7%) patient-days) and among those classified as severe (18,501 (8.8%) patient-days).ResultsAll but two hospitals in this cohort prescribed an IB to at least some of their patients with BPD.", [["Albuterol", "CHEMICAL", 0, 9], ["BPD", "DISEASE", 350, 353], ["Albuterol", "CHEMICAL", 0, 9], ["Albuterol", "SIMPLE_CHEMICAL", 0, 9], ["patient", "ORGANISM", 122, 129], ["patients", "ORGANISM", 145, 153], ["patient", "ORGANISM", 169, 176], ["patient", "ORGANISM", 235, 242], ["patients", "ORGANISM", 336, 344], ["patient", "SPECIES", 122, 129], ["patients", "SPECIES", 145, 153], ["patient", "SPECIES", 169, 176], ["patient", "SPECIES", 235, 242], ["patients", "SPECIES", 336, 344], ["Albuterol", "TREATMENT", 0, 9], ["BPD", "PROBLEM", 350, 353]]], ["The proportion of BPD infants who received IBs after 28 days of life varied considerably by hospital, ranging from 0 to 59% of patients across 44 hospitals (Fig. 2) .", [["BPD", "DISEASE", 18, 21], ["infants", "ORGANISM", 22, 29], ["patients", "ORGANISM", 127, 135], ["infants", "SPECIES", 22, 29], ["patients", "SPECIES", 127, 135], ["IBs", "TREATMENT", 43, 46], ["BPD", "OBSERVATION", 18, 21]]], ["When IBs are examined individually, inter-hospital variability remains.", [["IBs", "ORGANISM_SUBSTANCE", 5, 8], ["IBs", "PROTEIN", 5, 8], ["IBs", "PROBLEM", 5, 8]]], ["Albuterol use ranged from 0 to 53% in all BPD infants, whereas levalbuterol was not used at all in 18 hospitals but was as high as 43% of BPD infants in one hospital.", [["Albuterol", "CHEMICAL", 0, 9], ["BPD", "DISEASE", 42, 45], ["levalbuterol", "CHEMICAL", 63, 75], ["BPD", "DISEASE", 138, 141], ["Albuterol", "CHEMICAL", 0, 9], ["levalbuterol", "CHEMICAL", 63, 75], ["Albuterol", "SIMPLE_CHEMICAL", 0, 9], ["infants", "ORGANISM", 46, 53], ["levalbuterol", "SIMPLE_CHEMICAL", 63, 75], ["infants", "SPECIES", 46, 53], ["infants", "SPECIES", 142, 149], ["Albuterol", "TREATMENT", 0, 9], ["levalbuterol", "TREATMENT", 63, 75]]], ["Ipratropium bromide use varied from 0 to 19%.", [["Ipratropium bromide", "CHEMICAL", 0, 19], ["Ipratropium bromide", "CHEMICAL", 0, 19], ["Ipratropium bromide", "SIMPLE_CHEMICAL", 0, 19], ["Ipratropium bromide", "TREATMENT", 0, 19]]], ["Experience with BPD patients, measured by the average number of BPD patients seen by the hospital each year, was not associated with IB use and thus could not account for the variation in practice ( Table 2) .ResultsTo better understand IB use, the association between the number of patients receiving IBs and the length of therapy was explored by plotting the proportion of patient-days with IB exposure by the proportion of BPD patients who were ever exposed to an IB (Fig. 3) .", [["BPD", "DISEASE", 16, 19], ["BPD", "DISEASE", 64, 67], ["BPD", "DISEASE", 426, 429], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 283, 291], ["patient", "ORGANISM", 375, 382], ["patients", "ORGANISM", 430, 438], ["IBs", "PROTEIN", 302, 305], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 283, 291], ["patient", "SPECIES", 375, 382], ["patients", "SPECIES", 430, 438], ["IBs", "TREATMENT", 302, 305], ["therapy", "TREATMENT", 324, 331], ["IB exposure", "TREATMENT", 393, 404]]], ["Hospitals that prescribe IBs more frequently in BPD patients also tend to prescribe them for longer, with more patient-days of IB use (r 2 = 0.43, p value \u2264 0.001).DiscussionThis large multicenter retrospective study demonstrates that the use of IB in NICU patients with BPD is widespread, with 25% of the cohort receiving an IB.", [["BPD", "DISEASE", 48, 51], ["BPD", "DISEASE", 271, 274], ["patients", "ORGANISM", 52, 60], ["patient", "ORGANISM", 111, 118], ["patients", "ORGANISM", 257, 265], ["IBs", "PROTEIN", 25, 28], ["patients", "SPECIES", 52, 60], ["patient", "SPECIES", 111, 118], ["patients", "SPECIES", 257, 265], ["IBs", "TREATMENT", 25, 28], ["This large multicenter retrospective study", "TEST", 174, 216], ["BPD", "PROBLEM", 271, 274], ["widespread", "OBSERVATION_MODIFIER", 278, 288]]], ["The most important factors associated with IB use in infants with BPD were those undergoing tracheostomy, duration of corticosteroid and diuretic treatment, increased number of days on respiratory support, and need for invasive ventilation; all of which are markers of more severe respiratory disease.", [["respiratory", "ANATOMY", 185, 196], ["respiratory", "ANATOMY", 281, 292], ["BPD", "DISEASE", 66, 69], ["respiratory disease", "DISEASE", 281, 300], ["infants", "ORGANISM", 53, 60], ["infants", "SPECIES", 53, 60], ["BPD", "PROBLEM", 66, 69], ["tracheostomy", "TREATMENT", 92, 104], ["corticosteroid", "TREATMENT", 118, 132], ["diuretic treatment", "TREATMENT", 137, 155], ["respiratory support", "TREATMENT", 185, 204], ["invasive ventilation", "TREATMENT", 219, 239], ["more severe respiratory disease", "PROBLEM", 269, 300], ["respiratory support", "OBSERVATION", 185, 204], ["severe", "OBSERVATION_MODIFIER", 274, 280], ["respiratory disease", "OBSERVATION", 281, 300]]], ["We also found considerable variability in IB use between hospitals.", [["considerable", "OBSERVATION_MODIFIER", 14, 26], ["variability", "OBSERVATION_MODIFIER", 27, 38], ["IB", "OBSERVATION_MODIFIER", 42, 44]]], ["While some hospitals used the medicines infrequently, in one hospital the majority of infants with BPD received an IB.", [["BPD", "DISEASE", 99, 102], ["infants", "ORGANISM", 86, 93], ["infants", "SPECIES", 86, 93], ["the medicines", "TREATMENT", 26, 39], ["BPD", "PROBLEM", 99, 102]]], ["No identifiable site characteristic was found that could explain the inter-hospital variation; however, those hospitals that used IB in a higher percentage of patients also tended to use the medications for a longer duration.DiscussionCompared with our findings of 48% of severe BPD patients receiving an IB, Bamat et al., using the PHIS database to study cumulative medicine exposures in severe BPD patients between 2007 and 2016, found that 38% of infants with severe BPD were exposed to albuterol [17] .", [["BPD", "DISEASE", 279, 282], ["BPD", "DISEASE", 396, 399], ["BPD", "DISEASE", 470, 473], ["albuterol", "CHEMICAL", 490, 499], ["albuterol", "CHEMICAL", 490, 499], ["patients", "ORGANISM", 159, 167], ["patients", "ORGANISM", 283, 291], ["patients", "ORGANISM", 400, 408], ["infants", "ORGANISM", 450, 457], ["patients", "SPECIES", 159, 167], ["patients", "SPECIES", 283, 291], ["patients", "SPECIES", 400, 408], ["infants", "SPECIES", 450, 457], ["the medications", "TREATMENT", 187, 202], ["severe BPD", "PROBLEM", 272, 282], ["severe BPD", "PROBLEM", 389, 399], ["severe BPD", "PROBLEM", 463, 473], ["albuterol", "TREATMENT", 490, 499]]], ["Similar to our results, another study demonstrated significant variability in IB use, showing that the point prevalence of bronchodilator use in severe BPD patients in eight NICUs was 32% and ranged from 0 to 67% [19] .", [["BPD", "DISEASE", 152, 155], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["another study", "TEST", 24, 37], ["bronchodilator", "TREATMENT", 123, 137], ["severe BPD", "PROBLEM", 145, 155], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["variability", "OBSERVATION_MODIFIER", 63, 74], ["severe", "OBSERVATION_MODIFIER", 145, 151]]], ["In a cohort of infants born between 23 0/7 and 28 6/7 weeks of gestation, 32% received an IB with no statistical difference between infants with BPD and without BPD at 36 weeks PMA [20] .", [["BPD", "DISEASE", 145, 148], ["BPD", "DISEASE", 161, 164], ["PMA", "CHEMICAL", 177, 180], ["PMA", "CHEMICAL", 177, 180], ["infants", "ORGANISM", 15, 22], ["infants", "ORGANISM", 132, 139], ["infants", "SPECIES", 15, 22], ["infants", "SPECIES", 132, 139], ["BPD", "PROBLEM", 145, 148], ["BPD", "PROBLEM", 161, 164]]], ["Post-discharge use of IBs in infants who required respiratory support at 36 weeks PMA continued to increase over the first year of life, from 13% at 3 months corrected age to 31% at 12 months corrected age [21] .", [["respiratory", "ANATOMY", 50, 61], ["PMA", "CHEMICAL", 82, 85], ["PMA", "CHEMICAL", 82, 85], ["infants", "ORGANISM", 29, 36], ["IBs", "PROTEIN", 22, 25], ["infants", "SPECIES", 29, 36], ["IBs", "PROBLEM", 22, 25], ["respiratory support", "TREATMENT", 50, 69], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["Albuterol was the most common IB used post-discharge, and IB use was associated with lower gestational age and a diagnosis of BPD at 36 weeks PMA.DiscussionSlaughter et al. [11] recently used the PHIS database to identify a cohort of patients with evolving BPD and determined that 33% of infants with BPD at 28 days of life received at least one dose of an IB and that usage steadily increased in the first month of life.", [["Albuterol", "CHEMICAL", 0, 9], ["BPD", "DISEASE", 126, 129], ["PMA", "CHEMICAL", 142, 145], ["BPD", "DISEASE", 257, 260], ["BPD", "DISEASE", 301, 304], ["Albuterol", "CHEMICAL", 0, 9], ["PMA", "CHEMICAL", 142, 145], ["Albuterol", "SIMPLE_CHEMICAL", 0, 9], ["PMA", "SIMPLE_CHEMICAL", 142, 145], ["patients", "ORGANISM", 234, 242], ["infants", "ORGANISM", 288, 295], ["patients", "SPECIES", 234, 242], ["infants", "SPECIES", 288, 295], ["Albuterol", "TREATMENT", 0, 9], ["BPD", "PROBLEM", 126, 129], ["evolving BPD", "PROBLEM", 248, 260], ["BPD", "PROBLEM", 301, 304], ["an IB", "TREATMENT", 354, 359]]], ["They also described a large inter-hospital variation in bronchodilator use in their population.", [["a large inter-hospital variation", "PROBLEM", 20, 52], ["large", "OBSERVATION_MODIFIER", 22, 27], ["inter-hospital variation", "OBSERVATION", 28, 52]]], ["Similar to our findings, increased duration of positive pressure respiratory support via CPAP, NIMV, or mechanical ventilation, birth weight between 500 and 749 g, and birth at 24-26 weeks gestation were identified as factors associated with higher IB administration.", [["positive pressure respiratory support", "TREATMENT", 47, 84], ["CPAP", "TREATMENT", 89, 93], ["NIMV", "TREATMENT", 95, 99], ["mechanical ventilation", "TREATMENT", 104, 126], ["birth weight", "TEST", 128, 140], ["higher IB administration", "TREATMENT", 242, 266], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["duration", "OBSERVATION_MODIFIER", 35, 43], ["positive pressure", "OBSERVATION", 47, 64], ["respiratory support", "OBSERVATION", 65, 84], ["mechanical ventilation", "OBSERVATION", 104, 126]]], ["Unlike their cohort, a birth weight of <500 g and birth at <24 weeks of gestation were also identified as factors related to IB use in our cohort of patients with established BPD.", [["BPD", "DISEASE", 175, 178], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["a birth weight", "TEST", 21, 35], ["established BPD", "PROBLEM", 163, 178], ["BPD", "OBSERVATION", 175, 178]]], ["They did not observe a difference in IB exposure in infants with IVH, PDA, or NEC, though for all three co-morbidities we saw an increase in the odds of receiving IBs.", [["IVH", "DISEASE", 65, 68], ["NEC", "DISEASE", 78, 81], ["infants", "ORGANISM", 52, 59], ["NEC", "PATHOLOGICAL_FORMATION", 78, 81], ["IBs", "PROTEIN", 163, 166], ["infants", "SPECIES", 52, 59], ["IVH", "PROBLEM", 65, 68], ["PDA", "PROBLEM", 70, 73], ["NEC", "PROBLEM", 78, 81], ["all three co-morbidities", "PROBLEM", 94, 118], ["IBs", "PROBLEM", 163, 166], ["IVH", "OBSERVATION", 65, 68], ["NEC", "OBSERVATION", 78, 81], ["increase", "OBSERVATION_MODIFIER", 129, 137]]], ["In addition, they limited their report on bronchodilator use to the first 100 days of life and did not report data related to gestational age.", [["bronchodilator", "TREATMENT", 42, 56]]], ["For an infant born at 24 weeks, he or she has not reached their due date by 100 days of life.", [["infant", "SPECIES", 7, 13]]], ["Thus, while their peak use of bronchodilators occurred on day 99 at 10.3%, by following BPD infants during their entire NICU course or until 1 year after their due date, we found a higher proportion of hospitalized BPD infants received IBs in the later PMA period.", [["BPD", "DISEASE", 88, 91], ["BPD", "DISEASE", 215, 218], ["PMA", "CHEMICAL", 253, 256], ["infants", "ORGANISM", 219, 226], ["PMA", "SIMPLE_CHEMICAL", 253, 256], ["infants", "SPECIES", 92, 99], ["infants", "SPECIES", 219, 226], ["bronchodilators", "TREATMENT", 30, 45], ["IBs", "TREATMENT", 236, 239]]], ["Lastly, a higher percentage of BPD infants received IB in their cohort compared with ours (33% vs. 25%), which may reflect changing user patterns.DiscussionWe also found that higher rates of IB administration in a NICU were correlated with increased duration of IB treatment.", [["BPD", "DISEASE", 31, 34], ["infants", "SPECIES", 35, 42], ["BPD", "PROBLEM", 31, 34], ["IB administration", "TREATMENT", 191, 208], ["IB treatment", "TREATMENT", 262, 274], ["higher", "OBSERVATION_MODIFIER", 10, 16], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["BPD", "OBSERVATION", 31, 34], ["may reflect", "UNCERTAINTY", 111, 122]]], ["This finding reflects the wide variability in the use of these medications, likely due to practitioner or hospital preference.", [["these medications", "TREATMENT", 57, 74], ["wide", "OBSERVATION_MODIFIER", 26, 30], ["variability", "OBSERVATION_MODIFIER", 31, 42], ["likely due to", "UNCERTAINTY", 76, 89]]], ["Like initiating IB, there are no objective standards describing when to cease bronchodilator therapy, which likely contributes to the variation in patient-days.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["bronchodilator therapy", "TREATMENT", 78, 100]]], ["For practitioners who initiate IBs because they believe IBs are beneficial it may be unsurprising that they also tend to use them for a longer duration.DiscussionKnowing that a quarter of BPD infants and nearly half of severe BDP infants receive an IB, there is an urgent need to better understand the safety and efficacy of this medication in this population.", [["BPD", "DISEASE", 188, 191], ["BDP", "CHEMICAL", 226, 229], ["BDP", "CHEMICAL", 226, 229], ["infants", "ORGANISM", 192, 199], ["infants", "ORGANISM", 230, 237], ["IBs", "PROTEIN", 31, 34], ["IBs", "PROTEIN", 56, 59], ["infants", "SPECIES", 192, 199], ["infants", "SPECIES", 230, 237], ["IBs", "PROBLEM", 31, 34], ["IBs", "PROBLEM", 56, 59], ["this medication", "TREATMENT", 325, 340]]], ["It is unclear if the increased use of IB in infants with severe BPD was due to a positive clinical response, a lack of other effective therapies combined with worsening clinical status, or a result of a change in the makeup of the medical team caring for the infant.", [["BPD", "DISEASE", 64, 67], ["infants", "ORGANISM", 44, 51], ["infant", "ORGANISM", 259, 265], ["infants", "SPECIES", 44, 51], ["infant", "SPECIES", 259, 265], ["severe BPD", "PROBLEM", 57, 67], ["a positive clinical response", "PROBLEM", 79, 107], ["other effective therapies", "TREATMENT", 119, 144], ["worsening clinical status", "PROBLEM", 159, 184], ["increased", "OBSERVATION_MODIFIER", 21, 30]]], ["Pulmonologists, who are more familiar with IBs, may be more likely to be consulted in severe cases of BPD and recommend these drugs.", [["BPD", "DISEASE", 102, 105], ["BPD", "PROBLEM", 102, 105], ["these drugs", "TREATMENT", 120, 131]]], ["Concerns related to use of albuterol include worsening bronchomalacia, tachycardia, hypertension, cardiac arrhythmias, hypokalemia, hyperglycemia, increased risk of GERD, tremor, and increased agitation [22] [23] [24] .", [["cardiac", "ANATOMY", 98, 105], ["albuterol", "CHEMICAL", 27, 36], ["bronchomalacia", "DISEASE", 55, 69], ["tachycardia", "DISEASE", 71, 82], ["hypertension", "DISEASE", 84, 96], ["cardiac arrhythmias", "DISEASE", 98, 117], ["hypokalemia", "DISEASE", 119, 130], ["hyperglycemia", "DISEASE", 132, 145], ["GERD", "DISEASE", 165, 169], ["tremor", "DISEASE", 171, 177], ["agitation", "DISEASE", 193, 202], ["albuterol", "CHEMICAL", 27, 36], ["albuterol", "SIMPLE_CHEMICAL", 27, 36], ["cardiac", "ORGAN", 98, 105], ["albuterol", "TREATMENT", 27, 36], ["worsening bronchomalacia", "PROBLEM", 45, 69], ["tachycardia", "PROBLEM", 71, 82], ["hypertension", "PROBLEM", 84, 96], ["cardiac arrhythmias", "PROBLEM", 98, 117], ["hypokalemia", "PROBLEM", 119, 130], ["hyperglycemia", "PROBLEM", 132, 145], ["GERD", "PROBLEM", 165, 169], ["tremor", "PROBLEM", 171, 177], ["increased agitation", "PROBLEM", 183, 202], ["worsening", "OBSERVATION_MODIFIER", 45, 54], ["bronchomalacia", "OBSERVATION", 55, 69], ["tachycardia", "OBSERVATION", 71, 82], ["hypertension", "OBSERVATION", 84, 96], ["cardiac", "ANATOMY", 98, 105], ["arrhythmias", "OBSERVATION", 106, 117], ["hypokalemia", "OBSERVATION", 119, 130], ["hyperglycemia", "OBSERVATION", 132, 145], ["increased", "OBSERVATION_MODIFIER", 147, 156], ["GERD", "OBSERVATION", 165, 169], ["increased", "OBSERVATION_MODIFIER", 183, 192], ["agitation", "OBSERVATION_MODIFIER", 193, 202]]], ["Tolerance also occurs [25, 26] and evidence shows only a portion of BPD infants even respond to albuterol with improvement in their pulmonary mechanics [10] .", [["pulmonary", "ANATOMY", 132, 141], ["BPD", "DISEASE", 68, 71], ["albuterol", "CHEMICAL", 96, 105], ["albuterol", "CHEMICAL", 96, 105], ["infants", "ORGANISM", 72, 79], ["albuterol", "SIMPLE_CHEMICAL", 96, 105], ["pulmonary", "ORGAN", 132, 141], ["infants", "SPECIES", 72, 79], ["albuterol", "TREATMENT", 96, 105], ["pulmonary", "ANATOMY", 132, 141]]], ["The paucity of data surrounding the use of IB in infants with BPD, and especially those with severe BPD, is concerning given the common use of these drugs in these populations.", [["BPD", "DISEASE", 62, 65], ["BPD", "DISEASE", 100, 103], ["infants", "ORGANISM", 49, 56], ["infants", "SPECIES", 49, 56], ["BPD", "PROBLEM", 62, 65], ["severe BPD", "PROBLEM", 93, 103], ["these drugs", "TREATMENT", 143, 154], ["paucity", "OBSERVATION_MODIFIER", 4, 11]]], ["Unfortunately, this is a pattern common in severe BPD patients as they are exposed to many medications whose risks and benefits are incompletely understood [17] .", [["BPD", "DISEASE", 50, 53], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["severe BPD patients", "PROBLEM", 43, 62], ["many medications", "TREATMENT", 86, 102], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["BPD", "OBSERVATION", 50, 53]]], ["Several significant questions remain unanswered in the current literature regarding the use of IBs in infants with BPD.", [["BPD", "DISEASE", 115, 118], ["IBs", "ORGANISM_SUBSTANCE", 95, 98], ["infants", "ORGANISM", 102, 109], ["IBs", "PROTEIN", 95, 98], ["infants", "SPECIES", 102, 109], ["IBs", "PROBLEM", 95, 98], ["BPD", "PROBLEM", 115, 118], ["significant", "OBSERVATION_MODIFIER", 8, 19]]], ["Even the definition of BPD itself continues to evolve with little evidence on how the diagnostic criteria impact future outcomes [27, 28] .", [["BPD", "DISEASE", 23, 26], ["BPD", "PROBLEM", 23, 26], ["BPD", "OBSERVATION", 23, 26]]], ["A new definition of BPD that is based on subsequent childhood mortality rather than clinical status at 36 weeks PMA has been proposed, but remains to be thoroughly validated [29] .", [["BPD", "DISEASE", 20, 23], ["PMA", "CHEMICAL", 112, 115], ["PMA", "CHEMICAL", 112, 115], ["BPD", "PROBLEM", 20, 23], ["new", "OBSERVATION_MODIFIER", 2, 5], ["BPD", "OBSERVATION", 20, 23]]], ["Another limitation of the current BPD definition is that it is static and relies on a single point in time.", [["BPD", "DISEASE", 34, 37], ["BPD", "OBSERVATION", 34, 37]]], ["It is possible the use of the medications may change the respiratory support needs in a gradual manner, so studying the effects of medication use on growth trajectory and continued respiratory support after 36 weeks PMA will also be important.", [["respiratory", "ANATOMY", 57, 68], ["respiratory", "ANATOMY", 181, 192], ["PMA", "CHEMICAL", 216, 219], ["PMA", "SIMPLE_CHEMICAL", 216, 219], ["the medications", "TREATMENT", 26, 41], ["the respiratory support", "TREATMENT", 53, 76], ["medication use", "TREATMENT", 131, 145], ["growth trajectory", "TREATMENT", 149, 166], ["continued respiratory support", "TREATMENT", 171, 200], ["respiratory support", "OBSERVATION", 57, 76]]], ["In addition, future studies should consider assessing the effects of the use of one medication on the need for other medications.", [["future studies", "TEST", 13, 27], ["one medication", "TREATMENT", 80, 94], ["other medications", "TREATMENT", 111, 128]]], ["For example, in our population higher IB use was associated with more days receiving postnatal systemic corticosteroids and diuretics but no causation can be established with our data.", [["postnatal systemic corticosteroids", "TREATMENT", 85, 119], ["diuretics", "TREATMENT", 124, 133], ["our data", "TEST", 175, 183]]], ["If earlier IB use had the potential to decreases the use or amount of systemic corticosteroids administered, however, it may be advantageous to use more IBs given the comparative adverse effects between the two groups of drugs.DiscussionOur findings must be placed in the context of several limitations.", [["corticosteroids", "CHEMICAL", 79, 94], ["systemic corticosteroids", "TREATMENT", 70, 94], ["IBs", "TREATMENT", 153, 156], ["drugs", "TREATMENT", 221, 226]]], ["PHIS maintains quality standards for inclusion but was initially designed for administrative purposes rather than research.", [["administrative purposes", "TREATMENT", 78, 101]]], ["To record data on NEC, PDA, IVH, and tracheostomy, ICD-9 and ICD-10 codes were used which can be non-specific.", [["NEC", "DISEASE", 18, 21], ["IVH", "DISEASE", 28, 31], ["NEC", "PROBLEM", 18, 21], ["PDA", "PROBLEM", 23, 26], ["IVH", "PROBLEM", 28, 31], ["tracheostomy", "TREATMENT", 37, 49], ["ICD", "TREATMENT", 51, 54], ["ICD", "TREATMENT", 61, 64], ["IVH", "OBSERVATION", 28, 31], ["tracheostomy", "OBSERVATION", 37, 49], ["non-specific", "OBSERVATION_MODIFIER", 97, 109]]], ["Hospital charge data was used to collect information about 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Fig. 2 Proportion of infants born <32 weeks or <1500 grams receiving respiratory support at 28 day of life by hospital who recieved any bronchodilator and the proportion of infants by hospital who received albuterol, levalbuterol, or ipratropium bromide.", [["respiratory", "ANATOMY", 200, 211], ["albuterol", "CHEMICAL", 337, 346], ["levalbuterol", "CHEMICAL", 348, 360], ["ipratropium bromide", "CHEMICAL", 365, 384], ["albuterol", "CHEMICAL", 337, 346], ["levalbuterol", "CHEMICAL", 348, 360], ["ipratropium bromide", "CHEMICAL", 365, 384], ["infants", "ORGANISM", 152, 159], ["infants", "ORGANISM", 304, 311], ["albuterol", "SIMPLE_CHEMICAL", 337, 346], ["levalbuterol", "SIMPLE_CHEMICAL", 348, 360], ["ipratropium bromide", "SIMPLE_CHEMICAL", 365, 384], ["infants", "SPECIES", 152, 159], ["infants", "SPECIES", 304, 311], ["Hospital charge data", "TEST", 0, 20], ["respiratory support", "TREATMENT", 200, 219], ["any bronchodilator", "TREATMENT", 263, 281], ["albuterol", "TREATMENT", 337, 346], ["levalbuterol", "TREATMENT", 348, 360], ["ipratropium bromide", "TREATMENT", 365, 384]]], ["Ranges: Any 0-59%, albuterol 0-53%, levalbuterol 0-43%, and ipratropium bromide 0-19%.", [["albuterol", "CHEMICAL", 19, 28], ["levalbuterol", "CHEMICAL", 36, 48], ["ipratropium bromide", "CHEMICAL", 60, 79], ["albuterol", "CHEMICAL", 19, 28], ["levalbuterol", "CHEMICAL", 36, 48], ["ipratropium bromide", "CHEMICAL", 60, 79], ["albuterol", "SIMPLE_CHEMICAL", 19, 28], ["levalbuterol", "SIMPLE_CHEMICAL", 36, 48], ["ipratropium bromide", "SIMPLE_CHEMICAL", 60, 79], ["albuterol", "TREATMENT", 19, 28], ["levalbuterol", "TREATMENT", 36, 48], ["ipratropium bromide", "TREATMENT", 60, 79]]], ["Hospitals were included if they cared for at least 10 infants.", [["infants", "ORGANISM", 54, 61], ["infants", "SPECIES", 54, 61]]], ["The hospital number corresponeds across all four graphs. respiratory support and medication use.", [["respiratory support", "TREATMENT", 57, 76], ["medication use", "TREATMENT", 81, 95]]], ["The PHIS database does not log FiO2 data, NC flow rates, oxyhemoglobin saturations, or radiological interpretations which are used to define BPD according to the 2018 Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop guidelines [18] .", [["BPD", "DISEASE", 141, 144], ["oxyhemoglobin", "CHEMICAL", 57, 70], ["oxyhemoglobin", "SIMPLE_CHEMICAL", 57, 70], ["Human", "ORGANISM", 229, 234], ["Human", "SPECIES", 229, 234], ["The PHIS database", "TEST", 0, 17], ["FiO2 data", "TEST", 31, 40], ["NC flow rates", "TEST", 42, 55], ["oxyhemoglobin saturations", "TEST", 57, 82], ["radiological interpretations", "TEST", 87, 115], ["BPD", "PROBLEM", 141, 144]]], ["Including only infants on supplemental oxygen or respiratory support at 28-30 days of life may underestimate BPD but is practical to use in this study as the medications of interest are often initiated prior to 36 weeks PMA.", [["respiratory", "ANATOMY", 49, 60], ["oxygen", "CHEMICAL", 39, 45], ["BPD", "DISEASE", 109, 112], ["oxygen", "CHEMICAL", 39, 45], ["PMA", "CHEMICAL", 220, 223], ["infants", "ORGANISM", 15, 22], ["oxygen", "SIMPLE_CHEMICAL", 39, 45], ["PMA", "SIMPLE_CHEMICAL", 220, 223], ["infants", "SPECIES", 15, 22], ["supplemental oxygen", "TREATMENT", 26, 45], ["respiratory support", "TREATMENT", 49, 68], ["BPD", "PROBLEM", 109, 112], ["this study", "TEST", 140, 150], ["the medications", "TREATMENT", 154, 169]]], ["By only including patients who required respiratory support for three consecutive days, those with transient respiratory support needs were excluded.", [["respiratory", "ANATOMY", 109, 120], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["respiratory support", "TREATMENT", 40, 59], ["transient respiratory support", "TREATMENT", 99, 128]]], ["Although a reasonable assumption, categorizing eligible infants who were discharged home by 36 weeks PMA as mild BPD and those who died as severe BPD may result in misclassification bias.", [["BPD", "DISEASE", 113, 116], ["BPD", "DISEASE", 146, 149], ["PMA", "CHEMICAL", 101, 104], ["infants", "ORGANISM", 56, 63], ["infants", "SPECIES", 56, 63], ["mild BPD", "PROBLEM", 108, 116], ["severe BPD", "PROBLEM", 139, 149], ["misclassification bias", "PROBLEM", 164, 186]]], ["A complete understanding of the decisions made by the physician is beyond the scope of this study.", [["this study", "TEST", 87, 97]]], ["Causal effects of IB exposure and clinically useful outcomes such as change in BPD symptoms or severity, number of ventilator days, need for tracheostomy, need for systemic steroids, and duration of hospitalization cannot be determined from the retrospective PHIS data.DiscussionDespite these limitations, there are a number of strengths to our study.", [["BPD", "DISEASE", 79, 82], ["steroids", "CHEMICAL", 173, 181], ["steroids", "CHEMICAL", 173, 181], ["IB exposure", "PROBLEM", 18, 29], ["change in BPD symptoms", "PROBLEM", 69, 91], ["severity", "PROBLEM", 95, 103], ["tracheostomy", "TREATMENT", 141, 153], ["systemic steroids", "TREATMENT", 164, 181], ["our study", "TEST", 341, 350]]], ["For the first time to our knowledge, this study examines the use of IB in BPD and severe BPD patients by PMA, following them during the entire NICU course up until 1 year after their estimated date of delivery.", [["BPD", "DISEASE", 74, 77], ["BPD", "DISEASE", 89, 92], ["PMA", "CHEMICAL", 105, 108], ["PMA", "CHEMICAL", 105, 108], ["patients", "ORGANISM", 93, 101], ["PMA", "SIMPLE_CHEMICAL", 105, 108], ["patients", "SPECIES", 93, 101], ["this study", "TEST", 37, 47], ["IB in BPD", "TREATMENT", 68, 77], ["delivery", "TREATMENT", 201, 209]]], ["In addition, the study population comes from PHIS which comprises a large national representation of children's hospitals and our findings are likely generalizable to most NICUs caring for BPD patients in the United States.DiscussionIn summary, exposure of BPD patients to IB is widespread in the NICU, especially in cases of severe BPD.", [["BPD", "DISEASE", 189, 192], ["BPD", "DISEASE", 257, 260], ["BPD", "DISEASE", 333, 336], ["children", "ORGANISM", 101, 109], ["patients", "ORGANISM", 193, 201], ["patients", "ORGANISM", 261, 269], ["children", "SPECIES", 101, 109], ["patients", "SPECIES", 193, 201], ["patients", "SPECIES", 261, 269], ["the study population", "TEST", 13, 33], ["severe BPD", "PROBLEM", 326, 336], ["large", "OBSERVATION_MODIFIER", 68, 73], ["widespread", "OBSERVATION_MODIFIER", 279, 289], ["severe", "OBSERVATION_MODIFIER", 326, 332], ["BPD", "OBSERVATION", 333, 336]]], ["The use of IB varies widely between hospitals, with the current study unable to define any hospital related factors that could be influencing the variability.", [["the current study", "TEST", 52, 69]]], ["For infants with BPD, bronchodilator administration steadily increases after 36 weeks PMA until about 60 weeks PMA, and its use is associated with the need for respiratory support at 36 weeks PMA, duration of respiratory support and corticosteroid administration, and need for tracheostomy.", [["respiratory", "ANATOMY", 160, 171], ["respiratory", "ANATOMY", 209, 220], ["BPD", "DISEASE", 17, 20], ["PMA", "CHEMICAL", 111, 114], ["PMA", "CHEMICAL", 86, 89], ["PMA", "CHEMICAL", 111, 114], ["PMA", "CHEMICAL", 192, 195], ["infants", "ORGANISM", 4, 11], ["PMA", "SIMPLE_CHEMICAL", 86, 89], ["PMA", "SIMPLE_CHEMICAL", 111, 114], ["PMA", "SIMPLE_CHEMICAL", 192, 195], ["corticosteroid", "SIMPLE_CHEMICAL", 233, 247], ["infants", "SPECIES", 4, 11], ["BPD", "PROBLEM", 17, 20], ["bronchodilator administration", "TREATMENT", 22, 51], ["respiratory support", "TREATMENT", 160, 179], ["respiratory support", "TREATMENT", 209, 228], ["corticosteroid administration", "TREATMENT", 233, 262], ["tracheostomy", "TREATMENT", 277, 289], ["tracheostomy", "OBSERVATION", 277, 289]]], ["The high IB use and variability indicates an urgent need for future research in this vulnerable population.DiscussionFunding RM and EK receive support from the Office of the Director of the National Institutes of Health under award UG1OD024953.", [["UG1OD024953", "CHEMICAL", 232, 243], ["UG1OD024953", "CHEMICAL", 232, 243], ["high IB", "OBSERVATION_MODIFIER", 4, 11]]], ["The remaining authors did not receive funding.DiscussionAuthor contributions JE conceptualized and designed the study, interpreted the data, drafted the initial paper, and approved the final paper as submitted.", [["the study", "TEST", 108, 117]]], ["EK conceptualized and designed the study, accessed the PHIS database, interpreted the data, and approved the final paper as submitted.", [["the study", "TEST", 31, 40]]], ["CL, RM and EP assisted with study design, participated in interpretation of the data, reviewed, and revised the paper, and approved the final paper as submitted.Compliance with ethical standardsConflict of interest The authors have no conflicts of interest relevant to this article to disclose.", [["CL", "MULTI-TISSUE_STRUCTURE", 0, 2], ["ethical standards", "TREATMENT", 177, 194]]], ["Dr RM from time to time provides expert advice on legal matters.Compliance with ethical standardsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["ethical standards", "TREATMENT", 80, 97]]]], "PMC7184353": [["Since December 2019, starting from an initial outbreak in the Wuhan region in China, a new virus of the coronavirus family (CoVs) has spread rapidly throughout the world, being classified as \u2018pandemic\u2019 on 11 March 2020.", [["coronavirus", "ORGANISM", 104, 115], ["CoVs", "GENE_OR_GENE_PRODUCT", 124, 128], ["coronavirus", "SPECIES", 104, 115], ["China", "ANATOMY", 78, 83], ["new", "OBSERVATION_MODIFIER", 87, 90], ["virus", "OBSERVATION", 91, 96]]], ["The burden in terms of deaths of this new virus, named SARS-CoV-2, has exceeded that of the previous severe acute respiratory syndrome (SARS) epidemic during 2002.", [["deaths", "DISEASE", 23, 29], ["SARS", "DISEASE", 55, 59], ["acute respiratory syndrome", "DISEASE", 108, 134], ["SARS", "DISEASE", 136, 140], ["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["this new virus", "PROBLEM", 33, 47], ["the previous severe acute respiratory syndrome", "PROBLEM", 88, 134], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["respiratory syndrome", "OBSERVATION", 114, 134]]], ["Today, >1 million people are infected worldwide, known as coronavirus disease 2019 (COVID-19) cases, most of which occur in the age group 30\u201380 years, with mild to moderate flu-like manifestations such as fever and cough.", [["coronavirus disease", "DISEASE", 58, 77], ["flu", "DISEASE", 173, 176], ["fever", "DISEASE", 205, 210], ["cough", "DISEASE", 215, 220], ["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["coronavirus disease", "PROBLEM", 58, 77], ["COVID", "TEST", 84, 89], ["mild to moderate flu-like manifestations", "PROBLEM", 156, 196], ["fever", "PROBLEM", 205, 210], ["cough", "PROBLEM", 215, 220], ["infected", "OBSERVATION", 29, 37], ["coronavirus disease", "OBSERVATION", 58, 77], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["moderate", "OBSERVATION_MODIFIER", 164, 172], ["flu", "OBSERVATION", 173, 176], ["fever", "OBSERVATION", 205, 210], ["cough", "OBSERVATION", 215, 220]]], ["However, a variable percentage of people, \u223c20% in China, have developed severe forms of interstitial pneumonia, up to critical conditions, with a mortality rate of >2%.1 SARS-CoV-2, which is an RNA virus, has \u223c80% homology with the previous SARS-CoV.2 This evidence led to the generation of the hypothesis that the SARS-CoV-2 was able, like SARS-CoV, to use the angiotensin-converting enzyme 2 (ACE2) protein as a cell receptor through which enter cells.", [["interstitial", "ANATOMY", 88, 100], ["cell", "ANATOMY", 414, 418], ["cells", "ANATOMY", 448, 453], ["interstitial pneumonia", "DISEASE", 88, 110], ["SARS", "DISEASE", 170, 174], ["SARS", "DISEASE", 315, 319], ["angiotensin", "CHEMICAL", 362, 373], ["people", "ORGANISM", 34, 40], ["CoV-2", "ORGANISM", 175, 180], ["SARS-CoV-2", "ORGANISM", 315, 325], ["SARS-CoV", "ORGANISM", 341, 349], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 362, 393], ["ACE2", "GENE_OR_GENE_PRODUCT", 395, 399], ["cell", "CELL", 414, 418], ["cells", "CELL", 448, 453], ["SARS-CoV.2", "DNA", 241, 251], ["angiotensin-converting enzyme 2 (ACE2) protein", "PROTEIN", 362, 408], ["people", "SPECIES", 34, 40], ["SARS-CoV", "SPECIES", 315, 323], ["SARS-CoV", "SPECIES", 341, 349], ["interstitial pneumonia", "PROBLEM", 88, 110], ["a mortality rate", "TEST", 144, 160], ["SARS-CoV", "TEST", 170, 178], ["an RNA virus", "PROBLEM", 191, 203], ["the hypothesis", "PROBLEM", 291, 305], ["the SARS", "TEST", 311, 319], ["CoV", "TEST", 320, 323], ["the angiotensin-converting enzyme 2 (ACE2) protein", "TREATMENT", 358, 408], ["a cell receptor", "TREATMENT", 412, 427], ["variable", "OBSERVATION_MODIFIER", 11, 19], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["interstitial", "ANATOMY_MODIFIER", 88, 100], ["pneumonia", "OBSERVATION", 101, 110], ["RNA virus", "OBSERVATION", 194, 203]]], ["This has now been confirmed in different species.3 Moreover, it has been shown that the SARS-CoV-2 structure includes a distinct loop with flexible glycyl residues, leading to a receptor-binding domain with a higher affinity for ACE2 compared with SARS-CoV.4 The angiotensin-converting enzyme (ACE) and its close homologue ACE2 belong to the ACE family of dipeptidyl carboxydipeptidases, but have two opposing physiological functions.", [["SARS", "DISEASE", 88, 92], ["glycyl", "CHEMICAL", 148, 154], ["angiotensin", "CHEMICAL", 263, 274], ["glycyl", "CHEMICAL", 148, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 229, 233], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 263, 292], ["ACE", "GENE_OR_GENE_PRODUCT", 294, 297], ["ACE2", "GENE_OR_GENE_PRODUCT", 323, 327], ["ACE", "GENE_OR_GENE_PRODUCT", 342, 345], ["dipeptidyl carboxydipeptidases", "GENE_OR_GENE_PRODUCT", 356, 386], ["SARS-CoV-2 structure", "PROTEIN", 88, 108], ["flexible glycyl residues", "PROTEIN", 139, 163], ["receptor-binding domain", "PROTEIN", 178, 201], ["ACE2", "PROTEIN", 229, 233], ["angiotensin-converting enzyme", "PROTEIN", 263, 292], ["ACE", "PROTEIN", 294, 297], ["ACE2", "PROTEIN", 323, 327], ["ACE family", "PROTEIN", 342, 352], ["dipeptidyl carboxydipeptidases", "PROTEIN", 356, 386], ["the SARS-CoV-2 structure", "PROBLEM", 84, 108], ["flexible glycyl residues", "TREATMENT", 139, 163], ["a receptor-binding domain", "PROBLEM", 176, 201], ["ACE2", "PROBLEM", 229, 233], ["SARS", "PROBLEM", 248, 252], ["The angiotensin-converting enzyme (ACE)", "TREATMENT", 259, 298], ["its close homologue ACE2", "TREATMENT", 303, 327], ["dipeptidyl carboxydipeptidases", "TREATMENT", 356, 386], ["different species", "OBSERVATION", 31, 48], ["distinct", "OBSERVATION_MODIFIER", 120, 128], ["loop", "OBSERVATION", 129, 133], ["flexible glycyl residues", "OBSERVATION", 139, 163], ["physiological functions", "OBSERVATION", 410, 433]]], ["ACE cleaves angiotensin I to generate angiotensin II, which binds to the angiotensin II type 1 receptor (AT1R) to constrict blood vessels, thereby increasing blood pressure.", [["blood vessels", "ANATOMY", 124, 137], ["blood", "ANATOMY", 158, 163], ["angiotensin I", "CHEMICAL", 12, 25], ["angiotensin II", "CHEMICAL", 38, 52], ["angiotensin II", "CHEMICAL", 73, 87], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 12, 25], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 38, 52], ["angiotensin II type 1 receptor", "GENE_OR_GENE_PRODUCT", 73, 103], ["AT1R", "GENE_OR_GENE_PRODUCT", 105, 109], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 124, 137], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["ACE", "PROTEIN", 0, 3], ["angiotensin I", "PROTEIN", 12, 25], ["angiotensin II", "PROTEIN", 38, 52], ["angiotensin II type 1 receptor", "PROTEIN", 73, 103], ["AT1R", "PROTEIN", 105, 109], ["ACE cleaves angiotensin I", "TREATMENT", 0, 25], ["angiotensin II", "TREATMENT", 38, 52], ["the angiotensin II type 1 receptor (AT1R)", "TREATMENT", 69, 110], ["increasing blood pressure", "PROBLEM", 147, 172], ["blood vessels", "ANATOMY", 124, 137], ["increasing", "OBSERVATION_MODIFIER", 147, 157], ["blood pressure", "OBSERVATION", 158, 172]]], ["In contrast, ACE2 inactivates angiotensin II, generates angiotensin (1-7), a heptapeptide having a potent vasodilator function via the Mas receptor,5 and might also generate angiotensin (1-9) from angiotensin I, which is then processed to become angiotensin (1-7).", [["angiotensin II", "CHEMICAL", 30, 44], ["angiotensin (1-7)", "CHEMICAL", 56, 73], ["angiotensin (1-9", "CHEMICAL", 174, 190], ["angiotensin I", "CHEMICAL", 197, 210], ["angiotensin", "CHEMICAL", 246, 257], ["ACE2", "GENE_OR_GENE_PRODUCT", 13, 17], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 30, 44], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 56, 72], ["Mas receptor,5", "GENE_OR_GENE_PRODUCT", 135, 149], ["angiotensin (1-9", "GENE_OR_GENE_PRODUCT", 174, 190], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 197, 210], ["ACE2", "PROTEIN", 13, 17], ["angiotensin II", "PROTEIN", 30, 44], ["Mas receptor,5", "PROTEIN", 135, 149], ["angiotensin I", "PROTEIN", 197, 210], ["angiotensin", "TEST", 56, 67], ["a heptapeptide", "TREATMENT", 75, 89], ["a potent vasodilator function", "TREATMENT", 97, 126], ["the Mas receptor", "TEST", 131, 147], ["angiotensin", "TEST", 174, 185], ["angiotensin", "TEST", 246, 257], ["angiotensin", "OBSERVATION", 246, 257]]], ["ACE2 is a type I membrane protein expressed in the lungs, liver, testes, heart, kidneys, and intestine.6 Previous data support an increased ACE2 expression, especially in the myocardium, in several cardiovascular diseases (CVDs) such as hypertension and heart failure (HF), as a counter-regulatory, protective mechanism.7 Similarly, preclinical evidence exists that the AT1R blockers (ARBs), commonly used as anti-hypertensive drugs, might increase ACE2 expression, especially in the heart and kidney, during both acute and chronic treatment for CVDs such as hypertension, myocardial infarction, and HF.8\u201310 On the contrary, evidence about the up-regulation of ACE2 expression by ACE inhibitors (ACEIs) is more conflicting.11 Mineralocorticoid receptor antagonists have also been shown to increase ACE2 levels.12 Taken together, available observations suggest that chronic AT1R blockade results in ACE2 up-regulation, even though specific data on the lungs, which would be relevant to SARS-CoV-2 infection, are lacking and the correlation between measured soluble ACE2 and membrane-bound ACE2 is not known.13", [["membrane", "ANATOMY", 17, 25], ["lungs", "ANATOMY", 51, 56], ["liver", "ANATOMY", 58, 63], ["testes", "ANATOMY", 65, 71], ["heart", "ANATOMY", 73, 78], ["kidneys", "ANATOMY", 80, 87], ["intestine", "ANATOMY", 93, 102], ["myocardium", "ANATOMY", 175, 185], ["cardiovascular", "ANATOMY", 198, 212], ["heart", "ANATOMY", 254, 259], ["heart", "ANATOMY", 484, 489], ["kidney", "ANATOMY", 494, 500], ["myocardial", "ANATOMY", 573, 583], ["lungs", "ANATOMY", 951, 956], ["membrane", "ANATOMY", 1073, 1081], ["cardiovascular diseases", "DISEASE", 198, 221], ["CVDs", "DISEASE", 223, 227], ["hypertension", "DISEASE", 237, 249], ["heart failure", "DISEASE", 254, 267], ["HF", "DISEASE", 269, 271], ["ARBs", "CHEMICAL", 385, 389], ["CVDs", "DISEASE", 546, 550], ["hypertension", "DISEASE", 559, 571], ["myocardial infarction", "DISEASE", 573, 594], ["HF", "DISEASE", 600, 602], ["infection", "DISEASE", 996, 1005], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["type I", "GENE_OR_GENE_PRODUCT", 10, 16], ["membrane", "CELLULAR_COMPONENT", 17, 25], ["lungs", "ORGAN", 51, 56], ["liver", "ORGAN", 58, 63], ["testes", "ORGAN", 65, 71], ["heart", "ORGAN", 73, 78], ["kidneys", "ORGAN", 80, 87], ["intestine", "ORGAN", 93, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 140, 144], ["myocardium", "MULTI-TISSUE_STRUCTURE", 175, 185], ["heart", "ORGAN", 254, 259], ["AT1R blockers", "GENE_OR_GENE_PRODUCT", 370, 383], ["ARBs", "SIMPLE_CHEMICAL", 385, 389], ["ACE2", "GENE_OR_GENE_PRODUCT", 449, 453], ["heart", "ORGAN", 484, 489], ["kidney", "ORGAN", 494, 500], ["myocardial", "MULTI-TISSUE_STRUCTURE", 573, 583], ["ACE2", "GENE_OR_GENE_PRODUCT", 661, 665], ["ACE", "GENE_OR_GENE_PRODUCT", 680, 683], ["Mineralocorticoid receptor antagonists", "GENE_OR_GENE_PRODUCT", 726, 764], ["ACE2", "GENE_OR_GENE_PRODUCT", 798, 802], ["AT1R", "GENE_OR_GENE_PRODUCT", 873, 877], ["ACE2", "GENE_OR_GENE_PRODUCT", 898, 902], ["lungs", "ORGAN", 951, 956], ["SARS-CoV-2", "ORGANISM", 985, 995], ["ACE2", "GENE_OR_GENE_PRODUCT", 1064, 1068], ["membrane", "CELLULAR_COMPONENT", 1073, 1081], ["ACE2", "GENE_OR_GENE_PRODUCT", 1088, 1092], ["ACE2", "PROTEIN", 0, 4], ["type I membrane protein", "PROTEIN", 10, 33], ["ACE2", "PROTEIN", 140, 144], ["ACE2", "PROTEIN", 449, 453], ["ACE2", "PROTEIN", 661, 665], ["ACE2", "PROTEIN", 798, 802], ["AT1R", "PROTEIN", 873, 877], ["ACE2", "PROTEIN", 898, 902], ["ACE2", "PROTEIN", 1064, 1068], ["ACE2", "PROTEIN", 1088, 1092], ["SARS-CoV", "SPECIES", 985, 993], ["a type I membrane protein", "PROBLEM", 8, 33], ["an increased ACE2 expression", "PROBLEM", 127, 155], ["several cardiovascular diseases", "PROBLEM", 190, 221], ["CVDs", "PROBLEM", 223, 227], ["hypertension", "PROBLEM", 237, 249], ["heart failure", "PROBLEM", 254, 267], ["HF", "PROBLEM", 269, 271], ["the AT1R blockers", "TREATMENT", 366, 383], ["ARBs", "TREATMENT", 385, 389], ["anti-hypertensive drugs", "TREATMENT", 409, 432], ["ACE2 expression", "TREATMENT", 449, 464], ["chronic treatment", "TREATMENT", 524, 541], ["CVDs", "PROBLEM", 546, 550], ["hypertension", "PROBLEM", 559, 571], ["myocardial infarction", "PROBLEM", 573, 594], ["HF", "PROBLEM", 600, 602], ["ACE2 expression", "TREATMENT", 661, 676], ["ACE inhibitors", "TREATMENT", 680, 694], ["ACEIs", "TREATMENT", 696, 701], ["Mineralocorticoid receptor antagonists", "TREATMENT", 726, 764], ["ACE2 levels", "TEST", 798, 809], ["chronic AT1R blockade", "TREATMENT", 865, 886], ["ACE2", "TEST", 898, 902], ["SARS", "PROBLEM", 985, 989], ["CoV-2 infection", "PROBLEM", 990, 1005], ["measured soluble ACE2", "TEST", 1047, 1068], ["protein", "OBSERVATION", 26, 33], ["lungs", "ANATOMY", 51, 56], ["liver", "ANATOMY", 58, 63], ["testes", "ANATOMY", 65, 71], ["heart", "ANATOMY", 73, 78], ["kidneys", "ANATOMY", 80, 87], ["intestine", "ANATOMY", 93, 102], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["ACE2 expression", "OBSERVATION", 140, 155], ["myocardium", "ANATOMY", 175, 185], ["several", "OBSERVATION_MODIFIER", 190, 197], ["cardiovascular diseases", "OBSERVATION", 198, 221], ["hypertension", "OBSERVATION", 237, 249], ["heart", "ANATOMY", 254, 259], ["failure", "OBSERVATION", 260, 267], ["ACE2 expression", "OBSERVATION", 449, 464], ["heart", "ANATOMY", 484, 489], ["kidney", "ANATOMY", 494, 500], ["acute", "OBSERVATION_MODIFIER", 514, 519], ["chronic", "OBSERVATION_MODIFIER", 524, 531], ["hypertension", "OBSERVATION", 559, 571], ["myocardial", "ANATOMY", 573, 583], ["infarction", "OBSERVATION", 584, 594], ["lungs", "ANATOMY", 951, 956], ["infection", "OBSERVATION", 996, 1005]]]], "c7ff86fa29cc55c1e991a7d27dfed5fa1852aa55": [["view of the current situation, to reduce cross-infection, many hospitals have cancelled outpatient appointments (except for emergency and fever clinics).", [["infection", "DISEASE", 47, 56], ["fever", "DISEASE", 138, 143], ["cross-infection", "PROBLEM", 41, 56]]], ["This inevitably affects the diagnosis and treatment of patients with other diseases.", [["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["treatment", "TREATMENT", 42, 51], ["other diseases", "PROBLEM", 69, 83]]], ["As a doctor working on the frontline of the outbreak in Wuhan, I hope that with the joint efforts of medical staff across the country, we can control the development of the 2019-nCoV outbreak rapidly and reduce the mortality of patients with pneumonia.", [["pneumonia", "DISEASE", 242, 251], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["pneumonia", "PROBLEM", 242, 251], ["pneumonia", "OBSERVATION", 242, 251]]], ["I also hope the Department of Health will pay attention to the frontline doctors and provide adequate protective equipment to reduce their risk of infection.", [["infection", "DISEASE", 147, 156], ["adequate protective equipment", "TREATMENT", 93, 122], ["infection", "PROBLEM", 147, 156], ["infection", "OBSERVATION", 147, 156]]], ["Only in this way can the outbreak be controlled and patients continue seeking treat ment for other health conditions in hospitals.Early lessons from the frontline of the 2019-nCoV outbreakThe outbreak of the novel coronavirus (2019-nCoV) has been declared a public health emergency of international concern by WHO.", [["coronavirus", "DISEASE", 214, 225], ["2019-nCoV", "CHEMICAL", 227, 236], ["patients", "ORGANISM", 52, 60], ["coronavirus", "ORGANISM", 214, 225], ["patients", "SPECIES", 52, 60], ["coronavirus", "SPECIES", 214, 225], ["the novel coronavirus", "PROBLEM", 204, 225]]], ["1 2019-nCoV has spread throughout China and beyond.", [["1 2019-nCoV", "CHEMICAL", 0, 11], ["spread", "OBSERVATION_MODIFIER", 16, 22]]], ["In China, as of Feb 9, 2020, more than 37 000 people have a confirmed infection, and 812 people have died.", [["infection", "DISEASE", 70, 79], ["people", "ORGANISM", 46, 52], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 46, 52], ["people", "SPECIES", 89, 95], ["infection", "PROBLEM", 70, 79], ["infection", "OBSERVATION", 70, 79]]], ["2 Currently, the severe situation has not been effectively controlled, and many governments have sent special aeroplanes to take their citizens home.", [["the severe situation", "PROBLEM", 13, 33], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["situation", "OBSERVATION", 24, 33]]], ["Early in December, 2019, eight doctors discovered unexplained pneumonia and were warned by the police for", [["pneumonia", "DISEASE", 62, 71], ["unexplained pneumonia", "PROBLEM", 50, 71], ["pneumonia", "OBSERVATION", 62, 71]]]], "9879c2b89f8bc052983abe42d39ce778051009ad": [["IntroductionFor the vast majority of viral pathogens there is a paucity of drug-based therapies.", [["viral pathogens", "PROBLEM", 37, 52], ["drug-based therapies", "TREATMENT", 75, 95], ["viral pathogens", "OBSERVATION", 37, 52]]], ["Rather, it has been the development of vaccines that has been the mainstay of prevention and intervention strategies for combating human and animal viral diseases.", [["viral diseases", "DISEASE", 148, 162], ["human", "ORGANISM", 131, 136], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["vaccines", "TREATMENT", 39, 47], ["prevention", "TREATMENT", 78, 88], ["intervention strategies", "TREATMENT", 93, 116], ["combating human", "PROBLEM", 121, 136], ["animal viral diseases", "PROBLEM", 141, 162], ["viral diseases", "OBSERVATION", 148, 162]]], ["There are presently 15 viral vaccines approved for human use, excluding various subtypes, and the majority of these are live-attenuated formulations (reviewed in (1)).", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["15 viral vaccines", "TREATMENT", 20, 37]]], ["In general terms, these liveattenuated viral vaccines are highly effective because they elicit a balanced immune response in the recipient host, stimulating both cell-mediated and humoral immunity.", [["cell", "ANATOMY", 162, 166], ["cell", "CELL", 162, 166], ["these liveattenuated viral vaccines", "TREATMENT", 18, 53]]], ["However, for many viruses, especially those that have associated highly pathogenic characteristics as with Biological Safety Level-4 (BSL-4) restricted agents or retroviruses such as human immunodeficiency virus type 1 (HIV-1), the use of live-attenuated vaccines is not feasible.IntroductionA number of studies have demonstrated the importance of neutralizing antibodies in the protection or recovery from viral infections (2, 3) .", [["human immunodeficiency virus", "DISEASE", 183, 211], ["viral infections", "DISEASE", 407, 423], ["retroviruses", "ORGANISM", 162, 174], ["human immunodeficiency virus type 1", "ORGANISM", 183, 218], ["HIV-1", "ORGANISM", 220, 225], ["neutralizing antibodies", "PROTEIN", 348, 371], ["human immunodeficiency virus type 1", "SPECIES", 183, 218], ["HIV-1", "SPECIES", 220, 225], ["human immunodeficiency virus type 1", "SPECIES", 183, 218], ["HIV-1", "SPECIES", 220, 225], ["many viruses", "PROBLEM", 13, 25], ["Biological Safety Level", "TEST", 107, 130], ["BSL", "TEST", 134, 137], ["restricted agents", "TREATMENT", 141, 158], ["retroviruses", "TREATMENT", 162, 174], ["human immunodeficiency virus type", "PROBLEM", 183, 216], ["live-attenuated vaccines", "TREATMENT", 239, 263], ["studies", "TEST", 304, 311], ["neutralizing antibodies", "TREATMENT", 348, 371], ["viral infections", "PROBLEM", 407, 423], ["viruses", "OBSERVATION", 18, 25], ["highly", "OBSERVATION_MODIFIER", 65, 71], ["pathogenic", "OBSERVATION", 72, 82], ["viral infections", "OBSERVATION", 407, 423]]], ["Indeed, as obligate intracellular parasites, viruses pose significant challenges for the development of effective antiviral therapeutics.", [["intracellular", "ANATOMY", 20, 33], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 20, 33], ["obligate intracellular parasites", "PROBLEM", 11, 43], ["effective antiviral therapeutics", "TREATMENT", 104, 136], ["effective", "OBSERVATION_MODIFIER", 104, 113], ["antiviral", "OBSERVATION", 114, 123]]], ["Neutralizing polyclonal antibodies have a long history of being effective against some viruses and more recently, monoclonal antibodies (mAbs) have also shown success.", [["Neutralizing polyclonal antibodies", "PROTEIN", 0, 34], ["monoclonal antibodies", "PROTEIN", 114, 135], ["mAbs", "PROTEIN", 137, 141], ["Neutralizing polyclonal antibodies", "PROBLEM", 0, 34], ["some viruses", "PROBLEM", 82, 94], ["monoclonal antibodies", "TEST", 114, 135], ["viruses", "OBSERVATION", 87, 94]]], ["The humanized mAb Synagis (palivizumab), which is currently the only mAb against a viral disease approved by the US Food and Drug Administration (FDA), has been widely used as a prophylactic measure against respiratory syncytial virus (RSV) infections in neonates and immune-compromised individuals and is more cost-effective and efficacious than the original polyclonal product (4) .", [["Synagis", "CHEMICAL", 18, 25], ["palivizumab", "CHEMICAL", 27, 38], ["viral disease", "DISEASE", 83, 96], ["respiratory syncytial virus (RSV) infections", "DISEASE", 207, 251], ["palivizumab", "SIMPLE_CHEMICAL", 27, 38], ["respiratory syncytial virus", "ORGANISM", 207, 234], ["RSV", "ORGANISM", 236, 239], ["neonates", "ORGANISM", 255, 263], ["individuals", "ORGANISM", 287, 298], ["mAb", "PROTEIN", 69, 72], ["respiratory syncytial virus", "SPECIES", 207, 234], ["RSV", "SPECIES", 236, 239], ["The humanized mAb Synagis (palivizumab)", "TREATMENT", 0, 39], ["a viral disease", "PROBLEM", 81, 96], ["a prophylactic measure", "TREATMENT", 176, 198], ["respiratory syncytial virus", "PROBLEM", 207, 234], ["RSV) infections in neonates", "PROBLEM", 236, 263], ["immune-compromised individuals", "PROBLEM", 268, 298], ["viral disease", "OBSERVATION", 83, 96], ["syncytial virus", "OBSERVATION", 219, 234]]], ["Most recently, the anti-RSV palivizumab has been improved, and motavizumab has been shown to potently inhibit viral replication in the upper respiratory tract in a cotton rat model (5) .", [["upper respiratory tract", "ANATOMY", 135, 158], ["palivizumab", "CHEMICAL", 28, 39], ["motavizumab", "CHEMICAL", 63, 74], ["motavizumab", "CHEMICAL", 63, 74], ["anti-RSV palivizumab", "ORGANISM", 19, 39], ["motavizumab", "SIMPLE_CHEMICAL", 63, 74], ["upper respiratory", "ORGANISM_SUBDIVISION", 135, 152], ["tract", "ORGANISM_SUBDIVISION", 153, 158], ["rat", "ORGANISM", 171, 174], ["rat", "SPECIES", 171, 174], ["anti-RSV", "SPECIES", 19, 27], ["rat", "SPECIES", 171, 174], ["the anti-RSV palivizumab", "TREATMENT", 15, 39], ["motavizumab", "TREATMENT", 63, 74], ["viral replication in the upper respiratory tract", "PROBLEM", 110, 158], ["palivizumab", "OBSERVATION", 28, 39], ["improved", "OBSERVATION_MODIFIER", 49, 57], ["upper", "ANATOMY_MODIFIER", 135, 140], ["respiratory tract", "ANATOMY", 141, 158]]], ["Virus-neutralizing antibodies can also be administered passively to acutely infected individuals and be highly efficacious.", [["Virus", "ORGANISM", 0, 5], ["Virus-neutralizing antibodies", "PROTEIN", 0, 29], ["Virus", "PROBLEM", 0, 5], ["neutralizing antibodies", "TREATMENT", 6, 29], ["acutely infected individuals", "PROBLEM", 68, 96]]], ["The mechanism of passively administered antibody therapy can be viewed as that of an antiviral drug: suppressing infection and permitting the host to mount an effective immune response (6) .", [["infection", "DISEASE", 113, 122], ["passively administered antibody therapy", "TREATMENT", 17, 56], ["an antiviral drug", "TREATMENT", 82, 99], ["suppressing infection", "PROBLEM", 101, 122]]], ["Today, passively administered antibody is routinely used as an effective antiviral therapy or prophylactic for hepatitis B, varicella-zoster, rabies virus, measles virus, and others (reviewed in (2) ).", [["hepatitis B", "DISEASE", 111, 122], ["varicella-zoster", "DISEASE", 124, 140], ["rabies virus", "DISEASE", 142, 154], ["measles virus", "DISEASE", 156, 169], ["hepatitis B", "ORGANISM", 111, 122], ["varicella-zoster", "ORGANISM", 124, 140], ["rabies virus", "ORGANISM", 142, 154], ["measles virus", "ORGANISM", 156, 169], ["varicella-zoster", "SPECIES", 124, 140], ["rabies virus", "SPECIES", 142, 154], ["measles virus", "SPECIES", 156, 169], ["hepatitis B", "SPECIES", 111, 122], ["rabies virus", "SPECIES", 142, 154], ["measles virus", "SPECIES", 156, 169], ["passively administered antibody", "TREATMENT", 7, 38], ["an effective antiviral therapy", "TREATMENT", 60, 90], ["hepatitis B", "PROBLEM", 111, 122], ["varicella", "PROBLEM", 124, 133], ["zoster", "PROBLEM", 134, 140], ["rabies virus", "PROBLEM", 142, 154], ["measles virus", "PROBLEM", 156, 169]]], ["In most cases their use is a first-line therapy as a post-exposure measure or in circumstances where vaccination is not possible.", [["a first-line therapy", "TREATMENT", 27, 47], ["a post-exposure measure", "TREATMENT", 51, 74], ["vaccination", "TREATMENT", 101, 112], ["not possible", "UNCERTAINTY", 116, 128]]], ["However, serum polyclonal antibody preparations have associated problems related to toxicity and potential allergic reactions, as well as lot-to-lot variation and uncertain dosing regimes (7) .IntroductionThe major advances in furthering the development of specific mAbs has been through the use of bacterial phage-display platforms with combinatorial antibody libraries (8, 9) .", [["serum", "ANATOMY", 9, 14], ["toxicity", "DISEASE", 84, 92], ["allergic reactions", "DISEASE", 107, 125], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["mAbs", "GENE_OR_GENE_PRODUCT", 266, 270], ["serum polyclonal antibody", "PROTEIN", 9, 34], ["mAbs", "PROTEIN", 266, 270], ["serum polyclonal antibody preparations", "TREATMENT", 9, 47], ["associated problems", "PROBLEM", 53, 72], ["toxicity", "PROBLEM", 84, 92], ["potential allergic reactions", "PROBLEM", 97, 125], ["specific mAbs", "TREATMENT", 257, 270], ["bacterial phage", "TREATMENT", 299, 314], ["combinatorial antibody libraries", "TREATMENT", 338, 370], ["allergic", "OBSERVATION", 107, 115], ["antibody libraries", "OBSERVATION", 352, 370]]], ["Further, these phage libraries can be prepared to encode human antibodies as Fabs which contain the light-chain and the first two domains of the heavy-chain or single-chain variable domain fragments (scFvs) containing the variable domains of the light and heavy chains, and this technology has been complemented by innovative affinity maturation strategies to improve antibody binding (reviewed in (10) ).", [["human", "ORGANISM", 57, 62], ["Fabs", "GENE_OR_GENE_PRODUCT", 77, 81], ["human antibodies", "PROTEIN", 57, 73], ["Fabs", "PROTEIN", 77, 81], ["light-chain", "PROTEIN", 100, 111], ["heavy-chain", "PROTEIN", 145, 156], ["single-chain variable domain fragments", "PROTEIN", 160, 198], ["scFvs", "PROTEIN", 200, 205], ["variable domains", "PROTEIN", 222, 238], ["light and heavy chains", "PROTEIN", 246, 268], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["these phage libraries", "TREATMENT", 9, 30], ["human antibodies", "TEST", 57, 73], ["Fabs", "TEST", 77, 81], ["single-chain variable domain fragments (scFvs)", "TREATMENT", 160, 206], ["innovative affinity maturation strategies", "TREATMENT", 315, 356], ["antibody binding", "PROBLEM", 368, 384]]], ["These techniques in human phage-display antibody platforms have facilitated the rapid identification and isolation of specific human mAbs, eliminating the immunization, hybridoma development, and humanization processes.", [["hybridoma", "ANATOMY", 169, 178], ["human", "ORGANISM", 20, 25], ["human", "ORGANISM", 127, 132], ["mAbs", "GENE_OR_GENE_PRODUCT", 133, 137], ["human mAbs", "PROTEIN", 127, 137], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 127, 132], ["antibody platforms", "TEST", 40, 58], ["the rapid identification", "TEST", 76, 100], ["specific human mAbs", "TREATMENT", 118, 137], ["the immunization", "TREATMENT", 151, 167], ["hybridoma development", "TREATMENT", 169, 190]]], ["In the absence of available vaccines or antiviral drugs, the identification and characterization of new human monoclonal antibodies (hmAbs) that are able to neutralize viruses offers the possibility for effective preand post-exposure therapeutic modalities.", [["human", "ORGANISM", 104, 109], ["monoclonal antibodies", "GENE_OR_GENE_PRODUCT", 110, 131], ["hmAbs", "GENE_OR_GENE_PRODUCT", 133, 138], ["human monoclonal antibodies", "PROTEIN", 104, 131], ["hmAbs", "PROTEIN", 133, 138], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["available vaccines", "TREATMENT", 18, 36], ["antiviral drugs", "TREATMENT", 40, 55], ["the identification", "TEST", 57, 75], ["new human monoclonal antibodies", "TEST", 100, 131], ["effective preand post-exposure therapeutic modalities", "TREATMENT", 203, 256]]], ["Such antibodies may also help in our understanding of the virus entry process and its underlying mechanisms, the viral neutralization mechanisms, and in the eventual development of specific entry inhibitors, vaccines, and research tools.", [["antibodies", "PROTEIN", 5, 15], ["the virus entry process", "PROBLEM", 54, 77], ["the viral neutralization mechanisms", "PROBLEM", 109, 144], ["specific entry inhibitors", "TREATMENT", 181, 206], ["vaccines", "TREATMENT", 208, 216]]], ["There have been many recent examples of the development and isolation of hmAbs using phage-display methodologies reactive against important human viral pathogens including HIV-1 (11) (12) (13) (14) (15) (16) , the paramyxoviruses, Hendra virus (HeV) and Nipah virus (NiV) (17) , and the human SARS coronavirus (18) .IntroductionMany of these viral pathogens are also enveloped viruses, and it is almost without exception that all neutralizing antibodies to enveloped viruses are directed against the virus' envelope glycoproteins, and traditionally the antibody response has been the immunologic measure of vaccine efficacy (19) .", [["Hendra virus (HeV) and Nipah virus", "DISEASE", 231, 265], ["SARS coronavirus", "DISEASE", 293, 309], ["hmAbs", "SIMPLE_CHEMICAL", 73, 78], ["human", "ORGANISM", 140, 145], ["HIV-1 (11) (12) (13", "ORGANISM", 172, 191], ["Hendra virus", "ORGANISM", 231, 243], ["HeV", "ORGANISM", 245, 248], ["Nipah virus", "ORGANISM", 254, 265], ["NiV", "ORGANISM", 267, 270], ["human", "ORGANISM", 287, 292], ["SARS coronavirus", "ORGANISM", 293, 309], ["enveloped viruses", "ORGANISM", 457, 474], ["hmAbs", "PROTEIN", 73, 78], ["neutralizing antibodies", "PROTEIN", 430, 453], ["virus' envelope glycoproteins", "PROTEIN", 500, 529], ["human", "SPECIES", 140, 145], ["HIV-1", "SPECIES", 172, 177], ["Hendra virus", "SPECIES", 231, 243], ["Nipah virus", "SPECIES", 254, 265], ["human", "SPECIES", 287, 292], ["coronavirus", "SPECIES", 298, 309], ["human", "SPECIES", 140, 145], ["HIV-1", "SPECIES", 172, 177], ["Hendra virus", "SPECIES", 231, 243], ["HeV", "SPECIES", 245, 248], ["Nipah virus", "SPECIES", 254, 265], ["NiV", "SPECIES", 267, 270], ["human SARS coronavirus", "SPECIES", 287, 309], ["isolation of hmAbs", "TREATMENT", 60, 78], ["phage", "TREATMENT", 85, 90], ["important human viral pathogens", "PROBLEM", 130, 161], ["HIV", "TEST", 172, 175], ["the paramyxoviruses", "PROBLEM", 210, 229], ["Hendra virus", "PROBLEM", 231, 243], ["Nipah virus (NiV", "TREATMENT", 254, 270], ["the human SARS coronavirus", "PROBLEM", 283, 309], ["these viral pathogens", "PROBLEM", 336, 357], ["all neutralizing antibodies", "PROBLEM", 426, 453], ["viruses", "PROBLEM", 467, 474], ["the virus' envelope glycoproteins", "PROBLEM", 496, 529], ["the antibody response", "TEST", 549, 570], ["vaccine efficacy", "TREATMENT", 607, 623], ["paramyxoviruses", "ANATOMY", 214, 229], ["Hendra virus", "ANATOMY", 231, 243], ["viral pathogens", "OBSERVATION", 342, 357], ["enveloped", "OBSERVATION_MODIFIER", 367, 376], ["viruses", "OBSERVATION", 377, 384], ["viruses", "OBSERVATION", 467, 474]]], ["All known viral envelope glycoproteins are homo-or heterooligomers in their mature and functional forms (20) and multimeric proteins, like these, generally interact over large areas which often translate into important structural differences between monomeric subunits and the mature oligomer.", [["viral envelope glycoproteins", "PROTEIN", 10, 38], ["homo-or heterooligomers", "PROTEIN", 43, 66], ["multimeric proteins", "PROTEIN", 113, 132], ["monomeric subunits", "PROTEIN", 250, 268], ["All known viral envelope glycoproteins", "PROBLEM", 0, 38], ["heterooligomers", "PROBLEM", 51, 66], ["multimeric proteins", "PROBLEM", 113, 132], ["monomeric subunits", "TREATMENT", 250, 268], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["envelope glycoproteins", "OBSERVATION", 16, 38], ["mature oligomer", "OBSERVATION", 277, 292]]], ["This feature can also impart significant differences in antigenic structure which has been shown for a number of proteins such as the trimeric influenza HA glycoprotein (21) and HIV-1 gp120/gp41 (22) .", [["HIV-1", "ORGANISM", 178, 183], ["gp120", "ORGANISM", 184, 189], ["trimeric influenza HA glycoprotein", "PROTEIN", 134, 168], ["21", "PROTEIN", 170, 172], ["gp120", "PROTEIN", 184, 189], ["gp41", "PROTEIN", 190, 194], ["HIV-1", "SPECIES", 178, 183], ["HIV-1", "SPECIES", 178, 183], ["significant differences in antigenic structure", "PROBLEM", 29, 75], ["the trimeric influenza HA glycoprotein", "PROBLEM", 130, 168], ["HIV", "TEST", 178, 181], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["In addition, some viruses pose significant additional challenges such as antigenic variation of their structural proteins that are important neutralization determinants.", [["structural proteins", "PROTEIN", 102, 121], ["neutralization determinants", "PROTEIN", 141, 168], ["their structural proteins", "PROBLEM", 96, 121], ["viruses", "OBSERVATION", 18, 25], ["significant", "OBSERVATION_MODIFIER", 31, 42]]], ["Perhaps the best-characterized example of this particular problem is with primary HIV-1 isolates that exist across the many varied HIV-1 subtypes (23) .", [["HIV-1", "ORGANISM", 82, 87], ["isolates", "ORGANISM", 88, 96], ["HIV-1", "ORGANISM", 131, 136], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 131, 136], ["HIV-1", "SPECIES", 82, 87], ["HIV-1", "SPECIES", 131, 136], ["primary HIV-1 isolates", "PROBLEM", 74, 96], ["many", "OBSERVATION_MODIFIER", 119, 123], ["varied", "OBSERVATION_MODIFIER", 124, 130]]], ["In efforts to circumvent this issue, further improvements and enhancements in the techniques of phage-displayed antibody library panning have been developed in order to better select for broadly reactive mAbs or for mAbs reactive to particular subunits of a multi-subunit viral glycoprotein such as sequential antigen panning (SAP) and competitive antigen panning (CAP) methodologies (14, 15) .IntroductionIt is often critical that the antigens used for the panning and isolation of hmAbs from phage libraries be produced and/or purified using methods whereby they retain a near-native structure and conformation, such as an oligomeric configuration.", [["hmAbs", "GENE_OR_GENE_PRODUCT", 483, 488], ["mAbs", "PROTEIN", 204, 208], ["mAbs", "PROTEIN", 216, 220], ["multi-subunit viral glycoprotein", "PROTEIN", 258, 290], ["SAP", "PROTEIN", 327, 330], ["hmAbs", "PROTEIN", 483, 488], ["phage", "TEST", 96, 101], ["antibody library panning", "TREATMENT", 112, 136], ["broadly reactive mAbs", "TREATMENT", 187, 208], ["mAbs reactive", "PROBLEM", 216, 229], ["a multi-subunit viral glycoprotein", "TREATMENT", 256, 290], ["sequential antigen panning", "TREATMENT", 299, 325], ["the antigens", "TREATMENT", 432, 444], ["the panning", "TREATMENT", 454, 465], ["isolation of hmAbs from phage libraries", "TREATMENT", 470, 509], ["native structure", "OBSERVATION", 579, 595], ["oligomeric configuration", "OBSERVATION", 625, 649]]], ["A useful approach to develop viral membrane glycoproteins suitable for panning phage libraries or as antigens for eliciting antibody responses that recognize their native form is to engineer soluble and secreted versions of the molecules.", [["membrane", "ANATOMY", 35, 43], ["viral membrane glycoproteins", "PROTEIN", 29, 57], ["A useful approach", "TREATMENT", 0, 17], ["viral membrane glycoproteins", "TREATMENT", 29, 57], ["panning phage libraries", "TREATMENT", 71, 94], ["eliciting antibody responses", "PROBLEM", 114, 142]]], ["Often, this approach yields a quaternary structure similar to their native counterparts, and for animal viruses eukaryotic expression systems are typically employed such as recombinant bacculovirus or vaccinia virus, or transient or stable expression in cell culture (22, (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) .", [["cell culture", "ANATOMY", 254, 266], ["bacculovirus", "GENE_OR_GENE_PRODUCT", 185, 197], ["vaccinia virus", "ORGANISM", 201, 215], ["cell", "CELL", 254, 258], ["(24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34)", "SIMPLE_CHEMICAL", 272, 326], ["vaccinia virus", "SPECIES", 201, 215], ["a quaternary structure", "PROBLEM", 28, 50], ["animal viruses eukaryotic expression systems", "PROBLEM", 97, 141], ["recombinant bacculovirus", "PROBLEM", 173, 197], ["vaccinia virus", "PROBLEM", 201, 215], ["cell culture", "TEST", 254, 266], ["stable", "OBSERVATION_MODIFIER", 233, 239]]], ["This chapter will detail several methods that have been successfully employed to produce, purify, and characterize soluble and secreted versions of several viral envelope glycoproteins which have been successfully used as antigens to capture and isolate human phage-displayed mAbs.Recombinant Vaccinia Viruses and Expression PlasmidsThe methods described below outline the steps for recombinant viral glycoprotein production using vaccinia virus for HIV-1 gp140 and HeV and NiV soluble G glycoprotein (sG) and affinity purification of the glycoproteins.", [["human", "ORGANISM", 254, 259], ["mAbs", "GENE_OR_GENE_PRODUCT", 276, 280], ["Vaccinia Viruses", "ORGANISM", 293, 309], ["vaccinia virus", "ORGANISM", 431, 445], ["HIV-1", "ORGANISM", 450, 455], ["gp140", "ORGANISM", 456, 461], ["HeV", "ORGANISM", 466, 469], ["NiV soluble G glycoprotein", "GENE_OR_GENE_PRODUCT", 474, 500], ["viral envelope glycoproteins", "PROTEIN", 156, 184], ["antigens", "PROTEIN", 222, 230], ["human phage-displayed mAbs", "PROTEIN", 254, 280], ["Expression Plasmids", "DNA", 314, 333], ["recombinant viral glycoprotein", "PROTEIN", 383, 413], ["HIV-1 gp140", "PROTEIN", 450, 461], ["HeV and NiV soluble G glycoprotein", "PROTEIN", 466, 500], ["sG", "PROTEIN", 502, 504], ["glycoproteins", "PROTEIN", 539, 552], ["human", "SPECIES", 254, 259], ["vaccinia virus", "SPECIES", 431, 445], ["HIV-1", "SPECIES", 450, 455], ["human", "SPECIES", 254, 259], ["vaccinia virus", "SPECIES", 431, 445], ["HIV-1", "SPECIES", 450, 455], ["HeV", "SPECIES", 466, 469], ["NiV", "SPECIES", 474, 477], ["several viral envelope glycoproteins", "TREATMENT", 148, 184], ["isolate human phage", "TEST", 246, 265], ["Recombinant Vaccinia Viruses", "TREATMENT", 281, 309], ["Expression Plasmids", "TREATMENT", 314, 333], ["The methods", "TREATMENT", 333, 344], ["recombinant viral glycoprotein production", "TREATMENT", 383, 424], ["vaccinia virus", "TREATMENT", 431, 445], ["HIV", "PROBLEM", 450, 453], ["HeV and NiV soluble G glycoprotein (sG", "TREATMENT", 466, 504], ["affinity purification of the glycoproteins", "TREATMENT", 510, 552], ["Vaccinia Viruses", "OBSERVATION", 293, 309]]], ["In addition, recombinant viral glycoprotein production and affinity purification from stable HeV and NiV soluble F glycoprotein (sF)-secreting 293T cell lines will be detailed.", [["293T cell lines", "ANATOMY", 143, 158], ["HeV", "ORGANISM", 93, 96], ["NiV soluble F glycoprotein", "GENE_OR_GENE_PRODUCT", 101, 127], ["293T cell lines", "CELL", 143, 158], ["recombinant viral glycoprotein", "PROTEIN", 13, 43], ["NiV soluble F glycoprotein (sF)-secreting 293T cell lines", "CELL_LINE", 101, 158], ["HeV", "SPECIES", 93, 96], ["NiV", "SPECIES", 101, 104], ["recombinant viral glycoprotein production", "PROBLEM", 13, 54], ["affinity purification", "TEST", 59, 80], ["NiV soluble F glycoprotein (sF", "TREATMENT", 101, 131], ["secreting 293T cell lines", "TREATMENT", 133, 158], ["293T cell lines", "OBSERVATION", 143, 158]]], ["Additional purification and oligomeric analyses methods are also detailed, including size-exclusion gel filtration, sucrose gradient ultracentrifugation analysis, and Blue Native polyacrylamide gel electrophoresis (BN-PAGE) analysis.", [["sucrose", "CHEMICAL", 116, 123], ["sucrose", "CHEMICAL", 116, 123], ["polyacrylamide", "CHEMICAL", 179, 193], ["sucrose", "SIMPLE_CHEMICAL", 116, 123], ["Additional purification and oligomeric analyses methods", "TEST", 0, 55], ["exclusion gel filtration", "TREATMENT", 90, 114], ["sucrose gradient ultracentrifugation analysis", "TEST", 116, 161], ["Blue Native polyacrylamide gel electrophoresis", "TREATMENT", 167, 213], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["The design and construction of recombinant vaccinia viruses encoding HIV-1 gp140 and HeV and NiV sG as well as the characterization of the recombinant, soluble, and secreted viral glycoproteins have been detailed elsewhere (24, 40) .", [["recombinant", "ORGANISM", 31, 42], ["vaccinia viruses", "ORGANISM", 43, 59], ["HIV-1 gp140", "ORGANISM", 69, 80], ["HeV", "ORGANISM", 85, 88], ["NiV sG", "ORGANISM", 93, 99], ["HIV-1 gp140", "PROTEIN", 69, 80], ["HeV", "PROTEIN", 85, 88], ["NiV sG", "PROTEIN", 93, 99], ["recombinant, soluble, and secreted viral glycoproteins", "PROTEIN", 139, 193], ["HIV-1", "SPECIES", 69, 74], ["vaccinia viruses", "SPECIES", 43, 59], ["HIV-1", "SPECIES", 69, 74], ["HeV", "SPECIES", 85, 88], ["NiV", "SPECIES", 93, 96], ["recombinant vaccinia viruses", "TREATMENT", 31, 59], ["HeV and NiV sG", "TREATMENT", 85, 99], ["secreted viral glycoproteins", "PROBLEM", 165, 193]]], ["In this section for the purposes of additional illustration there will be an emphasis on the production and purification of soluble and secreted forms of the HeV and NiV F glycoprotein, including the analysis of oligomeric characteristics as well as the generation of stable cell lines secreting recombinant sF.", [["cell lines", "ANATOMY", 275, 285], ["HeV", "ORGANISM", 158, 161], ["NiV F glycoprotein", "GENE_OR_GENE_PRODUCT", 166, 184], ["cell lines", "CELL", 275, 285], ["sF", "GENE_OR_GENE_PRODUCT", 308, 310], ["HeV and NiV F glycoprotein", "PROTEIN", 158, 184], ["stable cell lines", "CELL_LINE", 268, 285], ["recombinant sF", "PROTEIN", 296, 310], ["HeV", "SPECIES", 158, 161], ["NiV", "SPECIES", 166, 169], ["NiV F glycoprotein", "TREATMENT", 166, 184], ["the analysis", "TEST", 196, 208], ["oligomeric characteristics", "TREATMENT", 212, 238], ["stable cell lines", "TREATMENT", 268, 285], ["stable", "OBSERVATION_MODIFIER", 268, 274], ["cell lines", "OBSERVATION", 275, 285]]], ["Add 5 ml of virus inoculum (MOI \u00bc 5) to each bottle and gently roll to spread the inoculum over the cell monolayer.Recombinant Vaccinia Viruses and Expression Plasmids4.", [["cell monolayer", "ANATOMY", 100, 114], ["cell monolayer", "CELL", 100, 114], ["Vaccinia Viruses", "ORGANISM", 127, 143], ["Plasmids4", "GENE_OR_GENE_PRODUCT", 159, 168], ["Expression Plasmids4", "PROTEIN", 148, 168], ["virus inoculum", "TREATMENT", 12, 26], ["Recombinant Vaccinia Viruses", "TREATMENT", 115, 143], ["inoculum", "OBSERVATION", 82, 90], ["cell monolayer", "OBSERVATION", 100, 114], ["Vaccinia Viruses", "OBSERVATION", 127, 143]]], ["Immediately add an additional 15 ml of OptiMEM to each roller bottle and gently roll to spread the inoculum over the cell monolayer.Recombinant Vaccinia Viruses and Expression Plasmids5.", [["cell monolayer", "ANATOMY", 117, 131], ["cell monolayer", "CELL", 117, 131], ["Vaccinia Viruses", "ORGANISM", 144, 160], ["Plasmids5", "GENE_OR_GENE_PRODUCT", 176, 185], ["Expression Plasmids5", "PROTEIN", 165, 185], ["OptiMEM to each roller bottle", "TREATMENT", 39, 68], ["Recombinant Vaccinia Viruses", "TREATMENT", 132, 160], ["Expression Plasmids5", "TREATMENT", 165, 185], ["inoculum", "OBSERVATION", 99, 107], ["cell monolayer", "OBSERVATION", 117, 131], ["Vaccinia Viruses", "OBSERVATION", 144, 160]]], ["Return the roller bottles to the 37\u00b0C incubator and allow the infection to proceed for 3 h at 0.5 rpm.Recombinant Vaccinia Viruses and Expression Plasmids6.", [["infection", "DISEASE", 62, 71], ["Vaccinia Viruses", "ORGANISM", 114, 130], ["Plasmids6", "GENE_OR_GENE_PRODUCT", 146, 155], ["Expression Plasmids6", "PROTEIN", 135, 155], ["C incubator", "TREATMENT", 36, 47], ["the infection", "PROBLEM", 58, 71], ["Recombinant Vaccinia Viruses", "TREATMENT", 102, 130], ["infection", "OBSERVATION", 62, 71], ["Vaccinia Viruses", "OBSERVATION", 114, 130]]], ["Following the 3-h incubation, add an additional 120 ml of OptiMEM and flow each roller bottle with CO 2 as described in Section 3.1.1.1, Step 6.Recombinant Vaccinia Viruses and Expression Plasmids7.", [["CO 2", "CHEMICAL", 99, 103], ["Vaccinia Viruses", "ORGANISM", 156, 172], ["Plasmids7", "GENE_OR_GENE_PRODUCT", 188, 197], ["Expression Plasmids7", "PROTEIN", 177, 197], ["OptiMEM and flow each roller bottle", "TREATMENT", 58, 93], ["Recombinant Vaccinia Viruses", "TREATMENT", 144, 172], ["Expression Plasmids7", "TREATMENT", 177, 197], ["Vaccinia Viruses", "OBSERVATION", 156, 172]]], ["Incubate the cells in 37\u00b0C incubator at 0.5 rpm for 40-50 h before harvesting the supernatant.", [["cells", "ANATOMY", 13, 18], ["supernatant", "ANATOMY", 82, 93], ["cells", "CELL", 13, 18]]], ["The supernatant can be stored at 4\u00b0C and ready for affinity purification.", [["supernatant", "ANATOMY", 4, 15], ["C", "SIMPLE_CHEMICAL", 35, 36], ["affinity purification", "TREATMENT", 51, 72]]], ["We recommend to process the supernatant as soonest as possible.Affinity PurificationThis is the first step of purification.", [["supernatant", "ANATOMY", 28, 39]]], ["Depending on the protein's nature or the tag engineered to the protein, different approaches can be carried out for affinity purification.", [["affinity purification", "TREATMENT", 116, 137]]], ["Here, we describe the use of (1) lentil lectin purification of the highly glycosylated HIV-1 gp140 and (2) S-protein agarose purification for the N-terminally S-peptide-tagged HeV/ NiV sG.Gp140 Purification Through Lentil Lectin Sepharose Affinity ColumnAll the buffers should be degassed and sterile-filtered.", [["Gp140", "CHEMICAL", 188, 193], ["lentil", "ORGANISM", 33, 39], ["lectin", "GENE_OR_GENE_PRODUCT", 40, 46], ["HIV-1 gp140", "ORGANISM", 87, 98], ["HeV", "ORGANISM", 176, 179], ["NiV", "ORGANISM", 181, 184], ["lentil lectin", "PROTEIN", 33, 46], ["highly glycosylated HIV-1 gp140", "PROTEIN", 67, 98], ["N-terminally S-peptide-tagged HeV/ NiV sG", "PROTEIN", 146, 187], ["HIV-1", "SPECIES", 87, 92], ["HIV-1", "SPECIES", 87, 92], ["NiV sG", "SPECIES", 181, 187], ["lentil lectin purification", "TREATMENT", 33, 59], ["the highly glycosylated HIV", "PROBLEM", 63, 90], ["S-protein agarose purification", "TREATMENT", 107, 137], ["HeV/ NiV sG", "TREATMENT", 176, 187], ["Gp", "TEST", 188, 190], ["Lentil Lectin Sepharose Affinity Column", "TREATMENT", 215, 254], ["All the buffers", "TREATMENT", 254, 269], ["NiV sG", "OBSERVATION", 181, 187]]], ["Load 25-ml bed volume of Lentil Lectin Sepharose TM 4B into a XK 26 column and allow the beads to settle.Gp140 Purification Through Lentil Lectin Sepharose Affinity Column2.", [["Gp140", "CHEMICAL", 105, 110], ["Gp140", "PROTEIN", 105, 110], ["Load", "TEST", 0, 4], ["Lentil Lectin Sepharose TM", "TREATMENT", 25, 51], ["a XK 26 column", "TREATMENT", 60, 74], ["the beads", "TREATMENT", 85, 94], ["Gp", "TEST", 105, 107], ["Lentil Lectin Sepharose Affinity Column2", "TREATMENT", 132, 172]]], ["Add 20% ethanol 3-5 cm above the sepharose surface.", [["surface", "ANATOMY", 43, 50], ["ethanol", "CHEMICAL", 8, 15], ["ethanol", "CHEMICAL", 8, 15], ["ethanol", "SIMPLE_CHEMICAL", 8, 15], ["20% ethanol", "TREATMENT", 4, 15]]], ["Push the column inlet adaptor downwards until tightly contacting with the ethanol leaving 2-3 cm of ethanol from the sepharose surface to the column inlet.", [["ethanol", "CHEMICAL", 74, 81], ["ethanol", "CHEMICAL", 100, 107], ["ethanol", "CHEMICAL", 74, 81], ["ethanol", "CHEMICAL", 100, 107], ["ethanol", "SIMPLE_CHEMICAL", 74, 81], ["ethanol", "SIMPLE_CHEMICAL", 100, 107], ["Push the column inlet adaptor", "TREATMENT", 0, 29], ["the ethanol", "TREATMENT", 70, 81], ["column", "ANATOMY", 142, 148], ["inlet", "ANATOMY_MODIFIER", 149, 154]]], ["Avoid formation of air bubbles.", [["air bubbles", "PROBLEM", 19, 30], ["air bubbles", "OBSERVATION", 19, 30]]], ["Tighten the connection via the O-ring using the knob on the top of the column inlet adaptor.Wash the beads with 3-5 bed volumes of equilibration buffer.Use a peristaltic pump to apply buffer through the input tubing.Wash the beads with 3-5 bed volumes of equilibration buffer.4.", [["O", "CHEMICAL", 31, 32], ["O-ring", "PROTEIN", 31, 37], ["column inlet adaptor", "PROTEIN", 71, 91], ["the O-ring", "TREATMENT", 27, 37], ["the column inlet adaptor", "TREATMENT", 67, 91], ["the beads", "TREATMENT", 97, 106], ["equilibration buffer", "TREATMENT", 131, 151], ["a peristaltic pump", "TREATMENT", 156, 174], ["the input tubing", "TREATMENT", 199, 215], ["the beads", "TREATMENT", 221, 230], ["equilibration buffer", "TREATMENT", 255, 275], ["knob", "ANATOMY_MODIFIER", 48, 52], ["beads", "OBSERVATION_MODIFIER", 101, 106], ["input tubing", "OBSERVATION", 203, 215], ["beads", "OBSERVATION_MODIFIER", 225, 230]]], ["Apply the prepared supernatant from Section 3.1.1.3 to the column.", [["supernatant", "ANATOMY", 19, 30], ["column", "ANATOMY", 59, 65]]], ["Use the peristaltic pump to maintain a constant flow rate of 3-4 ml/min.", [["the peristaltic pump", "TREATMENT", 4, 24], ["a constant flow rate", "TEST", 37, 57], ["peristaltic pump", "OBSERVATION", 8, 24]]], ["Save the flow-through until the purified protein has been obtained.", [["purified protein", "PROTEIN", 32, 48], ["the purified protein", "TEST", 28, 48], ["flow", "OBSERVATION", 9, 13]]], ["A small portion (1 ml) can be used for immunoprecipitation (Section 3.2.2.2).5.Wash the column with 300 ml of wash buffer I follow by 100 ml of wash buffer II to remove Triton.5.6.", [["Triton", "SIMPLE_CHEMICAL", 169, 175], ["A small portion", "TREATMENT", 0, 15], ["immunoprecipitation", "TEST", 39, 58], ["Section", "TEST", 60, 67], ["Triton", "TREATMENT", 169, 175], ["small", "OBSERVATION_MODIFIER", 2, 7], ["column", "OBSERVATION_MODIFIER", 88, 94]]], ["To elute the protein, apply elution buffer to the column, stop the flow after the first 10 ml of flow-through and incubate for 15 min.", [["elution buffer to the column", "TREATMENT", 28, 56], ["column", "ANATOMY", 50, 56]]], ["Collect 25 ml of the elution in a sterile 50-ml tube, stop the flow, and incubate for 15 min.", [["tube", "TISSUE", 48, 52], ["the elution", "TREATMENT", 17, 28], ["a sterile 50-ml tube", "TREATMENT", 32, 52]]], ["Repeat elution and incubation for 3-5 times to collect several 25-ml elutions.5.7.", [["Repeat elution", "TREATMENT", 0, 14], ["incubation", "TREATMENT", 19, 29]]], ["Combine the eluate and concentrate it to less than 2 ml followed by buffer exchange into protein buffer (PBS) using Centriprep 1 molecular weight cut-off centrifugal filter units.", [["Combine the eluate", "TREATMENT", 0, 18], ["buffer exchange into protein buffer (PBS", "TREATMENT", 68, 108], ["Centriprep", "TREATMENT", 116, 126], ["centrifugal filter units", "TREATMENT", 154, 178]]], ["Filter the purified protein through a 0.2-mm low proteinbinding syringe filter membrane and store at 4\u00b0C. Pre-wet the membrane with protein buffer before filtering.5.9.", [["membrane", "ANATOMY", 79, 87], ["membrane", "ANATOMY", 118, 126], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["purified protein", "PROTEIN", 11, 27], ["Filter", "TREATMENT", 0, 6], ["a 0.2-mm low proteinbinding syringe filter membrane", "TREATMENT", 36, 87], ["protein buffer", "TREATMENT", 132, 146], ["filter membrane", "OBSERVATION", 72, 87]]], ["To regenerate the column, apply 50 ml of high-pH buffer followed by 50 ml of low-pH buffer through the column.", [["high-pH buffer", "TREATMENT", 41, 55], ["low-pH buffer through the column", "TREATMENT", 77, 109], ["column", "ANATOMY", 18, 24], ["column", "ANATOMY", 103, 109]]], ["After the last low-pH wash, apply 200-ml regeneration buffer through the column followed by 200 ml PBS.5.11.", [["the last low-pH wash", "TREATMENT", 6, 26], ["regeneration buffer through the column", "TREATMENT", 41, 79]]], ["Finally, apply 200 ml 20% EtOH through the column and store the beads in 20% EtOH at 4\u00b0C. The beads can be reused for up to five times.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column1.", [["EtOH", "CHEMICAL", 26, 30], ["EtOH", "CHEMICAL", 77, 81], ["EtOH", "CHEMICAL", 26, 30], ["EtOH", "CHEMICAL", 77, 81], ["EtOH", "SIMPLE_CHEMICAL", 26, 30], ["EtOH", "SIMPLE_CHEMICAL", 77, 81], ["HeV", "ORGANISM", 135, 138], ["NiV", "ORGANISM", 139, 142], ["NiV sG", "PROTEIN", 139, 145], ["HeV", "SPECIES", 135, 138], ["NiV", "SPECIES", 139, 142], ["The beads", "TREATMENT", 90, 99], ["HeV/NiV sG Purification", "TREATMENT", 135, 158], ["S-Protein Agarose Affinity Column1", "TREATMENT", 167, 201], ["NiV sG", "OBSERVATION", 139, 145]]], ["Load 15 ml bed volume of S-protein agarose into a XK 26 column.", [["S-protein agarose", "CHEMICAL", 25, 42], ["S-protein agarose", "TEST", 25, 42]]], ["Always maintain at least 2-3 cm of buffer above the surface of the agarose.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column2.", [["surface", "ANATOMY", 52, 59], ["surface", "CELLULAR_COMPONENT", 52, 59], ["agarose", "SIMPLE_CHEMICAL", 67, 74], ["HeV", "ORGANISM", 75, 78], ["NiV", "ORGANISM", 79, 82], ["NiV sG", "PROTEIN", 79, 85], ["HeV", "SPECIES", 75, 78], ["NiV", "SPECIES", 79, 82], ["the agarose", "TREATMENT", 63, 74], ["HeV/NiV sG Purification", "TREATMENT", 75, 98], ["S-Protein Agarose Affinity Column2", "TREATMENT", 107, 141], ["at least 2-3 cm", "OBSERVATION_MODIFIER", 16, 31], ["NiV sG", "OBSERVATION", 79, 85]]], ["Allow the column inlet adaptor to be 3-5 cm above the buffer level allowing input buffer to enter the column dropwise.", [["the column inlet adaptor", "TREATMENT", 6, 30], ["column", "ANATOMY", 102, 108]]], ["Use a peristaltic pump to apply buffer through the inlet tubing.", [["a peristaltic pump", "TREATMENT", 4, 22], ["the inlet tubing", "TREATMENT", 47, 63], ["inlet tubing", "OBSERVATION", 51, 63]]], ["Solution passing through the column outlet depends on gravity.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column3.", [["HeV", "ORGANISM", 62, 65], ["NiV", "ORGANISM", 66, 69], ["NiV sG", "PROTEIN", 66, 72], ["HeV", "SPECIES", 62, 65], ["NiV", "SPECIES", 66, 69], ["Solution", "TREATMENT", 0, 8], ["HeV/NiV sG Purification", "TREATMENT", 62, 85], ["S-Protein Agarose Affinity Column3", "TREATMENT", 94, 128], ["column outlet", "OBSERVATION", 29, 42], ["NiV sG", "OBSERVATION", 66, 72]]], ["Wash the column with 6 \u00c2 bed volumes of PBS followed by 6 \u00c2 bed volumes of wash buffer II (refer to Section 2.5.2 for buffers).HeV/NiV sG Purification Through S-Protein Agarose Affinity Column4.", [["HeV", "ORGANISM", 127, 130], ["NiV", "ORGANISM", 131, 134], ["NiV sG", "PROTEIN", 131, 137], ["HeV", "SPECIES", 127, 130], ["NiV", "SPECIES", 131, 134], ["the column", "TREATMENT", 5, 15], ["6 \u00c2 bed volumes of PBS", "TREATMENT", 21, 43], ["wash buffer II", "TREATMENT", 75, 89], ["HeV/NiV sG Purification", "TREATMENT", 127, 150], ["S-Protein Agarose Affinity Column4", "TREATMENT", 159, 193], ["column", "OBSERVATION_MODIFIER", 9, 15], ["NiV sG", "OBSERVATION", 131, 137]]], ["Apply the prepared supernatant from Section 3.1.1.3 to the column.", [["supernatant", "ANATOMY", 19, 30], ["column", "ANATOMY", 59, 65]]], ["Maintain a flow rate of 3-4 ml/min by adjusting the peristaltic pump and a stopcock connected at the outlet tubing of the column.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column5.", [["HeV", "ORGANISM", 129, 132], ["NiV", "ORGANISM", 133, 136], ["NiV sG", "PROTEIN", 133, 139], ["HeV", "SPECIES", 129, 132], ["NiV", "SPECIES", 133, 136], ["a flow rate", "TEST", 9, 20], ["the peristaltic pump", "TREATMENT", 48, 68], ["a stopcock", "TREATMENT", 73, 83], ["the outlet tubing of the column", "TREATMENT", 97, 128], ["HeV/NiV sG Purification", "TREATMENT", 129, 152], ["S-Protein Agarose Affinity Column5", "TREATMENT", 161, 195], ["peristaltic pump", "OBSERVATION", 52, 68], ["outlet tubing", "OBSERVATION", 101, 114], ["column", "ANATOMY", 122, 128], ["NiV sG", "OBSERVATION", 133, 139]]], ["Wash the column with 3X bed volumes of wash buffer I followed by 6 \u00c2 bed volumes of wash buffer II and subsequently 6 \u00c2 bed volumes of PBS.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column6.", [["HeV", "ORGANISM", 139, 142], ["NiV", "ORGANISM", 143, 146], ["NiV sG", "PROTEIN", 143, 149], ["HeV", "SPECIES", 139, 142], ["NiV", "SPECIES", 143, 146], ["wash buffer I", "TREATMENT", 39, 52], ["wash buffer II", "TREATMENT", 84, 98], ["HeV/NiV sG Purification", "TREATMENT", 139, 162], ["S-Protein Agarose Affinity Column6", "TREATMENT", 171, 205], ["column", "OBSERVATION_MODIFIER", 9, 15], ["NiV sG", "OBSERVATION", 143, 149]]], ["To elute the bound protein, stop the pump and allow the PBS to drain until it reaches the surface of the beads.", [["surface", "ANATOMY", 90, 97], ["surface", "CELLULAR_COMPONENT", 90, 97], ["bound protein", "PROTEIN", 13, 26], ["the pump", "TREATMENT", 33, 41], ["the PBS", "TREATMENT", 52, 59], ["drain", "TREATMENT", 63, 68], ["surface", "OBSERVATION_MODIFIER", 90, 97], ["beads", "ANATOMY_MODIFIER", 105, 110]]], ["Add 15 ml of elution buffer.", [["elution buffer", "TREATMENT", 13, 27]]], ["Incubate the elution buffer with the beads for 10 min after collecting the first 8 ml of flow-through (this should still be the PBS).HeV/NiV sG Purification Through S-Protein Agarose Affinity Column7.", [["HeV", "ORGANISM", 133, 136], ["NiV", "ORGANISM", 137, 140], ["NiV sG", "PROTEIN", 137, 143], ["HeV", "SPECIES", 133, 136], ["NiV", "SPECIES", 137, 140], ["the elution buffer", "TREATMENT", 9, 27], ["the beads", "TREATMENT", 33, 42], ["HeV/NiV sG Purification", "TREATMENT", 133, 156], ["S-Protein Agarose Affinity Column7", "TREATMENT", 165, 199], ["NiV sG", "OBSERVATION", 137, 143]]], ["Collect 15 ml of the elution into a 50-ml sterile conical centrifuge tube containing 10 ml of neutralization buffer.HeV/NiV sG Purification Through S-Protein Agarose Affinity ColumnCheck the pH with pH strips and add more neutralization buffer if needed to obtain neutral pH.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column8.", [["HeV", "ORGANISM", 116, 119], ["NiV", "ORGANISM", 120, 123], ["HeV", "ORGANISM", 275, 278], ["NiV", "ORGANISM", 279, 282], ["NiV sG", "PROTEIN", 279, 285], ["HeV", "SPECIES", 275, 278], ["NiV", "SPECIES", 279, 282], ["the elution", "TREATMENT", 17, 28], ["a 50-ml sterile conical centrifuge tube", "TREATMENT", 34, 73], ["neutralization buffer", "TREATMENT", 94, 115], ["HeV/NiV sG Purification", "TREATMENT", 116, 139], ["S-Protein Agarose Affinity", "TREATMENT", 148, 174], ["the pH", "TEST", 187, 193], ["pH strips", "TREATMENT", 199, 208], ["more neutralization buffer", "TREATMENT", 217, 243], ["neutral pH", "TEST", 264, 274], ["HeV/NiV sG Purification", "TREATMENT", 275, 298], ["S-Protein Agarose Affinity Column8", "TREATMENT", 307, 341], ["NiV sG", "OBSERVATION", 279, 285]]], ["Repeat the elution and incubation 2-3 times.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column9.", [["HeV", "ORGANISM", 44, 47], ["NiV", "ORGANISM", 48, 51], ["NiV sG", "PROTEIN", 48, 54], ["HeV", "SPECIES", 44, 47], ["NiV", "SPECIES", 48, 51], ["Repeat the elution", "TREATMENT", 0, 18], ["incubation", "TEST", 23, 33], ["HeV/NiV sG Purification", "TREATMENT", 44, 67], ["S-Protein Agarose Affinity Column9", "TREATMENT", 76, 110], ["NiV sG", "OBSERVATION", 48, 54]]], ["Wash the column with 6X bed volume of PBS follow by 6X bed volume of 20% ethanol.", [["ethanol", "CHEMICAL", 73, 80], ["ethanol", "CHEMICAL", 73, 80], ["ethanol", "SIMPLE_CHEMICAL", 73, 80], ["6X bed volume of PBS", "TREATMENT", 21, 41], ["column", "ANATOMY", 9, 15]]], ["Store the beads in ethanol.", [["ethanol", "CHEMICAL", 19, 26], ["ethanol", "CHEMICAL", 19, 26], ["ethanol", "SIMPLE_CHEMICAL", 19, 26], ["beads", "OBSERVATION_MODIFIER", 10, 15]]], ["The beads can be reused for up to five times.", [["The beads", "TREATMENT", 0, 9]]], ["Combine all neutralized elution with the first 8 ml flowthrough from Step 6.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column11.", [["HeV", "ORGANISM", 76, 79], ["NiV", "ORGANISM", 80, 83], ["NiV sG", "PROTEIN", 80, 86], ["HeV", "SPECIES", 76, 79], ["NiV", "SPECIES", 80, 83], ["Combine all neutralized elution", "TREATMENT", 0, 31], ["HeV/NiV sG Purification", "TREATMENT", 76, 99], ["S-Protein Agarose Affinity Column11", "TREATMENT", 108, 143], ["NiV sG", "OBSERVATION", 80, 86]]], ["Concentrate the elution to less than 2 ml and buffer-exchange the elution into protein buffer (PBS) using Centriprep 1 molecular weight cut-off centrifugal filter units.HeV/NiV sG Purification Through S-Protein Agarose Affinity Column12.", [["HeV", "ORGANISM", 169, 172], ["NiV", "ORGANISM", 173, 176], ["NiV sG", "PROTEIN", 173, 179], ["HeV", "SPECIES", 169, 172], ["NiV", "SPECIES", 173, 176], ["buffer-exchange the elution into protein buffer (PBS)", "TREATMENT", 46, 99], ["Centriprep", "TREATMENT", 106, 116], ["centrifugal filter units", "TREATMENT", 144, 168], ["HeV/NiV sG Purification", "TREATMENT", 169, 192], ["S-Protein Agarose Affinity Column12", "TREATMENT", 201, 236], ["NiV sG", "OBSERVATION", 173, 179]]], ["Filter the purified protein through a 0.2-mm low proteinbinding filter membrane and store at 4\u00b0C. Pre-wet the membrane with the same protein buffer before filtering.Stable Cell-Line Expressing Soluble RecombinantHeV/NiV sFPlasmid Construction ConsiderationsSeveral considerations may be required while constructing the expression plasmid: for example, Kozak translation initiation sequence and an ATG start codon for proper initiation of translation, promoter/enhancer and termination sequences, the expression plasmid employed, the type of antibiotic selection, the cell line employed, codon optimization of the viral RNA sequence, mutation and modifications on the amino acid sequence to enhance expression and secretion, the tag required in facilitating protein purification, etc. The sF construct described here has been optimized based on all the above concerns.", [["membrane", "ANATOMY", 71, 79], ["membrane", "ANATOMY", 110, 118], ["Cell", "ANATOMY", 172, 176], ["cell line", "ANATOMY", 567, 576], ["amino acid", "CHEMICAL", 667, 677], ["amino acid", "CHEMICAL", 667, 677], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["Cell", "CELL", 172, 176], ["cell line", "CELL", 567, 576], ["amino acid", "AMINO_ACID", 667, 677], ["purified protein", "PROTEIN", 11, 27], ["expression plasmid", "DNA", 319, 337], ["Kozak translation initiation sequence", "DNA", 352, 389], ["ATG start codon", "DNA", 397, 412], ["promoter/enhancer and termination sequences", "DNA", 451, 494], ["expression plasmid", "DNA", 500, 518], ["viral RNA sequence", "DNA", 613, 631], ["amino acid sequence", "PROTEIN", 667, 686], ["sF construct", "DNA", 788, 800], ["Filter", "TREATMENT", 0, 6], ["a 0.2-mm low proteinbinding filter membrane", "TREATMENT", 36, 79], ["Pre-wet the membrane", "TREATMENT", 98, 118], ["the same protein buffer", "TREATMENT", 124, 147], ["Soluble RecombinantHeV/NiV sFPlasmid Construction", "TREATMENT", 193, 242], ["Kozak translation", "TREATMENT", 352, 369], ["an ATG start codon", "TREATMENT", 394, 412], ["translation, promoter/enhancer and termination sequences", "TREATMENT", 438, 494], ["the expression plasmid", "TREATMENT", 496, 518], ["antibiotic selection", "TREATMENT", 541, 561], ["the cell line", "TREATMENT", 563, 576], ["codon optimization", "TREATMENT", 587, 605], ["the viral RNA sequence", "TREATMENT", 609, 631], ["mutation", "PROBLEM", 633, 641], ["the amino acid sequence", "TREATMENT", 663, 686], ["the tag", "PROBLEM", 724, 731], ["facilitating protein purification", "TREATMENT", 744, 777], ["filter membrane", "OBSERVATION", 64, 79], ["cell line", "OBSERVATION", 567, 576]]], ["Figure 2 .1 show the diagram of the construct of our sF GCN.", [["sF GCN", "CANCER", 53, 59], ["sF GCN", "PROTEIN", 53, 59], ["Figure", "TEST", 0, 6], ["sF GCN", "OBSERVATION", 53, 59]]], ["The vector employed was a promoter-modified pcDNA 3.1 Hygro (\u00fe).", [["pcDNA", "ORGANISM", 44, 49], ["promoter", "DNA", 26, 34], ["pcDNA 3.1 Hygro (\u00fe)", "DNA", 44, 63]]], ["The enhanced CMV promoter was imported from phCMV 1 vector that allows high expression level of the human and mouse codon-optimized sF.", [["CMV", "ORGANISM", 13, 16], ["phCMV 1", "GENE_OR_GENE_PRODUCT", 44, 51], ["human", "ORGANISM", 100, 105], ["mouse", "ORGANISM", 110, 115], ["CMV promoter", "DNA", 13, 25], ["phCMV 1 vector", "DNA", 44, 58], ["human and mouse codon-optimized sF", "DNA", 100, 134], ["human", "SPECIES", 100, 105], ["mouse", "SPECIES", 110, 115], ["CMV", "SPECIES", 13, 16], ["human", "SPECIES", 100, 105], ["mouse", "SPECIES", 110, 115], ["The enhanced CMV promoter", "TREATMENT", 0, 25], ["CMV promoter", "OBSERVATION", 13, 25]]], ["The Hygromycin selection marker allows the selection of transfected 293T cell which is resistant to the commonly used Geneticin antibiotic.", [["293T cell", "ANATOMY", 68, 77], ["Hygromycin", "CHEMICAL", 4, 14], ["Geneticin", "CHEMICAL", 118, 127], ["Geneticin", "CHEMICAL", 118, 127], ["Hygromycin", "SIMPLE_CHEMICAL", 4, 14], ["293T cell", "CELL", 68, 77], ["Geneticin", "SIMPLE_CHEMICAL", 118, 127], ["transfected 293T cell", "CELL_LINE", 56, 77], ["The Hygromycin selection marker", "TREATMENT", 0, 31], ["transfected 293T cell", "PROBLEM", 56, 77], ["Geneticin antibiotic", "TREATMENT", 118, 138], ["293T cell", "OBSERVATION", 68, 77]]], ["Replacing the C-terminal transmembrane and cytoplasmic tail domain of F is the trimeric GCN4 motif (41, 42) that allows stabilization of the protein trimeric structure (26, 43) and hence enhances the expression and secretion of the protein.", [["cytoplasmic", "ANATOMY", 43, 54], ["C", "CHEMICAL", 14, 15], ["transmembrane", "CELLULAR_COMPONENT", 25, 38], ["cytoplasmic", "ORGANISM_SUBSTANCE", 43, 54], ["F", "GENE_OR_GENE_PRODUCT", 70, 71], ["C-terminal transmembrane and cytoplasmic tail domain", "PROTEIN", 14, 66], ["F", "PROTEIN", 70, 71], ["trimeric GCN4 motif", "PROTEIN", 79, 98], ["protein trimeric structure", "PROTEIN", 141, 167], ["the C-terminal transmembrane", "TREATMENT", 10, 38], ["the trimeric GCN4 motif", "TEST", 75, 98], ["terminal", "ANATOMY_MODIFIER", 16, 24], ["transmembrane", "ANATOMY_MODIFIER", 25, 38], ["cytoplasmic tail", "OBSERVATION", 43, 59]]], ["This is followed by the 15-amino-acid S-peptide that facilitates purification and immunodetection of the sF by S-protein agarose and anti-S-peptide antibody.", [["amino-acid", "CHEMICAL", 27, 37], ["15-amino-acid", "CHEMICAL", 24, 37], ["15-amino-acid", "SIMPLE_CHEMICAL", 24, 37], ["sF", "GENE_OR_GENE_PRODUCT", 105, 107], ["S-protein agarose", "GENE_OR_GENE_PRODUCT", 111, 128], ["anti-S-peptide antibody", "GENE_OR_GENE_PRODUCT", 133, 156], ["sF", "PROTEIN", 105, 107], ["anti-S-peptide antibody", "PROTEIN", 133, 156], ["amino-acid S-peptide", "TREATMENT", 27, 47], ["the sF", "TEST", 101, 107], ["S-protein agarose", "TEST", 111, 128], ["anti-S-peptide antibody", "TEST", 133, 156]]], ["A factor Xa cleavage site (IEGR) is also engineered upstream to the S-peptide tag allowing removal of the tag by enzymatic digestion.", [["Xa", "GENE_OR_GENE_PRODUCT", 9, 11], ["factor Xa cleavage site", "DNA", 2, 25], ["IEGR", "DNA", 27, 31], ["S-peptide tag", "DNA", 68, 81], ["A factor Xa cleavage site", "PROBLEM", 0, 25], ["the S-peptide tag", "TREATMENT", 64, 81], ["removal", "TREATMENT", 91, 98]]], ["Standard cloning procedures were employed to construct the plasmid.Transient ExpressionBefore generating a stable cell line, several optimizations may be required to obtain the best expression level.", [["plasmid", "ANATOMY", 59, 66], ["cell line", "ANATOMY", 114, 123], ["cell line", "CELL", 114, 123], ["plasmid", "DNA", 59, 66], ["stable cell line", "CELL_LINE", 107, 123], ["Standard cloning procedures", "TREATMENT", 0, 27], ["the plasmid", "TREATMENT", 55, 66], ["a stable cell line", "TREATMENT", 105, 123], ["stable", "OBSERVATION_MODIFIER", 107, 113], ["cell line", "OBSERVATION", 114, 123]]], ["This can be investigated in transient expression using various cell lines to obtain the best result.", [["cell lines", "ANATOMY", 63, 73], ["cell lines", "CELL", 63, 73], ["cell lines", "CELL_LINE", 63, 73], ["various cell lines", "TREATMENT", 55, 73], ["cell lines", "OBSERVATION", 63, 73]]], ["We describe here the transient transfection of the sF construct in 293T cells using lipid-based transfection procedure.", [["293T cells", "ANATOMY", 67, 77], ["sF", "GENE_OR_GENE_PRODUCT", 51, 53], ["293T cells", "CELL", 67, 77], ["lipid", "SIMPLE_CHEMICAL", 84, 89], ["sF construct", "DNA", 51, 63], ["293T cells", "CELL_LINE", 67, 77], ["lipid-based transfection procedure", "TREATMENT", 84, 118]]], ["The expression level can be analyzed using immuno-or affinity precipitations from the cell lysate and supernatant followed by SDS-PAGE and Western blotting to access the secretion level.Cell Line EstablishmentOnce the best expression construct has been optimized with the best cell line, a stable cell line can be generated.", [["cell lysate", "ANATOMY", 86, 97], ["supernatant", "ANATOMY", 102, 113], ["Cell", "ANATOMY", 186, 190], ["cell line", "ANATOMY", 277, 286], ["cell line", "ANATOMY", 297, 306], ["cell lysate", "ORGANISM_SUBSTANCE", 86, 97], ["Cell", "CELL", 186, 190], ["cell line", "CELL", 277, 286], ["cell line", "CELL", 297, 306], ["cell line", "CELL_LINE", 277, 286], ["stable cell line", "CELL_LINE", 290, 306], ["immuno-or affinity precipitations", "TREATMENT", 43, 76], ["the cell lysate", "TREATMENT", 82, 97], ["the secretion level", "TEST", 166, 185], ["Cell Line EstablishmentOnce", "TREATMENT", 186, 213], ["the best cell line", "TREATMENT", 268, 286], ["a stable cell line", "TREATMENT", 288, 306], ["cell line", "OBSERVATION", 277, 286], ["stable", "OBSERVATION_MODIFIER", 290, 296], ["cell line", "OBSERVATION", 297, 306]]], ["In order to select a stable cell clone expressing the soluble glycoprotein, the minimum concentration of the appropriate selection antibiotic required to kill the non-transfected host cell line needs to be determined.", [["cell clone", "ANATOMY", 28, 38], ["cell line", "ANATOMY", 184, 193], ["cell clone", "CELL", 28, 38], ["host cell line", "CELL", 179, 193], ["stable cell clone", "CELL_LINE", 21, 38], ["soluble glycoprotein", "PROTEIN", 54, 74], ["non-transfected host cell line", "CELL_LINE", 163, 193], ["a stable cell clone", "TREATMENT", 19, 38], ["the soluble glycoprotein", "TREATMENT", 50, 74], ["the appropriate selection antibiotic", "TREATMENT", 105, 141], ["the non-transfected host cell line", "TREATMENT", 159, 193], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["cell clone", "OBSERVATION", 28, 38], ["host cell line", "OBSERVATION", 179, 193]]], ["Because natural resistance varies among cell lines, we recommend testing a range of antibiotic concentrations on 25% confluent cells.", [["cell lines", "ANATOMY", 40, 50], ["cells", "ANATOMY", 127, 132], ["cell lines", "CELL", 40, 50], ["cells", "CELL", 127, 132], ["cell lines", "CELL_LINE", 40, 50], ["natural resistance", "PROBLEM", 8, 26], ["testing", "TEST", 65, 72], ["antibiotic concentrations", "TREATMENT", 84, 109], ["resistance", "OBSERVATION_MODIFIER", 16, 26], ["cell lines", "OBSERVATION", 40, 50]]], ["Choose the concentration that prevents growth within 2-3 days and kills all cells within 5-7 days.", [["cells", "ANATOMY", 76, 81], ["cells", "CELL", 76, 81], ["the concentration", "TREATMENT", 7, 24]]], ["The procedures described here have been optimized for 293T cells.", [["293T cells", "ANATOMY", 54, 64], ["293T cells", "CELL", 54, 64], ["293T cells", "CELL_LINE", 54, 64], ["The procedures", "TREATMENT", 0, 14]]], ["To the cells remaining on the plate for cell line generation, add 2 ml of PBS to wash the cells without disturbing the monolayer.Cell Line Establishment4.", [["cells", "ANATOMY", 7, 12], ["cell line", "ANATOMY", 40, 49], ["cells", "ANATOMY", 90, 95], ["monolayer", "ANATOMY", 119, 128], ["Cell", "ANATOMY", 129, 133], ["cells", "CELL", 7, 12], ["cell line", "CELL", 40, 49], ["cells", "CELL", 90, 95], ["monolayer", "CELL", 119, 128], ["Cell", "CELL", 129, 133], ["the plate", "TREATMENT", 26, 35], ["cell line generation", "TREATMENT", 40, 60], ["PBS", "TREATMENT", 74, 77], ["Cell Line Establishment4", "TREATMENT", 129, 153], ["cell line", "OBSERVATION", 40, 49]]], ["Remove the PBS and add 0.5 ml of trypsin-EDTA.", [["trypsin-EDTA", "CHEMICAL", 33, 45], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 33, 45], ["the PBS", "TREATMENT", 7, 14], ["trypsin-EDTA", "TREATMENT", 33, 45]]], ["Allow trypsinization for 3-5 s before aspirating the trypsin.Cell Line Establishment5.", [["Cell", "ANATOMY", 61, 65], ["trypsin", "GENE_OR_GENE_PRODUCT", 53, 60], ["Cell", "CELL", 61, 65], ["trypsin", "PROTEIN", 53, 60], ["aspirating the trypsin", "PROBLEM", 38, 60], ["Cell Line Establishment5", "TREATMENT", 61, 85]]], ["Use 1-ml fresh DMEM-10 medium to resuspend the cells and transfer the cells into a 25-cm 2 tissue culture flask.Cell Line Establishment6.", [["cells", "ANATOMY", 47, 52], ["cells", "ANATOMY", 70, 75], ["Cell", "ANATOMY", 112, 116], ["cells", "CELL", 47, 52], ["cells", "CELL", 70, 75], ["Cell", "CELL", 112, 116], ["1-ml fresh DMEM", "TREATMENT", 4, 19], ["the cells", "TREATMENT", 43, 52], ["tissue culture flask", "TEST", 91, 111], ["Cell Line Establishment6", "TREATMENT", 112, 136]]], ["Add 4 ml of DMEM-10 to the flask and allow cells to adhere at 37\u00b0C, 5-8% CO 2 for several hours or overnight.Cell Line Establishment7.", [["cells", "ANATOMY", 43, 48], ["Cell", "ANATOMY", 109, 113], ["CO 2", "CHEMICAL", 73, 77], ["cells", "CELL", 43, 48], ["Cell", "CELL", 109, 113], ["DMEM", "TREATMENT", 12, 16], ["Cell Line Establishment7", "TREATMENT", 109, 133]]], ["Once cells have adhered, replace the medium with fresh DMEM-10 supplemented with 150 mg/ml Hygromycin B.Cell Line Establishment8.", [["cells", "ANATOMY", 5, 10], ["DMEM-10", "CHEMICAL", 55, 62], ["cells", "CELL", 5, 10], ["the medium with fresh DMEM", "TREATMENT", 33, 59]]], ["Prepare another flask with the same selection medium for non-transfected cells to monitor the action of the antibiotic.", [["cells", "ANATOMY", 73, 78], ["cells", "CELL", 73, 78], ["non-transfected cells", "CELL_LINE", 57, 78], ["non-transfected cells", "PROBLEM", 57, 78], ["the antibiotic", "TREATMENT", 104, 118]]], ["Change and replace the selection medium when necessary by observing the color change of the medium.", [["the selection medium", "TREATMENT", 19, 39]]], ["Changing the medium will also remove dead cells.", [["cells", "ANATOMY", 42, 47], ["cells", "CELL", 42, 47], ["dead cells", "CELL_TYPE", 37, 47], ["dead cells", "PROBLEM", 37, 47], ["dead cells", "OBSERVATION", 37, 47]]], ["Non-expressing cells should die within several days and expressing colonies will start to form.", [["cells", "ANATOMY", 15, 20], ["colonies", "ANATOMY", 67, 75], ["cells", "CELL", 15, 20], ["Non-expressing cells", "CELL_TYPE", 0, 20], ["Non-expressing cells", "PROBLEM", 0, 20], ["expressing colonies", "PROBLEM", 56, 75]]], ["For 293T cells, this may take 7-10 days depending on the transfection efficiency.", [["293T cells", "ANATOMY", 4, 14], ["293T cells", "CELL", 4, 14], ["293T cells", "CELL_LINE", 4, 14], ["the transfection efficiency", "PROBLEM", 53, 80], ["transfection efficiency", "OBSERVATION", 57, 80]]], ["When all dead cells have been removed and colonies are growing well, the cells should be transferred into a 75-cm 2 tissue culture flask to form monolayer.Cell Line Establishment11.", [["cells", "ANATOMY", 14, 19], ["colonies", "ANATOMY", 42, 50], ["cells", "ANATOMY", 73, 78], ["monolayer", "ANATOMY", 145, 154], ["Cell", "ANATOMY", 155, 159], ["cells", "CELL", 14, 19], ["cells", "CELL", 73, 78], ["monolayer", "CELL", 145, 154], ["Cell Line Establishment11", "CELL", 155, 180], ["dead cells", "CELL_TYPE", 9, 19], ["all dead cells", "PROBLEM", 5, 19], ["Cell Line Establishment11", "TREATMENT", 155, 180]]], ["Aspirate medium from the 25-cm 2 flask and add 2 ml of PBS.", [["Aspirate", "TEST", 0, 8], ["2 ml of PBS", "TREATMENT", 47, 58], ["medium", "OBSERVATION_MODIFIER", 9, 15], ["25-cm", "OBSERVATION_MODIFIER", 25, 30]]], ["Gently rock the flask before aspirating the PBS.", [["Gently rock the flask", "TREATMENT", 0, 21], ["the PBS", "TREATMENT", 40, 47]]], ["Once cells have reached confluence, split them at 1 in 5 dilution in selection medium.", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10], ["confluence", "OBSERVATION_MODIFIER", 24, 34]]], ["Keep 1 ml of supernatant for affinity precipitation to monitor the secretion level.Cell Line Establishment15.", [["supernatant", "ANATOMY", 13, 24], ["Cell", "ANATOMY", 83, 87], ["Cell Line Establishment15", "CELL", 83, 108], ["affinity precipitation", "TREATMENT", 29, 51], ["the secretion level", "TEST", 63, 82], ["Cell Line Establishment15", "TREATMENT", 83, 108]]], ["When cells reach confluence at the third passage, proceed to Section 3.3.3.2.Single-Cell Isolation1.", [["cells", "ANATOMY", 5, 10], ["Cell", "ANATOMY", 84, 88], ["cells", "CELL", 5, 10], ["Section", "TEST", 61, 68], ["Single-Cell Isolation1", "TREATMENT", 77, 99], ["Cell Isolation1", "OBSERVATION", 84, 99]]], ["Aspirate the medium from the 75-cm 2 flask and add 8-ml PBS.", [["Aspirate", "TEST", 0, 8], ["8-ml PBS", "TREATMENT", 51, 59], ["medium", "OBSERVATION_MODIFIER", 13, 19]]], ["Gently rock the flask before aspirating the PBS.", [["Gently rock the flask", "TREATMENT", 0, 21], ["the PBS", "TREATMENT", 40, 47]]], ["Add 100 ml/well of the diluted cells from step 4 to the 100-ml selection medium in the inner 60 wells of the prepared 96-well plates from step 5.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["diluted cells", "CELL_LINE", 23, 36], ["the diluted cells", "TREATMENT", 19, 36]]], ["Each well now should have less than one cell.Single-Cell Isolation7.", [["cell", "ANATOMY", 40, 44], ["Cell", "ANATOMY", 52, 56], ["cell", "CELL", 40, 44], ["Single-Cell Isolation7", "TREATMENT", 45, 67], ["Cell Isolation7", "OBSERVATION", 52, 67]]], ["Allow colonies to form in 37\u00b0C, 5-8% CO 2 for 10-14 days.Single-Cell IsolationObserve each well under microscope to identify single-colony wells after 10 days.Single-Cell Isolation8.", [["colonies", "ANATOMY", 6, 14], ["Cell", "ANATOMY", 64, 68], ["Cell", "ANATOMY", 166, 170], ["CO 2", "CHEMICAL", 37, 41], ["Cell", "CELL", 64, 68], ["Allow colonies", "CELL_LINE", 0, 14], ["Single-Cell IsolationObserve", "TREATMENT", 57, 85], ["Single-Cell Isolation8", "TREATMENT", 159, 181], ["Cell Isolation8", "OBSERVATION", 166, 181]]], ["When the color of the medium starts to change, transfer all single colonies individually by pipetting up and down into 24-well plates with 1-ml selection medium added to the each well.Single-Cell Isolation9.", [["colonies", "ANATOMY", 67, 75], ["Cell", "ANATOMY", 191, 195], ["1-ml selection medium", "TREATMENT", 139, 160], ["Single-Cell Isolation9", "TREATMENT", 184, 206], ["Cell Isolation9", "OBSERVATION", 191, 206]]], ["Allow monolayer to form in 37\u00b0C, 5-8% CO 2 for 4-6 days.", [["monolayer", "ANATOMY", 6, 15], ["CO 2", "CHEMICAL", 38, 42], ["monolayer", "CELL", 6, 15]]], ["When cells reach 70%-90% confluence, take 0.9 ml of supernatant from each well for immunoprecipitation and Western blotting (Section 3.2.2.2) to assess for the strongest secreting clone.", [["cells", "ANATOMY", 5, 10], ["supernatant", "ANATOMY", 52, 63], ["clone", "ANATOMY", 180, 185], ["cells", "CELL", 5, 10], ["clone", "CELL", 180, 185], ["secreting clone", "CELL_LINE", 170, 185], ["immunoprecipitation", "TREATMENT", 83, 102], ["Western blotting", "TEST", 107, 123], ["Section", "TEST", 125, 132], ["the strongest secreting clone", "PROBLEM", 156, 185]]], ["Replace the selection medium in the 24-well plate.", [["the selection medium", "TREATMENT", 8, 28], ["medium", "OBSERVATION_MODIFIER", 22, 28]]], ["Once the best clone has been determined, it can then be expanded into a larger tissue culture flask.Single-Cell Isolation10.", [["tissue", "ANATOMY", 79, 85], ["Cell", "ANATOMY", 107, 111], ["clone", "CELL", 14, 19], ["tissue", "TISSUE", 79, 85], ["a larger tissue culture flask", "PROBLEM", 70, 99], ["Single-Cell Isolation10", "TREATMENT", 100, 123], ["larger tissue", "OBSERVATION_MODIFIER", 72, 85], ["culture flask", "OBSERVATION", 86, 99]]], ["Aspirate the medium from the well of the selected clone, add 1 ml PBS.", [["clone", "ANATOMY", 50, 55], ["clone", "CELL", 50, 55], ["Aspirate", "TEST", 0, 8], ["1 ml PBS", "TREATMENT", 61, 69]]], ["Add 0.3 ml trypsin-EDTA after removing the PBS and allow trypsinization for 3 s.", [["trypsin-EDTA", "CHEMICAL", 11, 23], ["EDTA", "CHEMICAL", 19, 23], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 11, 23], ["trypsin", "PROTEIN", 11, 18], ["EDTA", "TREATMENT", 19, 23], ["the PBS", "TREATMENT", 39, 46], ["trypsinization", "TREATMENT", 57, 71]]], ["Remove trypsin and resuspend cells in 1 ml DMEM-10.Single-Cell Isolation11.", [["cells", "ANATOMY", 29, 34], ["Cell", "ANATOMY", 58, 62], ["trypsin", "GENE_OR_GENE_PRODUCT", 7, 14], ["cells", "CELL", 29, 34], ["trypsin", "PROTEIN", 7, 14], ["trypsin and resuspend cells", "TREATMENT", 7, 34], ["Single-Cell Isolation11", "TREATMENT", 51, 74], ["Cell Isolation11", "OBSERVATION", 58, 74]]], ["Transfer the resuspended cells into a 75-cm 2 tissue culture flask added with 19 ml of selection medium.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["resuspended cells", "CELL_TYPE", 13, 30], ["the resuspended cells", "TREATMENT", 9, 30], ["a 75-cm 2 tissue culture flask", "TREATMENT", 36, 66], ["selection medium", "TREATMENT", 87, 103]]], ["Allow the cells to grow to confluence in 37\u00b0C, 5-8% CO 2 ; this may take up to 1 week.Single-Cell Isolation12.", [["cells", "ANATOMY", 10, 15], ["Cell", "ANATOMY", 93, 97], ["CO 2", "CHEMICAL", 52, 56], ["cells", "CELL", 10, 15], ["Single-Cell Isolation12", "TREATMENT", 86, 109], ["Cell Isolation12", "OBSERVATION", 93, 109]]], ["Repeat the cloning (Steps 1-11) at least once to ensure stable expression and to obtain the best possible secreting clone.Single-Cell Isolation13.", [["clone", "ANATOMY", 116, 121], ["Cell", "ANATOMY", 129, 133], ["clone", "CELL", 116, 121], ["secreting clone", "CELL_LINE", 106, 121], ["secreting clone", "PROBLEM", 106, 121], ["Single-Cell Isolation13", "TREATMENT", 122, 145], ["stable", "OBSERVATION", 56, 62]]], ["Once a desirable clone has been obtained, expand the cell to larger flasks for freezing to keep as stock.", [["cell", "ANATOMY", 53, 57], ["clone", "CELL", 17, 22], ["cell", "CELL", 53, 57]]], ["Proceed to Section 3.2.4 for protein expression.Cell Culture for ExpressionOnce a stable cell line has been established, it can then be grown into roller bottles for larger-scale protein production.", [["Cell", "ANATOMY", 48, 52], ["cell line", "ANATOMY", 89, 98], ["Cell", "CELL", 48, 52], ["cell line", "CELL", 89, 98], ["stable cell line", "CELL_LINE", 82, 98], ["protein expression", "PROBLEM", 29, 47], ["Cell Culture", "TEST", 48, 60], ["a stable cell line", "TREATMENT", 80, 98], ["larger-scale protein production", "PROBLEM", 166, 197], ["stable", "OBSERVATION_MODIFIER", 82, 88], ["cell line", "OBSERVATION", 89, 98]]], ["The following protocol describes the large-scale production of secreted sF from 293T cells in roller bottles.", [["293T cells", "ANATOMY", 80, 90], ["sF", "GENE_OR_GENE_PRODUCT", 72, 74], ["293T cells", "CELL", 80, 90], ["sF", "PROTEIN", 72, 74], ["293T cells", "CELL_LINE", 80, 90], ["large", "OBSERVATION_MODIFIER", 37, 42]]], ["For protein expression, addition of selection antibiotic is not necessary.", [["protein expression", "PROBLEM", 4, 22], ["selection antibiotic", "TREATMENT", 36, 56]]], ["Because of the weak adherent nature of 293T derivative cells, gelatin treatment of the roller bottle surface is necessary to avoid the formation of cell clumps which will decrease the protein secretion level.", [["293T derivative cells", "ANATOMY", 39, 60], ["bottle surface", "ANATOMY", 94, 108], ["cell clumps", "ANATOMY", 148, 159], ["gelatin", "CHEMICAL", 62, 69], ["293T derivative cells", "CELL", 39, 60], ["gelatin", "SIMPLE_CHEMICAL", 62, 69], ["cell", "CELL", 148, 152], ["293T derivative cells", "CELL_LINE", 39, 60], ["293T derivative cells", "TREATMENT", 39, 60], ["gelatin treatment", "TREATMENT", 62, 79], ["the roller bottle surface", "TREATMENT", 83, 108], ["cell clumps", "PROBLEM", 148, 159], ["the protein secretion level", "PROBLEM", 180, 207], ["weak", "OBSERVATION_MODIFIER", 15, 19], ["adherent", "OBSERVATION_MODIFIER", 20, 28], ["293T derivative cells", "OBSERVATION", 39, 60], ["cell clumps", "OBSERVATION", 148, 159]]], ["Wash the cells with 50 ml PBS gently without disturbing the monolayer and remove the PBS.Cell Culture for Expression7.", [["cells", "ANATOMY", 9, 14], ["monolayer", "ANATOMY", 60, 69], ["Cell", "ANATOMY", 89, 93], ["cells", "CELL", 9, 14], ["monolayer", "CELL", 60, 69], ["Cell", "CELL", 89, 93], ["the cells", "TREATMENT", 5, 14], ["disturbing the monolayer", "TREATMENT", 45, 69], ["the PBS", "TREATMENT", 81, 88], ["Cell Culture", "TEST", 89, 101], ["Expression7", "TEST", 106, 117]]], ["Add 120 ml of OptiMEM and pump with CO 2 to each roller bottle as described in Section 3.1.1.1, Step 6.Cell Culture for Expression8.", [["Cell", "ANATOMY", 103, 107], ["CO 2", "CHEMICAL", 36, 40], ["Cell", "CELL", 103, 107], ["OptiMEM and pump with CO 2 to each roller bottle", "TREATMENT", 14, 62], ["Cell Culture", "TEST", 103, 115], ["Expression8", "TEST", 120, 131]]], ["Allow protein secretion for 4-5 days or until the cell starts to detach.", [["cell", "ANATOMY", 50, 54], ["cell", "CELL", 50, 54], ["protein secretion", "PROBLEM", 6, 23]]], ["Harvest the supernatant as described in Section 3.1.1.3.S-Affinity PurificationThis step is essentially similar to Section 3.1.2.2 except replacing all buffers to the list in Section 2.5.3 and omitting the PBS wash in step 5.", [["supernatant", "ANATOMY", 12, 23], ["Harvest", "TREATMENT", 0, 7], ["Affinity Purification", "TREATMENT", 58, 79], ["the PBS wash", "TREATMENT", 202, 214], ["essentially", "OBSERVATION_MODIFIER", 92, 103], ["similar", "OBSERVATION", 104, 111]]], ["The protein concentration and yield can then be estimated.", [["The protein concentration", "TREATMENT", 0, 25]]], ["We use the Bradford method (44) to estimate the protein concentration at 595-nm OD.", [["the Bradford method", "TREATMENT", 7, 26]]], ["At this point, a small portion of the purified protein can be analyzed on SDS-PAGE follow by Coomassie staining (Fig. 2.3 ).", [["Coomassie", "CHEMICAL", 93, 102], ["Coomassie", "SIMPLE_CHEMICAL", 93, 102], ["purified protein", "PROTEIN", 38, 54], ["the purified protein", "TREATMENT", 34, 54], ["SDS", "TEST", 74, 77], ["Coomassie staining", "TEST", 93, 111], ["Fig.", "TEST", 113, 117], ["small", "OBSERVATION_MODIFIER", 17, 22]]], ["Proceed to Section 3.3 for molecular weight purification.Molecular Weight Purification by Gel FiltrationFollowing S-affinity purification, the concentrated purified protein can be analyzed on SDS-PAGE followed by Coomassie staining to assess the purity and yield.", [["Coomassie", "CHEMICAL", 213, 222], ["Coomassie", "SIMPLE_CHEMICAL", 213, 222], ["concentrated purified protein", "PROTEIN", 143, 172], ["molecular weight purification", "TREATMENT", 27, 56], ["Molecular Weight Purification", "TREATMENT", 57, 86], ["Gel Filtration", "TREATMENT", 90, 104], ["S-affinity purification", "TREATMENT", 114, 137], ["the concentrated purified protein", "TREATMENT", 139, 172]]], ["In most cases, there will be presence of small amount of contaminating proteins especially when purification is done from serum medium.", [["serum", "ANATOMY", 122, 127], ["serum", "ORGANISM_SUBSTANCE", 122, 127], ["contaminating proteins", "PROTEIN", 57, 79], ["small amount of contaminating proteins", "PROBLEM", 41, 79], ["serum medium", "TEST", 122, 134], ["small", "OBSERVATION_MODIFIER", 41, 46], ["amount", "OBSERVATION_MODIFIER", 47, 53]]], ["Hence, further purification is needed.", [["further purification", "TREATMENT", 7, 27]]], ["Gel filtration chromatography separates molecules on the basis of size.", [["Gel filtration chromatography", "TEST", 0, 29], ["size", "OBSERVATION_MODIFIER", 66, 70]]], ["This method can also be used to estimate the molecular masses of globular proteins in their native condition base on their migration through a chromatographic matrix packed in a column.", [["matrix", "CELLULAR_COMPONENT", 159, 165], ["globular proteins", "PROTEIN", 65, 82], ["This method", "TREATMENT", 0, 11], ["the molecular masses of globular proteins", "PROBLEM", 41, 82], ["a chromatographic matrix packed in a column", "TREATMENT", 141, 184], ["masses", "OBSERVATION", 55, 61], ["globular proteins", "OBSERVATION", 65, 82], ["column", "ANATOMY", 178, 184]]], ["Pre-packed columns with various matrix of different fractionation range are available commercially from GE healthcare.Molecular Weight Purification by Gel FiltrationThe approximate molecular mass of a certain protein can be estimated from a calibrated curve obtained from a series of standard proteins with known molecular masses.", [["matrix", "CELLULAR_COMPONENT", 32, 38], ["Pre-packed columns", "TREATMENT", 0, 18], ["Molecular Weight Purification", "TREATMENT", 118, 147], ["Gel Filtration", "TREATMENT", 151, 165], ["The approximate molecular mass", "PROBLEM", 165, 195], ["a calibrated curve", "TEST", 239, 257], ["known molecular masses", "PROBLEM", 307, 329], ["fractionation range", "OBSERVATION", 52, 71], ["molecular", "OBSERVATION_MODIFIER", 181, 190], ["mass", "OBSERVATION", 191, 195], ["molecular", "OBSERVATION_MODIFIER", 313, 322], ["masses", "OBSERVATION", 323, 329]]], ["Standard calibration protein kits can be obtained commercially from, for example, GE healthcare, Sigma, etc., with well-described calibrating protocols.", [["Standard calibration protein kits", "TEST", 0, 33]]], ["Once the molecular weight of the different oligomeric species has been determined, a preparative chromatography can be carried out to isolate the desired oligomeric species.Molecular Weight Purification by Gel FiltrationHere, we describe the use of a calibrated Superdex 200 10/ 300 GL gel filtration column to estimate the approximate molecular mass of the different oligomeric species of the soluble viral glycoprotein using example of HeV and NiV sF GCN.", [["HeV", "ORGANISM", 438, 441], ["NiV", "ORGANISM", 446, 449], ["oligomeric species", "PROTEIN", 154, 172], ["oligomeric species", "PROTEIN", 368, 386], ["soluble viral glycoprotein", "PROTEIN", 394, 420], ["NiV sF GCN", "PROTEIN", 446, 456], ["HeV", "SPECIES", 438, 441], ["NiV sF GCN", "SPECIES", 446, 456], ["a preparative chromatography", "TEST", 83, 111], ["a calibrated Superdex", "TREATMENT", 249, 270], ["GL gel filtration column", "TREATMENT", 283, 307], ["the approximate molecular mass", "PROBLEM", 320, 350], ["the soluble viral glycoprotein", "TREATMENT", 390, 420], ["oligomeric species", "OBSERVATION", 154, 172], ["mass", "OBSERVATION", 346, 350], ["oligomeric species", "OBSERVATION", 368, 386]]], ["We also describe the use of HiLoad 16/60 Superdex 200 prep grade gel filtration column XK 16 to separate the different oligomeric species of affinity-purified sF.Analytic ChromatographyBefore analyzing the soluble viral glycoprotein, calibrate the column with a series of protein standards.", [["sF", "GENE_OR_GENE_PRODUCT", 159, 161], ["affinity-purified sF", "PROTEIN", 141, 161], ["soluble viral glycoprotein", "PROTEIN", 206, 232], ["HiLoad", "TREATMENT", 28, 34], ["Superdex", "TREATMENT", 41, 49], ["prep grade gel filtration column XK", "TREATMENT", 54, 89], ["Analytic ChromatographyBefore", "TEST", 162, 191], ["the soluble viral glycoprotein", "TREATMENT", 202, 232], ["a series of protein standards", "TREATMENT", 260, 289]]], ["The Superdex 200 10/300 GL gel filtration column employed here has been calibrated with the molecular weights (29-669 kDa) calibration kit.", [["The Superdex", "TREATMENT", 0, 12], ["GL gel filtration column", "TREATMENT", 24, 48], ["the molecular weights", "TEST", 88, 109]]], ["As depicted in Fig. 2.4 , the calibration curve generated was used to estimate the approximate size of the HeV sF GCN.", [["HeV", "ORGANISM", 107, 110], ["HeV sF GCN", "PROTEIN", 107, 117], ["HeV sF GCN", "SPECIES", 107, 117], ["Fig.", "TEST", 15, 19], ["the calibration curve", "TEST", 26, 47], ["size", "OBSERVATION_MODIFIER", 95, 99], ["HeV sF GCN", "OBSERVATION", 107, 117]]], ["Welldescribed calibrating protocols are included in commercially available gel filtration molecular weights calibration kit.", [["Welldescribed calibrating protocols", "TREATMENT", 0, 35], ["gel filtration", "TREATMENT", 75, 89]]], ["Below is a simple procedure used to determine the approximate size of the sF.Analytic Chromatography1.", [["sF", "DNA", 74, 76], ["a simple procedure", "TREATMENT", 9, 27], ["size", "OBSERVATION_MODIFIER", 62, 66]]], ["The inlet tubing of the column should be connected to the appropriate buffer through the P-500 pump.", [["The inlet tubing of the column", "TREATMENT", 0, 30], ["the P-500 pump", "TREATMENT", 85, 99], ["inlet tubing", "OBSERVATION", 4, 16], ["column", "ANATOMY", 24, 30]]], ["Set the back pressure limit to 1.5 MPa.Analytic Chromatography2.", [["the back pressure limit", "TEST", 4, 27]]], ["Connect the column outlet tubing to the optical unit through a flow cell of the UV detector.Analytic Chromatography3.", [["cell", "ANATOMY", 68, 72], ["the column outlet tubing", "TREATMENT", 8, 32], ["column", "OBSERVATION", 12, 18], ["outlet tubing", "OBSERVATION", 19, 32], ["flow cell", "OBSERVATION", 63, 72], ["UV detector", "OBSERVATION", 80, 91]]], ["Wash the column with at least 3 \u00c2 column volume (3 \u00c2 24 ml) with sterile deionized water with a flow rate of 24 ml/h.4.Equilibrate the column with the appropriate protein buffer from Section 2.5 with at least 3 \u00c2 of the column volume with the same flow rate.4.5.", [["Wash the column", "TREATMENT", 0, 15], ["3 \u00c2 column volume", "TREATMENT", 30, 47], ["sterile deionized water", "TREATMENT", 65, 88], ["a flow rate", "TREATMENT", 94, 105], ["the column volume", "TEST", 216, 233], ["column", "ANATOMY", 9, 15], ["column", "OBSERVATION_MODIFIER", 135, 141], ["column volume", "OBSERVATION", 220, 233], ["flow rate", "OBSERVATION", 248, 257]]], ["Set the sensitivity to 1.0 ABS for 3-5 mg of sF, sG, and gp140 and 0.2 ABS for 70 ml of the recommended concentration of the protein standards.", [["gp140", "PROTEIN", 57, 62], ["Set the sensitivity", "TEST", 0, 19], ["ABS", "TEST", 27, 30], ["sG", "TEST", 49, 51], ["gp140", "TREATMENT", 57, 62], ["the protein standards", "TREATMENT", 121, 142]]], ["Do not exceed 5 mg of protein and 500 ml of sample volume.", [["sample", "ANATOMY", 44, 50], ["protein", "TREATMENT", 22, 29], ["sample volume", "TEST", 44, 57]]], ["Apply each protein standards as a separate run.4.6.", [["each protein standards", "TREATMENT", 6, 28]]], ["Set the baseline for the UV detector and set the chart speed to 30 cm/h.", [["the UV detector", "TEST", 21, 36]]], ["Proceed to next step for sample application once a stable baseline is observed.4.7.", [["sample", "ANATOMY", 25, 31], ["sample application", "TREATMENT", 25, 43], ["stable", "OBSERVATION_MODIFIER", 51, 57]]], ["Stop the pump and disconnect the column's inlet tubing from the pump.", [["the pump", "TREATMENT", 5, 13], ["the column's inlet tubing", "TREATMENT", 29, 54], ["the pump", "TREATMENT", 60, 68]]], ["Apply affinity-purified protein or protein standard to the column by using a 1-ml syringe and reconnect the input tubing to the pump.", [["affinity-purified protein", "PROTEIN", 6, 31], ["affinity-purified protein", "TREATMENT", 6, 31], ["a 1-ml syringe", "TREATMENT", 75, 89], ["the input tubing", "TREATMENT", 104, 120], ["the pump", "TREATMENT", 124, 132], ["input tubing", "OBSERVATION", 108, 120]]], ["Use the same sample volume for all protein standards and the unknown sample.", [["sample", "ANATOMY", 13, 19], ["all protein standards", "TREATMENT", 31, 52]]], ["Wash the column with at least 2 \u00c2 column volume of sterile deionized water followed by 3 \u00c2 column volume of 20% ethanol.", [["ethanol", "CHEMICAL", 112, 119], ["ethanol", "CHEMICAL", 112, 119], ["ethanol", "SIMPLE_CHEMICAL", 112, 119], ["Wash the column", "TREATMENT", 0, 15], ["sterile deionized water", "TREATMENT", 51, 74], ["3 \u00c2 column volume", "TREATMENT", 87, 104], ["column", "ANATOMY", 9, 15]]], ["Store column in 20% ethanol.4.12.", [["ethanol", "CHEMICAL", 20, 27], ["ethanol", "CHEMICAL", 20, 27], ["ethanol", "SIMPLE_CHEMICAL", 20, 27], ["column", "OBSERVATION_MODIFIER", 6, 12]]], ["Obtain the elution volume (V e ) by measuring the volume of the eluent from the point of sample application to the center of the elution peak.", [["the elution volume (V e )", "TREATMENT", 7, 32], ["the eluent", "TREATMENT", 60, 70], ["the elution peak", "TEST", 125, 141], ["elution peak", "OBSERVATION", 129, 141]]], ["Determine the void volume (V o ), which is the V e of blue dextran (2 mg/ml).", [["blue dextran", "CHEMICAL", 54, 66], ["blue dextran", "SIMPLE_CHEMICAL", 54, 66], ["the void volume", "TEST", 10, 25], ["the V e of blue dextran", "TREATMENT", 43, 66]]], ["Calculate the K av values for each protein by using the formula4.where V c is the total column volume.", [["K av", "GENE_OR_GENE_PRODUCT", 14, 18], ["V c", "GENE_OR_GENE_PRODUCT", 71, 74], ["V c", "PROTEIN", 71, 74], ["the K av values", "TEST", 10, 25], ["each protein", "TEST", 30, 42], ["the formula4", "TREATMENT", 52, 64], ["the total column volume", "TREATMENT", 78, 101], ["total", "OBSERVATION_MODIFIER", 82, 87], ["column volume", "OBSERVATION", 88, 101]]], ["Generate a calibration curve by plotting the calculated K av for each protein standard against the log of the known molecular weight.4.15.", [["K", "CHEMICAL", 56, 57], ["K av", "PROTEIN", 56, 60], ["a calibration curve", "TEST", 9, 28], ["the calculated K av", "TREATMENT", 41, 60]]], ["Calculate the estimated molecular weight of the soluble viral glycoprotein from the calibrated curve.4.16.", [["soluble viral glycoprotein", "PROTEIN", 48, 74], ["the soluble viral glycoprotein", "TREATMENT", 44, 74], ["the calibrated curve", "TEST", 80, 100]]], ["Take 2-10 ml from each fraction of all peaks from the soluble glycoprotein for native gel analysis (Section 3.5) to observe the oligomeric species.", [["soluble glycoprotein", "PROTEIN", 54, 74], ["the soluble glycoprotein", "TREATMENT", 50, 74], ["native gel analysis", "TEST", 79, 98], ["the oligomeric species", "PROBLEM", 124, 146], ["oligomeric species", "OBSERVATION", 128, 146]]], ["Figure 2 .5 shows a representative result of 3.", [["Figure", "TEST", 0, 6]]], ["Pool the selected peak fractions and concentrate it to 1 ml using Centriprep 1 molecular weight cut-off centrifugal filter units.4.4.", [["the selected peak fractions", "TREATMENT", 5, 32], ["Centriprep", "TREATMENT", 66, 76], ["centrifugal filter units", "TREATMENT", 104, 128]]], ["Observe 2-10 mg of the purified protein again on a native gel.", [["purified protein", "PROTEIN", 23, 39], ["the purified protein", "TREATMENT", 19, 39], ["a native gel", "TREATMENT", 49, 61]]], ["Figure 2 .6C shows the purified HeV sF GCN trimer on a native gel.Sucrose Gradient UltracentrifugationNative oligomeric forms of the purified soluble glycoprotein can also be analyzed by sucrose gradient centrifugation.", [["sucrose", "CHEMICAL", 187, 194], ["Sucrose", "CHEMICAL", 66, 73], ["sucrose", "CHEMICAL", 187, 194], ["HeV", "ORGANISM", 32, 35], ["Sucrose", "SIMPLE_CHEMICAL", 66, 73], ["sucrose", "SIMPLE_CHEMICAL", 187, 194], ["purified HeV sF GCN trimer", "PROTEIN", 23, 49], ["purified soluble glycoprotein", "PROTEIN", 133, 162], ["Figure", "TEST", 0, 6], ["a native gel", "TREATMENT", 53, 65], ["Sucrose Gradient Ultracentrifugation", "TREATMENT", 66, 102], ["the purified soluble glycoprotein", "TREATMENT", 129, 162], ["sucrose gradient centrifugation", "TREATMENT", 187, 218], ["HeV sF", "OBSERVATION", 32, 38], ["GCN trimer", "OBSERVATION", 39, 49]]], ["As shown in Fig. 2 .7, two species (large aggregate and trimer) of HeV sF GCN were observed in the sucrose gradient.", [["sucrose", "CHEMICAL", 99, 106], ["sucrose", "CHEMICAL", 99, 106], ["HeV", "ORGANISM", 67, 70], ["sF GCN", "GENE_OR_GENE_PRODUCT", 71, 77], ["sucrose", "SIMPLE_CHEMICAL", 99, 106], ["HeV sF GCN", "PROTEIN", 67, 77], ["two species", "PROBLEM", 23, 34], ["HeV sF GCN", "TEST", 67, 77], ["large", "OBSERVATION_MODIFIER", 36, 41], ["aggregate", "OBSERVATION_MODIFIER", 42, 51], ["sF GCN", "OBSERVATION", 71, 77], ["sucrose gradient", "OBSERVATION", 99, 115]]], ["This is consistent with the gel filtration profile as shown in Fig. 2 5.", [["the gel filtration profile", "TEST", 24, 50], ["consistent with", "UNCERTAINTY", 8, 23]]], ["Collect fractions of approximately 800 ml from the bottom of the gradient using a Beckman fraction recovery system and automated fraction collector.Sucrose Gradient Ultracentrifugation6.", [["Sucrose", "CHEMICAL", 148, 155], ["Sucrose", "SIMPLE_CHEMICAL", 148, 155], ["Collect fractions", "TEST", 0, 17], ["a Beckman fraction recovery system", "TREATMENT", 80, 114], ["Sucrose Gradient Ultracentrifugation6", "TREATMENT", 148, 185], ["bottom", "ANATOMY_MODIFIER", 51, 57], ["gradient", "OBSERVATION_MODIFIER", 65, 73], ["fraction collector", "OBSERVATION", 129, 147]]], ["Take 15 ml from each fraction for native gel analysis to observe the oligomeric species.Native Gel Analysis by BN-PAGE SystemNative gel analysis allows the visualization of the soluble glycoprotein on polyacrylamide gel electrophoresis in its native form.", [["polyacrylamide", "CHEMICAL", 201, 215], ["soluble glycoprotein", "PROTEIN", 177, 197], ["native gel analysis", "TEST", 34, 53], ["the oligomeric species", "PROBLEM", 65, 87], ["the soluble glycoprotein", "TREATMENT", 173, 197], ["polyacrylamide gel electrophoresis", "TREATMENT", 201, 235], ["oligomeric species", "OBSERVATION", 69, 87]]], ["This allows the estimation of the size of the native oligomeric species.", [["native oligomeric species", "PROTEIN", 46, 71], ["size", "OBSERVATION_MODIFIER", 34, 38], ["native", "OBSERVATION_MODIFIER", 46, 52], ["oligomeric species", "OBSERVATION", 53, 71]]], ["It is most helpful in analyzing the fractions separated from gel filtration and sucrose gradient.", [["sucrose", "CHEMICAL", 80, 87], ["sucrose", "CHEMICAL", 80, 87], ["sucrose", "SIMPLE_CHEMICAL", 80, 87], ["gel filtration", "TREATMENT", 61, 75], ["sucrose gradient", "TREATMENT", 80, 96], ["most helpful", "UNCERTAINTY", 6, 18], ["sucrose gradient", "OBSERVATION", 80, 96]]], ["Many modifications have been made based on the original method, for example, in observing the native forms of HIV-1 Env (30, 46, 47) .", [["HIV-1 Env", "ORGANISM", 110, 119], ["HIV-1", "SPECIES", 110, 115], ["HIV-1", "SPECIES", 110, 115], ["HIV", "TEST", 110, 113], ["HIV", "OBSERVATION", 110, 113]]], ["We find that the commercially available BN-PAGE system from Invitrogen Corp. is most suitable for our soluble glycoprotein analysis.", [["Invitrogen Corp.", "ORGANISM", 60, 76], ["glycoprotein", "PROTEIN", 110, 122], ["our soluble glycoprotein analysis", "TEST", 98, 131]]], ["In this BN-PAGE system, the Coomassie 1 G-250 binds to proteins and confers a negative charge while maintaining the proteins in their native state.", [["Coomassie 1 G-250", "CHEMICAL", 28, 45], ["Coomassie 1 G-250", "SIMPLE_CHEMICAL", 28, 45], ["Coomassie 1 G-250", "SPECIES", 28, 45], ["the Coomassie", "TREATMENT", 24, 37]]], ["Below are the procedures we use to analyze our soluble glycoproteins using the BN-PAGE system followed by Western blotting.Prepare samples as followsFor 20 ml, add 5 ml of 4X NativePAGE TM sample buffer and 0.5 ml of NativePAGE TM 5% G-250 to 14.5 ml of protein sample.", [["samples", "ANATOMY", 131, 138], ["soluble glycoproteins", "PROTEIN", 47, 68], ["the procedures", "TREATMENT", 10, 24], ["our soluble glycoproteins", "TREATMENT", 43, 68], ["4X NativePAGE TM sample buffer", "TREATMENT", 172, 202], ["NativePAGE TM", "TREATMENT", 217, 230], ["protein sample", "TEST", 254, 268]]], ["Set up the electrophoresis system using the NativePAGE TM Novex 1 3-12% Bis-Tris Gels 1.0 mm, 15 well and the XCell SureLock TM Mini-Cell as described by the manufacturer.", [["Cell", "ANATOMY", 133, 137], ["Bis-Tris Gels", "CHEMICAL", 72, 85], ["Bis-Tris Gels", "SIMPLE_CHEMICAL", 72, 85], ["the NativePAGE TM Novex", "TREATMENT", 40, 63]]], ["Rinse the wells with 1X running buffer and load the samples before adding the cathode buffer.Prepare samples as follows5.", [["samples", "ANATOMY", 52, 59], ["samples", "ANATOMY", 101, 108], ["1X running buffer", "TREATMENT", 21, 38], ["the cathode buffer", "TREATMENT", 74, 92]]], ["Load 5 ml of NativeMark TM Unstained Protein Standard for Coomassie stain and 7 ml added with 1 ml of 5% G-250 for Western blotting.Prepare samples as follows6.", [["samples", "ANATOMY", 140, 147], ["G-250", "CHEMICAL", 105, 110], ["Coomassie", "CHEMICAL", 58, 67], ["Coomassie", "SIMPLE_CHEMICAL", 58, 67], ["G-250", "SIMPLE_CHEMICAL", 105, 110], ["NativeMark TM", "TREATMENT", 13, 26], ["Coomassie stain", "TEST", 58, 73]]], ["Perform the electrophoresis at 150 V for 2 h at room temperature.Coomassie StainThe G-250 in the cathode buffer stains the proteins during electrophoresis.", [["G-250", "CHEMICAL", 84, 89], ["Coomassie", "CHEMICAL", 65, 74], ["G-250", "CHEMICAL", 84, 89], ["Coomassie", "SIMPLE_CHEMICAL", 65, 74], ["G-250", "SIMPLE_CHEMICAL", 84, 89], ["the electrophoresis", "TEST", 8, 27], ["Coomassie Stain", "TEST", 65, 80], ["The G", "TEST", 80, 85], ["the cathode buffer", "TREATMENT", 93, 111], ["electrophoresis", "TEST", 139, 154]]], ["Therefore, further staining is not required.", [["further staining", "TEST", 11, 27]]], ["However, this depends on the sensitivity required.", [["the sensitivity", "TEST", 25, 40]]], ["After electrophoresis, place gel in container with fixing solution enough to cover the gel.", [["electrophoresis", "TREATMENT", 6, 21], ["fixing solution", "TREATMENT", 51, 66]]], ["Microwave the gel to near-boiling and cool for 1 min on an orbital shaker.Notes1.", [["Notes1", "PROTEIN", 74, 80], ["Microwave the gel", "TREATMENT", 0, 17], ["orbital", "ANATOMY", 59, 66], ["shaker", "OBSERVATION", 67, 73]]], ["Tris is an inhibitor for DTSSP cross-linker.", [["Tris", "CHEMICAL", 0, 4], ["DTSSP cross-linker", "SIMPLE_CHEMICAL", 25, 43], ["Tris", "TREATMENT", 0, 4], ["an inhibitor", "TREATMENT", 8, 20], ["DTSSP cross-linker", "TREATMENT", 25, 43]]], ["If DTSSP will be used with the protein in downstream analysis, HEPES can be used as an alternate neutralization buffer.Notes2.", [["HEPES", "CHEMICAL", 63, 68], ["DTSSP", "SIMPLE_CHEMICAL", 3, 8], ["HEPES", "SIMPLE_CHEMICAL", 63, 68], ["DTSSP", "PROTEIN", 3, 8], ["Notes2", "PROTEIN", 119, 125], ["DTSSP", "PROBLEM", 3, 8], ["the protein in downstream analysis", "TEST", 27, 61], ["HEPES", "TREATMENT", 63, 68], ["an alternate neutralization buffer", "TREATMENT", 84, 118]]], ["Arginine prevents protein aggregation and is used in protein refolding.", [["Arginine", "CHEMICAL", 0, 8], ["Arginine", "CHEMICAL", 0, 8], ["Arginine", "SIMPLE_CHEMICAL", 0, 8], ["Arginine", "TREATMENT", 0, 8], ["protein aggregation", "PROBLEM", 18, 37], ["protein refolding", "TREATMENT", 53, 70], ["protein aggregation", "OBSERVATION", 18, 37]]], ["It also helps in elution of proteins and antibody.", [["antibody", "PROTEIN", 41, 49], ["proteins and antibody", "PROBLEM", 28, 49]]], ["Addition of arginine is optional, but we find that it is necessary for sF purification.Notes3.", [["arginine", "CHEMICAL", 12, 20], ["arginine", "CHEMICAL", 12, 20], ["arginine", "AMINO_ACID", 12, 20], ["sF", "PROTEIN", 71, 73], ["Notes3", "PROTEIN", 87, 93], ["arginine", "TREATMENT", 12, 20], ["sF purification", "TREATMENT", 71, 86]]], ["Cells should be very dense.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["very", "OBSERVATION_MODIFIER", 16, 20], ["dense", "OBSERVATION", 21, 26]]], ["Estimation of the following days of incubation for cell growth is based on each T-150 flask containing greater than 3.0 \u00c2 10 7 cells.", [["cell", "ANATOMY", 51, 55], ["cells", "ANATOMY", 127, 132], ["cell", "CELL", 51, 55], ["cells", "CELL", 127, 132], ["incubation", "TREATMENT", 36, 46], ["cell growth", "TEST", 51, 62], ["each T", "TEST", 75, 81]]], ["To obtain the maximum yield of pure protein, the cells must be very dense when seeded into roller bottles and when infected with purified recombinant vaccinia virus.Notes4.", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["recombinant vaccinia virus", "ORGANISM", 138, 164], ["Notes4", "PROTEIN", 165, 171], ["vaccinia virus", "SPECIES", 150, 164], ["purified recombinant vaccinia virus", "TREATMENT", 129, 164], ["vaccinia virus", "OBSERVATION", 150, 164]]], ["Ensure cell clumps are broken up by repeatedly pipetting the suspension up and down.", [["cell", "ANATOMY", 7, 11], ["cell", "CELL", 7, 11], ["Ensure cell clumps", "TREATMENT", 0, 18], ["cell clumps", "OBSERVATION", 7, 18]]], ["An even cell suspension is necessary for an even monolayer in the roller bottles.", [["cell", "ANATOMY", 8, 12], ["monolayer", "ANATOMY", 49, 58], ["cell", "CELL", 8, 12], ["monolayer", "CELL", 49, 58], ["An even cell suspension", "TREATMENT", 0, 23], ["an even monolayer in the roller bottles", "TREATMENT", 41, 80], ["cell suspension", "OBSERVATION", 8, 23]]], ["Formation of cell clumps in the roller bottles will decrease the protein yield.5.A 10-ml pipette without a cotton stopper is connected to a tube that connects to a 10% CO 2 , 90% air tank with a pressure controller and indicator; a 0.2-mm filter membrane should be connected to the tubing.5.6.", [["cell", "ANATOMY", 13, 17], ["tube", "ANATOMY", 140, 144], ["membrane", "ANATOMY", 246, 254], ["CO", "CHEMICAL", 168, 170], ["cell", "CELL", 13, 17], ["tube", "TISSUE", 140, 144], ["cell clumps", "PROBLEM", 13, 24], ["the roller bottles", "TREATMENT", 28, 46], ["a cotton stopper", "TREATMENT", 105, 121], ["a tube", "TREATMENT", 138, 144], ["a 10% CO", "TREATMENT", 162, 170], ["a pressure controller", "TREATMENT", 193, 214], ["a 0.2-mm filter membrane", "TREATMENT", 230, 254], ["the tubing", "TREATMENT", 278, 288], ["cell clumps", "OBSERVATION", 13, 24], ["tube", "OBSERVATION", 140, 144], ["air tank", "OBSERVATION", 179, 187], ["tubing", "OBSERVATION", 282, 288]]], ["Pre-wet the filter unit membrane with PBS, 0.1% Triton 1 X-100 or the appropriate washing buffer before filtering the supernatant.", [["filter unit membrane", "ANATOMY", 12, 32], ["supernatant", "ANATOMY", 118, 129], ["Triton 1 X-100", "CHEMICAL", 48, 62], ["Triton 1 X-100", "SIMPLE_CHEMICAL", 48, 62], ["Pre-wet the filter unit membrane", "TREATMENT", 0, 32], ["PBS", "TREATMENT", 38, 41], ["0.1% Triton", "TREATMENT", 43, 54], ["the appropriate washing buffer", "TREATMENT", 66, 96], ["filter", "OBSERVATION", 12, 18]]], ["This can be done by filtering 50-100 mlL of wash buffer prior to sample filtering.", [["sample", "ANATOMY", 65, 71], ["wash buffer", "TREATMENT", 44, 55]]], ["We find that this procedure will decrease protein lost during filtration.", [["this procedure", "TREATMENT", 13, 27], ["decrease protein", "PROBLEM", 33, 49]]], ["This step is essential for purification of sF.5.7.", [["sF.5.7", "PROTEIN", 43, 49], ["purification", "TEST", 27, 39]]], ["Gelatin treatment is optional.", [["Gelatin", "CHEMICAL", 0, 7], ["Gelatin", "GENE_OR_GENE_PRODUCT", 0, 7], ["Gelatin treatment", "TREATMENT", 0, 17]]], ["However for 293T and derivatives cells, gelatin-treated surface allows the cells to adhere better during the medium-changing procedures of transfection and hence yields better transfection results.", [["293T", "ANATOMY", 12, 16], ["cells", "ANATOMY", 33, 38], ["surface", "ANATOMY", 56, 63], ["cells", "ANATOMY", 75, 80], ["gelatin", "CHEMICAL", 40, 47], ["293T", "CELL", 12, 16], ["derivatives cells", "CELL", 21, 38], ["gelatin", "SIMPLE_CHEMICAL", 40, 47], ["cells", "CELL", 75, 80], ["derivatives cells", "CELL_LINE", 21, 38], ["derivatives cells", "TREATMENT", 21, 38], ["gelatin", "TREATMENT", 40, 47], ["the cells", "TREATMENT", 71, 80], ["changing procedures of transfection", "TREATMENT", 116, 151]]], ["Coat 2 ml per well of sterile 0.1% Gelatin onto a six-well tissue culture plate.", [["Gelatin", "SIMPLE_CHEMICAL", 35, 42], ["tissue", "TISSUE", 59, 65], ["sterile 0.1% Gelatin", "TREATMENT", 22, 42]]], ["Rinse twice with sterile PBS before using.5.8.", [["Rinse", "TREATMENT", 0, 5], ["sterile PBS", "TREATMENT", 17, 28]]], ["Use this medium for S-column purification as described in Section 3.2.5.", [["S-column purification", "TREATMENT", 20, 41]]], ["There will still be contaminating serum protein at this stage.", [["serum", "ANATOMY", 34, 39], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["serum protein", "PROTEIN", 34, 47], ["contaminating serum protein", "PROBLEM", 20, 47]]], ["Apply the neutralized elution to another round of S-column purification in smaller scale.", [["the neutralized elution", "TREATMENT", 6, 29], ["S-column purification", "TREATMENT", 50, 71]]], ["Scale down all buffers for 2 ml bed volume of S-Agarose.", [["S-Agarose", "CHEMICAL", 46, 55], ["S-Agarose", "PROBLEM", 46, 55]]], ["Use 10 ml Poly-Prep Chromatography Columns (Bio-Rad Laboratories, Inc).", [["10 ml Poly-Prep Chromatography Columns", "TREATMENT", 4, 42]]], ["The flow rate is entirely depending on gravity.", [["The flow rate", "TEST", 0, 13], ["flow rate", "OBSERVATION", 4, 13]]], ["Depending on the expected protein yield, several columns may be required.5.It is estimated that 1 ml bed volume of S-Agarose is able to capture at least 1 mg sF.", [["several columns", "TREATMENT", 41, 56], ["S-Agarose", "TREATMENT", 115, 124]]], ["We use three columns for sF GCN and more than 6 mg can be recovered from supernatant of ten roller bottles.", [["supernatant", "ANATOMY", 73, 84], ["GCN", "CHEMICAL", 28, 31], ["three columns for sF GCN", "TREATMENT", 7, 31]]]], "a13b8a9cfa381774d3d48973920658307bdca601": [["IntroductionAcute respiratory infections (ARIs) are the leading causes of morbidity and mortality throughout the world, particularly in developing nations [1] .", [["respiratory", "ANATOMY", 18, 29], ["IntroductionAcute respiratory infections", "DISEASE", 0, 40], ["ARIs", "DISEASE", 42, 46], ["IntroductionAcute respiratory infections (ARIs)", "PROBLEM", 0, 47], ["morbidity", "PROBLEM", 74, 83], ["respiratory", "ANATOMY", 18, 29], ["infections", "OBSERVATION", 30, 40], ["morbidity", "OBSERVATION", 74, 83]]], ["Respiratory syncytial virus (RSV) is the most common viral cause of lower respiratory tract infection in young children, followed by parainfluenza viruses (PIVs) types 1, 2 and 3, influenza virus A and B, and adenoviruses.", [["lower respiratory tract", "ANATOMY", 68, 91], ["Respiratory syncytial virus (RSV)", "DISEASE", 0, 33], ["respiratory tract infection", "DISEASE", 74, 101], ["parainfluenza viruses", "DISEASE", 133, 154], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["lower", "ORGANISM", 68, 73], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["children", "ORGANISM", 111, 119], ["parainfluenza viruses", "ORGANISM", 133, 154], ["3", "GENE_OR_GENE_PRODUCT", 177, 178], ["influenza virus A", "ORGANISM", 180, 197], ["B", "GENE_OR_GENE_PRODUCT", 202, 203], ["adenoviruses", "ORGANISM", 209, 221], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["children", "SPECIES", 111, 119], ["parainfluenza", "SPECIES", 133, 146], ["influenza virus", "SPECIES", 180, 195], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["parainfluenza viruses", "SPECIES", 133, 154], ["Respiratory syncytial virus (RSV", "PROBLEM", 0, 32], ["lower respiratory tract infection", "PROBLEM", 68, 101], ["parainfluenza viruses", "PROBLEM", 133, 154], ["influenza virus A and B", "PROBLEM", 180, 203], ["adenoviruses", "PROBLEM", 209, 221], ["syncytial virus", "OBSERVATION", 12, 27], ["most common", "OBSERVATION_MODIFIER", 41, 52], ["lower", "ANATOMY_MODIFIER", 68, 73], ["respiratory tract", "ANATOMY", 74, 91], ["infection", "OBSERVATION", 92, 101]]], ["However, the characteristics of viral transmission are poorly understood.", [["viral", "OBSERVATION", 32, 37]]], ["Significant understanding is required about the role of household contacts, persistence and recurrence, re-infection, potentially predisposing risk factors, age-related risks, and the effect of prior exposure and past strain infection are not well defined.", [["infection", "DISEASE", 225, 234], ["recurrence", "PROBLEM", 92, 102], ["re-infection", "PROBLEM", 104, 116], ["prior exposure", "PROBLEM", 194, 208], ["past strain infection", "PROBLEM", 213, 234]]], ["Insight into the aforementioned information will arm us with more potent way of tackling infectious viral epidemics and lower the burden of healthcare cost.IntroductionHousehold studies [2] [3] [4] [5] and community studies [6] [7] [8] show RSV to re-infect repeatedly throughout life, which points to a potentially significant role for re-infections within the population that may be fundamental to RSV persistence within the community.", [["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 186, 201], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 224, 235], ["RSV", "ORGANISM", 241, 244], ["RSV", "ORGANISM", 400, 403], ["RSV", "SPECIES", 241, 244], ["RSV", "SPECIES", 400, 403], ["tackling infectious viral epidemics", "PROBLEM", 80, 115], ["Household studies", "TEST", 168, 185], ["community studies", "TEST", 206, 223], ["RSV", "PROBLEM", 241, 244], ["re-infections", "PROBLEM", 337, 350], ["may be", "UNCERTAINTY", 378, 384], ["RSV", "OBSERVATION", 400, 403]]], ["Finally, RSV is typical of many viral infections with respect to inducing less than solid immunity, and being antigenically and genotypically diverse.IntroductionIn addition to being the leading cause of upper and lower respiratory tract infections in infants and young children [9] , RSV is the most common cause of bronchitis and pneumonia in children younger than one year of age [10] .", [["lower respiratory tract", "ANATOMY", 214, 237], ["RSV", "DISEASE", 9, 12], ["viral infections", "DISEASE", 32, 48], ["respiratory tract infections", "DISEASE", 220, 248], ["RSV", "DISEASE", 285, 288], ["bronchitis", "DISEASE", 317, 327], ["pneumonia", "DISEASE", 332, 341], ["RSV", "ORGANISM", 9, 12], ["solid", "CANCER", 84, 89], ["upper", "ORGANISM_SUBDIVISION", 204, 209], ["lower", "ORGANISM_SUBDIVISION", 214, 219], ["respiratory tract", "ORGANISM_SUBDIVISION", 220, 237], ["infants", "ORGANISM", 252, 259], ["children", "ORGANISM", 270, 278], ["RSV", "ORGANISM", 285, 288], ["children", "ORGANISM", 345, 353], ["infants", "SPECIES", 252, 259], ["children", "SPECIES", 270, 278], ["children", "SPECIES", 345, 353], ["RSV", "SPECIES", 9, 12], ["RSV", "SPECIES", 285, 288], ["RSV", "PROBLEM", 9, 12], ["many viral infections", "PROBLEM", 27, 48], ["upper and lower respiratory tract infections", "PROBLEM", 204, 248], ["RSV", "PROBLEM", 285, 288], ["bronchitis", "PROBLEM", 317, 327], ["pneumonia", "PROBLEM", 332, 341], ["RSV", "OBSERVATION", 9, 12], ["many", "OBSERVATION_MODIFIER", 27, 31], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infections", "OBSERVATION", 38, 48], ["upper", "ANATOMY_MODIFIER", 204, 209], ["lower", "ANATOMY_MODIFIER", 214, 219], ["respiratory tract", "ANATOMY", 220, 237], ["infections", "OBSERVATION", 238, 248], ["most common", "OBSERVATION_MODIFIER", 296, 307], ["bronchitis", "OBSERVATION", 317, 327], ["pneumonia", "OBSERVATION", 332, 341]]], ["The peak incidence of RSV infection occurs in children aged 2-8 months [11] , with over half of all children being infected with RSV by their first birthday [12] .IntroductionDuring each influenza season, it has been estimated that 30-40% of school-aged children develop symptomatic infection and that they are the main source for transmission to healthy adults and children, and to those in high-risk groups [13] [14] [15] [16] [17] [18] .", [["RSV infection", "DISEASE", 22, 35], ["RSV", "DISEASE", 129, 132], ["infection", "DISEASE", 283, 292], ["[13] [14] [15] [16] [17] [18]", "CHEMICAL", 409, 438], ["RSV", "ORGANISM", 22, 25], ["children", "ORGANISM", 46, 54], ["children", "ORGANISM", 100, 108], ["RSV", "ORGANISM", 129, 132], ["children", "ORGANISM", 254, 262], ["children", "ORGANISM", 366, 374], ["[13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 409, 438], ["children", "SPECIES", 46, 54], ["children", "SPECIES", 100, 108], ["children", "SPECIES", 254, 262], ["children", "SPECIES", 366, 374], ["RSV", "SPECIES", 22, 25], ["RSV", "SPECIES", 129, 132], ["RSV infection", "PROBLEM", 22, 35], ["symptomatic infection", "PROBLEM", 271, 292], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["RSV", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["infected", "OBSERVATION", 115, 123], ["symptomatic", "OBSERVATION_MODIFIER", 271, 282], ["infection", "OBSERVATION", 283, 292]]], ["Of the children who develop symptomatic influenza infection, only a small proportion are admitted to hospital and it is likely that hospital admissions may represent only a small part of the total influenzaassociated morbidity [19, 20] .IntroductionUniversal influenza vaccinations is not (yet) recommended for children; this is partly due to lack of data regarding the burden of laboratory-confirmed influenza in children making a meaningful cost effectiveness analysis of a universal influenza vaccination program difficult.", [["influenza infection", "DISEASE", 40, 59], ["influenza", "DISEASE", 401, 410], ["children", "ORGANISM", 7, 15], ["children", "ORGANISM", 311, 319], ["children", "ORGANISM", 414, 422], ["children", "SPECIES", 7, 15], ["children", "SPECIES", 311, 319], ["children", "SPECIES", 414, 422], ["symptomatic influenza infection", "PROBLEM", 28, 59], ["the total influenzaassociated morbidity", "PROBLEM", 187, 226], ["IntroductionUniversal influenza vaccinations", "TREATMENT", 237, 281], ["influenza", "PROBLEM", 401, 410], ["a universal influenza vaccination program", "TREATMENT", 474, 515], ["symptomatic", "OBSERVATION_MODIFIER", 28, 39], ["influenza", "OBSERVATION", 40, 49], ["infection", "OBSERVATION", 50, 59], ["small", "OBSERVATION_MODIFIER", 68, 73], ["small", "OBSERVATION_MODIFIER", 173, 178]]], ["Decisions regarding the introduction of influenza vaccine in healthy children require an accurate evaluation of influenza disease burden in the inpatient and outpatient settings, as well as the socioeconomic impact of the disease.", [["influenza disease", "DISEASE", 112, 129], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["influenza vaccine", "TREATMENT", 40, 57], ["an accurate evaluation", "TEST", 86, 108], ["influenza disease burden", "PROBLEM", 112, 136], ["the disease", "PROBLEM", 218, 229], ["influenza", "OBSERVATION", 112, 121], ["disease", "OBSERVATION", 222, 229]]], ["The aim of this study was to examine the transmission of influenza and other respiratory viruses from children to their family member in the household.", [["influenza", "DISEASE", 57, 66], ["respiratory viruses", "DISEASE", 77, 96], ["influenza", "ORGANISM", 57, 66], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["this study", "TEST", 11, 21], ["influenza", "PROBLEM", 57, 66], ["other respiratory viruses", "PROBLEM", 71, 96], ["respiratory viruses", "OBSERVATION", 77, 96]]], ["Our results give an estimation of the extent and impact of respiratory viruses, including influenza, in a cohort of children attending the emergency department but not admitted to hospital.MethodsAs described before [21] , an initial prospective, clusterrandomized trial of the effect of mask use on respiratory virus transmission in households was conducted during two successive winter seasons between 2006 and 2007 in Sydney, Australia.", [["respiratory viruses", "DISEASE", 59, 78], ["influenza", "DISEASE", 90, 99], ["respiratory virus transmission", "DISEASE", 300, 330], ["children", "ORGANISM", 116, 124], ["respiratory virus", "ORGANISM", 300, 317], ["children", "SPECIES", 116, 124], ["respiratory viruses", "PROBLEM", 59, 78], ["influenza", "PROBLEM", 90, 99], ["mask use", "TREATMENT", 288, 296], ["respiratory virus transmission", "TREATMENT", 300, 330], ["respiratory viruses", "OBSERVATION", 59, 78]]], ["The current study was conducted prospectively as an extension of the aforementioned over three consecutive winters between 2006 and 2008 in Sydney, Australia.", [["The current study", "TEST", 0, 17]]], ["The hospital acts as a specialized tertiary referral hospital for the western metropolitan area of Sydney, Australia, which has a population of 1.5 million people, and 15 local government areas.", [["people", "SPECIES", 156, 162]]], ["Over 70,000 sick children and their families are cared for each year in this area [22] .", [["children", "ORGANISM", 17, 25], ["children", "SPECIES", 17, 25]]], ["The study protocol was approved by the Human Research Ethics Committee of the Children's Hospital at Westmead.RecruitmentChildren aged <1-15 years presenting with ILI (an ILI was defined as fever >38 \u2022 C and cough and/or sore throat in the absence of a known cause), but who were not subsequently admitted to hospital were identified using an electronic triage system.", [["ILI", "DISEASE", 163, 166], ["ILI", "DISEASE", 171, 174], ["fever", "DISEASE", 190, 195], ["cough", "DISEASE", 208, 213], ["sore throat", "DISEASE", 221, 232], ["Human", "ORGANISM", 39, 44], ["Human", "SPECIES", 39, 44], ["Children", "SPECIES", 121, 129], ["The study protocol", "TEST", 0, 18], ["ILI", "PROBLEM", 163, 166], ["an ILI", "PROBLEM", 168, 174], ["fever", "PROBLEM", 190, 195], ["cough", "PROBLEM", 208, 213], ["sore throat", "PROBLEM", 221, 232]]], ["Inclusion criteria for the families were that all household members were healthy at the time the child was presented to the emergency department (ED), and that they agreed to follow-up for the duration of the study.Follow-up and case definitionAn investigator-administered questionnaire was used to collect information on symptoms, relevant medical history including medication, influenza vaccination status and health related visits prior to the ED visit.", [["child", "ORGANISM", 97, 102], ["the study", "TEST", 205, 214], ["symptoms", "PROBLEM", 322, 330], ["medication", "TREATMENT", 367, 377]]], ["A combined nose and throat swab was collected from the index child for nucleic acid testing using a multiplex PCR assay.", [["nose", "ANATOMY", 11, 15], ["throat swab", "ANATOMY", 20, 31], ["nucleic acid", "CHEMICAL", 71, 83], ["nose", "ORGANISM_SUBDIVISION", 11, 15], ["throat swab", "ORGANISM_SUBSTANCE", 20, 31], ["A combined nose and throat swab", "PROBLEM", 0, 31], ["nucleic acid testing", "TEST", 71, 91], ["a multiplex PCR assay", "TEST", 98, 119], ["nose", "ANATOMY", 11, 15], ["throat", "ANATOMY", 20, 26]]], ["All children were discharged from ED on the same day.Follow-up and case definitionTwo adult family members from the child's direct household (i.e. parents/caregivers or siblings aged 16 years and older) were followed up for a week to determine if they developed an ILI.", [["ILI", "DISEASE", 265, 268], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12], ["child", "SPECIES", 116, 121], ["an ILI", "PROBLEM", 262, 268], ["ILI", "OBSERVATION", 265, 268]]], ["During this follow up period we also collected information regarding the course of the child's illness, requirement for medical visits, and work absenteeism.Follow-up and case definitionIf the two family members developed respiratory disease symptoms on follow up (fever, myalgia, arthralgia, sore throat, cough, sneezing, runny nose, nasal congestion, and headache), a home visit was conducted on the same day and swabs were collected and tested for a range of respiratory viruses.Laboratory testingAn in-house multiplex, real-time, reverse transcriptase polymerase chain reaction (RT-PCR; primer and probe sequences available on request) for influenza A and B, parainfluenzaviruses, RSV, picornavirus (enterovirus, rhinovirus), adenoviruses, coronaviruses 229E and OC43, and human metapneumovirus (hMPV) was performed [23] .", [["respiratory", "ANATOMY", 222, 233], ["nasal", "ANATOMY", 335, 340], ["swabs", "ANATOMY", 415, 420], ["illness", "DISEASE", 95, 102], ["respiratory disease", "DISEASE", 222, 241], ["fever", "DISEASE", 265, 270], ["myalgia", "DISEASE", 272, 279], ["arthralgia", "DISEASE", 281, 291], ["sore throat", "DISEASE", 293, 304], ["cough", "DISEASE", 306, 311], ["sneezing", "DISEASE", 313, 321], ["runny nose", "DISEASE", 323, 333], ["nasal congestion", "DISEASE", 335, 351], ["headache", "DISEASE", 357, 365], ["respiratory viruses", "DISEASE", 462, 481], ["RSV, picornavirus (enterovirus, rhinovirus)", "DISEASE", 685, 728], ["human metapneumovirus", "DISEASE", 777, 798], ["throat", "ORGANISM_SUBDIVISION", 298, 304], ["nasal", "ORGANISM_SUBDIVISION", 335, 340], ["influenza A", "ORGANISM", 644, 655], ["B", "GENE_OR_GENE_PRODUCT", 660, 661], ["parainfluenzaviruses", "GENE_OR_GENE_PRODUCT", 663, 683], ["RSV", "ORGANISM", 685, 688], ["picornavirus", "ORGANISM", 690, 702], ["enterovirus", "ORGANISM", 704, 715], ["rhinovirus", "ORGANISM", 717, 727], ["adenoviruses", "ORGANISM", 730, 742], ["coronaviruses 229E", "ORGANISM", 744, 762], ["OC43", "GENE_OR_GENE_PRODUCT", 767, 771], ["human", "ORGANISM", 777, 782], ["metapneumovirus", "ORGANISM", 783, 798], ["hMPV", "ORGANISM", 800, 804], ["reverse transcriptase", "PROTEIN", 534, 555], ["RSV", "SPECIES", 685, 688], ["human", "SPECIES", 777, 782], ["metapneumovirus", "SPECIES", 783, 798], ["RSV", "SPECIES", 685, 688], ["human metapneumovirus", "SPECIES", 777, 798], ["hMPV", "SPECIES", 800, 804], ["respiratory disease symptoms", "PROBLEM", 222, 250], ["fever", "PROBLEM", 265, 270], ["myalgia", "PROBLEM", 272, 279], ["arthralgia", "PROBLEM", 281, 291], ["sore throat", "PROBLEM", 293, 304], ["cough", "PROBLEM", 306, 311], ["sneezing", "PROBLEM", 313, 321], ["runny nose", "PROBLEM", 323, 333], ["nasal congestion", "PROBLEM", 335, 351], ["headache", "PROBLEM", 357, 365], ["swabs", "TEST", 415, 420], ["Laboratory testingAn", "TEST", 482, 502], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 534, 581], ["RT-PCR", "TEST", 583, 589], ["primer and probe sequences", "TEST", 591, 617], ["influenza", "PROBLEM", 644, 653], ["parainfluenzaviruses", "PROBLEM", 663, 683], ["RSV", "PROBLEM", 685, 688], ["picornavirus", "PROBLEM", 690, 702], ["enterovirus", "PROBLEM", 704, 715], ["rhinovirus", "PROBLEM", 717, 727], ["adenoviruses", "PROBLEM", 730, 742], ["coronaviruses", "PROBLEM", 744, 757], ["OC43", "PROBLEM", 767, 771], ["human metapneumovirus (hMPV", "TEST", 777, 804], ["sore throat", "ANATOMY", 293, 304], ["runny nose", "ANATOMY", 323, 333], ["nasal", "ANATOMY", 335, 340], ["congestion", "OBSERVATION", 341, 351], ["respiratory viruses", "OBSERVATION", 462, 481], ["RSV", "ANATOMY", 685, 688]]], ["The method was evaluated against respiratory virus antigen positive (by immunofluorescence) upper respiratory tract samples (55 cases of RSV, 35 influenza B, 60 influenza A, 45 parainfluenzaviruses, 25 hMPV, 50 adenoviruses), and PCR positive (all confirmed by sequencing) upper respiratory tract samples (68 cases of rhinovirus and 20 enterovirus infections), and 150 antigen negative samples.", [["upper respiratory tract samples", "ANATOMY", 92, 123], ["upper respiratory tract samples", "ANATOMY", 273, 304], ["samples", "ANATOMY", 386, 393], ["influenza B", "DISEASE", 145, 156], ["influenza A", "DISEASE", 161, 172], ["enterovirus infections", "DISEASE", 336, 358], ["upper respiratory tract samples", "CANCER", 92, 123], ["RSV", "ORGANISM", 137, 140], ["A", "CANCER", 171, 172], ["parainfluenzaviruses", "CANCER", 177, 197], ["hMPV", "ORGANISM", 202, 206], ["adenoviruses", "ORGANISM", 211, 223], ["upper respiratory tract samples", "CANCER", 273, 304], ["rhinovirus", "ORGANISM", 318, 328], ["enterovirus", "ORGANISM", 336, 347], ["respiratory virus", "SPECIES", 33, 50], ["RSV", "SPECIES", 137, 140], ["hMPV", "SPECIES", 202, 206], ["The method", "TEST", 0, 10], ["respiratory virus antigen", "TEST", 33, 58], ["immunofluorescence", "TEST", 72, 90], ["upper respiratory tract samples", "TEST", 92, 123], ["RSV", "TEST", 137, 140], ["influenza B", "TEST", 145, 156], ["influenza A", "TEST", 161, 172], ["parainfluenzaviruses", "TEST", 177, 197], ["hMPV", "TEST", 202, 206], ["PCR positive", "PROBLEM", 230, 242], ["upper respiratory tract samples", "TEST", 273, 304], ["rhinovirus", "PROBLEM", 318, 328], ["20 enterovirus infections", "PROBLEM", 333, 358], ["upper", "ANATOMY_MODIFIER", 92, 97], ["respiratory tract", "ANATOMY", 98, 115], ["upper", "ANATOMY_MODIFIER", 273, 278], ["respiratory tract", "ANATOMY", 279, 296]]], ["The sensitivity of the real-time PCR for RSV, influenza A, influenza B, parainfluenza, hMPV and adenoviruses was 15% higher than antigen detection by immunofluorescence (testing both the antigen positive and negative samples) and the specificity was 100%.", [["samples", "ANATOMY", 217, 224], ["influenza A", "DISEASE", 46, 57], ["influenza B", "DISEASE", 59, 70], ["parainfluenza", "DISEASE", 72, 85], ["RSV", "ORGANISM", 41, 44], ["influenza A", "ORGANISM", 46, 57], ["influenza B", "ORGANISM", 59, 70], ["parainfluenza", "ORGANISM", 72, 85], ["hMPV", "ORGANISM", 87, 91], ["adenoviruses", "ORGANISM", 96, 108], ["samples", "CANCER", 217, 224], ["influenza B", "SPECIES", 59, 70], ["parainfluenza", "SPECIES", 72, 85], ["hMPV", "SPECIES", 87, 91], ["RSV", "SPECIES", 41, 44], ["influenza A", "SPECIES", 46, 57], ["hMPV", "SPECIES", 87, 91], ["the real-time PCR", "TEST", 19, 36], ["RSV", "PROBLEM", 41, 44], ["influenza", "PROBLEM", 46, 55], ["influenza B", "TEST", 59, 70], ["parainfluenza", "PROBLEM", 72, 85], ["hMPV", "PROBLEM", 87, 91], ["adenoviruses", "TEST", 96, 108], ["antigen detection", "TEST", 129, 146], ["immunofluorescence", "TEST", 150, 168], ["the antigen", "TEST", 183, 194], ["the specificity", "TEST", 230, 245]]], ["All coronavirus positive samples in the study were confirmed by sequencing.Statistical analysisData were analyzed using Epi Info TM (CDC, USA, version 3.3.2).", [["samples", "ANATOMY", 25, 32], ["coronavirus", "ORGANISM", 4, 15], ["All coronavirus positive samples", "TEST", 0, 32], ["the study", "TEST", 36, 45], ["Statistical analysisData", "TEST", 75, 99], ["Epi", "TEST", 120, 123], ["version", "TEST", 143, 150], ["coronavirus", "OBSERVATION_MODIFIER", 4, 15]]], ["Descriptive statistics was used to describe age, symptoms, and vaccination rates, etc. Comparison among groups was made with the Fisher exact test for categorical variables.", [["symptoms", "PROBLEM", 49, 57], ["vaccination rates", "TREATMENT", 63, 80], ["the Fisher exact test", "TEST", 125, 146]]], ["A paired t test p value <0.05 was considered significant.Study populationDemographic, clinical and laboratory information on 168 children with ILI and their families were analyzed (Table 1) .", [["ILI", "DISEASE", 143, 146], ["children", "ORGANISM", 129, 137], ["children", "SPECIES", 129, 137], ["A paired t test p value", "TEST", 0, 23], ["ILI", "PROBLEM", 143, 146]]], ["Sixty-three percent of the children (107/168) attended some form of childcare, leaving 61 (36%) children with no structured exposure of this type to other children outside the home.", [["children", "ORGANISM", 27, 35], ["children", "ORGANISM", 96, 104], ["children", "ORGANISM", 155, 163], ["children", "SPECIES", 27, 35], ["children", "SPECIES", 96, 104], ["children", "SPECIES", 155, 163]]], ["39/168 (23%) children had a Table 1 Characteristics of children/families with and without a child with a laboratoryconfirmed infection.", [["infection", "DISEASE", 125, 134], ["children", "ORGANISM", 13, 21], ["children", "ORGANISM", 55, 63], ["children", "SPECIES", 13, 21], ["children", "SPECIES", 55, 63], ["a laboratoryconfirmed infection", "PROBLEM", 103, 134], ["infection", "OBSERVATION", 125, 134]]], ["Table 3 , influenza and rhinoviruses were the most common viruses detected.", [["influenza and rhinoviruses", "DISEASE", 10, 36], ["influenza", "ORGANISM", 10, 19], ["rhinoviruses", "ORGANISM", 24, 36], ["influenza", "PROBLEM", 10, 19], ["rhinoviruses", "PROBLEM", 24, 36], ["rhinoviruses", "OBSERVATION", 24, 36]]], ["The remaining ten children had dual or co-infection-adenovirus and rhinovirus in 4/166 (2.4%), rhinovirus and coronavirus OC43 in 2/166, and one child with each of influenza A and enterovirus, influenza A and rhinovirus, RSV and enterovirus, and adenovirus and hMPV.Study populationNo single symptom was predictive of influenza when compared to other viral causes of ILI.", [["rhinovirus and coronavirus OC43", "DISEASE", 95, 126], ["influenza A", "DISEASE", 164, 175], ["influenza A and rhinovirus, RSV and enterovirus, and adenovirus and hMPV", "DISEASE", 193, 265], ["influenza", "DISEASE", 318, 327], ["ILI", "DISEASE", 367, 370], ["children", "ORGANISM", 18, 26], ["adenovirus", "ORGANISM", 52, 62], ["rhinovirus", "ORGANISM", 67, 77], ["rhinovirus", "ORGANISM", 95, 105], ["coronavirus OC43", "ORGANISM", 110, 126], ["child", "ORGANISM", 145, 150], ["influenza A", "ORGANISM", 164, 175], ["enterovirus", "ORGANISM", 180, 191], ["influenza A", "ORGANISM", 193, 204], ["rhinovirus", "ORGANISM", 209, 219], ["RSV", "ORGANISM", 221, 224], ["enterovirus", "ORGANISM", 229, 240], ["adenovirus", "ORGANISM", 246, 256], ["hMPV", "ORGANISM", 261, 265], ["children", "SPECIES", 18, 26], ["coronavirus", "SPECIES", 110, 121], ["child", "SPECIES", 145, 150], ["influenza A and rhinovirus", "SPECIES", 193, 219], ["RSV", "SPECIES", 221, 224], ["coronavirus OC43", "SPECIES", 110, 126], ["influenza A", "SPECIES", 164, 175], ["influenza A", "SPECIES", 193, 204], ["RSV", "SPECIES", 221, 224], ["adenovirus", "SPECIES", 246, 256], ["hMPV", "SPECIES", 261, 265], ["dual or co-infection", "PROBLEM", 31, 51], ["adenovirus", "PROBLEM", 52, 62], ["rhinovirus", "PROBLEM", 67, 77], ["rhinovirus", "PROBLEM", 95, 105], ["coronavirus OC43", "PROBLEM", 110, 126], ["influenza A", "PROBLEM", 164, 175], ["enterovirus", "PROBLEM", 180, 191], ["influenza A", "PROBLEM", 193, 204], ["rhinovirus", "PROBLEM", 209, 219], ["RSV", "PROBLEM", 221, 224], ["enterovirus", "PROBLEM", 229, 240], ["adenovirus", "PROBLEM", 246, 256], ["hMPV", "PROBLEM", 261, 265], ["Study population", "TEST", 266, 282], ["single symptom", "PROBLEM", 285, 299], ["influenza", "PROBLEM", 318, 327], ["ILI", "PROBLEM", 367, 370], ["co-infection", "OBSERVATION", 39, 51], ["coronavirus OC43", "OBSERVATION", 110, 126], ["influenza", "OBSERVATION", 164, 173], ["single", "OBSERVATION_MODIFIER", 285, 291], ["symptom", "OBSERVATION", 292, 299], ["ILI", "OBSERVATION", 367, 370]]], ["However, when compared with RSV, the latter manifested as a lower respiratory tract infection, namely, with respiratory distress and wheezing whereas influenza cases were more likely to experience high fever (>39 \u2022 C).", [["lower respiratory tract", "ANATOMY", 60, 83], ["respiratory", "ANATOMY", 108, 119], ["respiratory tract infection", "DISEASE", 66, 93], ["respiratory distress", "DISEASE", 108, 128], ["wheezing", "DISEASE", 133, 141], ["influenza", "DISEASE", 150, 159], ["fever", "DISEASE", 202, 207], ["RSV", "ORGANISM", 28, 31], ["respiratory tract", "ORGANISM_SUBDIVISION", 66, 83], ["RSV", "SPECIES", 28, 31], ["RSV", "PROBLEM", 28, 31], ["a lower respiratory tract infection", "PROBLEM", 58, 93], ["respiratory distress", "PROBLEM", 108, 128], ["wheezing", "PROBLEM", 133, 141], ["influenza cases", "PROBLEM", 150, 165], ["high fever", "PROBLEM", 197, 207], ["lower", "ANATOMY_MODIFIER", 60, 65], ["respiratory tract", "ANATOMY", 66, 83], ["infection", "OBSERVATION", 84, 93], ["respiratory distress", "OBSERVATION", 108, 128]]], ["There was also no difference between laboratory positive and negative children in regards to the number or type of symptoms they reported.", [["children", "ORGANISM", 70, 78], ["children", "SPECIES", 70, 78], ["symptoms", "PROBLEM", 115, 123], ["no", "UNCERTAINTY", 15, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28]]], ["The factor significantly associated with children being diagnosed with a laboratory-confirmed infection was age \u22641 year (RR: 0.78, 95% CI: 0.62-0.98, p = <0.05).", [["infection", "DISEASE", 94, 103], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["infection", "PROBLEM", 94, 103], ["RR", "TEST", 121, 123], ["CI", "TEST", 135, 137], ["p", "TEST", 150, 151], ["infection", "OBSERVATION", 94, 103]]], ["Being from a larger family or having more than three children in the household, or attending some form of childcare was not a significant association. pathogen detected.", [["children", "ORGANISM", 53, 61], ["children", "SPECIES", 53, 61], ["pathogen", "PROBLEM", 151, 159]]], ["Viral pathogens were detected in 42.3% (11/26) of the symptomatic family members.", [["Viral", "ORGANISM", 0, 5], ["Viral pathogens", "TEST", 0, 15]]], ["In all 11 cases only a single pathogen was isolated: two cases each of RSV and adenovirus, and one case each of PIV-3 and coronavirus OC43.", [["RSV and adenovirus", "DISEASE", 71, 89], ["RSV", "ORGANISM", 71, 74], ["adenovirus", "ORGANISM", 79, 89], ["PIV-3", "GENE_OR_GENE_PRODUCT", 112, 117], ["coronavirus", "ORGANISM", 122, 133], ["coronavirus", "SPECIES", 122, 133], ["RSV", "SPECIES", 71, 74], ["adenovirus", "SPECIES", 79, 89], ["PIV-3", "SPECIES", 112, 117], ["a single pathogen", "PROBLEM", 21, 38], ["RSV", "PROBLEM", 71, 74], ["adenovirus", "TREATMENT", 79, 89], ["PIV", "TEST", 112, 115], ["coronavirus OC43", "PROBLEM", 122, 138]]], ["Other viruses detected included picornaviruses (4/11 rhinoviruses, 1/11 uncharacterized non-sequenced picornavirus).", [["rhinoviruses", "ORGANISM", 53, 65], ["Other viruses", "PROBLEM", 0, 13], ["picornaviruses", "PROBLEM", 32, 46], ["rhinoviruses", "PROBLEM", 53, 65], ["viruses", "OBSERVATION", 6, 13]]], ["In 6/11 cases, the virus detected for the adult family members was the same as what was detected in their child.", [["the virus", "PROBLEM", 15, 24]]], ["Only one case was detected where the parent had a laboratory-confirmed infection and the child did not.", [["infection", "DISEASE", 71, 80], ["child", "ORGANISM", 89, 94], ["infection", "PROBLEM", 71, 80], ["infection", "OBSERVATION", 71, 80]]], ["The lower estimate of the household risk of transmission of respiratory viruses, based on concordant, proven infection in both child and adult, from a single sick child to adult household contacts is therefore 3% per week.", [["respiratory viruses", "DISEASE", 60, 79], ["infection", "DISEASE", 109, 118], ["respiratory viruses", "PROBLEM", 60, 79], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["respiratory viruses", "OBSERVATION", 60, 79], ["infection", "OBSERVATION", 109, 118]]], ["It is known that adults have a lower rate of laboratory detection of viral infections compared to children, and this was confirmed in our study, with only 42% of symptomatic family members compared to 60% of symptomatic children, being PCR positive for a respiratory virus.", [["viral infections", "DISEASE", 69, 85], ["respiratory virus", "DISEASE", 255, 272], ["adults", "ORGANISM", 17, 23], ["children", "ORGANISM", 98, 106], ["children", "ORGANISM", 220, 228], ["children", "SPECIES", 98, 106], ["children", "SPECIES", 220, 228], ["viral infections", "PROBLEM", 69, 85], ["our study", "TEST", 134, 143], ["PCR", "TEST", 236, 239], ["a respiratory virus", "PROBLEM", 253, 272], ["viral infections", "OBSERVATION", 69, 85], ["respiratory virus", "OBSERVATION", 255, 272]]], ["Based on symptoms, the rate of transmission could be as high as 12% per week.", [["symptoms", "PROBLEM", 9, 17]]], ["In some cases, two adults took time off (26/128, 25%).Study populationWe found that among the healthy children \u226415 years of age meeting a clinical case definition of ILI, 60% were found to have a laboratory-confirmed respiratory virus.", [["ILI", "DISEASE", 166, 169], ["respiratory virus", "DISEASE", 217, 234], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["Study populationWe", "TEST", 54, 72], ["a laboratory", "TEST", 194, 206], ["respiratory virus", "PROBLEM", 217, 234], ["respiratory virus", "OBSERVATION", 217, 234]]], ["The results of this study demonstrated that influenza A, rhinoviruses and picornaviruses were the most commonly detected viruses from pediatric outpatients using an ILI definition that included a fever \u226538 \u2022 C.Study populationIn a previous study based on epidemiology surveillance data it was estimated that influenza accounted for 24-35% of excess outpatient visits observed in children less than 3 years of age during the winter [24] .", [["influenza A, rhinoviruses and picornaviruses", "DISEASE", 44, 88], ["fever", "DISEASE", 196, 201], ["influenza", "DISEASE", 308, 317], ["influenza A", "ORGANISM", 44, 55], ["rhinoviruses", "ORGANISM", 57, 69], ["picornaviruses", "ORGANISM", 74, 88], ["outpatients", "ORGANISM", 144, 155], ["children", "ORGANISM", 379, 387], ["outpatients", "SPECIES", 144, 155], ["children", "SPECIES", 379, 387], ["influenza A", "SPECIES", 44, 55], ["this study", "TEST", 15, 25], ["influenza A", "PROBLEM", 44, 55], ["rhinoviruses", "PROBLEM", 57, 69], ["picornaviruses", "PROBLEM", 74, 88], ["a fever", "PROBLEM", 194, 201], ["a previous study", "TEST", 229, 245], ["epidemiology surveillance data", "TEST", 255, 285], ["influenza", "PROBLEM", 308, 317], ["influenza", "OBSERVATION", 44, 53]]], ["In response to this finding was the assumption by Tsolia et al. that even if other viruses are co-circulating in the community it appears that influenza predominates and is the main cause of respiratory morbidity in outpatients [25] .", [["respiratory", "ANATOMY", 191, 202], ["influenza", "DISEASE", 143, 152], ["respiratory morbidity", "DISEASE", 191, 212], ["other viruses", "PROBLEM", 77, 90], ["influenza", "PROBLEM", 143, 152], ["respiratory morbidity", "PROBLEM", 191, 212], ["influenza", "OBSERVATION", 143, 152], ["respiratory morbidity", "OBSERVATION", 191, 212]]], ["This may be true in other settings but in our cohort, influenza A and B only accounted for 37% of the laboratory-confirmed illnesses.", [["influenza A and B", "DISEASE", 54, 71], ["influenza A", "ORGANISM", 54, 65], ["B", "CANCER", 70, 71], ["influenza", "PROBLEM", 54, 63], ["illnesses", "PROBLEM", 123, 132], ["may be", "UNCERTAINTY", 5, 11]]], ["A range of different viruses were detected.DiscussionThis study provides quantitative, prospective data on rates of household transmission of infection from children to adults, and shows that defined ILI symptoms may not differentiate between infection with influenza or other respiratory viruses.", [["infection", "DISEASE", 142, 151], ["infection", "DISEASE", 243, 252], ["influenza", "DISEASE", 258, 267], ["respiratory viruses", "DISEASE", 277, 296], ["children", "ORGANISM", 157, 165], ["children", "SPECIES", 157, 165], ["different viruses", "PROBLEM", 11, 28], ["This study", "TEST", 53, 63], ["infection", "PROBLEM", 142, 151], ["defined ILI symptoms", "PROBLEM", 192, 212], ["infection", "PROBLEM", 243, 252], ["influenza", "PROBLEM", 258, 267], ["other respiratory viruses", "PROBLEM", 271, 296], ["range", "OBSERVATION_MODIFIER", 2, 7], ["different", "OBSERVATION_MODIFIER", 11, 20], ["viruses", "OBSERVATION", 21, 28], ["infection", "OBSERVATION", 142, 151], ["infection", "OBSERVATION", 243, 252], ["respiratory viruses", "OBSERVATION", 277, 296]]], ["The results confirm that during winter, influenza viruses are not the only respiratory pathogens which are responsible for a febrile illness and hospital visits in this cohort of children.", [["influenza viruses", "DISEASE", 40, 57], ["febrile illness", "DISEASE", 125, 140], ["influenza viruses", "ORGANISM", 40, 57], ["children", "ORGANISM", 179, 187], ["children", "SPECIES", 179, 187], ["influenza viruses", "SPECIES", 40, 57], ["influenza viruses", "PROBLEM", 40, 57], ["respiratory pathogens", "PROBLEM", 75, 96], ["a febrile illness", "PROBLEM", 123, 140]]], ["While these viruses were not serious enough to require the child to be admitted to hospital, taking into account lost days from work and school, hospital admissions and mortality rates in infants and the elderly, the health and economic costs are considerable.", [["infants", "ORGANISM", 188, 195], ["infants", "SPECIES", 188, 195], ["viruses", "OBSERVATION", 12, 19]]], ["Children often carry these viruses to their homes and spread infection to younger siblings or to their parents, whereas those admitted to hospital tend to shed the virus abundantly for prolonged periods, thus potentiating spread [10] .DiscussionIn Australia, timely community-level information about respiratory tract infection is scarce.", [["respiratory tract", "ANATOMY", 300, 317], ["infection", "DISEASE", 61, 70], ["respiratory tract infection", "DISEASE", 300, 327], ["Children", "ORGANISM", 0, 8], ["respiratory tract", "ORGANISM_SUBDIVISION", 300, 317], ["Children", "SPECIES", 0, 8], ["respiratory tract infection", "PROBLEM", 300, 327], ["respiratory tract", "ANATOMY", 300, 317], ["infection", "OBSERVATION", 318, 327]]], ["Lambert et al. [26] examined the burden of respiratory illness during winter in a cohort of urban children.", [["respiratory", "ANATOMY", 43, 54], ["respiratory illness", "DISEASE", 43, 62], ["children", "ORGANISM", 98, 106], ["children", "SPECIES", 98, 106], ["respiratory illness", "PROBLEM", 43, 62], ["respiratory", "ANATOMY", 43, 54], ["illness", "OBSERVATION", 55, 62]]], ["They reported that the risk factors for ILI included younger age, fewer people residing in the household, structured exposure to other children outside the home, and a higher household income.", [["ILI", "DISEASE", 40, 43], ["people", "ORGANISM", 72, 78], ["children", "ORGANISM", 135, 143], ["people", "SPECIES", 72, 78], ["children", "SPECIES", 135, 143], ["ILI", "PROBLEM", 40, 43]]], ["While we cannot comment on risk factors for ILI, we found that being \u22641 year of age was significant for being diagnosed with a respiratory illness.", [["respiratory", "ANATOMY", 127, 138], ["ILI", "DISEASE", 44, 47], ["respiratory illness", "DISEASE", 127, 146], ["ILI", "PROBLEM", 44, 47], ["a respiratory illness", "PROBLEM", 125, 146], ["respiratory", "ANATOMY", 127, 138], ["illness", "OBSERVATION", 139, 146]]], ["As documented in this study, the rate of laboratory-confirmed illness was not related to the number of people living in the house.", [["illness", "DISEASE", 62, 69], ["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["this study", "TEST", 17, 27], ["illness", "PROBLEM", 62, 69]]], ["This is in comparison to many other studies in developed settings, which have found that the rate of infections within the household decreases with increasing household incomes, thought to be a reflection of household crowding [27] .", [["infections", "DISEASE", 101, 111], ["many other studies", "TEST", 25, 43], ["infections", "PROBLEM", 101, 111], ["infections", "OBSERVATION", 101, 111]]], ["Our findings are however, in line with the results from the previous Australian study ref, who also reported that there was no significant relationship between crowding and reported illness.DiscussionThese results have global relevance to respiratory disease control planning.", [["respiratory", "ANATOMY", 239, 250], ["illness", "DISEASE", 182, 189], ["respiratory disease", "DISEASE", 239, 258], ["crowding and reported illness", "PROBLEM", 160, 189], ["respiratory disease control planning", "TREATMENT", 239, 275], ["no", "UNCERTAINTY", 124, 126], ["significant", "OBSERVATION_MODIFIER", 127, 138], ["illness", "OBSERVATION", 182, 189], ["respiratory disease", "OBSERVATION", 239, 258]]], ["Blocking transmission of respiratory viruses is an important part of halting spread of disease and epidemics.", [["respiratory viruses", "DISEASE", 25, 44], ["respiratory viruses", "PROBLEM", 25, 44], ["disease", "PROBLEM", 87, 94], ["epidemics", "PROBLEM", 99, 108], ["respiratory viruses", "OBSERVATION", 25, 44], ["disease", "OBSERVATION", 87, 94]]], ["Using barriers such as face masks and gloves, isolating people known to be infected as well as introducing hygiene measures (e.g. hand washing) are effective ways of containing respiratory virus epidemics.", [["hand", "ANATOMY", 130, 134], ["respiratory virus epidemics", "DISEASE", 177, 204], ["people", "ORGANISM", 56, 62], ["hand", "ORGANISM_SUBDIVISION", 130, 134], ["respiratory virus", "ORGANISM", 177, 194], ["people", "SPECIES", 56, 62], ["barriers", "TREATMENT", 6, 14], ["face masks", "TREATMENT", 23, 33], ["gloves", "TREATMENT", 38, 44], ["infected", "PROBLEM", 75, 83], ["introducing hygiene measures", "TREATMENT", 95, 123], ["hand washing)", "TREATMENT", 130, 143], ["respiratory virus epidemics", "PROBLEM", 177, 204], ["infected", "OBSERVATION", 75, 83], ["respiratory virus", "OBSERVATION", 177, 194]]], ["This is particularly important for children because it will help to protect them as well as reduce the chance of transmission to other household members.DiscussionWhile the children in our study were not admitted to hospital with respiratory illness, these events consumed considerable resources, both in social and family terms.", [["respiratory", "ANATOMY", 230, 241], ["respiratory illness", "DISEASE", 230, 249], ["children", "ORGANISM", 35, 43], ["children", "ORGANISM", 173, 181], ["children", "SPECIES", 35, 43], ["children", "SPECIES", 173, 181], ["respiratory illness", "PROBLEM", 230, 249]]], ["73% of the cohort had visited their local GP, 40% had received antibiotics and in 38% of cases, a family member had missed work to care for the sick child.", [["antibiotics", "TREATMENT", 63, 74]]], ["For this cohort of children, the cost of these visits would amount to AU$4070.", [["children", "ORGANISM", 19, 27], ["children", "SPECIES", 19, 27]]], ["The costs calculated here do not capture the full cost attributable to the illness.", [["illness", "DISEASE", 75, 82], ["the illness", "PROBLEM", 71, 82], ["illness", "OBSERVATION", 75, 82]]], ["The direct out-of-pocket costs to individuals can be substantial and includes costs for pharmaceuticals (both over-the counter and prescribed), travel related costs for GP visits and hospital visits, and gap payments for GP's consultation.", [["pharmaceuticals", "TREATMENT", 88, 103], ["GP's consultation", "TEST", 221, 238], ["substantial", "OBSERVATION_MODIFIER", 53, 64]]], ["In addition, there are the costs associated with lost economic production.", [["lost economic production", "PROBLEM", 49, 73], ["costs", "OBSERVATION", 27, 32], ["lost", "OBSERVATION_MODIFIER", 49, 53], ["economic", "OBSERVATION_MODIFIER", 54, 62], ["production", "OBSERVATION_MODIFIER", 63, 73]]], ["Of the family members interviewed, 38% took time to care for the child.", [["child", "ORGANISM", 65, 70]]], ["Previous studies have shown that parental work loss for the care of sick children forms a substantial proportion of the total cost of influenza in children [28, 29] .", [["work loss", "DISEASE", 42, 51], ["influenza", "DISEASE", 134, 143], ["children", "ORGANISM", 73, 81], ["children", "ORGANISM", 147, 155], ["children", "SPECIES", 73, 81], ["children", "SPECIES", 147, 155], ["Previous studies", "TEST", 0, 16], ["influenza", "PROBLEM", 134, 143]]], ["Cohen and Nettleman [28] found that the mean duration of work loss (3.2 days) due to influenza in these children would translate into US $300 in lost wages (assuming US $93 for a day's salary for a parent in the United States).DiscussionIn our study, we found a high proportion of probably inappropriate antibiotic use in the community, since about 42% of the patients, most of whom had a viral infection identified as the cause of their febrile illness, received antibiotics prior to presenting to hospital.", [["influenza", "DISEASE", 85, 94], ["viral infection", "DISEASE", 389, 404], ["febrile illness", "DISEASE", 438, 453], ["children", "ORGANISM", 104, 112], ["patients", "ORGANISM", 360, 368], ["children", "SPECIES", 104, 112], ["patients", "SPECIES", 360, 368], ["work loss", "PROBLEM", 57, 66], ["influenza", "PROBLEM", 85, 94], ["our study", "TEST", 240, 249], ["a viral infection", "PROBLEM", 387, 404], ["their febrile illness", "PROBLEM", 432, 453], ["antibiotics", "TREATMENT", 464, 475], ["probably", "UNCERTAINTY", 281, 289], ["inappropriate", "OBSERVATION_MODIFIER", 290, 303], ["antibiotic", "OBSERVATION", 304, 314], ["viral", "OBSERVATION_MODIFIER", 389, 394], ["infection", "OBSERVATION", 395, 404]]], ["This is similar to the results from Tsolia et al. [30] who also found an excess of antibiotic use in their cohort of outpatient children (\u22656 months to <14 years) with influenza.", [["influenza", "DISEASE", 167, 176], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["influenza", "PROBLEM", 167, 176]]], ["They found that the most common reason for justified antibiotic administration was acute otitis media.", [["otitis", "DISEASE", 89, 95], ["justified antibiotic administration", "TREATMENT", 43, 78], ["acute otitis media", "PROBLEM", 83, 101], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["otitis", "OBSERVATION", 89, 95]]], ["In our study, 37% of the children who were PCR positive for influenza received antibiotics.", [["influenza", "DISEASE", 60, 69], ["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33], ["our study", "TEST", 3, 12], ["PCR", "TEST", 43, 46], ["influenza", "PROBLEM", 60, 69], ["antibiotics", "TREATMENT", 79, 90]]], ["In the comparator study, influenza accounted for 37% of all antibiotic courses given to outpatients with febrile respiratory infection during the period studied.", [["respiratory", "ANATOMY", 113, 124], ["influenza", "DISEASE", 25, 34], ["febrile respiratory infection", "DISEASE", 105, 134], ["outpatients", "SPECIES", 88, 99], ["the comparator study", "TEST", 3, 23], ["influenza", "PROBLEM", 25, 34], ["all antibiotic courses", "TREATMENT", 56, 78], ["febrile respiratory infection", "PROBLEM", 105, 134], ["infection", "OBSERVATION", 125, 134]]], ["The study by Neuzil et al. [31] also analyzed excess antibiotic use attributable to influenza.", [["influenza", "DISEASE", 84, 93], ["The study", "TEST", 0, 9], ["excess antibiotic use", "TREATMENT", 46, 67], ["influenza", "PROBLEM", 84, 93], ["influenza", "OBSERVATION", 84, 93]]], ["They found an average of 0.072 excess courses of antibiotics per preschool-aged child.", [["child", "ORGANISM", 80, 85], ["antibiotics", "TREATMENT", 49, 60], ["average", "OBSERVATION_MODIFIER", 14, 21]]], ["The inappropriate or excess use of antibiotics could theoretically by reduced and perhaps avoided by inclusion of rapid influenza testing for evaluation of febrile infants on assessment during the influenza season as early antiviral treatment has been shown to reduce both the use of antibiotic treatment and the length of hospital stay [32] .", [["febrile", "DISEASE", 156, 163], ["influenza", "DISEASE", 197, 206], ["infants", "ORGANISM", 164, 171], ["infants", "SPECIES", 164, 171], ["antibiotics", "TREATMENT", 35, 46], ["rapid influenza testing", "TEST", 114, 137], ["evaluation", "TEST", 142, 152], ["febrile infants", "PROBLEM", 156, 171], ["assessment", "TEST", 175, 185], ["the influenza season", "TREATMENT", 193, 213], ["early antiviral treatment", "TREATMENT", 217, 242], ["antibiotic treatment", "TREATMENT", 284, 304]]], ["As only 31% of the children recruited were under one year of age, the use and role of antivirals in these children could be considered.", [["children", "ORGANISM", 19, 27], ["children", "ORGANISM", 106, 114], ["children", "SPECIES", 19, 27], ["children", "SPECIES", 106, 114], ["antivirals", "TREATMENT", 86, 96]]], ["A recent study indicated that antiviral use in hospitalised children under 12 months of age is safe [33] .DiscussionIn 2008 the American Advisory Committee on Immunization Practices (ACIP) recommended routine influenza immunization in all children aged 6 months to 18 years [18] .", [["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 239, 247], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 239, 247], ["A recent study", "TEST", 0, 14], ["Immunization Practices (ACIP)", "TREATMENT", 159, 188], ["routine influenza immunization", "TREATMENT", 201, 231]]], ["The recommendation of childhood influenza vaccination by the ACIP was justified along several grounds.", [["influenza", "DISEASE", 32, 41], ["ACIP", "ORGANISM", 61, 65], ["ACIP", "SPECIES", 61, 65], ["childhood influenza vaccination", "TREATMENT", 22, 53]]], ["Major factors included the burden of childhood disease, healthcare utilization, and caregiver absenteeism.", [["childhood disease", "PROBLEM", 37, 54]]], ["While this vaccine may not have protected all the children in our cohort, it may have prevented 32 cases of influenza in the cohort.", [["influenza", "DISEASE", 108, 117], ["children", "ORGANISM", 50, 58], ["children", "SPECIES", 50, 58], ["influenza", "PROBLEM", 108, 117]]], ["Vaccines to protect against RSV and parainfluenzaviruses may also be available in the future.", [["RSV", "ORGANISM", 28, 31], ["RSV", "SPECIES", 28, 31], ["RSV", "SPECIES", 28, 31], ["Vaccines", "TREATMENT", 0, 8], ["RSV", "PROBLEM", 28, 31], ["parainfluenzaviruses", "TREATMENT", 36, 56]]], ["For family members, aside from recommending the use of the influenza vaccine, masks and hand washing may be other methods of preventing the spread in these households.DiscussionThere are some considerations when interpreting the findings of this study.", [["hand", "ANATOMY", 88, 92], ["hand", "ORGANISM_SUBDIVISION", 88, 92], ["the influenza vaccine", "TREATMENT", 55, 76], ["masks", "TREATMENT", 78, 83], ["hand washing", "TREATMENT", 88, 100], ["this study", "TEST", 241, 251]]], ["While this study was conducted over three consecutive winters, the study recruited from only one site, and was limited to examining children whose family members had agreed to participate in the study.", [["children", "ORGANISM", 132, 140], ["children", "SPECIES", 132, 140], ["this study", "TEST", 6, 16], ["the study", "TEST", 63, 72], ["the study", "TEST", 191, 200]]], ["Although we may have missed children with a potential respiratory illness, we were able to prospectively examine the impact of the child's illness on the family members as in order to be recruited, the family members had to have been symptom-free prior to the date of recruitment.ConclusionOur results demonstrate that during winter influenza viruses are not the only respiratory pathogens which are responsible for illness and hospital visits in children.", [["respiratory illness", "DISEASE", 54, 73], ["illness", "DISEASE", 139, 146], ["influenza viruses", "DISEASE", 333, 350], ["illness", "DISEASE", 416, 423], ["children", "ORGANISM", 28, 36], ["winter influenza viruses", "ORGANISM", 326, 350], ["children", "ORGANISM", 447, 455], ["children", "SPECIES", 28, 36], ["children", "SPECIES", 447, 455], ["winter influenza viruses", "SPECIES", 326, 350], ["a potential respiratory illness", "PROBLEM", 42, 73], ["symptom", "PROBLEM", 234, 241], ["winter influenza viruses", "PROBLEM", 326, 350], ["respiratory pathogens", "PROBLEM", 368, 389], ["illness", "PROBLEM", 416, 423]]], ["While these viruses were not serious enough to require the child to be admitted to hospital, they were responsible for excess GP, ED visit and antibiotic use.", [["antibiotic use", "TREATMENT", 143, 157], ["viruses", "OBSERVATION", 12, 19]]], ["This study has provided solid estimates of transmission rates of respiratory viruses between children and family members.", [["respiratory viruses", "DISEASE", 65, 84], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["This study", "TEST", 0, 10], ["respiratory viruses", "OBSERVATION", 65, 84]]]]}